Characterisation of the Formin Protein FHOD1 in Striated Muscle by Dwyer, Joseph
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 












Download date: 06. Nov. 2017







Characterisation of the Formin 



















“I never practice; I always play.” ~ Wanda Landowska 
 
"The saddest aspect of life right now is that science gathers knowledge faster than 
society gathers wisdom." ~ Isaac Asimov 
 
“One becomes firmly established in practice only after attending to it for a long time, 
without interruption and with an attitude of devotion.” ~ Yoga Sutra I.14 
 
 
This thesis is dedicated to my parents: 
 Dr. John P. Dwyer and Mrs. Angela Micioni Dwyer   
Their love and support have helped guide me through my studies and I will always be 










I would like to thank the following people for their help and support.  My first 
supervisor Dr. Elisabeth Ehler for her help and support throughout my research studies.  
Her enthusiasm and kindness have provided me much of the motivation and inspiration 
for my work.  My second supervisor Prof. Anne Ridley for her helpful discussions and 
for the donation of expression constructs.  Dr. Thomas Iskratsch for the donation of 
expression constructs and general support.  Without his help in learning the relevant 
molecular biology techniques this project would not have been possible.  Dr. Sue Perera 
for her invaluable help in learning GST pull-down assays, for general lab support, and 
for her friendship.  Dr. Atsushi Fukuzawa for his support in the lab with the yeast two-
hybrid technique.  Dr. Ay Lin Kho for her assistance in the neonatal rat cardiomyocyte 
preps.  I would like to extend a very warm thanks to Ms. Birgit Brandmeier for her 
general lab support and for her friendship.  The current and previous members of Dr. 
Elisabeth Ehler’s group for help and support in the lab: Dr. Thomas Randall, Dr. Sagair 
Hussain, Ms. Marlene Plüß, Ms. Nadine Gose, and Ms. Nadine Lohmann.  The current 
and previous members of Prof. Mathias Gautel’s group for their help and support in the 
lab: Prof. Mathias Gautel, Dr. Alexander Alexandrovich, Dr. Martin Rees, Mr. 
Christopher Jenkins, Dr. Mark Holt, Mr. Andrea Ghisleni, Dr. Sarah Waters, and Dr. 
Elena Rostkova.  Dr. Daniel Soong and Dr. Peter Stevenson for their assistance with the 
confocal microscopes.  I would also like to thank Dr. Pauline Bennett and Ms. Amanda 
Wilson for their helpful discussions regarding the intercalated disk.  From the group of 
Dr. Maddy Parsons I would like to thank Dr. Asier Jayo, for advice on performing F-
actin quantification in cells and Ms. Giulia Villari, for many in depth scientific 
discussions and for her kindness and friendship.  The Randall Protein Production 
Facility for their assistance with cloning: Dr. Paul Brown, Mrs. Renée Tata, Dr. Mitla 
Garcia-Maya.  I would also like to acknowledge the memory of Henrietta Lacks and her 
contribution to science in the creation of HeLa cells.  I would like to thank all of my 
friends in the Randall Division for their help and support throughout my studies, 
especially, Ms. Ivanka Sevrieva, Ms. Maira Silva, Dr. Thomas Kampourakis, Dr. 
Andrea Knowles, Ms. Rumena Begum, Ms. Upamali Perera, Ms. Rachael Inglis, Mr. 
   
4 
 
Richard Downes, and Ms. Louise Moyle. I would like to give a special thanks to Dr. 
Sehrish Rafique, Ms. Kaye Batten, and Mrs. Stefanie Hoffart for their love and support. 
I would also like to thank Ms. Francesca Ludwinski for her friendship and support 
during all of my scientific studies.  I would like to give a very warm thanks to Ms. 
Marie Lecomte who has provided me with a decade of friendship and the inspiration to 
study science.  Lastly I would like to give the biggest thanks to my family: Dr. John P. 
Dwyer, Mrs. Angela Micioni Dwyer, Ms. Francesca Dwyer, and Jack Dwyer.  I would 
also like to thank my grandmother Mrs. Thea Stanchieri Micioni and Dusty Dwyer who 
are sadly no longer with us but will remain in my heart forever.  My family are my 
biggest inspiration and provide me the strength and will to excel in every aspect of life.  
 
Sources of Funding: 
Thank you to King’s College London and the British Heart Foundation for their 
funding, help, and support.  Thank you to the Randall Division of Cell & Molecular 




















Formin homology 2 domain containing protein 1 (FHOD1) is a diaphanous related 
formin of the FHOD subclass. In a similar manner to other formins, FHOD1 has 
primarily been found to regulate the polymerisation of actin-based structures in cells.  
In muscle, actin is a major constituent of both skeletal and cardiac myocytes, with the 
thin filament system of sarcomeres and the cytoskeleton being partly composed of 
actin.  FHOD proteins have previously been highlighted as important regulators of 
muscle cell biology since FHOD3, a close relative of FHOD1 was shown to be essential 
for myofibrillar maintenance.  There is little known about the regulation of actin-based 
structures in muscle cells.  We therefore aimed to characterise FHOD1 and probe into 
its involvement in myofibrillar and cytoskeletal regulation.  In this study of FHOD1 we 
addressed various aspects of the protein including its expression pattern and 
localisation, function, regulation, and novel interacting partners.  Insight into the 
expression pattern of FHOD1 was gained by examining relative protein levels in 
different tissues, including both healthy and diseased heart.  Subcellular localisation 
was addressed in a number of fluorescence microscopy experiments through antibody 
localisation studies in muscle tissue and cultured cells and through transient 
transfection of GFP tagged constructs.  Expression of GFP tagged fragments and 
mutants helped to delineate the functional distribution of the FHOD1 molecule in cells.  
The function of the protein was further probed via molecular knockdown by RNAi and 
by looking at the capacity of FHOD1 to polymerise actin in cells. The role of formins in 
the heart was more broadly addressed by drug inhibition of their actin polymerising 
capacity. Previous studies have suggested that the Rho family of small GTPases as well 
as the Src kinases regulate FHOD1.  Involvement of the GTPases and Src was shown 
through biochemical experiments.  Finally, a number of Yeast2Hybrid assays were 
performed using different domains of FHOD1 to screen for novel binding partners.  Our 
findings would suggest that FHOD1 is a crucial regulator of the myofibrillar apparatus 
and the cytoskeleton at the level of actin in striated muscle. 
 
  Table of Contents 
6 
 
II Table of Contents 
 
I Abstract ........................................................................................................................... 5 
II Table of Contents .......................................................................................................... 6 
III List of Figures ............................................................................................................ 13 
IV List of Tables ............................................................................................................. 18 
V. Abbreviations ............................................................................................................. 19 
1. Introduction ................................................................................................................. 26 
1.1 Muscle ................................................................................................................... 26 
1.1.1 Smooth Muscle ............................................................................................... 28 
1.1.2 Cardiac Muscle ............................................................................................... 29 
1.1.3 Skeletal Muscle ............................................................................................... 31 
1.1.4 Contractile Mechanism of Striated Muscle .................................................... 32 
1.2 The Sarcomere ....................................................................................................... 33 
1.2.1 The Z-disk ....................................................................................................... 35 
1.2.2 The M-band..................................................................................................... 35 
1.2.3 Titin ................................................................................................................. 36 
1.3 Actin ...................................................................................................................... 36 
1.3.1 Actin Polymerisation ...................................................................................... 37 
1.3.2 Thin Filaments ................................................................................................ 40 
1.4 Regulation of Actin Polymerisation ...................................................................... 41 
1.4.1 Arp2/3 ............................................................................................................. 42 
1.4.2 Other Actin Regulatory Proteins..................................................................... 43 
1.5 Other Mechanisms of Actin Regulation ................................................................ 44 
1.5.1 Actin Capping ................................................................................................. 45 
1.5.2 Actin Disassembly .......................................................................................... 47 
1.5.3 Actin Cross-Linking ....................................................................................... 49 
1.6. Regulation and Dynamics of Actin-based Structures ........................................... 50 
1.6.1 Lamellipodia ................................................................................................... 53 
1.6.2 Filopodia ......................................................................................................... 55 
  Table of Contents 
7 
 
1.6.3 Stress Fibres .................................................................................................... 56 
1.7 Formins .................................................................................................................. 58 
1.7.1 Formins as Actin Nucleators and Elongators ................................................. 60 
1.8 DRF Domain Structure .......................................................................................... 61 
1.8.1 The FH2 Domain ............................................................................................ 62 
1.8.2 The FH1 Domain ............................................................................................ 63 
1.8.3 The DID and DAD .......................................................................................... 64 
1.9 Regulation of DRFs by Rho Family Small GTPases ............................................ 65 
1.10 Formins and Cell Signalling ................................................................................ 68 
1.11 Other Activities of Formins ................................................................................. 69 
1.11.1 Formins as Actin Bundlers ........................................................................... 70 
1.11.2 Formins as Actin Severing and Actin Depolymerisation Factors................. 71 
1.11.3 Formins and the Regulation of Microtubules ............................................... 72 
1.12 FHOD1 ................................................................................................................ 73 
1.12.1 The Formin Homology Protein, FHOD1 ...................................................... 73 
1.12.2 Cellular Roles of FHOD1 ............................................................................. 76 
1.12.3 FHOD1 and the Regulation of Microtubules ................................................ 80 
1.12.4 Regulation of FHOD1 ................................................................................... 81 
1.12.5 Additional Kinases that Phosphorylate FHOD1 ........................................... 87 
1.12.6 Further Insights into FHOD1 Function from other Interacting Partners ...... 88 
1.13 FHOD3 ................................................................................................................ 95 
1.13.1 The Formin Homology Protein, FHOD3 ...................................................... 95 
1.13.2 Preliminary Work with FHOD3 – Motivation for Work with FHOD1 in 
Striated Muscle ........................................................................................................ 96 
1.14 Formins in Disease .............................................................................................. 97 
1.14.1 Formins in Cardiac Disease .......................................................................... 98 
1.14.2 Insights from MLP deficient mice ................................................................ 99 
1.15 Conclusion ......................................................................................................... 101 
1.16 Hypothesis and Aims ......................................................................................... 102 
2. Materials and Methods .............................................................................................. 105 
2.1 Specimens ............................................................................................................ 105 
2.1.1 Mice .............................................................................................................. 105 
2.1.2 Murine Samples ............................................................................................ 105 
2.1.3 COS-1 Cells .................................................................................................. 105 
  Table of Contents 
8 
 
2.1.4 Yeast ............................................................................................................. 106 
2.2 Cell Culture ......................................................................................................... 106 
2.2.1 Neonatal Rat Cardiomyocytes ...................................................................... 106 
2.2.2 Adult Rat Cardiomyocytes............................................................................ 108 
2.2.3 COS-1 Cells .................................................................................................. 108 
2.2.4 C2C12 Cells .................................................................................................. 108 
2.2.5 HeLa Cells .................................................................................................... 108 
2.2.6 Latrunculin B Treatment ............................................................................... 109 
2.2.7 SMIFH2 Treatment ....................................................................................... 111 
2.3 Antibodies ........................................................................................................... 111 
2.3.1 Validation of Novel Antibodies .................................................................... 116 
2.4 Preparation of Transfection Constructs ............................................................... 116 
2.4.1 First Strand cDNA Synthesis with Reverse Transcriptase ........................... 116 
2.4.2 PCR ............................................................................................................... 116 
2.4.3 Cloning.......................................................................................................... 118 
2.4.4 Sequencing .................................................................................................... 119 
2.4.5 Constructs ..................................................................................................... 119 
2.4.6 Validation of Expression Constructs ............................................................ 120 
2.5 RNA Interference ................................................................................................ 120 
2.6 Library Screens and Interactions Assays using the Yeast Two-Hybrid System . 121 
2.7 Protein Expression ............................................................................................... 122 
2.8 GST Pull-down Assay ......................................................................................... 123 
2.9 Resolution of Protein Samples by Gel Electrophoresis ....................................... 124 
2.9.1 SDS-PAGE and Western Blotting ................................................................ 124 
2.9.2 Quantification of Western Blots ................................................................... 125 
2.9.2.1 Statistical Analysis used for Quantification of Western Blots .................. 126 
2.9.3 Coomassie Staining....................................................................................... 126 
2.10 Transient Expression Studies ............................................................................ 127 
2.10.1 Transient Transfection of Neonatal Rat Cardiomyocytes ........................... 127 
2.10.2 Transient Transfection of COS-1 Cells ...................................................... 127 
2.10.3 Transient Transfection of C2C12 Cells ...................................................... 127 
2.10.4 Transient Transfection of HeLa Cells ......................................................... 127 
2.11 Immunofluorescence ......................................................................................... 128 
  Table of Contents 
9 
 
2.11.1 Staining of Cultured Cells........................................................................... 128 
2.11.2 Staining of Tissue Sections ......................................................................... 128 
2.11.3 Confocal Microscopy .................................................................................. 129 
2.11.4 Quantification of F-actin Staining .............................................................. 129 
2.11.5 Scoring of Myofibrillar Integrity for F-actin/Myofibril Depolymerisation 
Assay ...................................................................................................................... 130 
2.11.6 Calculation of Fusion Index in Differentiating C2C12 Cells ..................... 130 
2.12 Sequence Alignment .......................................................................................... 131 
2.12.1 Amino Acid Sequence Alignment .............................................................. 131 
2.12.2 Nucleic Acid Sequence Alignment ............................................................. 131 
2.13 Buffers/Solutions/Media ................................................................................... 131 
3. Expression and Localisation of FHOD1 ................................................................... 134 
3.1 Validation of Commercially Available Anti-FHOD1 Antibodies ...................... 134 
3.2 Expression of FHOD1 in Muscle ........................................................................ 146 
3.3 Localisation Studies in Heart Muscle .................................................................. 149 
3.3.1 Localisation of Endogenous FHOD1 in Neonatal Rat Cardiomyocytes ...... 151 
3.3.2 Localisation of Endogenous FHOD1 in Adult Rat Cardiomyocytes ............ 154 
3.3.3 Localisation of Endogenous FHOD1 in Adult Mouse Heart Tissue Sections
 ............................................................................................................................... 156 
3.4 Expression and Localisation of FHOD1 in Differentiating C2C12 Myoblasts ... 161 
3.4.1 Expression of FHOD1 in Differentiating C2C12 Myoblasts........................ 162 
3.4.2 Localisation of Endogenous FHOD1 in Differentiating C2C12 Myoblasts . 164 
3.5 Overexpression of Full-length FHOD1 in Neonatal Rat Cardiomyocytes .......... 172 
3.5.1 Targeting of the Full-Length FHOD1 in Neonatal Rat Cardiomyocytes ..... 174 
3.6 Subcellular Targeting of FHOD1 Domains in Neonatal Rat Cardiomyocytes ... 177 
3.6.1 Overexpression of the FH2 Domain [642-1031] .......................................... 178 
3.6.2 Overexpression of the GBD-DID [1-340] .................................................... 179 
3.6.3 Overexpression of the GBD [1-116] ............................................................. 181 
3.6.4 Overexpression of the DID [117-340] .......................................................... 182 
-1191]............................................ 183 
3.7 Discussion ........................................................................................................... 184 
3.7.1 Expression of FHOD1 in Muscle Tissue ...................................................... 184 
3.7.2 Localisation of Endogenous FHOD1 in Muscle Samples ............................ 188 
3.7.3 Overexpression of FHOD1 in NRCs ............................................................ 191 
  Table of Contents 
10 
 
3.7.6 Conclusion .................................................................................................... 195 
3.7.5 Future Directions .......................................................................................... 195 
4. Functional Characterisation of FHOD1 .................................................................... 199 
4.1 Overexpression of FHOD1 Mutant Constructs in Neonatal Rat Cardiomyocytes
 ................................................................................................................................... 199 
4.1.1 Overexpression of FHOD1 3A [1-1191] and FHOD1 3D [1-1191] 
Phosphomutants ..................................................................................................... 201 
-1128] and FHOD1 V228E [1-1191] 204 
4.2 Localisation of Phosphorylated FHOD1 in Heart Sections ................................. 207 
4.3 F-actin Regulating Activity of FHOD1 ............................................................... 213 
4.4 Myofibril/F-actin Depolymerisation Assay ......................................................... 218 
4.5 RNAi Mediated Knockdown Studies .................................................................. 226 
4.5.1 Design and Validation of shRNA Constructs ............................................... 227 
4.5.2 Knockdown of FHOD1 in Neonatal Rat Cardiomyocytes ........................... 232 
4.5.3 RNAi Rescue Experiments in Neonatal Rat Cardiomyocytes ...................... 241 
4.5.4 Knockdown of FHOD1 in Day 3 C2C12 Cells ............................................ 244 
4.5.5 Knockdown of FHOD1 in Day 7 C2C12 Cells ............................................ 245 
4.6 Treatment with the Formin Inhibitor SMIFH2 .................................................... 248 
4.7 Discussion ........................................................................................................... 252 
4.7.1 Mapping the Functional Layout of FHOD1 in Cardiomyocytes .................. 252 
4.7.2 The F-actin Regulatory Activity of FHOD1 ................................................. 255 
4.7.3 Loss-of-Function Studies in Muscle Cells .................................................... 259 
4.7.4 Involvement of Formins in Regulation of the Myofibrillar Apparatus ........ 264 
4.7.5 Conclusion .................................................................................................... 266 
4.7.6 Future Directions .......................................................................................... 267 
5. Regulation of FHOD1 ............................................................................................... 271 
5.1 Regulation of FHOD1 by the Rho Family Small GTPases and their Effectors .. 271 
5.1.1 Validation of the N-Terminal GST-tagged FHOD1 Construct .................... 272 
5.1.2 Conditions used for GST Pull-Down Assays ............................................... 274 
5.1.3 Assessment of Binding of FHOD1 with the Rho family small GTPases and 
their Effectors ........................................................................................................ 276 
5.2 Regulation of FHOD1 by Src Kinase .................................................................. 279 
5.2.1 Assessment of Binding of FHOD1 with Src ................................................. 280 
5 ............................................................................................................................. 282 
  Table of Contents 
11 
 
.3 Discussion .......................................................................................................... 282 
5.3.1 Interaction between the FHOD1 N-terminus, the Rho Family Small GTPases, 
and their Effector Molecules.................................................................................. 282 
5.3.2 Interaction between the FHOD1 N-terminus and Src ................................... 284 
5.3.3 Conclusion .................................................................................................... 286 
5.3.4 Future Directions .......................................................................................... 287 
6. Novel Protein-Protein Interactions ............................................................................ 289 
6.1 Yeast Two-Hybrid Screens with FHOD1............................................................ 289 
6.2 cDNA Library Screen with FHOD1 GBD-DID [1-340] ..................................... 292 
6.2.1 Novel Interaction Partners with FHOD1 GBD-DID [1-340] ....................... 294 
6.2.2 Yeast Two-Hybrid assays with FHOD1 GBD-DID [1-340] ........................ 297 
6.2.3 Validation of GST-tagged FHOD1 GBD-DID Construct ............................ 300 
6.2.4 GST Pull-downs with FHOD1 GBD-DID [1-340] ....................................... 301 
6.3 cDNA Library Screen with FHOD1 [340-585] ................................................... 304 
6.3.1 Novel Interaction Partners with FHOD1 [340-585] ..................................... 306 
6.3.2 Binding between FHOD1 and NRAP ........................................................... 307 
6.3.3 Yeast Two-Hybrid Assays with FHOD1 [340-585] ..................................... 309 
6.3.4 Co-localisation Studies with FHOD1 and NRAP ......................................... 312 
6.4 FHOD1 in MLP
-/-
 Hearts ..................................................................................... 315 
6.4.1 Localisation of FHOD1 in MLP
-/-
 Hearts ..................................................... 315 
6.4.2 Expression of FHOD1 in MLP
-/-
 Hearts ....................................................... 318 
6.5 Discussion ........................................................................................................... 320 
6.5.1 Interactions with the FHOD1 GBD-DID Region ......................................... 320 
6.5.2 Interactions with FHOD1 [340-585]............................................................. 322 
6.5.3 Alterations in FHOD1 in MLP
-/-
 Mice .......................................................... 324 
6.5.4 Insights into DCM Phenotype....................................................................... 327 
6.5.5 Conclusion .................................................................................................... 329 
6.5.6 Future Directions .......................................................................................... 329 
7. Discussion ................................................................................................................. 333 
7.1 Expression of FHOD1 ......................................................................................... 333 
7.2 Localisation of FHOD1 ....................................................................................... 335 
7.3 Potential Mechanisms Guiding FHOD1 Localisation ......................................... 338 
7.4 Effects of FHOD1 Activation in Cardiomyocytes .............................................. 340 
7.5 Role of FHOD1 and Formins in the Regulation of Muscle Cytoarchitecture ..... 343 
  Table of Contents 
12 
 
7.5.1 FHOD1 as an Actin Polymerising Protein in Muscle ................................... 347 
7.5.2 FHOD1 as a Capping Protein in Muscle ...................................................... 349 
7.5.3 FHOD1 as an Actin Side Binding Protein/Actin Bundler in Muscle ........... 351 
7.5.4 FHOD1 as a Signalling Effector in Muscle .................................................. 352 
7.5.6 Functional Significance of FHOD1 at the Intercalated Disk ........................ 354 
7.5.7 Unified View of Potential FHOD1 Functions in Muscle Cells .................... 355 
7.6 FHOD1 in Cardiac Disease ................................................................................. 358 
7.7 Insights from Interacting Partners ....................................................................... 361 
7.7.1 Potential Contribution of FHOD3 ................................................................ 361 
7.7.2 Potential Contribution of Src ........................................................................ 362 
7.7.3 Potential Contribution of NRAP ................................................................... 363 
7.8 Conclusion ........................................................................................................... 364 
7.9 Future Directions ................................................................................................. 365 
8. References ................................................................................................................. 369 
  List of Figures 
13 
 
III List of Figures 
 
 
Figure 1.1: Major Regions of Striated Muscle Sarcomeres ............................................ 27 
Figure 1.2: Smooth Muscle ............................................................................................. 29 
Figure 1.3: Striated Muscle ............................................................................................. 31 
Figure 1.4: The Sarcomere .............................................................................................. 34 
Figure 1.5: The Polymerisation of Actin......................................................................... 39 
Figure 1.6: The Thin Filaments of Striated Muscle ........................................................ 41 
Figure 1.7: Actin Polymerisation: Arp2/3 versus Formins ............................................. 43 
Figure 1.8: Other Mechanisms of Actin Regulation ....................................................... 45 
Figure 1.9: Actin-Based Structures in Cells .................................................................... 52 
Figure 1.10: Domain Structure of Formins ..................................................................... 61 
Figure 1.11: Formin Mediated Actin Assembly ............................................................. 63 
Figure 1.12: The GTPase Cycle ...................................................................................... 66 
Figure 1.13: Domain Map of FHOD1 ............................................................................. 74 
Figure 1.14: Schematic of FHOD1 Regions of Binding for Identified Interaction 
Partners (Part I) ............................................................................................................... 89 
Figure 1.14: Schematic of FHOD1 Regions of Binding for Identified Interaction 
Partners (Part II) .............................................................................................................. 90 
Figure 1.15: Schematic of Subcellular Localisations of FHOD1 Interactions (Part I) ... 92 
Figure 1.15: Schematic of Subcellular Localisations of FHOD1 Interactions (Part II) .. 93 
Figure 1.16: Cardiac Disease .......................................................................................... 99 
Figure 3.1: Maps of FHOD1 Expression Constructs used for Antibody Validation .... 135 
Figure 3.2: Validation of anti-FHOD1 Antibodies against FHOD1 Constructs ........... 137 
Figure 3.3: Assessment of Cross-Reactivity against FHOD3 with the anti-FHOD1 
Antibodies by Western Blotting .................................................................................... 139 
  List of Figures 
14 
 
Figure 3.4: Validation of anti-FHOD1 Antibodies with Full-length FHOD1 by 
Fluorescence Confocal Microscopy .............................................................................. 141 
Figure 3.5: Assessing the Reactivity of the anti-FHOD1 Antibodies against GFP by 
Fluorescence Confocal Microscopy .............................................................................. 142 
Figure 3.6: Validation of anti-FHOD1 Antibodies with Full-length FHOD3 by 
Fluorescence Confocal Microscopy .............................................................................. 143 
Figure 3.7: Sequence Comparison between Human and Rodent FHOD1 .................... 145 
Figure 3.8: Expression of FHOD1 in Striated Muscle .................................................. 148 
Figure 3.9: Expression of FHOD1 in Cultured Neonatal Rat and Adult Rat 
Cardiomyocytes............................................................................................................. 151 
Figure 3.10: Localisation of Endogenous FHOD1 in Neonatal Rat Cardiomyocytes .. 153 
Figure 3.11: Localisation of Endogenous FHOD1 in Adult Rat Cardiomyocytes ....... 156 
Figure 3.12: Localisation of Endogenous FHOD1 with the Polyclonal Goat C14 
Antibody in Murine Hearts ........................................................................................... 159 
Figure 3.13: Localisation of Endogenous FHOD1 with the Polyclonal Goat C20 
Antibody in Murine Hearts ........................................................................................... 160 
Figure 3.14: Negative Control for Fluorophore Coupled Secondary Antibodies ......... 161 
Figure 3.15: Expression of FHOD1 in Differentiating C2C12 Myoblasts ................... 163 
Figure 3.16: Localisation of Endogenous FHOD1 with the Polyclonal Goat C14 
Antibody in Differentiating C2C12 Myoblasts ............................................................. 165 
Figure 3.17: Localisation of Endogenous FHOD1 with the Polyclonal Goat C20 
Antibody in Differentiating C2C12 Myoblasts ............................................................. 167 
Figure 3.18: Localisation of Endogenous FHOD1 with the Polyclonal Mouse Antibody 
in Differentiating C2C12 Myoblasts ............................................................................. 169 
Figure 3.19: Expression Test of Different FHOD1 Constructs in COS-1 Cells ........... 173 
Figure 3.20: Overexpression of Full-length GFP-tagged FHOD1 in Neonatal Rat 
Cardiomyocytes............................................................................................................. 176 
Figure 3.21: Overexpression of Full-length TOMATO-tagged FHOD1 in Neonatal Rat 
Cardiomyocytes............................................................................................................. 177 
  List of Figures 
15 
 
Figure 3.22: Overexpression of the FHOD1 FH2 Domain in Neonatal Rat 
Cardiomyocytes............................................................................................................. 179 
Figure 3.23: Overexpression of FHOD1 GBD-DID in Neonatal Rat Cardiomyocytes 180 
Figure 3.24: Overexpression of the FHOD1 GBD in Neonatal Rat Cardiomyocytes .. 182 
Figure 3.25: Overexpression of the FHOD1 DID in Neonatal Rat Cardiomyocytes.... 183 
Figure 3.26: Overexpression of FHOD1 GBD in Neonatal Rat Cardiomyocytes ...... 184 
Figure 4.1: Expression Test of Different FHOD1 Constructs in COS-1 cells .............. 201 
Figure 4.2: Overexpression of FHOD1 Phosphomutant Constructs in Neonatal Rat 
Cardiomyocytes............................................................................................................. 203 
Figure 4.3: Overexpression of the FHOD1 DAD Construct in Neonatal Rat 
Cardiomyocytes............................................................................................................. 205 
Figure 4.4: Overexpression of the FHOD1 V228E Construct in Neonatal Rat 
Cardiomyocytes............................................................................................................. 206 
Figure 4.5: C-terminal Sequence Comparison between Human and Rodent FHOD1 .. 208 
Figure 4.6: Validation of anti-FHOD1 Phospho-Threonine1141 Antibody via Western 
Blot Studies ................................................................................................................... 209 
Figure 4.7: Validation of the Anti-FHOD1 PhosphoThr1141 Antibody in Neonatal Rat 
Cardiomyocytes by Fluorescence Microscopy ............................................................. 210 
Figure 4.8: Validation of the Phospho-Thr1141 FHOD1 Antibody in COS-1 Cells by 
Fluorescence Microscopy.............................................................................................. 212 
Figure 4.9: Localisation of Phosphorylated FHOD1 in Murine Hearts ........................ 213 
Figure 4.10: Quantification of the Actin Regulating Activity of FHOD1 in HeLa Cells
 ....................................................................................................................................... 215 
Figure 4.11: Actin Regulating Activity of FHOD1 in HeLa Cells ............................... 216 
Figure 4.12: Myofibril Recovery Assay in FHOD1-Transfected Neonatal Rat 
Cardiomyocytes............................................................................................................. 222 
Figure 4.13: Myofibril Recovery Assay in Mutant FHOD1-Transfected Neonatal Rat 
Cardiomyocytes............................................................................................................. 224 
  List of Figures 
16 
 
Figure 4.14: Sequence Alignment of the FHOD1 shRNA Constructs with Human and 
Rodent FHOD1 DNA Sequence ................................................................................... 227 
Figure 4.15: Validation of RNAi Technique by Western Blotting ............................... 229 
Figure 4.16: Validation of RNAi Technique by Fluorescence Confocal Microscopy .. 231 
Figure 4.17: The Effects of the FHOD1 shRNAs in Neonatal Rat Cardiomyocytes at 
Day 3 ............................................................................................................................. 233 
Figure 4.18: The Effects of the FHOD1 shRNAs in Neonatal Rat Cardiomyocytes at 
Day 5 ............................................................................................................................. 234 
Figure 4.19: The Effects of the FHOD1 shRNAs in Neonatal Rat Cardiomyocytes at 
Day 8 ............................................................................................................................. 236 
Figure 4.20: The Effects of the FHOD1 shRNAs on the Z-disk and the A-band ......... 238 
Figure 4.21: The Effects of the FHOD1 shRNAs on the M-band and the Intercalated 
Disk ............................................................................................................................... 240 
Figure 4.22: Rescue of RNAi Mediated Effects by FHOD1 Overexpression .............. 243 
Figure 4.23: The Effects of the  FHOD1 shRNAs in Day 3 C2C12 Cells .................... 245 
Figure 4.24: The Effects of the FHOD1 shRNAs in Day 7 C2C12 Cells ..................... 247 
Figure 4.25: Fusion Index in Day 7 FHOD1 shRNA-transfected C2C12 Cells ........... 248 
Figure 4.26: Effects of the Formin Inhibitor SMIFH2 on Myofibrils and the Sarcomere
 ....................................................................................................................................... 250 
Figure 4.27: Effects of the Formin Inhibitor SMIFH2 on the M-band and the 
Intercalated Disk ........................................................................................................... 251 
Figure 5.1: Expression Test for GST-FHOD1 [1-513] ................................................. 274 
Figure 5.2: Assessing the Interaction between the FHOD1 N-terminus with Members of 
the Rho Family Small GTPases .................................................................................... 278 
Figure 5.3: Assessing the Interaction between the FHOD1 N-terminus with Effectors of 
the Rho Family Small GTPases .................................................................................... 279 
Figure 5.4: Assessing the Interaction between FHOD1 and Src ................................... 281 
Figure 6.1: Schematic Representation of the LexA/Gal4 Yeast Two-Hybrid System . 290 
Figure 6.2: Map of FHOD1 Bait Constructs ................................................................. 291 
  List of Figures 
17 
 
Figure 6.3: Validation of the FHOD1 GBD-DID [1-340] Bait Construct .................... 293 
Figure 6.4: Yeast Two-Hybrid Assay with the FHOD1 GBD-DID [1-340] Bait 
Construct ....................................................................................................................... 299 
Figure 6.5: Expression Test for GST-FHOD1 GBD-DID [1-340] ............................... 301 
Figure 6.6: Assessing the Interaction between the FHOD1 GBD-DID fragment and 
Potential Interacting Partners ........................................................................................ 303 
Figure 6.7: Validation of the FHOD1 [340-585] Bait Construct .................................. 305 
Figure 6.8: Domain Map of NRAP ............................................................................... 307 
Figure 6.9: Binding between FHOD1 and NRAP ......................................................... 309 
Figure 6.10: Yeast Two-Hybrid Assay with the FHOD1 [340-585] Bait Construct .... 311 
Figure 6.11: Co-Localisation of FHOD1 and NRAP in Murine Hearts ....................... 312 
Figure 6.12: Negative Control for Fluorophore-Coupled Secondary Antibodies ......... 315 
Figure 6.13: Localisation of FHOD1 in MLP-/- Murine Hearts ................................... 318 

























  List of Tables 
18 
 
IV List of Tables 
 
Table 1.1: Assessing the Potential Interaction between FHOD1 and the Rho family 
Small GTPases ................................................................................................................ 83 




Table 2.2: List of Secondary Antibodies and Counterstains used for Western Blotting 
and Immunofluorescence Studies ................................................................................. 115 
Table 2.3: List of PCR Primers Used to Amplify FHOD1 Constructs ......................... 118 
Table 2.4: List of Oligonucleotides Used to Design RNAi Contructs .......................... 121 
Table 2.5: List of Buffers, Solutions, and Media Used in all Experimental Procedures
 ....................................................................................................................................... 132 
Table 3.1: Summary of Antibody Studies ..................................................................... 171 
Table 3.2: Expression Profile of FHOD1 in Mammalian Tissues ................................ 186 
Table 4.1: Quantification of Myofibril Integrity in FHOD1 Transfected Neonatal Rat 
Cardiomyocytes............................................................................................................. 220 
Table 6.1: Results of cDNA Library Screen with FHOD1 GBD-DID [1-340] ............ 294 











(-) end – pointed end 
(+) end – barbed end 
°C – the degree of Celsius 
3AT – 3-amino-1,2,4-triazole 
A – Alanine 
a.a. – amino acid 
ABD – actin binding domain 
ADF – actin depolymerising factor 
ADP – adenosinediphosphate 
AML – acute myeloid leukaemia 
ARC – adult rat cardiomyocyte 
Arp – actin related protein 
ATP – adenosinetriphosphate 
A-zone – anisotropic zone 
b.p. – base pair 
bHLH - basic helix-loop-helix 
BPB – bromophenol blue 
BSA – bovine serum albumin 
BWM – body wall muscles 
C - Cysteine 
CA – constitutively active 
CAA – cardiac muscle actin 
CACP - Camptodactyly-arthropathy-coxa-vara-pericarditis 
CC – coiled coil 
CD – cluster of differentiation 
cDNA – complementary DNA 
cGMP – cyclic guanosinemonophosphate 
CHF - cardiovascular basic helix-loop-helix factor 
CK – casein kinase 




C-terminus – carboxy terminus 
CYA – cytoplasmic actin 
CYK – cytokinesis defect 
D – Aspartic Acid 
DAAM – dishevelled associated activator of morphogenesis 
DAD – diaphanous autoregulatory domain 
DAPI - 4',6-diamidino-2-phenylindole 
DCM – dilated cardiomyopathy 
DD – dimerisation domain 
Dia – diaphanous 
DID – diaphanous inhibitory domain 
DLG – discs large 
DMEM – Dulbecco's Modified Eagle's Medium 
DMSO - Dimethyl sulfoxide 
DN – dominant negative 
DNA – deoxyribonucleic acid 
dNTP – deoxyribonucleotide triphosphate 
DRF – diaphanous related formin 
DTT – dithiothreitol 
E – Glutamic acid 
ECL – enhanced chemilimuinescence 
ECM – extracellular matrix 
EDTA - ethylenediaminetetraacetic acid 
EGTA - ethylene glycol tetraacetic acid 
F-actin – filamentous actin 
FAK – focal adhesion kinase 
FH – formin homology 
FHOD – formin homology domain containing protein 
FHOS – formin homology overexpressed in the spleen 
FIZ - FLT3-interacting zinc finger 
FMN – formin 
FRL - formin related gene in leukocytes 
G – Glycine 




GAP - GTPase activating protein  
GBD – GTPase binding domain 
GDI - guanine nucleotide-dissociation inhibitors 
GDP – guanosinediphosphate 
GEF – guanine nucleotide exchange factor 
GFP – green fluorescent protein 
GMP-PNP - 5'-Guanylyl imidodiphosphate 
GST – glutathione S-transferase 
GTP – guanosinetriphosphate 
H/His – Histidine  
HA – haemagglutinin 
HCM – hypertrophic cardiomyopathy 
HEPES - 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HEY - hairy/enhancer-of-split related with YRPW motif  
ICD – intercalated disk 
INF- inverted formin 
IPTG - isopropyl β-D-1-thiogalactopyranoside 
IRAP - insulin-responsive aminopeptidase 
I-zone – Isotropic zone 
Kb – kilobases 
kDa – kilodaltons 
KO - knockout 
L/Leu – Leucine 
LARG – leukaemia associated Rho-GEF 
LIMK – LIM kinase 
LiOAc - Lithium acetate 
MAGUK - membrane associated gyanylate kinases 
mDia – mammalian diaphanous 
MLL - mixed-lineage leukaemia protein 
MLP – muscle lim protein 
MLV – mouse leukaemia virus 
MRTF – myocardin-related transcription factor 
mRNA – messenger RNA 




N – Asparagine 
NLS – nuclear localisation signal 
NP - nonyl phenoxypolyethoxylethanol 
NRAP – nebulin-related anchoring protein 
NRC – neonatal rat cardiomyocyte 
N-terminus – amino terminus 
ORF – open reading frame 
P – proline 
PAGE – polyacrylamide gel electrophoresis 
PAK - p21-activated kinase 
PBD – PAK binding domain 
PBS – phosphate buffered saline 
PCR – polymerase chain reaction 
PFA – paraformaldehyde 
PK – protein kinase 
PKGI - cyclic GMP-dependent protein kinase I 
PLZF - promyelocytic leukaemia zinc finger protein 
PRKCBP - with protein kinase C binding protein 
PVA - polyvinylalcohol 
qRT-PCR – quantitative real-time polymerase chain reaction 
R - Arginine 
RNA – ribonucleic acid 
ROCK – Rho associated protein kinase 
RT – reverse transcriptase 
S/Ser – Serine 
SDS – sodium dodecyl sulphate 
SFK – Src family kinase 
SH – Src homology 
shRNA – small hairpin RNA 
siRNA – short interfering RNA 
SKA – skeletal muscle actin 
SMA – smooth muscle actin 
SMC – smooth muscle cell 




SOX – SRY-box 
SR – super repeat  
SRE – serum response element 
SRF – serum response factor 
SRY - sex determining region Y 
SV40 - Simian vacuolating virus 40 
T/Thr - Threonine 
TA – tibialis anterior 
TE – Tris/EDTA 
Tn – troponin 
UAS - upstream activations sequences 
UTR – untranslated region 
V – Valine 
VSMC – vascular smooth muscle cells 
W/Trp – Tryptophan 
WASP - Wiskott-Aldrich syndrome protein 
WH2 – WASP homology 2 domain 
WISH – WASP interacting SH3-domain protein 
WISH/DIP1 - WASP-interacting SH3-domain protein/diaphanous-interacting protein 1 
WT – wild type 
XRCC - X-ray repair complementing defective repair in Chinese hamster cells 














































Cellular movement is brought on by the interaction between actin and myosin.  Acto-
myosin mediated contractions form the basis of many important cellular events, such as 
cell polarisation and migration (Lammermann and Sixt 2009; Mseka et al. 2009).  This 
interaction is also crucial in mediating muscle contraction.  In striated muscle, actin and 
myosin are arranged in a highly ordered manner as myofibrils (Dwyer et al. 2012).  The 
basic repeating contractile unit of a myofibril is referred to as the sarcomere.  A 
sarcomere is defined as the area between two Z-disks, the lateral borders of a single 
sarcomere (Figure 1.1).  The Z-disks anchor the actin (thin) filaments while the myosin 
(thick) filaments emanate from the centre of the sarcomere (Huxley 1953; Koubassova 
and Tsaturyan 2011).  Some of the earliest work on muscle used X-ray diffraction 
studies and electron microscopy to resolve this highly specialised arrangement of thick 
and thin filaments (Huxley and Perutz 1951; Hanson and Huxley 1953).   Muscle was 
topologically divided into two sections (Figure 1.1).  The lighter sections near the Z-
disks were referred to as the I (isotropic) zones and were found to contain only thin 
filaments.  A darker region near the centre of the sarcomere was referred to as the A 
(anisotropic) zone and was found to contain a mixture of both thick and thin filaments.  
Additionally, another lighter zone was found in the very centre of the sarcomere (the H 
zone) and was composed only of thick filaments (Huxley and Niedergerke 1954; 
Huxley and Hanson 1954).  Muscle contraction was subsequently found to be mediated 
by the sliding of thin filaments past the thick filaments, and that this was powered by 
ATP hydrolysis due to the intrinsic ATPase activity of myosin (Hanson and Huxley 
1953).  With the advent of more advanced techniques, such as fluorescence microscopy, 
our understanding of the precise molecular events governing muscle contraction as well 

































Figure 1.1: Major Regions of Striated Muscle Sarcomeres.  Electron micrograph from adult 
mouse hearts with some of the major sarcomeric demarcations resolved and labelled.  The 
borders of the sarcomere are the Z-disks (Z) whereas the M-band is visualised in the middle 
(M).  The light isotropic (I) zones are visualised on either side of the Z-disks and correspond to 
the thin (actin) filaments.  The darker staining anisotropic (A) zone is visualised either side of 
the M-band and contains a mixture of thin and thick (myosin) filaments.  The H zone (H) is 
seen proximal to either side of the M-band as a region lighter than the A-zone and contains 





1.1.1 Smooth Muscle 
  
Muscle is divided into two major groups: smooth muscle and striated muscle.  Smooth 
muscle cells (SMCs) make up the majority of the vasculature, the gastrointestinal, and 
the urogenitary tract (Figure 1.2 A).  Control of smooth muscle is involuntary and is 
mediated by the autonomic nervous system and hormonal triggers (Webb 2003).  The 
organisation and regulation of the myofilaments in smooth muscle differs substantially 
from that seen in striated muscle, although the basic contractile mechanism is conserved 
in all three muscle types.  In smooth muscle, actin filaments are arranged as hexagonal 
arrays that form cable like bundles, with the myosin filaments interspersed around the 
actin filaments (Gabella 1984; Gunst and Tang 2000; Webb 2003).  This results in an 
oblique arrangement of filaments that form a lattice like network throughout cells.  A 
third network of intermediate filaments associate with the actin filaments, are involved 
in regulating cell shape and force transmission (Small and Gimona 1998) and include 
desmin (Paulin and Li 2004) and vimentin (Frank and Warren 1981).  Dense bodies 
serve to anchor thin filaments in the cytoplasm and are rich in proteins such as -actinin 
(Fay et al. 1983), desmin, and vimentin.  The actin filaments are anchored at the 
membrane in regions known as dense plaques.  Dense plaques serve as sites of 
transmission of mechanical force to the extra cellular matrix (ECM) (Figure 1.2 B).  
Mechanical coupling between neighbouring SMCs occurs through attachment plaques 
(Gunst and Tang 2000).  The basic contractile mechanism in smooth muscle relies on 
the actin filaments sliding past the myosin filaments.  Contraction is mediated by Ca
2+
 
specific effects on the myosin filaments which eventually trigger phosphorylation of 
myosin light chain.  The ATPase activity of myosin then results in induction of cross 
bridge cycling (Webb 2003).  Thin filaments are also decorated with caldesmon and 
tropomyosin, which participate in contractile regulation (Marston and Smith 1985).  


















1.1.2 Cardiac Muscle 
 
As mentioned above, striated muscle differs greatly from smooth muscle in appearance 
and regulation.  As their name suggests striated muscles are distinguished by their 
characteristic cross-striated/banded appearance, a feature accounted for by the presence 
of highly ordered sarcomeres (Figure 1.3).  Striated muscle can further be divided into 
two groups: cardiac muscle and skeletal muscle.  The structure of cardiac muscle is 
described below. 
 
Figure 1.2: Smooth Muscle. A) Human vascular smooth muscle cells found in the 
arterial wall lining stained with haematoxylin and eosin.  Figure taken from (Panchenko 
et al. 2009). B)  Schematic of the basic contractile apparatus in a smooth muscle cell.  
Smooth muscle cells are long and spindle shaped.  The thin (actin) filaments are anchored 
at the membrane by dense plaques.  Dense bodies anchor the thin filaments in the 





During embryonic development, the heart becomes the first fully functional organ in 
mammals (Olson and Srivastava 1996).  A myogenic organ derived from the embryonic 
mesoderm, the primary function of the heart is to pump oxygenated blood throughout 
the body.  Cardiac muscle occupies the walls of the heart making up a region known as 
the myocardium.  It is composed of contractile cells, termed cardiomyocytes.  
Cardiomyocytes exist as branched networks of cells containing one or two centrally 
located nuclei (Figure 1.3 A-B).  The coordinated contraction of the cardiomyocytes 
enables the heart to pump blood systemically.  Innervation of cardiac muscle occurs 
involuntarily via the autonomic nervous system.   
 
The contractile apparatus of cardiomyocytes is constituted by actin and myosin 
filaments arranged as myofibrils.  The structural integrity of myofibrils is partly 
determined by an intermediate filament network comprising of desmin, which with the 
aid of proteins like plectin anchors myofibrils at the membrane in sites called 
costameres (Severs 2000; Konieczny et al. 2008).  Costameres are rib-like structures 
rich in vinculin and are responsible for mediating force transmission to the ECM via 
linkages from the Z-disk to the membrane (Samarel 2005).  Neighbouring 
cardiomyocytes are electro-mechanically linked at sites called intercalated disks.  
Within the intercalated disk, cells are electrically coupled by structures called gap 
junctions (Rohr 2004).  Mechanical linkage is made possible by insertion of terminal 
thin filaments into the adherens junction portion of the intercalated disks (Dwyer et al. 
2012).  Cardiomyocytes are also characterised by sarcolemmal membrane invaginations 
above the Z-disks, called t-tubules (Severs 2000).  Like smooth muscle, striated muscle 
requires the presence of Ca
2+
 to initiate contraction of myofilaments.  T-tubules are rich 
in L-type calcium channels which allow for the entry of Ca
2+ 
which further stimulate 
more release of Ca
2+
 from the sarcoplasmic reticulum (SR).  Hence, T-tubules are 
involved in excitation contraction coupling in cardiomyocytes (Beuckelmann and Wier 
1988; Leach et al. 2005; Orchard and Brette 2008).  An incredibly complex cell with a 
number of specialised structures, cardiomyocytes are further stabilised by a vast 
cytoskeletal network (Hein et al. 2000) involving dystrophin (Klietsch et al. 1993) and 
integrins connecting the cytoskeleton to the ECM through the membrane, and other 
intercalated disk proteins like the catenins and cadherins which are involved in coupling 














1.1.3 Skeletal Muscle 
 
Skeletal muscle represents the other type of striated muscle found in vertebrates.  It is 
found throughout the body attached to bones by connective tissue.  Skeletal muscle is 
essential in the way that it allows for the generation of movement.  Unlike cardiac and 
smooth muscle, skeletal muscle is under voluntary control via the peripheral nervous 
system.  Skeletal muscles can be distinguished via a number of classification systems.  
From the most basic standpoint, skeletal muscles are either classed as fast twitch 
muscles or slow twitch muscles.  Fast twitch muscle are often white and utilise 
glycolysis for more specialised motor activities.  On the other hand, slow twitch 
muscles are red in colour due to the presence of myoglobin and utilise oxidative 
enzymes for more sustained motor activity (Schiaffino and Reggiani 2011).  Regardless 
of fibre type, skeletal muscles are composed of myofibres, which are the result of fusion 
Figure 1.3: Striated Muscle. A) Longitudinal heart sections from wild type mice stained 
with haematoxylin and eosin.  Figure taken from (Moza et al. 2007). B) Schematic of the 
ultrastructure of cardiac muscle. C) Longitudinal skeletal muscle sections from wild type 
mice stained with haematoxylin and eosin.  Figure taken from (Ware et al. 2003).  D)  




of many myoblasts which then differentiate into myocytes (Abmayr and Pavlath 2012).  
The resulting myofibres are long and cylindrical in shape with many peripherally 
located nuclei (Figure 1.3 C-D).  Fused cells contract in syncytium to produce force. 
 
The basic organisation of a skeletal muscle myocyte is similar to that seen in 
cardiomyocytes.  The contractile apparatus is composed of actin and myosin arranged as 
myofibrils.  In skeletal muscle, myofibrils are anchored to the membrane at costameres 
via the Z-disk and the M-band (Pardo et al. 1983).  Like in cardiac muscle, anchorage to 
the membrane via the Z-disk primarily occurs via the intermediate filament protein 
desmin (Granger and Lazarides 1979; O'Neill et al. 2002).  This is also mediated via the 
skeletal muscle specific protein nebulin, which has been suggested to associate with 
desmin (Costa et al. 2004; Tonino et al. 2010).  Dystrophin, a member of the spectrin 
superfamily, plays a particularly important role in stabilising the sarcomeric 
cytoskeleton in skeletal muscle (Ahn and Kunkel 1993).  Dystrophin localises to the 
cytoplasmic face of the sarcolemma (Minetti et al. 1992) and has been found to be 
especially relevant in stabilising the M-band (Porter et al. 1992; Williams and Bloch 
1999).  One difference between skeletal and cardiac muscle is the location of the t-
tubule system.  In a skeletal muscle myocyte, the t-tubule system can be found above 
the A/I junction (Dwyer et al. 2012).  Skeletal muscle myocytes also lack intercalated 
disks and instead have intercellular junctions as well as myotendinous junctions.  
Although skeletal and cardiac muscle may differ slightly in their ultrastructural 
organisation, the layout of their sarcomeres and the regulation of their contractile 
mechanism remain very similar. 
 
1.1.4 Contractile Mechanism of Striated Muscle 
 
Contraction of striated muscle is a markedly different process to that seen in smooth 
muscle.  Although the process is Ca
2+
 dependent, it is the thin filaments rather than the 
thick filaments which are Ca
2+
 sensitive (Gordon et al. 1997).  Ca
2+ 
acts on the troponin-
tropomyosin complex of thin filaments by binding troponin-C (TnC) (Poole et al. 2006).  
This leads to a conformational change of the troponin-tropomyosin complex resulting in 
the exposure of the myosin binding sites on actin, allowing the association of myosin 




reversibly bind two actin molecules and drive the sliding of the thin and thick filaments 
past each other, promoted by the energy produced due to the intrinsic ATPase activity 
of myosin (Lorenz and Holmes 2010).  During contraction, the thick filaments remain 
centrally located within the context of the sarcomere and mediate shortening of the thin 
filaments along the horizontal axis of the sarcomere.  Overall, contractile force in 
striated muscle requires the interaction between the thin actin filaments and the thick 




1.2 The Sarcomere 
 
The basic repeating contractile unit of muscle is the sarcomere, a highly complex 
multiprotein assembly and defined as the area in between two Z-disks (Figure 1.4). The 
Z-disk anchors the thin (actin) filaments of the sarcomere.  The length of the thin 
filaments to both sides of the Z-disk is now commonly referred to as the I-band.  In the 
centre of each sarcomere is the M-band, which serves for tightly packing and anchoring 
the thick filaments, composed of myosin molecules (Auerbach et al. 1999; Boateng and 
Goldspink 2008; Ehler and Gautel 2008; Sanger and Sanger 2008).  The length of the 
region containing thick filaments on either side of the M-band is referred to as the A-
band.  Each part of the sarcomere plays an integral role in maintaining stability and 














Figure 1.4: The Sarcomere.  Schematic 
representation of the sarcomere and some of its 
more notable features.  The major demarcations 
are shown and include the Z-disk, I-band, A-band, 
and M-band. The Z-disks represent the lateral 
borders of the sarcomere.  The I-bands refer to the 
lengths of the thin filaments on either side of the 
Z-disks.  The M-band represents the centre of the 
sarcomere.  The A-band represents the length of 
the thick filaments on either side of the M-band.  
Thin filaments (actin) are depicted in red with 
some of the most relevant accessory proteins, such 
as tropomyosin and the troponin complex. Thick 
filaments (myosin) are depicted in dark green. The 
barbed, or growing, end of actin is capped by 
CapZ (light green) and is anchored at the Zdisk. 
The Z-disk is partly comprised of sarcomeric -
actinin (dark blue).  The pointed, slow growing, 
end of actin is capped by tropomodulin (light blue) 
and faces towards the centre of each sarcomere.  
The M-band of the sarcomere is party comprised 
of myomesin and M-protein (grey).  Titin, a giant 
elastic protein is shown in pink.  Refer to Figure 





1.2.1 The Z-disk 
 
The sarcomere is best delineated by focusing on some of the major proteins that 
determine its structure.  The primary component of the Z-disk is -actinin, a member of 
the actin binding spectrin family of proteins (Figure 1.4).  -actinin plays an important 
structural role within the topology of the sarcomere (Sjoblom et al. 2008).  The most 
notable function of -actinin is the anchorage of thin filaments via their barbed end.  
This occurs partly through the interaction between -actinin and CapZ, which stabilises 
the barbed end of thin filaments (Papa et al. 1999).  -actinin also arranges thin 
filaments into cross linked arrays via its actin binding domain (ABD).  This occurs 
through -actinin forming symmetric anti-parallel homodimers along its length, thus 
exposing the ABDs at the ends of the rod domain (Djinovic-Carugo et al. 1999).  The 
resulting network of -actinin at the borders of the sarcomere resemble a lattice like 
basket weave structure, although this depends on the type of contraction exhibited on 
muscle (Goldstein et al. 1986), and with variable thickness depending on the type of 
striated muscle (Luther 2009).  The Z-disks therefore serve mainly as a site for thin 
filaments anchorage. 
 
1.2.2 The M-band 
 
The M-band is situated in the centre of the sarcomere and contains a number of proteins 
that determine the structure and stability of the thick filaments (Figure 1.4).  Some of 
the notable proteins include myomesin (Grove et al. 1984; Bähler et al. 1985; Auerbach 
et al. 1999), M-protein (Masaki and Takaiti 1974; Bähler et al. 1985), and the 
myomesin splice variant EH-myomesin (Price 1987; Price and Gomer 1993; Steiner et 
al. 1999; Agarkova et al. 2000).  Particular attention has been placed on myomesin as a 
crucial determinant of M-band regulation.  Myomesin is a member of the 
immunoglobulin superfamily (Bantle et al. 1996) and contains many immunoglobulin-
like and fibronectin type III domains (Auerbach et al. 1999).  Myomesin has also been 
found to be expressed in all the examined types of vertebrate striated muscle (Agarkova 
et al. 2000).  One of the main proposed roles of myomesin is the incorporation of the 




via its C-terminal domain through dimerisation with its last domain (Lange et al. 2005).  
The thick filaments are accordingly incorporated by binding of myosin to the N-
terminus of myomesin (Obermann et al. 1997).  Thus, the M-band serves primarily as a 




Another notable component of the sarcomere is the giant protein titin (Figure 1.4).  
Titin, a very large protein with a molecular weight of 3000 kDa, makes up the third 
elastic filament system of sarcomeres.  Titin spans the length of half a sarcomere, from 
the Z-disk to the M-band (Granzier and Labeit 2004).  Titin has a number of proposed 
roles.  It has been suggested that titin provides a template for sarcomere length 
(Agarkova and Perriard 2005).  Additionally, titin plays a role in the integration of both 
thick (Agarkova and Perriard 2005; Lange et al. 2005) and thin filament (Kulke et al. 
2001; Luther 2009) networks into the frame of the sarcomere.  The N-terminus of titin 
binds capZ and -actinin at the Z-disks and is cross linked in the thin filament system.  
The C-terminal end of titin extends into the region of the M-band where it binds 
myosin.  It additionally binds myosin binding protein C (MyBP-C), another important 
component of the thick filaments (Fürst et al. 1988; Labeit et al. 1992).  A number of 
other roles have been proposed for titin, such as the protein acting as an elastic 
molecular spring during sarcomeric stretching (Labeit and Kolmerer 1995), a blueprint 
for sarcomere assembly (Trinick 1994), and as a signalling hub for mechanosensing 
(Gautel 2011).  A multitude of proteins make up the sarcomere and many more proteins 
are continuously being revealed.  This paints a complex picture of a highly dynamic 
structure that was once viewed as static.  
1.3 Actin  
 
Actin is a ~42kDa protein that is ubiquitously expressed and conserved throughout 
eukaryotic evolution.  The actin monomer consists of 375 residues which are the same 
in human and chicken and differ minimally in yeast (Luther 2009).  In humans, actin 
exists as 6 isoforms which derive from the same ancestral gene.  The actin isoforms are 




α-cardiac muscle actin (α-CAA), α-smooth muscle actin (α-SMA), γ-smooth muscle 
actin (γ-SMA), β-cytoplasmic actin (β-CYA), and γ-cytoplasmic actin (γ-CYA).  Actin 
isoforms exhibit tissue and cell-type specific expression as well as being 
developmentally regulated (Tondeleir et al. 2009). 
 
Actin is polymerised into microfilaments, so named for having the smallest diameter 
compared to the other filament types, which make up the majority of the cytoskeleton in 
most cell types.  The cytoskeleton is a complex three dimensional network of 
microfilaments, intermediate filaments, microtubules, and accessory proteins. It 
represents a crucial feature of cytoarchitecture as it mediates functions ranging from 
stability to motility. The dynamic nature of the cytoskeleton dictates that it must be able 
to rearrange and form discrete structures. This is crucial in order to fulfil a variety of 
physiologically relevant processes such as wound healing, morphogenesis, and muscle 
contraction (Naumanen et al. 2008).  
 
1.3.1 Actin Polymerisation 
 
Formation of actin filaments occurs through polymerisation (Figure 1.5).  Monomeric, 
or globular (G) actin is polymerised into helical, or filamentous (F) actin by virtue of its 
ATP binding activity.  G-actin can bind ATP in its ATP binding cleft in a 1:1 complex 
allowing a conformational change to take place so that it may be added to other 
monomers to create F-actin.  The intrinsic ATPase activity of actin allows hydrolysis of 
ATP to ADP and subsequent dissociation of monomers to replenish the available pool 
of G-actin (Carlier and Pantaloni 1986).  ATP is hydrolysed to ADP with a half time of 
2sec (Blanchoin and Pollard 2002) whereas inorganic phosphate dissociates more 
slowly with a half time of 6min (Melki et al. 1996; Pollard 2007).  The growing end of 
an actin filament is known as the barbed (+) end, whereas monomers are lost at the 
pointed (-) end.   Although monomers can be added to and lost at both ends of a 
filament, in vitro kinetic studies have shown that filament growth is greatly favoured 
over loss since monomer addition is 5-10 times faster at the barbed end (Pollard et al. 
2000; Chhabra and Higgs 2007).  Continuous cycles of monomer addition and loss 
allow for a steady state treadmilling effect to be reached to create motile force (Pollard 




vivo.  Nucleation is the rate limiting step of polymerisation (Chesarone and Goode 
2009).  Initial nucleation of filaments is very unfavourable and the majority of the 
cytosolic pool of G-actin is sequestered by profilin, further preventing spontaneous 
nucleation (Kaiser et al. 1999; Kovar 2006; Chhabra and Higgs 2007).  Thus, there are a 
variety of mechanisms that regulate actin dynamics at the level of filament nucleation, 
elongation, stabilisation, as well as there being a vast number of determinants dictating 
the actin structures being formed.  In other words, the presence of other regulatory and 
accessory proteins determine the kind of actin-based structure that is formed (Chhabra 

















Figure 1.5: The Polymerisation of Actin.  A schematic representation of the basic steps involved in the 
polymerisation of G-actin into F-actin. A) G-actin is not capable of being polymerised until it has bound ATP. B) 
ATP-bound G-actin begin to form stable trimers during initial nucleation. C) After the initially slow nucleation step, 
elongation takes place with ATP-bound G-actin monomers rapidly associating with the growing (+) end of F-actin 
filaments. Actin slowly hydrolyses ATP to ADP and dissociates upon doing so. Loss of G-actin takes place at the 







1.3.2 Thin Filaments 
 
As mentioned above, within the context of muscle, polymerised actin filaments are 
referred to as thin filaments (Figure 1.6).  Thin filaments are not only made of actin but 
a variety of other proteins that regulate the length and stability of the filaments.  Thin 
filaments do not exist in a treadmilling state, but rather represent microfilaments that 
have been stabilised by a number of proteins.  The pointed ends of thin filaments are 
bound by tropomodulin (Fowler et al. 1993; Gregorio et al. 1995).  Tropomodulin 
capping blocks elongation and depolymerisation at the barbed ends but requires the 
presence of tropomyosin to do so (Weber et al. 1994).  The actin nucleating protein 
leiomodin has also been shown to regulate thin filaments at their pointed ends in a 
tropomyosin dependent manner (Chereau et al. 2008; Skwarek-Maruszewska et al. 
2010).  At the other end of the thin filaments, CapZ seems to be the major capping 
protein and binds with high affinity thus preventing further polymerisation and 
depolymerisation (Caldwell et al. 1989).  CapZ also reportedly interacts with nebulin to 
form a structural link between thin filaments (Pappas et al. 2008).  Nebulin is a giant 
protein, only found in skeletal muscle, that spans almost the entire length of the thin 
filaments but stops just short of the pointed end (Wang and Williamson 1980; Castillo 
et al. 2009).  Initially thought to participate in myofibrillogenesis and to determine thin 
filament length, it is more likely that nebulin is involved in myofibrillar maintenance 
(Bang et al. 2006) and stabilisation of the thin filament core (Littlefield and Fowler 
2008).  The equivalent of nebulin in cardiac muscle is nebulette, a significantly smaller 
member of the nebulin family.  Nebulette also plays a role maintaining thin filament 
stability since disruption of nebulette expression resulted in reduced thin filament length 
in cardiomyocytes (Moncman and Wang 2002; Pappas et al. 2011).  Although a number 
of proteins have been implicated in regulating thin filament function, the polymerisation 



















1.4 Regulation of Actin Polymerisation  
 
The polymerisation of actin is difficult for a number of reasons.  Apart from 
spontaneous actin nucleation being a thermodynamically unfavourable process requiring 
energy, it has also been found that nucleation cores of actin dimers and trimers are 
unstable (Sept and McCammon 2001; Paul and Pollard 2009).  Processes involving 
actin polymerisation require rapid and effective bursts at specific sites (Chesarone and 
Goode 2009).  The existence of multiple nucleation and elongation factors allows the 
polymerisation of actin to be carefully regulated.  A varied cellular milieu of actin 
interacting proteins allows the formation of different actin-based structures, such as 
lamellipodia, filopodia, and pseudopodia to be possible.  Nucleation factors promote the 
formation of a filament and can initiate this from the pool of profilin-actin.  They 
essentially regulate the timing of filament formation.  Elongation factors move with the 
barbed ends of filaments and protect them from inactivating capping proteins.  These 
factors control the extent of filament growth (Chesarone and Goode 2009). 
 
 
Figure 1.6: The Thin Filaments of Striated Muscle.  A schematic representation of a thin 
filament that is found in striated muscle.  Thin filaments are made of polymerised actin.  The 
barbed ends of thin filaments are capped by CapZ and the pointed ends are capped by 
tropomodulin to prevent any addition or loss of monomers.  Thin filaments are also 
decorated with the troponin complex (troponin I, C, and T) and tropomyosin, which 






1.4.1 Arp2/3  
 
The first nucleation factor to be identified was the Arp2/3 complex (Figure 1.7 A).  The 
Arp2/3 complex is a multiprotein assembly that nucleates pre-existing actin filaments at 
a 70˚ angle to promote the outgrowth of a new daughter filament (Machesky et al. 1994) 
and can also cross-link actin filaments (Mullins et al. 1998).   The Arp2/3 complex is 
comprised of two actin related proteins (Arp2 and 3) and 5 regulatory subunits: ARPC1 
(40-kDa subunit); ARPC2 (35-kDa subunit); ARPC3 (21-kDa subunit); ARPC4 (20-
kDa subunit); and ARPC5 (16-kDa subunit) (Pollard 2007).  Arp2/3 forms a nucleation 
core by structurally mimicking G-actin monomers (Chesarone and Goode 2009).   
Microscopy has shown that Arp2/3 remains associated with the pointed end of actin 
filaments.  Arp2/3 inhibits monomer addition and loss at the pointed and increases 
polymerisation at the barbed end (Mullins et al. 1998).  Therefore, by binding, 
stabilising, and inhibiting the loss of actin monomers, the Arp2/3 complex promotes the 
formation of branched actin filament networks.  Branched networks are crucial for the 
formation of lamellipodia in cell migration (Naumanen et al. 2008).  Dendritic networks 
based on Arp2/3 nucleation are also essential for the formation of focal adhesions.  The 
highly specialised nature of Arp2/3 is really made apparent by the fact that the 70˚ 
outgrowth of daughter filaments maximises the potential for membrane protrusions 

















1.4.2 Other Actin Regulatory Proteins 
 
Another more recently described actin nucleator is leiomodin (Chereau et al. 2008).  
Leiomodin is similar in structure to tropomodulin and contains a Wiskott-Aldrich 
syndrome protein (WASP) homology 2 (WH2) domain (Qualmann and Kessels 2009).  
Leiomodin is expressed as both a smooth muscle isoform and a striated muscle isoform, 
that is exclusively present in foetal and adult heart and adult skeletal muscle (Conley 
2001; Conley et al. 2001).  Leiomodin was found to be a strong nucleator of thin 
filaments in muscle cells as well as being integral in mediating sarcomeric maintenance 
(Chereau et al. 2008).   It was also found to antagonise the effects of tropomodulin in 
regulating the lengths of thin filaments (Tsukada et al. 2010).  Other notable proteins 
that regulate actin polymerisation include spire (Schuldt 2005; Sitar et al. 2011), N-
Figure 1.7: Actin Polymerisation: Arp2/3 versus Formins. Schematic diagram depicting 
actin polymerisation by Arp2/3 and formins as well as the structures they localise to. A) The 
Arp2/3 complex mediates the formation of dendritically branched actin filaments. It binds to 
the side of a pre-existing filament and nucleates a new daughter filament at a 70˚ angle from 
the mother filament. These structures are typically seen in the formation of lamellipodia. B) 
Formins polymerise actin into linear unbranched structures. They remain processively 
associated with the barbed end of filaments. These structures are essential in the formation of 





WASP (Martinez-Quiles et al. 2001; Takano et al. 2010), and cordon bleu (Qualmann 
and Kessels 2009; Husson et al. 2011). 
 
1.5 Other Mechanisms of Actin Regulation 
 
While actin filament formation occurs through nucleation and elongation, a number of 
other processes exist that regulate actin filaments.  As mentioned above, profilin serves 
to sequester G-actin monomers to prevent spontaneous polymerisation. Profilin 
represents a major actin binding protein and also serves to facilitate actin polymerisation 
(Figure 1.8 A), particularly in the presence of assembly factors, by catalysing the 
conversion of ADP-actin to ATP-actin. Other actin binding proteins participate in the 
regulation of actin filaments at the level of capping (Figure 1.8 B), disassembly (Figure 
















1.5.1 Actin Capping 
 
Actin capping proteins bind the ends of actin filaments and play roles in the stabilisation 
of filaments, prevention of filament disassembly, and regulation of filament length.  
Capping proteins either bind the pointed end or barbed end of actin filaments in order to 
prevent actin monomer addition or dissociation (Figure 1.8 B). 
The best characterised group of pointed end capping proteins is the tropomodulin family 
(Tmod 1-4).  There have been four mammalian tropomodulin described, as well as three 
Figure 1.8: Other Mechanisms of Actin Regulation. A) Profilin serves to sequester G-
actin monomers to prevent spontaneous assembly but can also facilitate polymerisation by 
catalysing the exchange for ADP to ATP in actin. Apart from nucleation and elongation, 
actin filaments are regulated via other mechanisms, such as capping, severing/disassembly, 
and cross-linking. B) An actin filament capped at its (+) end by CapZ/CP and capped at its (-
) end by tropomodulin. C) Actin filaments can undergo severing by cofilin. The resulting 
actin rods/bundles can serve for further elongation or can undergo disassembly upon 
association of AIP1. D) Actin filaments can be tightly packed into parallel bundles by -
actinin. E) Actin filaments can be cross-linked into orthogonal networks. (+), barbed end; (-





larger variants termed the leiomodins (Lmod 1-3) (Yamashiro et al. 2012).  
Tropomodulins have been shown to bind both tropomyosin and actin at the ends of actin 
filaments in order to prevent elongation or depolymerisation (Weber et al. 1994).  
Furthermore, the presence of tropomyosin influences the strength of binding to the actin 
filament pointed end.  In actin filaments lacking tropomyosin, Tmod1 was shown to be 
a leaky capper, in that actin monomer addition and dissociation was reduced but not 
completely blocked.  However, the presence of tropomyosin on thin filaments resulted 
in tighter capping activity of Tmod1.  Tropomodulins thus possess both tropomyosin-
independent and tropomyosin-dependent mechanisms of pointed end capping (Figure 
1.8 B).  Tropomyosin-independent pointed end capping is thought to predominantly 
occur through binding of actin via the C-terminal LRR-Cap domain on tropomodulin 
(Fowler et al. 2003; Yamashiro et al. 2012).  On the other hand, tropomyosin-dependent 
binding occurs through binding to both tropomyosin and actin via the N-terminal TM-
Cap domain on tropomodulin, with two binding sites on tropomyosin and two binding 
sites on actin proposed. The physiological relevance of the tropomodulins has been 
highlighted in mouse knockout studies. Global Tmod1 knockouts have been reported to 
exhibit aberrant cardiac myofibril assembly, aborted cardiac morphogenesis, and 
embryonic lethality by E9.5 (Fritz-Six et al. 2003; Ochala et al. 2014), 
 
Actin capping activity is not solely restricted to the tropomodulins (or pointed end 
capping for that matter).  Another notable actin capping protein is Capping Protein 
(CP), aptly named for its ability to prevent growth of actin filaments from the barbed 
end (Figure 1.8 B) (Cooper and Sept 2008).  Furthermore, CP is involved in the 
tethering of actin filaments (Bearer 1991). CP participates in the formation of Arp2/3-
driven dendritic networks in vitro (Nicholson-Dykstra et al. 2005) and in cultured cells 
(Mejillano et al. 2004).  Studies performed in vivo also indicated that CP plays roles in 
morphogenesis and differentiation.  CP is also expressed in striated muscle, where it is 
referred to as CapZ (Figure 1.6), by virtue of its localization to the Z-disks. Notably, 
one molecule of CapZ is required to bind the barbed end of an actin filament (Schafer et 
al. 1993; Cooper and Sept 2008).  In the context of striated muscle, CapZ is thought to 
function by anchoring actin filaments to the Z-disk and/or preventing aberrant growth of 
actin filaments into adjacent sarcomeres. As mentioned above, CapZ seems to require 
an interaction with nebulin in order to preserve the structural link between adjacent 




expression of assembled CapZ and results in misalignment of the barbed ends of actin 
filaments (Pappas et al. 2008). The role of CapZ in the maintenance of filament stability 
could also remain central to its function since CapZ was shown to prevent disassembly 
of actin filaments in the presence of cofilin, coronin, and Aip1 in single filament studies 
(Kueh et al. 2008). 
1.5.2 Actin Disassembly 
 
While actin capping primarily serves to stabilise filaments by preventing further 
elongation or disassembly, factors that promote disassembly of actin filaments are 
required to rapidly replenish the available pool of monomeric G-actin that are needed 
during instances of the dynamic treadmilling events that are required to promote 
protrusive movement of filaments (Kueh et al. 2008; Brieher 2013). Actin disassembly 
factors therefore contribute significantly to the highly dynamic nature of actin filaments 
and the cytoskeleton. A number of mechanisms of actin disassembly have been 
proposed, including the following: induction of loss of G-actin monomers from the 
filament pointed due ATP hydrolysis; severing of actin filaments; induction of loss of 
G-actin monomers from the barbed end in a process referred to as dynamic instability 
and promotion of whole filament destabilisation (Kueh et al. 2008; Brieher 2013). 
Notable factors involved in actin disassembly include gelsolin and actin depolymerising 
factor (ADF)/cofilin. 
 
Gelsolin acts on actin by severing actin filaments in two and by capping the growing 
barbed end in a Ca
2+
-dependent process (Kwiatkowski 1999). There are at least six 
other members of the gelsolin family that may play distinct roles in a number of cellular 
processes: villin, adseverin, capG, advillin, supervillin and flightless I (Silacci et al. 
2004). Interestingly, the initially discovered gelsolin protein exists as both cytoplasmic 
and plasma isoforms. Gelsolin binds and severs actin filaments in the presence of 
calcium and remains bound to the barbed end of the resulting actin filament. Uncapping 
occurs through gelsolin binding phosphatidylinositol lipids (Silacci et al. 2004). 
Gelsolin has been reported to play roles in the regulation of cell motility. Studies using 
homozygous gelsolin knockout mice revealed that this protein was required for 
retraction processes but not for filopodial formation in neuronal growth cones (Lu et al. 




with gelsolin indicated that this actin disassembly factor enhanced cell migration by 
increasing the rate at which cells migrated through a porous filter (Cunningham et al. 
1991; Silacci et al. 2004). The importance of actin severing in the regulation of 
processes requiring actin has been further highlighted by the fact that gelsolin is 
involved in processes including phagocytosis (Witke et al. 2001), apoptosis (Kothakota 
et al. 1997), and tissue morphogenesis (Crowley et al. 2000). 
 
ADF/Cofilin is another well-studied family of actin disassembly factors. Cofilin, one of 
the more notable members of this family, preferentially binds ADP-actin to promote 
severing (Figure 1.8 B) of actin filaments or depolymerisation of actin filaments from 
the pointed ends. One mechanism by which this occurs could be by coupling ATP 
hydrolysis to filament turnover, therefore increasing the rate of monomer dissociation 
from the pointed end (Carlier et al. 1997; Kueh et al. 2008). However, cofilin’s ability 
to promote depolymerisation of filament pointed ends is a subject of dispute (Bravo-
Cordero et al. 2013); therefore its severing activity is the subject of primary focus. 
Cofilin’s actions on actin are dependent on the concentration ratio of cofilin to actin. 
When the concentration of actin is higher than that of cofilin, cofilin has been shown to 
continuously sever actin filaments, as has been demonstrated in vitro (Andrianantoandro 
and Pollard 2006; Bamburg and Bernstein 2010). Under such instances of persistent 
severing, severed portions of filaments can be further elongated via their newly created 
barbed ends. Furthermore, G-actin monomers sequestered by cofilin serve to replenish 
the pool of available G-actin for further elongation once subunits are exchanged for 
profilin. In situations where the concentration of cofilin is higher than that of actin, 
cofilin will rapidly but not persistently sever actin filaments while remaining bound to 
actin, resulting in the generation of actin bundles/rods (Andrianantoandro and Pollard 
2006; Bamburg and Bernstein 2010). Actin bundles can either be further elongated or 
can be depolymerised in the presence of actin interacting protein 1 (AIP1) to replenish 
the available pool of G-actin monomers (Figure 1.8 C). While in vitro work has shed 
light onto the mechanisms of filament depolymerisation, factors involved in actin 
disassembly have been found to play important roles in vivo. One study used transgenic 
mice, in which conditional knockout of ADF and cofilin were performed in the nervous 
system. ADF and cofilin depletion resulted in blockade of F-actin retrograde flow and 
irregular microtubule growth, two factors which contributed to failure of neuritogenesis 




birth by day 8 and are partly characterised by disrupted sarcomere architecture and 
accumulation of F-actin in skeletal muscle. These anomalies arose by postnatal day 7, 
thus indicating that cofilin-2 plays a role in myofibrillar maintenance rather than 
myogenesis (Agrawal et al. 2012). 
1.5.3 Actin Cross-Linking 
 
Actin cross-linking proteins are involved in the construction of the molecular scaffolds 
required for processes ranging from cellular motility to adhesion. Actin cross-linking 
proteins can link the actin cytoskeleton to extracellular matrix proteins (e.g., ankyrin, 
laminin and dystroglycan (Lee and Dominguez 2010)) and can also contribute to the 
formation of cross-linked or bundled networks of F-actin found in structures such as 
stress fibres (Wang 1984) and dorsal arcs (Heath 1981), among others (Tseng et al. 
2005; Lee and Dominguez 2010). Generally speaking, actin cross-linking proteins tend 
to function as dimers and bind actin via multiple binding sites, the locations of which 
partly determine the actin network formed (Stevenson et al. 2012). Furthermore, smaller 
actin cross-linking proteins tend to contribute to the organization of F-actin into parallel 
bundles. Larger actin cross-linking proteins, on the other hand, tend to exhibit more 
complex behaviour in that their effects are concentration specific. Larger actin cross-
linking proteins tend to organise actin filaments into networks or gels at lower cross-
linking protein concentrations and they organize actin filaments into bundled networks 
or composite networks (a mixture of cross-linked and bundled actin filament networks) 
at higher cross-linking protein concentrations (Lieleg et al. 2010). 
 
Actin cross-linking proteins that promote the formation of actin bundles, in which actin 
filaments are aligned along their axes by the same polarity and are tightly packed 
(Bartles 2000) include notable actin bundling proteins such as fascin (Jansen et al. 
2011) and -actinin (Broderick and Winder 2005). -actinin, a member of the spectrin 
family of proteins, represents the archetypal actin bundling protein. In vitro studies have 
indicated that -actinin organises actin into loose networks at low concentrations of -
actinin to actin. At higher concentrations of -actinin to actin, -actinin organises actin 
filaments into tight bundles (Figure 1.8 D) (Tseng and Wirtz 2001; Tseng et al. 2005). 
Apart from the actin-crosslinking activity that it possesses in the sarcomere, -actinin 




actin filaments that usually interact with myosin II motors (Pellegrin and Mellor 2007; 
Naumanen et al. 2008). They create contractile force and are responsible for processes 
such as the stabilisation of the trailing edge of cells during migration and for contracting 
the rear end of the cell. Studies have indicated that -actinin often plays an 
indispensable role in the formation of stress fibres. In U2OS human osteosarcoma cells, 
partial knockdown of -actinin-1, one of the major non-muscle -actinin isoforms, with 
short hairpin RNA (shRNA) resulted in reduced formation of radial stress fibres (Oakes 
et al. 2012). Similarly, U2OS cells depleted of -actinin-1 displayed reduced formation 
of dorsal stress fibres (Kovac et al. 2013). 
 
The filamin family of proteins has also been highlighted as important actin binding 
proteins. Filamin-A is the most abundant and widely expressed member of the filamin 
family and notably cross-links cortical actin filaments into three-dimensional orthogonal 
networks (Figure 1.8 E). This is mediated through the N-terminal actin binding domain 
on filamin-A and binding of filamin-A to actin at large angles (Yue et al. 2013). The 
filamin proteins have proposed roles in cell migration as has been indicated in a number 
of studies. For example, knockdown of filamin-A and B in Jurkat cells impaired the 
initiation of cell migration (Baldassarre et al. 2009). Mutations of filamin-A have also 
been linked to human diseases such as periventricular heterotopia, an X-linked brain 
malformation (Feng and Walsh 2004). 
 
When examined in a modular fashion, actin binding proteins exhibit individually 
important roles. However, when viewed on a more holistic level and when the 
formation of complex actin-based structures is concerned, one can discern a complex 
interplay of many of the factors and processes described above.  
1.6. Regulation and Dynamics of Actin-based Structures  
 
There are at least 15 types of actin-based structures that have been described in 
metazoan cells. These actin-based structures arise from the polymerisation of G-actin to 
F-actin in a tightly controlled temporal and spatial process to give rise to distinct 
structures. Not only is actin polymerised into the helical filaments, but these filaments 
have the capacity to be further organised into higher order assemblies, giving rise to 




cells, which are far less complex by virtue of the number of actin-based structures they 
possesses as well as their more clearly delineated spatial arrangement, actin-based 
structures in metazoan cells are of numerous kinds and often overlap spatially (Chhabra 
and Higgs 2007). 
 
Actin-based structures that protrude from the plasma membrane can be thought of as 
sheet-like structures or finger-like structures. Sheet-like protrusive actin-based 
structures include lamellipodia, ruffles, phagocytic cups, podosomes, and invadopodia 
(Mattila and Lappalainen 2008). Finger-like protrusive actin-based structures describe 
filopodia and microvilli. The term stress fibre has been broadly adopted to describe 
contractile actin filaments that interact with myosin motors. The multitude of processes 
and actin binding proteins described above converge in a carefully timed manner at 
tightly regulated locations to give rise to higher order actin networks, dynamic motile 







Figure 1.9: Actin-Based 
Structures in Cells. A) 
Lamellipodia are sheet-like 
membrane protrusions formed near 
the leading edge of cells. Their actin 
filament network is of a branched 
nature. Filaments are nucleated by 
the Arp2/3 complex and can be 
further elongated by Ena/Vasp or 
members of the formin family. The 
actin turnover function of proteins 
like cofilin, which resides beneath 
the lamellipodium serve to replenish 
the available pool of G-actin for 
further elongation and can provide 
new filaments for further 
elongation. B) Filopodia are finger-
like projections composed of linear 
actin filaments that are polymerized 
by formins or Ena/Vasp and are 
bundled by fascin. C) An example 
of a ventral stress fibre, the most 
commonly observed type of stress 
fibre. Ventral stress fibres are 
composed of actin filaments 
bundled by –actinin. Myosin II 
motors facilitate the generation of 
contractile force. Ventral stress 
fibres are anchored at each end by 
integrin-rich focal adhesions. (+), 









Lamellipodia are examples of membrane protrusions that form at the leading edge of 
migrating cells (Figure 1.9 A). The lamellipodium is a sheet-like actin-based structure 
that attaches to the extracellular substratum and can occur during crawling cell motility 
and during cell spreading (Vinzenz et al. 2012). The lamellipodium describes the area 
closest to the leading edge of a cell, whereas the larger, less dynamic, and more 
adhesive lamella describes the area behind the lamellipodium, which stretches towards 
the cell body (Delorme et al. 2007). The distribution and nature of the actin filaments 
(as well as the actin binding proteins that regulate them) differ between the 
lamellipodium and the lamella (although some overlap may occur) and is partly 
dependent on the level of tension exerted on the cell. The Arp2/3 complex and cofilin 
primarily associate with the lamellipodium and promote the nucleation/treadmilling of 
F-actin that it required for membrane protrusion to occur (Welch et al. 1997; Svitkina 
and Borisy 1999; Delorme et al. 2007).  The lamella is more typically characterised by 
the presence of proteins involved in contraction, such as myosin II and tropomyosin 
(Ponti et al. 2004; Gupton et al. 2005; Delorme et al. 2007). 
 
The dense actin networks comprising lamellipodial networks are predominantly that of 
an Arp2/3-mediated dendritically branched nature. It is widely accepted that Arp2/3 is 
the predominant actin nucleator of lamellipodial networks in most cells. Furthermore, 
the Arp2/3 complex is a crucial regulator of lamellipodial networks since inhibition of 
Arp2/3 activity has been found to disrupt lamellipodial assembly (Suraneni et al. 2012). 
Actin nucleation and elongation primarily occur in a confined area near the leading edge 
of the cell. While Arp2/3 might be primarily responsible for nucleating filaments and 
promoting branched networks, distinct actin binding proteins have been suggested to 
elongate actin filaments towards the plasma membrane, namely Ena/VASP and 
members of the formin family of proteins (Figure 1.9 A) (Chesarone and Goode 2009). 
Targeted depletion of Ena/VASP and formins in cells has been associated with the 
formation of lamellipodial networks comprised of shorter actin filaments and 
highlighted the importance of these factors for lamellipodial actin dynamics (Bear et al. 




As mentioned above, cofilin localises to the base of the lamellipodium. In this context, 
cofilin is thought to support Arp2/3-mediated nucleation of filaments through the 
creation of newly severed filaments (Figure 1.9). Cofilin is also thought to promote 
retrograde flow of filaments in order for the lamellipodium to expand. In other words, 
the actin severing and depolymerising activities of cofilin provide further substrate (i.e., 
new barbed ends on actin filaments and liberated G-actin monomers) required for the 
polymerisation of actin filaments within lamellipodia. Evidence for this model has come 
from numerous studies (Oser and Condeelis 2009; Bravo-Cordero et al. 2013). One 
study in Ptk1 cells found that activation of cofilin promoted actin turnover in the 
lamellipodia (Delorme et al. 2007). Furthermore, cofilin activation induced widening of 
the lamellipodia, narrowing of the area between the lamella and lamellipodium, and 
inhibited membrane protrusion. These findings would suggest that a balance of cofilin 
activity is required in order for efficient cycles of actin severing and polymerisation to 
occur. Indeed, regulatory mechanisms have been identified that describe the inactivation 
of cofilin at membrane protrusions. For example, phosphorylation of cofilin by LIM 
kinase results in cofilin inactivation in lamellipodia (Oser and Condeelis 2009). Cofilin 
is also negatively regulated by binding of cortactin, although this mechanism appears to 
be specific to invasive protrusions (Bravo-Cordero et al. 2013).  
 
While cofilin regulates the actin meshwork at the base of lamellipodia, capping proteins 
have been found to regulate filaments at the tips of these membrane protrusions. 
Capping is an essential process required for the formation of lamellipodia. For example, 
one study found that CP is required for Arp2/3-mediated actin-based motility  (Loisel et 
al. 1999) and a subsequent study found that depletion of CP resulted in disruption of 
lamellipodial formation in favour of filopodial formation (Mejillano et al. 2004). 
Capping proteins are thought to regulate the extent of filament formation in 
lamellipodia, an effect which can be antagonised by elongation factors. One study found 
that Ena/VASP displaces CP from the barbed ends of actin filaments in order to further 
elongate them (Bear et al. 2002). In this same study, Ena/VASP-mediated actin 
networks were less branched and filaments were longer, suggesting that an interplay 
between elongation factors and capping proteins occurs to regulate the geometry of the 






Filopodia are thin finger-like plasma membrane protrusions that are rich in actin (Figure 
1.9 B). Within filopodial protrusions, actin filaments are organised into parallel bundles, 
with their barbed ends oriented towards the plasma membrane (Chesarone and Goode 
2009). Furthermore, the actin network found within filopodia is characterised by long, 
unbranched actin filaments. The structural and molecular composition of filopodia can 
vary between cell types, but overall, these structures have been found to play roles in 
cellular sensing, cellular migration, and cell-cell interactions (Yang and Svitkina 2011). 
 
Filopodia are formed when actin filaments push against the plasma membrane, leading 
to the formation of protrusions. The participation of elongation factors is crucial in this 
setting, with strong evidence pointing to the contribution to the formin family of 
proteins and Ena/VASP (Figure 1.9 B). For instance, overexpression and knockdown 
studies have implied that the formin mDia2 is required for the formation of filopodia 
(Yang et al. 2007; Block et al. 2008; Chesarone and Goode 2009). Similarly, Ena/VASP 
proteins have been described to be concentrated at filopodial tips and contribute to the 
formation of such structures (Lebrand et al. 2004; Yang and Svitkina 2011). However, 
while these two family of proteins have undisputed and even overlapping roles in 
filopodial formation, their interaction with various actin networks and cross-talk with 
other actin binding proteins may vary according to cell type. Consequently, two main 
models have been proposed for the elongation of filaments in filopodia. In the 
convergent elongation model, the aforementioned elongation factors polymerise actin 
filaments derived from Arp2/3-mediated branched networks found in lamellipodia 
(Svitkina et al. 2003; Mattila and Lappalainen 2008). In the alternative tip nucleation 
model, de novo formation of actin filaments occurs in the filopodial tip and is not 
coupled to an underlying lamelliopodial network (Mattila and Lappalainen 2008). While 
the second model is thought to be primarily driven by formins, the participation of the 
Ena/VASP proteins cannot be dismissed. For example, neuronal cells depleted of 
Ena/VASP were unable to form filopodia, although overexpression of Dia2 was shown 
to rescue filopodial formation (Dent et al. 2007; Mattila and Lappalainen 2008). 
 
Another notable player in filopodial formation is fascin. Metazoan cells express three 




distribution. Fascin is notably overexpressed in a variety of metastatic tumors (Kureishy 
et al. 2002). Regardless of the model of filopodial growth, it is widely accepted that the 
association of fascin with formin or Ena/VASP-induced actin bundles is required for 
completion of filopodial formation (Figure 1.9 B). Fascin cross-links the parallel actin 
filaments in filopodia to form stable, rigid bundles (Mattila and Lappalainen 2008; 
Yang and Svitkina 2011). Fascin binds actin filaments via two major sites, the mutation 
of which results in disrupted filopodial formation (Yang et al. 2013). Furthermore, 
electron microscopy studies have shown that fascin can bundle between 10 and 30 actin 
filaments to form filopodia that are 60-200nm in diameter (Mattila and Lappalainen 
2008). Studies in human keratinocytes would suggest that actin filaments in filopodia 
undergo cycles of elongation, stabilisation, and persistence, which is influenced by 
binding of fascin. For example, levels of fascin are reduced upon regrowth of filopodia 
in order for further elongation of actin filaments to occur (Schafer et al. 2011). 
1.6.3 Stress Fibres 
 
As mentioned previously, stress fibres are bundles of 10-30 actin filaments that 
typically interact with myosin motors and are involved in the generation of contractile 
force in non-muscle cells (Cramer et al. 1997; Pellegrin and Mellor 2007). Stress fibre 
formation is often modulated by Rho family GTPase signalling events (Ridley and Hall 
1992a; Tojkander et al. 2012). Stress fibres are involved in cellular processes including 
the stabilisation of cell shape (Kumar et al. 2006), production of force (Guolla et al. 
2012), and mechanotransduction (Hayakawa et al. 2008; Tojkander et al. 2012). Stress 
fibres are usually cross-linked into bundles by -actinin, although this is not the only 
actin cross-linking protein that has been described at stress fibres. The predominant 
categories of stress fibres that have been well-described are the following: transverse 
arcs, dorsal stress fibres, and ventral stress fibres (Figure 1.9 C).  
 
The different types of stress fibres are distinguished by their subcellular localization, 
association with focal adhesions, dynamics of their actin filaments, and function. 
Transverse arcs form underneath the lamella in protrusive cells (i.e., migrating cells), 
are not tethered on either end by a focal adhesions, and are thought to facilitate 
retrograde movement of actin from the leading edge of to the cell centre, near the 




Mellor 2007). Dorsal stress fibres do not exhibit periodic staining for -actinin and 
myosin, are non-contractile, have uniformly aligned actin filaments in terms of polarity, 
and are attached at one end by a focal adhesion at the base of the cell. The non-tethered 
end of dorsal stress fibres emanates towards the dorsal surface of the cell and often 
terminates into a transverse arc at their proximal ends (Pellegrin and Mellor 2007; 
Naumanen et al. 2008; Tojkander et al. 2012). Dorsal stress fibres play notable roles in 
cell migration, such as contributing to the maturation of adhesion complexes (Vallenius 
2013). Ventral stress fibres (Figure 1.9 C) are the most commonly observed stress fibres 
and mediate the generation of contractile force. This stress fibre type is found on the 
ventral side of the cell (i.e., the base of the cell) and is tethered on both sides by separate 
integrin-rich focal adhesions (Pellegrin and Mellor 2007). While dorsal stress fibres and 
transverse arcs primarily exert their functions at the leading edge of migrating cells, 
ventral stress fibres often play role at the trailing edge, with involvement in tail 
retraction as an example (Pellegrin and Mellor 2007; Tojkander et al. 2012; Vallenius 
2013). 
 
Actin dynamics also differ between stress fibre subsets, especially concerning the steps 
in their assembly (Hotulainen and Lappalainen 2006), although these dynamic events in 
different types of stress fibres can often converge. Actin filaments in transverse arcs are 
thought to be derived primarily from actin filaments found at the leading edge 
(Nemethova et al. 2008), especially Arp2/3-nucleated filaments found in lamellipodia 
(Hotulainen and Lappalainen 2006). Elongated filaments are bound, cross-linked, and 
bundled by –actinin. Bundles of myosin II are subsequently incorporated into nascent 
arcs. Completion of transverse arc formation takes place through annealing of the 
smaller actin bundles.  As these contractile bundles mature, they move away from the 
plasma membrane toward the centre of the cell (Hotulainen and Lappalainen 2006; 
Tojkander et al. 2012). Dorsal stress fibres, on the other hand, are initiated from focal 
adhesions, complex macromolecular protein assemblies which contribute to the 
generation of mechanical stability and the forces required for cell movement. Although 
the precise mechanisms accounting for actin growth from these structures remains 
elusive, elongation of actin from focal adhesions is thought to be mediated by formins 
during dorsal stress fibre formation (Le Clainche and Carlier 2008). Elongated filaments 




stress fibre formation is thought to take place through the interplay between dorsal 
stress fibres and transverse arcs. As retrograde flow of actin in the lamellipodia drives 
transverse arcs towards the cell centre, these structures collide with dorsal stress fibres 
and become attached to their proximal ends. The fusion of dorsal stress fibres and 
transverse arcs subsequently gives rise to a contractile stress fibre that is anchored by a 
focal adhesion at each end (Hotulainen and Lappalainen 2006). Ventral stress fibres can 
also result from the fusion of two dorsal stress fibres (Small et al. 1998; Tojkander et al. 
2012). Thus, the regulation of the numerous actin-based structures in cells take place via 
numerous mechanisms and involve a varied set of proteins. The participation of formins 
as actin regulatory proteins is often highlighted in the formation of these structures.  
1.7 Formins 
 
Where Arp2/3 is responsible for creating branched networks, the family of formin 
proteins polymerises actin into linear unbranched structures (Figure 1.7 B).  Such 
structures include linear actin filaments seen in filopodia, those required for formation 
of the cytokinetic contractile ring, as well as filaments in lamellipodia (Wallar and 
Alberts 2003).  Many formins are strong nucleators and can elongate actin filaments in 
an Arp2/3 independent manner (Pruyne et al. 2002).  Unlike Arp2/3, formins act by 
associating with the barbed ends of actin filaments.  Formins do not necessarily inhibit 
elongation by capping filaments, rather they regulate the rate of monomer addition.  
They also promote elongation by preventing the association of other capping proteins 
that would prevent growth otherwise (Moseley et al. 2004; Chhabra and Higgs 2007).  
Many formins act as dimers through association via their FH2 domains (Chhabra and 
Higgs 2007).  Formins are said to catalyse the nucleation of actin filaments by binding 
and stabilising the spontaneously formed actin dimers and trimers.  They elongate 
filaments by remaining associated with growing filaments allowing rapid addition of 
actin monomers (Higashida et al. 2004; Chhabra and Higgs 2007).  Structurally similar, 
formins are not functionally redundant and exhibit different actin elongation kinetics.  
Coupled with the fact that they exhibit varying levels of expression according to tissue 
and show distinct subcellular localisation, formins can direct the formation of diverse 
actin-based structures (Chesarone and Goode 2009).  Although formins and Arp2/3 
function downstream of distinct effector signalling pathways, this is not to say that they 




cooperate for leading edge actin-based structures and filopodia formation (Yang et al. 
2007).  Arp2/3 and formins have been reported to work synergistically in actin 
polymerisation as electron micrographs have revealed Arp2/3 associated with the 
pointed end and formins associated with the growing barbed end of the same actin 
filament (Chesarone and Goode 2009).  
 
Formins are multidomain proteins found in all eukaryotes ranging from yeast, 
invertebrates, plants, and mammals (Kovar 2006).  They are large proteins typically 
over 1,000 amino acids in length (Higgs 2005).  The high degree of structural homology 
found across all species suggests that they have been conserved throughout eukaryotic 
evolution.  Currently there are 15 mammalian formins documented which have been 
divided into several groups.  Phylogenetic analysis of the formin domains has revealed 
that they fall into 8 categories which include Diaphanous (Dia), dishevelled associated 
activator of morphogenesis (DAAM), formin related gene in leukocytes (FRL), formin 
homology domain containing (FHOD), inverted formin (INF) 1, INF 2, 
formin/cappuccino (FMN), and delphilin (Higgs 2005; Schulte et al. 2008).  The 
diaphanous related formins (DRFs) mediate cytoskeletal remodelling downstream of 
Rho family small GTPase signalling events. Through these signalling pathways DRFs 
have been proposed to link G-protein coupled signals to cytoskeletal rearrangement and 
modulate gene expression.  Formins have been found to participate in important 
processes requiring motility, including embryonic development and phagocytosis.  In 
fact, the first formin identified, mouse formin 1 was encoded by the mouse limb 
deformity (ld) gene and was thought to be essential for proper limb and kidney 
formation (Mass et al. 1990; Woychik et al. 1990; Evangelista et al. 2003).   However, 
such defects were eventually attributed to disruption of the gremlin gene (Zuniga et al. 
2004).  In humans, naturally occurring mutations in formins mDia1 and -3 have also 
been implicated in non-syndromic deafness and ovarian failure, respectively.   Defects 
in formins have also been proposed to contribute to cancer progression.  To date, most 
of our understanding of formins is derived from research on mDia and Bni1 (Higgs 







1.7.1 Formins as Actin Nucleators and Elongators 
 
Formins have been implicated in rearranging both the actin and microtubule 
cytoskeletons (Bartolini et al. 2008).  They have been found to participate in a wide 
range of cellular roles during cell division, migration, adhesion, and intracellular 
trafficking (Goode and Eck 2007).  During such processes, formins have been found to 
create a wide array of actin-based structures in cells.  Both FMN1 (Kobielak et al. 2004) 
and mDia1 were found to mediate cell-cell adhesion by assembling radial actin cables 
and actin rich contacts, respectively (Goode and Eck 2007).  mDia1 also participated in 
the formation of Rho-induced stress fibres (Nakano et al. 1999).  Stress fibres are 
bipolar arrays of bundled actin filaments that interact with myosin II motors, as 
described above (Naumanen et al. 2008).  They create contractile force and are 
responsible for stabilising the trailing edge of cells during migration and for contracting 
the rear end of the cell. Although very similar in structure, formins direct the formation 
of different actin-based structures.  For example, the mouse formin mDia2 has been 
implicated in formation of lamellar filament assembly (Chhabra and Higgs 2007), since 
lamellipodial formation was inhibited when mDia2 was knocked down by short 
interfering RNAs (siRNAs) (Yang et al. 2007).  Furthermore, in fission yeast 
(Schizosaccharomyces pombe), formins display very specialised roles in the way that 
particular formins are required for formation of a given structure which cannot be 
substituted for by the action of another formin.  For example, Cdc12p is responsible for 
formation of the contractile ring (Chang et al. 1997), For3p is required for actin cable 
assembly (Chang et al. 1997), and Fus1p is required for conjugation (yeast mating) 
(Petersen et al. 1998).  Similarly in budding yeast (Saccharomyces cerevesiae), formins 
are responsible for the formation of actin cables around the cleavage site during division 
(Evangelista et al. 2002).  Also in yeast, Bni1p and Bnr1p work together to make actin 
filaments for cell polarisation (Sagot et al. 2002).  Formins are continuously being 
shown to play a number of essential roles in regulation of actin polymerisation in a vast 







1.8 DRF Domain Structure  
 
Formin function is best understood by dissecting their structure.  Most DRFs 
characterised so far have been found to share many of the same modular domains 
(Higgs 2005).  DRFs are characterised by formin homology (FH) domains, a GTPase 
binding domain (GBD), a diaphanous inhibitory domain (DID), and a diaphanous 
autoregulatory domain (DAD).  The structure of a typical DRF is usually GBD-DID-
FH1-FH2-DAD (Figure 1.10 A).  Formins share most similarity in their carboxy-termini 
(C-termini) with the highest degree of homology in the FH2 domain and the DAD, both 
of which contain core consensus sequences.  Sequence divergence is more apparent in 
the amino-termini (N-termini), which contain the GBD and the DID domain. The N-
termini of formins usually mediate their subcellular localisation and sequence 
divergence may confer distinct compartmental targeting to each formin.  DRFs can 
essentially be divided in two halves, with the C-terminal half being the actin 
polymerisation apparatus and the N-terminus being the regulatory portion of the protein 
(Goode and Eck 2007).  A substantial proportion of information regarding the structure 
and function of each domain has come from overexpression studies using cell lines and 
crystallisation studies of mDia1 (Li and Higgs 2003; Li and Higgs 2005; Otomo et al. 











Figure 1.10: Domain Structure of Formins.  Schematic representation of the domain 
structure seen in diaphanous related formins, namely mDia1.  A) The major domains in the 
N-terminus include the GBD, DID, as well as a DD and CC.  The C-terminus contains the 
FH1, FH2, and DAD. B) mDia in its autoinhibited closed confirmation.  The protein is 
maintained in an inactive state via an autoinhibitory intramolecular interaction via its N-
terminal DID and its C-terminal DAD until binding by a Rho family small GTPase in the 
GBD, which alleviates the interaction. GBD, GTPase binding domain; DID, diaphanous 
inhibitory domain; DD, dimerization domain; CC, coiled coil motif; FH, formin homology; 






1.8.1 The FH2 Domain  
 
The formin homology (FH) 2 domain is the most highly conserved among DRFs 
(Figure 1.10 A).  Although originally thought to span ~100 amino acids, sequence 
comparison among formins has revealed that the FH2 domain actually spans ~500 
amino acids.  It normally lies downstream of the FH1 domain towards the C-terminus 
and is the largest domain, containing many bundles of α-helices (Paul and Pollard 
2009). The FH2 domain is the actin interacting portion of formins.  More importantly, it 
drives actin nucleation as it has been found that recombinant FH2 domains alone were 
enough to create actin filaments (Pruyne et al. 2002; Chhabra and Higgs 2007).  In 
mammalian cells the FH2 domain of mDia was sufficient to induce accumulation of 
polymerised actin (Copeland and Treisman 2002).  The FH2 domain also associates 
with the barbed end of actin as has been made evident in fluorescent microscopy studies 
in Xenopus fibroblasts, using the GFP-tagged FH2 domain from mDia1 and 2 
(Higashida et al. 2004).  The precise mechanism by which the FH2 domain interacts 
with actin and polymerises it is still somewhat disputed but crystallisation studies have 
provided some insight.  Co-crystal structures of formin FH2 domains and actin have 
revealed that the FH2 domains form flexible but stable doughnut shaped dimeric rings 
around actin (Kovar 2006).  Each side contacts with actin, with up to 4 total contacts 
proposed.  It is also apparent that each side only has one contact with actin at any time.  
Dimerisation of the FH2 domain is essential for formin function.  Crystal structures 
have revealed that an FH2 hemidimer bridges two actin subunits, hence it can contribute 
to the stabilisation of nucleation seeds (Chesarone and Goode 2009). The FH2 domain 
is thus interacting with actin in a dynamic equilibrium involving rapid cycles of 
association and dissociation. This would make processive movement possible as 
formins remain associated with the growing end of actin filaments. Different models of 
processive association have been proposed.  Most evidence points to formins 
processively moving with filaments via a stairstep mechanism (Zigmond et al. 2003; Xu 
et al. 2004). This involves the addition of a new actin monomer followed by the 
dissociation of the FH2 domain from the previous monomer and re-association with the 
new one (Chesarone and Goode 2009) (Figure 1.11). However there are reports of other 




FH2 domains dimerise to form head-to-tail dimers that are thought to wrap around the 
barbed ends of actin filaments like a sleeve (Xu et al. 2004; Otomo et al. 2005b).  The 
FH2 domain can influence actin dynamics by increasing rate of nucleation, altering 













1.8.2 The FH1 Domain 
 
N-terminally to the FH2 domain lies the FH1 domain (Figure 1.10 A). The FH1 domain 
of DRFs contains varying numbers of stretches of polyproline residues and is less 
conserved than the FH2 domain. These polyproline tracks (PPPPP) are predicted to 
form type II polyproline helices (Rivero et al. 2005).  This results in FH1 domains that 
are much less structured, rope-like domains capable of mediating a number of protein 
interactions (Chhabra and Higgs 2007; Chesarone and Goode 2009).  In terms of protein 
interactions, FH1 domains have been found to bind Src homology (SH) and Wasp 
homology (WH) domains (Young and Copeland 2010).  For instance, the FH1 domain 
Figure 1.11: Formin Mediated Actin Assembly.  Schematic representation of formin 
mediated actin assembly.  Formins dimerise via their FH2 domains, which create doughnut 
shaped antiparallel dimers.  The FH2 domains bind actin and polymerise filaments by 
remaining processively associated with their growing barbed ends and facilitating the addition 
of profilin-actin monomers.  The FH1 domain functions by binding profilin-actin monomers 
and concentrating them at the growing ends of filaments.  Profilin is seen in orange, actin in 





of the yeast formin Bnr1p binds the SH3 domain of Hof1p in a Rho dependent manner 
to regulate cytokinesis (Vallen et al. 2000). More notably yet, the FH1 domain binds 
profilin with high affinity through its polyproline motifs as shown by co-
immunoprecipitation experiments (Watanabe et al. 1997).  Binding on profilin occurs 
on a groove with a stretch of highly conserved aromatic amino acids (Schutt et al. 
1993).  As mentioned previously, profilin is an actin binding protein that sequesters G-
actin.  It prevents spontaneous nucleation of actin filaments but facilitates the elongation 
of F-actin by rapidly mobilising them to the barbed end (Higgs 2005; Chhabra and 
Higgs 2007).  The interaction between the FH1 domain and profilin-actin has been 
found to be central to the actin polymerisation activity of formins.  Profilin greatly 
accelerates elongation of filaments associated with FH1 and FH2 domains (Kovar et al. 
2003; Romero et al. 2004) and profilin-actin binding to the FH1 domain has been shown 
to be the rate limiting step in formin mediated actin polymerisation (Paul and Pollard 
2008).  It has been proposed that the FH1 domains concentrate profilin-actin monomers 
near the barbed end of an actin filament (Figure 1.11).  Experiments also suggest that 
the FH1 domain functions by passing profilin-actin monomers to the FH2 domain in the 
correct orientation for addition (Higgs 2005).  The FH1-profilin-actin complex may 
form a transient ring like structure by interacting with the FH2 domain by virtue of the 
flexibility that the FH1 domains possess. The actin monomer binds the FH2 domain and 
is then added to the growing filament followed by dissociation of the FH1-profilin-
actin-FH2 ring (Vavylonis et al. 2006).  Together, the FH1 and FH2 domains have been 
shown to remain processively associated with the growing ends of actin filaments 
(Kovar and Pollard 2004).  Overall, the FH1 domain is required for the actin 
polymerising activity of formins by facilitating the addition of profilin-actin at the 
growing ends of actin filaments (Chang et al. 1997). 
 
1.8.3 The DID and DAD 
 
Formins are held in an inactive conformation through an interaction between the N-
terminal DID and the C-terminal DAD (Figure 1.10 B). The DAD is not necessarily a 
domain but really only a stretch of 20-30 amino acids found downstream of the FH2 
domain (Higgs 2005).  The intramolecular interaction masks the FH1 and FH2 domain, 




autoinhibitory mechanism first came from experiments using constructs of mDia1 and 
mDia2 (Watanabe et al. 1999).  Truncation mutations lacking the DAD or N-terminal 
region resulted in activation (Higgs 2005).  Activation is commonly achieved by 
binding of a Rho family small GTPase in the GBD, which is usually N-terminal to the 
DID.  It has also been shown that Rho GTPases have to be activated in order to bind the 
GBD of formins (Tominaga et al. 2000).  This partly alleviates the intramolecular 
interaction by displacing the DID from the DAD.  However, activation may not be 
merely due to steric displacement and could be the result of a more complex process.  
Overall, formins are self-regulated by this autoinhibitory mechanism to prevent aberrant 
actin polymerisation. 
 
1.9 Regulation of DRFs by Rho Family Small GTPases  
 
Rho family small GTPases are a subgroup of the Ras superfamily of GTP-dependent 
enzymes. They link extracellular stimuli to intracellular signalling cascades that induce 
cytoskeletal rearrangements (Heasman and Ridley 2008; Naumanen et al. 2008).  This 
partly occurs through binding and modulating the effector proteins that dictate 
cytoskeletal structure.  As their name partly suggests, Rho GTPases are GTP binding 
proteins.  They become activated upon binding GTP and become inactive upon 
hydrolysis of GTP to GDP, by virtue of their intrinsic GTPase capability (Figure 1.12).  
Regulation of Rho GTPases takes place through guanine nucleotide exchange factors 
(GEFs), GTPase activating proteins (GAPs), and guanine nucleotide-dissociation 
inhibitors (GDIs) (Heasman and Ridley 2008).  Rho GTPases are central in regulating 
many processes including the cell cycle, cell morphology (Braga 2000), and cell 
























Mammalian Rho GTPases include over 20 intracellular signalling molecules, the most 
extensively studied being RhoA, Rac, and Cdc42 (Heasman and Ridley 2008).  Rho 
GTPases signal the formation of a variety of actin-based structures.  For example, all 
three Rho isoforms have been shown to induce the formation of stress fibres (Wheeler 
and Ridley 2004).  Rho isoforms also play roles in a number of cellular processes such 
as endosomal trafficking (Ellis and Mellor 2000) and regulation of cell-cell contact 
formation (Braga et al. 1997).  RhoA was one of the first of the small GTPases to be 
identified (Ridley and Hall 1992b).  Its role in cytoskeletal organisation has been 
frequently highlighted and it is generally thought to participate in the formation of stress 
fibres (Ridley and Hall 1992a).  RhoA has a number of downstream targets that mediate 
cytoskeletal regulation.  One well characterised pathway involves the kinase ROCK.  
GTP-bound RhoA binds and activates Rho associated protein kinase (ROCK) I and II 
(Alberts et al. 1998; Ridley 2006).  ROCK then phosphorylates and activates LIMK 
Figure 1.12: The GTPase Cycle. Schematic diagram showing the mechanism underlying the 
regulation of Rho GTPases. In their GDP bound state, Rho GTPases are inactive.  Rho GDP 
dissociation inhibitor (GDI) prevents dissociation of GDP.  Activation is achieved upon 
binding GTP, which is facilitated by interactions with guanine nucleotide exchange factors 
(GEFs). Subsequent deactivation is achieved through hydrolysis of GTP to GDP, which is 
stimulated through an interaction with a GTPase activating protein (GAP). GTP, guanosine 





(Ohashi et al. 2000) which subsequently phosphorylates and inactivates the actin 
filament severing protein cofilin (Yang et al. 1998).  This has the effect of stabilising 
actin-based structures in cells. ROCK-I is one of the major effector molecules that lies 
downstream the RhoA pathway (Ridley 2006).  ROCK-I participates in the signalling 
events that link G-protein mediated signals, such as thrombin activation in vascular 
cells, to cytoskeletal remodelling (Takeya et al. 2008).  ROCK-I is classically associated 
with mediating the formation of stress fibres (Pellegrin and Mellor 2007).  
 
Rac stimulate formation of lamellipodia and membrane ruffling (Ridley et al. 1992; 
Ridley and Hall 1992b) and have been demonstrated to be involved in processes such as 
mediating axonal guidance in the brain (Chen et al. 2007). The effects of Rac are 
sometimes thought to be antagonistic to the action of Rho although the Rho/ROCK 
pathway and Rac signalling can both converge at the level of cofilin inhibition.  
However, instead of acting on ROCK, activated Rac acts on the kinase PAK (Knaus et 
al. 1998).  PAK then phosphorylates LIMK which then inactivates cofilin (Edwards et 
al. 1999; Ridley 2006). Rac acts via numerous signalling pathways and can play diverse 
roles therefore the above description is by no means exhaustive. For example, Rac is a 
component of the Nox2-dependent NADPH oxidase complex in cardiac cells. In this 
context, Rac has been shown to be essential in promoting the association of the 
cytosolic components with the membrane bound components of the complex (Satoh et 
al. 2006).      
 
Another well studied member of the Rho family small GTPases, Cdc42 has been 
primarily implicated in the formation of filopodia (Zamudio-Meza et al. 2009).  Cdc42 
has been shown to participate in processes like regulation of cell polarity and was found 
to do so via the polarity protein partitioning-defective-6 (PAR6) complex (Etienne-
Manneville and Hall 2003). Cdc42 can also bind to WASP and N-WASP (Rohatgi et al. 
2000) to stimulate actin polymerisation via the Arp2/3 complex (Ridley 2006). The 
wide array of structures formed by members of the Rho family small GTPases thus vary 
between cell type and depend on their interacting partners. 
 
DRFs are regulated by multiple GTPases.  They were found to be activated by Rho 
family members including Rho, Rac, Cdc42, and Rif (Pellegrin and Mellor 2005; Kovar 




formin have been shown to drive specific cellular processes.  For example, the 
interaction between RhoB and mDia2 was shown to drive the events required for 
endosomal trafficking (Wallar et al. 2007), whereas the interaction between Rac and 
mDia2 was required for contractile actin ring formation during erythroblast enucleation 
(Ji et al. 2008).  Conversely, formins have also been found to regulate Rho GTPase 
activity.  The FH2 domain of mDia1 was found to bind Rho-GEF LARG, which lead to 
activation of RhoA (Kitzing et al. 2007).  Although the basic consensus regarding DRF 
activation is that activation is achieved by binding of a Rho family member within the 
N-terminus of the formins, the mechanism may be more complicated than previously 
thought.  This has been illustrated by the fact that RhoA was shown to bind the N-
terminus of mDia1 with high affinity, but this only resulted in minimal activation of the 
DRF (Li and Higgs 2003; Goode and Eck 2007).  However, regulation of formins is not 
restricted to direct interactions with GTPases. A number of formins, including Bni1p 
(Evangelista et al. 2003), FHOD1 (Takeya et al. 2008), and FHOD3 (Iskratsch et al. 
2013a) have been found to be regulated by phosphorylation.  Nevertheless, the 
dominant mechanism by which formin activity and localisation is regulated seems to be 
Rho family small GTPase mediated. 
 
1.10 Formins and Cell Signalling  
 
 
Formins have also been found to initiate signalling to mediate cytoskeletal 
rearrangements and to regulate gene expression in the nucleus. A number of studies 
have indicated that such signalling may be bridged by Src. Src is a member of the Src 
family of non-receptor tyrosine kinases.  Src activity is often associated with cancer 
biology, namely metastasis, as it participates in regulation of cell motility and gene 
transcription (Summy and Gallick 2003). Src regulates adhesive structures and integrin-
cytoskeletal interactions (Felsenfeld et al. 1999) through the phosphorylation of key 
focal adhesion proteins.   One notable function of this kinase is that it phosphorylates 
focal adhesion kinase (FAK) to promote turnover of focal adhesions (Parsons 2003). 
Interestingly, Src also participates in Rho mediated signalling that culminates in events 





Src activity has been found to lie downstream of many formins (Tominaga et al. 2000).  
Src regulates a number of processes ranging from cell differentiation, migration, but its 
role is most frequently highlighted in oncogenesis and tumour metastasis since it was 
found in the Rous sarcoma virus (Guarino 2010). The cross talk between formins and 
Src appears to be rather complex.  In one instance, mDia1 was found to indirectly 
regulate focal adhesion turnover by regulating the targeting of Src to focal adhesions in 
a cancer cell line (Yamana et al. 2006).  Src has also been shown to bind DRFs via its 
SH3 domain. The mDia-Src interaction mediates signalling to the serum response 
element (SRE) (Tominaga et al. 2000; Evangelista et al. 2003). The SRE is a short gene 
regulatory sequence that controls transcription of immediate early genes like c-fos and 
β-actin upon growth factor stimulation.  It involves activation of the serum response 
factor (SRF) transcription factor which stimulates transcription after binding to 
promoter regions (Westendorf 2001; Miano et al. 2007).  It was found that mDia1 and 2 
along with Src signalled downstream of Rho and activated transcription from the SRE 
independently of ROCK and profilin (Tominaga et al. 2000). FHOD1 was also found to 
be a potent stimulator of gene expression from the SRE (Westendorf 2001) and may 
directly involve its proposed actin regulatory activities as well as cross-talk with well-
established cytoskeletal regulators, such as Src, which are discussed below. SRF 
activation appears to be a common target of formins, but especially of formin homology 
proteins. 
 
1.11 Other Activities of Formins 
 
Formins are classically viewed as actin nucleators and elongators. These notions have 
predominantly stemmed from in vitro experiments using purified formin proteins. Such 
studies have described how formins nucleate actin filaments, exhibit processive 
movement along actin filaments while protecting the filament from capping proteins, 
and have described the interplay between formins and profilin in accelerating the rate of 
actin filament elongation (Harris and Higgs 2006; Breitsprecher and Goode 2013). 
However, numerous studies have emerged describing other roles of formins, which has 
led to views regarding canonical formin activities to further include other cytoskeletal 




been described include actin bundling, actin severing, actin depolymerisation, and, 
more-notably, the regulation of microtubules. 
 
1.11.1 Formins as Actin Bundlers 
 
The bundling activity of formins has been explored in a number of studies. One study 
found that FRL1 and mDia2 were capable of bundling filaments, whereas mDia1 was 
not (Harris et al. 2006). Furthermore the FH2 domain was sufficient to induce the 
bundling associated with these formins. Fluorescence and electron microscopy 
experiments revealed that FRL1 and mDia2 did not result in a cross-linked morphology 
of their actin networks, but rather induced the formation of thick actin bundles. In the 
same experiment, it was found that FRL1 associated with its bundled network and that 
this was purported to be mediated by its previously reported actin side binding activity 
(Harris et al. 2004; Harris et al. 2006). Similarly, FRL2 and 3 have also been 
documented to possess actin bundling activity in vitro, as measured by F-actin pelleting 
assays (Vaillant et al. 2008). The exact contribution of formin-induced actin bundling 
with respect to the formation of cellular structures is not always clear, however. While 
FRL2 and mDia2 both possess actin bundling activity and induce the formation of 
filopodia, which require bundled actin filaments, it is unclear which function of these 
formins (i.e., nucleation, elongation, or bundling) contributed to filopodial formation 
(Harris et al. 2010). While bundling activity at the filopodial tip could be a possibility, 
an elongation function seems more appropriate since elongators are likely to exert their 
function at the tips of filopodia according to the more-accepted models of actin filament 
elongation within these structures. More-recent efforts, which have tried to resolve the 
gap between this formin function and its effect on actin-based structures, have identified 
DAAM-1 as playing a crucial role in maintaining filopodial integrity via its actin 
bundling activity. One study found that DAAM-1 is a potent actin bundler that is bound 
and stably recruited by fascin along the filopodial shaft, where it binds to the sides of 
fascin-bundled filaments (Jaiswal et al. 2013). Furthermore, silencing of DAAM-1 
resulted in perturbed filopodial structure and reduced filopodial density, thereby 
suggesting that its actin bundling activity is crucial for the maintenance of filopodia. 
FHOD1, which is further discussed below, also possess bundling activity (Schonichen 
et al. 2013) and has been found to play a role in the formation of bundled actin 





1.11.2 Formins as Actin Severing and Actin Depolymerisation Factors 
 
The abilities of formins to nucleate and elongate filaments also extend to a seemingly 
converse function, with reports of formins severing actin filaments and accelerating 
their depolymerisation (Breitsprecher and Goode 2013). This was the particular case in 
a study which examined the mouse formin INF2. A construct containing the functional 
domains and C-terminus of INF2 was found to behave similarly to other formins in that 
it inhibited the elongation of filaments in the absence of profilin, and accelerated the 
elongation kinetics in the presence of profilin-bound actin monomers (Chhabra and 
Higgs 2006). Interestingly, at higher concentrations, this construct was also found to 
have a biphasic effect on actin kinetics in that it first stimulated polymerisation followed 
by depolymerisation. This effect was not present in experiments utilizing mDia1 and 
FRL1. Furthermore, addition of Pi (inorganic phosphate) abolished INF2’s 
depolymerisation activity but had no effect on its ability to polymerise filaments, 
thereby suggesting that release of Pi during the ATP hydrolysis event that takes place 
during actin polymerisation could be a stimulator of INF2’s depolymerising activity. 
INF2’s ability to depolymerise filaments was partly attributed to its C-terminal portion, 
which was found to sequester actin monomers and prevent elongation from the barbed 
end. However, it was also found that the FH regions were required along with the C-
terminus, and that these portions bound to the side of actin filaments and resulted in 
their severing, an activity that more-likely contributed to the enhanced depolymerisation 
rates noted rather than just monomer sequestration by the C-terminus alone. 
Furthermore, a WH2 motif was also found to partly mediate the depolymerisation 
activities of INF2, although it could conceivably have contributed less to the severing 
activity of the protein (Chhabra and Higgs 2006). Actin filament severing has not been 
limited to INF2 since FRL1 has also been reported to sever actin filaments in order to 








1.11.3 Formins and the Regulation of Microtubules 
 
More-substantial evidence has also emerged implicating formins in the regulation of 
microtubules than in the aforementioned supplementary functions (Bartolini and 
Gundersen 2010). Microtubules, essential components of the cytoskeleton, are dynamic 
structures composed of polymers of 12-15 protofilaments, made of / tubulin 
heterodimers (Bartolini and Gundersen 2010). Microtubules play a number of essential 
roles within the cell ranging from vesicular transport and cell division to cell motility 
and polarity. Formins have generally been shown to regulate microtubule dynamics by 
binding and stabilising microtubules directly,  by affecting microtubule dynamics via an 
interaction with an accessory protein, and/or affecting the post-translational state of 
microtubules (Breitsprecher and Goode 2013). One study found that the functional FH 
domains of mDia2 were sufficient to directly bind and stabilise microtubules under 
disassembly conditions (Bartolini et al. 2008). mDia was also reported to associate with 
EB1 and APC, two microtubule-end binding proteins, and through the cooperation of 
this complex of proteins, contributed to microtubule stability and the promotion of cell 
migration (Wen et al. 2004). Formins can also promote stabilisation of microtubules by 
inducing their acetylation. One study implemented active constructs of nearly every 
mammalian formin and revealed that the induction of microtubule acetylation was a 
function common to many formins, albeit to varying degrees (Thurston et al. 2012). 
Furthermore, constructs solely comprised of the functional FH domains were sufficient 
to induce acetylation for most formins. 
 
While the description of formin activities that extend beyond their actin nucleation and 
elongation activities pose fundamental questions about the involvement of these 
processes in regulating higher order cytoskeletal structures as well as their involvement 
in broader cellular functions, this area of research requires further investigation. Indeed, 
the regulation of microtubules by formins could be a function more common among the 
class, since not every formin that has been tested has necessarily been found to possess 







1.12.1 The Formin Homology Protein, FHOD1  
 
Formin homology proteins are a subfamily of DRFs and Rho family dependent 
effectors.  Like other formins, they are actin regulators, and also play important roles in 
organogenesis, tissue homeostasis, and cancer cell division (Katoh 2004).  In humans 
the FHOD protein that has been best characterised thus far is the formin homology 2 
domain containing protein 1 (FHOD1) (Figure 1.13).  FHOD1 was first discovered as a 
binding partner for the acute myeloid leukaemia (AML1β) transcription factor in the 
littoral cells of the spleen (Westendorf et al. 1999). Formerly known as formin 
homology overexpressed in the spleen (FHOS), its name was changed to FHOD1 to 
meet the criteria on Guidelines for Human Gene Nomenclature.  The originally 
described FHOD1 isoform is a 1,165 amino acid protein with a molecular weight of 
~128kDa. It is translated from a 4kb mRNA transcript which is transcribed from the 
FHOD1 gene (Gene ID: 29109) found on human chromosome 16q22.1. The gene is 
comprised of a 3,495bp open reading frame (ORF) with an 18bp stretch in the 5' 
untranslated region (UTR) and a 260bp 3' UTR containing polyU termination signals. 
















Initial sequence comparison of FHOD1 revealed that it was homologous to other DRFs 
within its C-terminus, namely between amino acids 716-1070.  Characterisation initially 
revealed a relatively small FH1 domain of 42 amino acids containing only 3 polyproline 
stretches, although this region is actually larger.  The FH2 domain was found 
downstream of the FH1 domain and was within the region spanning amino acids 716-
1070.  The N-terminus of FHOD1 bears the lowest homology to other formins 
(Westendorf et al. 1999).  FHOD1 was also found to have a DID, also referred to as the 
FH3 domain.  The DID of FHOD1 has been reported to span amino acids 115-340.  
Crystal structures have shown it is composed of repeat bundles of 14 α-helices followed 
Figure 1.13: Domain Map of FHOD1.  A) Schematic representation of the full length short 
variant of human FHOD1. B) Schematic representation of the full length long variant of 
human FHOD1.  The major FHOD1 domains are shown including the alternatively spliced 
exons (E12-13) found in the larger FHOD1 isoform.  The ROCKI phosphorylation sites are 
also highlighted in the DAD.  Domain borders are highlighted and include the amino acid 
(a.a.) lengths and their corresponding base pair (b.p.) sequence on the FHOD1 DNA 
sequence. The domains downstream of the alternatively spliced exons are labelled with 
respect to the long FHOD1 amino acid and base pair sequence.  GBD, GTPase binding 
domain; DID, diaphanous inhibitory domain; FH, formin homology; DAD, diaphanous 





by 4 armadillo repeats to form an elongated superhelical domain (Schulte et al. 2008).  
Other features of the protein included a coiled-coil motif, a Glycine-Proline rich 
collagen like domain, a potential bipartite nuclear localisation signal (NLS), a basic 
NLS, and a number of putative phosphorylation sites for kinases like PKA and PKC 
(Westendorf et al. 1999).  The coiled-coil motif, found C-terminal to the core FH2 
domain but within the boundaries of the larger FH2 domain, is central to the function of 
FHOD1.  It mediates self-association of the protein, a prerequisite for its actin 
regulating activity (Madrid et al. 2005).  The layout of FHOD1 is very similar to other 
DRFs and has allowed studies to extrapolate on the function of this formin. 
 
Analysis of expression patterns showed that FHOD1 was expressed in many 
haematopoietic cell lines and it was first thought to be involved in antigen 
internalisation, B cell or erythrocyte maturation, as well as splenic development 
(Westendorf et al. 1999).   FHOD1 mRNA was found to be transcribed in the spleen, 
lymph nodes, bone marrow, peripheral blood lymphocytes, and liver.  Fainter 
expression was observed in muscle, lung, heart, kidney, and colon.  Expression is absent 
from the central nervous system (Gill et al. 2004).  Another study noted substantial 
expression of FHOD1 in vascular smooth muscle cells (VSMCs) and vascular 
endothelial cells in the aortic and coronary vasculature (Wang et al. 2004).  More recent 
studies also found that FHOD1 is the most abundantly expressed formin in mouse 
megakaryocytes and is also expressed in platelets (Thomas et al. 2011).  Furthermore, 
expression of FHOD1 protein was confirmed in SMCs, aorta, bladder, brain, lung, 
skeletal muscle, stomach and testis by Staus et al. 2011.  However, this study did not 
note any FHOD1 protein expression in the heart (Staus et al. 2011a) which would 
contradict previous work that found FHOD1 mRNA in heart (Gill et al. 2004).  These 
differences could be explained due to antibody specificity or species-specific 
differences in FHOD1 expression.  Although widely expressed, FHOD1 has been found 
to undergo differential alternative splicing.  Tojo et al. 2003 described two different 
splice variants of the FHOD1 mRNA transcripts.  One contained a 78bp insertion (exon 
12-13) and was found to be mainly expressed in skeletal muscle and faintly in the heart 
and was 1,191 amino acids in length (Figure 1.13).  The second variant had a 24bp 
insertion which encoded a STOP codon to form a truncated protein. This variant was 





A more-recent study took an immunohistochemical approach in the hopes of delineating 
FHOD1’s expression pattern in 26 human tissues and found that FHOD1 was widely 
expressed in a variety of tissues, but was restricted to certain cell types. The most 
intense staining for FHOD1, using a polyclonal rabbit anti-FHOD1 antibody generated 
by the Human Protein Atlas (HPA) programme, was seen in the small blood vessels of 
the spleen, endometrium, ovary, and in peritoneal vessels below the mesothelium 
(Gardberg et al. 2013). Another study looking at expression level of all 15 formins in 22 
different human cell and tissue types using quantitative real-time polymerase chain 
reaction (qRT-PCR) found that FHOD1 was the most abundantly expressed formin 
across the different samples that were tested. Interestingly, FHOD1’s sister homolog, 
FHOD3, was found to display the lowest expression levels as well as contrasting 
expression pattern to FHOD1 in muscle. FHOD1 expression was higher in cardiac 
muscle than in skeletal muscle, whereas expression of FHOD3 was higher in skeletal 
muscle than in cardiac muscle (Krainer et al. 2013). Furthermore, these findings were 
also confirmed by Western blotting, thus strengthening their validity.   
 
1.12.2 Cellular Roles of FHOD1 
 
The capacity of FHOD1 to regulate the actin cytoskeleton has been thoroughly explored 
in a number of studies.  Koka et al. 2003 found that FHOD1 enhances cell migration in 
an integrin dependent manner using transfection studies.  FHOD1 overexpressing cells 
were found to have elongated morphology.  It was found that activated FHOD1 was 
targeted to actin and stabilised stress fibre formation and that this was dependent on the 
presence of the FH1 and FH2 domains. The FH1 domain is required for actin 
reorganisation whereas the FH2 domain is needed for self-association of FHOD1 (Koka 
et al. 2003; Takeya and Sumimoto 2003).  Further to these early studies,  the 
mechanisms of FHOD1 mediated cell elongation were clarified when it was shown that 
FHOD1 also coordinated microtubules by causing them to align along the long axis of 
the cell and overlap with stress fibres (Gasteier et al. 2005).  N-terminal FHOD1 
constructs also revealed that the first 421 residues are crucial to mediating its 
subcellular targeting to cell peripheries (Koka et al. 2003). This was in agreement with 
previous studies that found FHOD1 localising to membrane edges and cell extensions 




for its F-actin binding activity.  Using active FHOD1 mutants lacking the N or C-
termini it was also noted that in COS-7 cells FHOD1 formed thick actin stress fibres 
and localised to these structures (Takeya and Sumimoto 2003).  It was also shown that 
stress fibre induction upon FHOD1 activation was dependent on the association of 
FHOD1 with the actin-based structures and that these effects were independent of 
Arp2/3 (Gasteier et al. 2003).  The upstream signalling events that dictated stress fibre 
formation were also concluded to be a product of Rho-ROCK signalling and were Src-
independent (Koka et al. 2005). 
 
While it has become well established that activation of FHOD1 predominantly results in 
a stress fibre phenotype, this has begged the question as to whether FHOD1 is 
mediating stress fibre formation through actin reorganisation rather than promoting 
nucleation/elongation of actin filaments. One study tested FHOD1 using in vitro actin 
polymerisation assays and found that it inhibited actin polymerisation and that this 
inhibition was intensified upon FHOD1 activation. Even in the presence of profilin, 
FHOD1 only possessed a weak capacity to elongate actin filaments compared to mDia1 
(Schonichen et al. 2013). Instead, in vitro actin bundling assays, performed by way of 
centrifugation assays and electron microscopy analysis, revealed that FHOD1 bundles 
pre-existing actin filaments and that its bundling activity was increased upon activation. 
Furthermore, while the barbed end capping activity of FHOD1 was mediated by the 
FH2 domain, its actin bundling activity was dependent on the presence of the N-
terminal actin binding domain. This notion was confirmed in localization studies using 
neuroblastoma cells expressing constitutively active Rac1 and in COS7 cells. Wild-type 
FHOD1 and an N-terminal construct of FHOD1 (amino acids 1-573; FHOD1 short 
variant) co-localised with actin arcs and stress fibres whereas a truncation mutant of 
FHOD1, lacking the N-terminus but retaining the FH2 domain, did not (Schonichen et 
al. 2013). The observation that FHOD1 N-terminus is required for its stress fibre 
bundling activity was consistent with previous reports of the actin binding activity of 
this region (Takeya and Sumimoto 2003). A subsequent study attempted to elucidate the 
mechanisms by which FHOD1 regulates stress fibre formation and revealed that 
FHOD1 stimulated the formation/organization of and is preferentially associated with 
transverse arcs and ventral stress fibres but actually inhibited dorsal stress fibre growth 
(Schulze et al. 2014). The involvement of the FHOD1 N-terminus was once again 




stress fibres and co-localisation with myosin II. However, this is in sight contrast to 
previous studies which identified the linker region and helical domain of FHOD1 as the 
actin binding site that lies outside the FH2 domain (Figure 1.13) (Schonichen et al. 
2013). Regardless of the position of any additional actin binding sites/activity found 
outside of the FH2 domain, it has become clear that FHOD1 is involved in regulating 
the dynamics of specific stress fibre types and that this activity could extend beyond the 
archetypal actin nucleation/elongation functions that are readily ascribed to formin 
proteins. 
 
Although in vitro studies suggest that FHOD1 preferentially caps the barbed ends of 
actin filaments rather than elongating them, the involvement of this formin in the 
formation of cell-matrix adhesions (i.e. focal adhesions) in the context of cell spreading 
have indicated its potential capacity to polymerise actin (Iskratsch et al. 2013b). The 
initiation of focal adhesion formation takes place through receptor-matrix binding along 
the cell periphery, and namely involves the integrins, a family of heterodimeric 
transmembrane ECM receptor proteins (Campbell and Humphries 2011). Integrin 
binding to ECM ligands results in clustering and the propagation of a number of 
signalling events that contribute to focal adhesion growth. The activation and 
recruitment of Src is one of the earliest events in focal adhesion initiation (Hamadi et al. 
2009) and is important in driving the recruitment and activation of focal adhesion 
components via phosphorylation of key proteins such as FAK, which in turn 
phosphorylates other adhesive components and further contributes to focal adhesion 
formation (Parsons 2003). Furthermore, integrin clustering results in initiation of the Src 
family kinase (SFK)-dependent actin polymerisation events that are required for cell 
spreading (Yu et al. 2011), although the precise actin polymerisation machinery has yet 
to be identified. Iskratsch et al. 2013 found that FHOD1 was recruited to early integrin 
clusters in a SFK-dependent manner and this occurred upstream of ROCK activation. 
FHOD1 depletion was also found to reduce actin polymerisation at integrin clusters, to 
cause impaired cell spreading, and impaired early adhesion maturation into focal 
adhesions (Iskratsch et al. 2013b). These findings occurred in contrast to FHOD1’s 
proposed capping activity (Schonichen et al. 2013) but asserted previous claims that 
FHOD1 can enhance actin polymerisation in cyto (Watanabe et al. 1999; Gasteier et al. 




could elongate pre-existing filaments and this could be a tightly spatio-temporally 
regulated process that is controlled by effector molecules like the SFKs. 
 
As with other DRFs, initial efforts found that FHOD1 was a potent transcriptional 
activator of the SRE.  These data were ascertained using N and C-terminal FHOD1 
truncation mutants which rendered the protein active, thus having caused it to stimulate 
transcription from the SRE (Westendorf 2001; Gasteier et al. 2003).  Gene expression 
from the SRE was found to be dependent on ERK/MAPK activation and the native 
skeletal actin promoter was activated through FHOD1 via the SRF binding site (Boehm 
et al. 2005).  Furthermore, FHOD1 was shown to directly interact with components of 
ERK/MAPK pathway by co-immunoprecipitation: FHOD1 directly interacted with 
MEK and Raf-1 and associated with these signalling effectors at stress fibres and 
lamellipodia, respectively. Self-association of FHOD1 was also found to be required for 
its transcriptional activity, since deletion of the coiled-coil motif prevented SRE 
transcription (Madrid et al. 2005).  Subsequent work then noted that transcriptional 
activity of FHOD1 was dependent on Src activity (Koka et al. 2005).  FHOD1 thus 




Most studies have reported FHOD1 as a cytoplasmic protein although it has been found 
to have a potential role in the nucleus (Menard et al. 2006).   It has been described how 
caspase can cleave FHOD1 during apoptosis.  This lead to the exposure of the two NLS 
in the resulting two FHOD1 fragments that were targeted to the nucleus.  The FHOD1 
617-1164 fragment in particular localised to nucleoli where it inhibited transcription by 
RNA polymerase I (Menard et al. 2006).  This highlights the possibility of FHOD1 
participating in apoptosis, but whether this is physiologically relevant or just an artefact 
of cell culture is an issue that remains to be determined.   Experiments thus far have 
implicated FHOD1 predominantly as an actin regulatory protein although it may also 






1.12.3 FHOD1 and the Regulation of Microtubules 
 
While the interplay between formins and microtubules is still a comparatively budding 
area of research, some work has also indicated that FHOD1 could be a regulator of 
microtubule dynamics. Initial evidence for the possible role of FHOD1 in regulating 
microtubules came from an observation that the overexpression of constitutively active 
FHOD1 led to the formation of stress fibres and the concomitant alignment of 
microtubules (Gasteier et al. 2005). Another study attempted to characterise the 
microtubule regulating activity of nearly every formin by implementing constructs 
comprised of their function FH domains (FH1-FH2). While Dia1,2,&3, DAAM-1&2, 
FMNL1, and INF1 were found to be strong acetylators of microtubules and FMNL2&3 
and INF2 were found to be weak acetylators, FHOD1, FHOD3, and Fmn1 were not 
found to induce acetylation of microtubules via their isolated FH domains (Thurston et 
al. 2012). Furthermore, the FH1-FH2 domains of FHOD1 and FHOD3 were unable to 
induce the formation of stress fibres nor were they able to stimulate SRF reporter gene 
activation, while other formin constructs were able to do so. On the other hand, 
truncation mutants of FHOD1 and FHOD3 comprised of longer versions of the protein 
(FHOD1ΔDAD or FHOD3ΔN) were able to induce the formation of stress fibres and 
microtubule coalignment in HeLa cells. Furthermore, FHOD3ΔN induced microtubule 
acetylation and activation of the SRF reporter gene, indicating that other modules of this 
protein, apart from the FH1-FH2 portion, are required for its actin and microtubule 
modulating activity. Unfortunately, this study was unable to recapitulate all of these 
experiments with FHOD1ΔDAD, citing inadequate levels of expression for this 
construct (Thurston et al. 2012). Another study silenced FHOD1 in U2OS cells and 
found that FHOD1 depletion in post mitotic cells resulted in perturbations in the 
microtubule and stress fibre network, although this phenotype was subsequently rescued 
by overexpression of siRNA-resistant HA-tagged full-length FHOD1 (Floyd et al. 
2013). While the coordination of the microtubule and actin cytoskeletons may be a 
central function of FHOD1, further work will be required to elucidate the role of 






1.12.4 Regulation of FHOD1  
 
Early characterisation of FHOD1 suggested that its activation was regulated by the 
autoinhibitory interaction, typical to DRFs, which masked the FH1 and FH2 domains.  
This interaction was found to be mediated by polybasic residues between amino acids 
1490 and 904-1165 (Westendorf 2001).  The autoregulatory region of FHOD1 bears 
notable homology to the DAD regions of other DRFs, namely, mDia1, Bni1, and SepA 
(Takeya and Sumimoto 2003).   The DAD also contains a number of conserved Serine 
and Threonine residues (Takeya et al. 2008).  Further biochemical characterisation 
revealed that 60 amino acids in the DAD region specifically mediate the interaction 
with the N-terminus.  The N-terminal DID was found to contain a functional 
hydrophobic autoregulatory motif, MDXLL, that contributed to the interaction 
(Schonichen et al. 2006).  A Valine residue at position 228 was found to be central to 
mediating the autoinhibitory interaction since mutation to a Glutamic acid residue 
disrupted DAD binding (Schulte et al. 2008). 
 
Like other formins, it has been suggested that FHOD1 is activated by binding of a Rho 
family small GTPase.  It had first become apparent that FHOD1 interacted with Rac1 
but not RhoA or Cdc42 (Gasteier et al. 2003).  These first reports describing this 
interaction found that Rac1 and FHOD1 also co-localised in the cytoplasm of HeLa 
cells.  The interaction was found to be mediated by the polybasic domain in the Rac1 C-
terminus and a region on FHOD1 between the DID and FH1 domain between amino 
acids 422-717, a possible GBD.  However, the interaction with Rac1 was independent 
of it being bound to GTP or GDP (Westendorf 2001) and is independent of the coiled-
coil motif on FHOD1 (Madrid et al. 2005).  A later study then revealed that activation 
of Rac recruits both Rac and FHOD1 to actin in membrane ruffles and lamellipodia 
(Gasteier et al. 2003).  This same study speculated that even though FHOD1 does not 
interact with Rho it still acts downstream of it to form stress fibres. 
 
Initial sequence analysis and experiments with Rac have placed the GBD in a region 
downstream of the DID and overlapping the FH1 domain. However, recent 
crystallisation studies have proven the existence of another GBD N-terminally to the 




ubiquitin superfold.  This region was found to bear similar sequence to the GBD of Raf, 
Byr2, PI3Kγ, moesin, and ubiquitin.  Deletion of this region in DAD truncation mutants 
lead to impairment of actin regulating activity and SRE transcription.  Moreover, this 
newly discovered GBD was purported to directly interact with Ras and not Rac, as 
found by isothermal titration calorimetry (ITC) (Schulte et al. 2008). Ras, another 
member of the small GTPases, has been highlighted in propagating signalling events via 
the MAPK/ERK pathway via proteins such as Raf (Jelinek et al. 1996). However, the 
interaction between the FHOD1 GBD and Ras is dubious considering that the FHOD1 
GBD did not interact with Ras using GST pull-down assays (Table 1.1). Furthermore, 
the ITC experiments used in this study relied on the mutation of residues within the 
GBD in order to isolate possible regions of binding. Out of the three stable GBD 
mutants (P41K, D46R, and L61K), only the P41K mutant bound Ras. The wild-type 
FHOD1 GBD fragment was not addressed in ITC experiments. Ras only interacted with 
the GBD when GppNHp loaded, and hence in its activated state, versus the negative 
interaction displayed in its GDP-bound state. This would be suggestive of the specificity 
of the putative interaction between the GBD and Ras but the implementation of site-
directed mutagenesis in order to achieve the interaction, the lack of reproducibility in 
binding across the FHOD1 GBD mutants, and the lack of a positive interaction in GST 
pull-down experiments would suggest that the interaction is merely artefactual and 
further analyses would be required. The FHOD1-Rac interaction also remains 
questionable as a study attempting to co-immunoprecipitate the two proteins was unable 
to do so, suggesting they do not bind (Thomas et al. 2011).  So far, work has suggested 
that FHOD1 may have two independent GTPase binding regions, although the GBD 
found in the most N-terminal part of the protein is the more likely candidate.  Further 
work will be required by way of characterising FHOD1 and possibly identifying a Rho 
family small GTPase that binds the more N-terminal GBD and activates FHOD1 to 















Although doubtful, there is some evidence suggesting an interaction between the 
FHOD1 GBD and a number of Rho family GTPases and related molecules. One study 
co-expressed the FHOD1 GBD with constitutively active variants of Rac1, Rac2, Rac3, 
Table 1.1: Assessing the Potential Interaction between FHOD1 and the Rho family 
Small GTPases. Summary of the published literature that reported attempts to find a 
physical interaction between FHOD1, or portions thereof (especially the N-terminus and 
GBD), and members of the Rho family small GTPases and related molecules. To date, the 
most-likely interaction to have been demonstrated took place between a central portion of 





RhoA, Cdc42, and Ras in NIH3T3 cells (Schulte et al. 2008). The three Rac variants 
efficiently recruited the FHOD1 GBD to the plasma membrane, where the two proteins 
co-localised, as gauged by immunofluorescence imaging. The other GTPases that were 
investigated resulted in less profound recruitment of the FHOD1 GBD. However, such 
results cannot be taken as sufficient evidence of a direct interaction between the FHOD1 
GBD and these cytoskeletal effector molecules since co-localisation of two proteins in 
cyto does not necessarily equate to their direct association. Therefore, supporting 
evidence from biochemical and molecular biology interaction assays would be required 
in order to compliment such findings and confirm if the FHOD1 GBD directly interacts 
with a Rho family small GTPase.    
 
To date, none of the Rho family small GTPases have been shown to definitely bind the 
FHOD1 GBD using biochemical methods (Table 1.1). This is in contrast to other 
mammalian formins that have been shown to bind one or more member of these 
cytoskeletal effectors. The first formin-GTPase interaction to be described was that 
between mDia1 and RhoA (Kühn and Geyer 2014). GTP-bound RhoA has been shown 
to bind the GBD of mDia1 and to contribute to the activation of this formin (Lammers 
et al. 2005; Lammers et al. 2008; Kühn and Geyer 2014). Furthermore, numerous Rho 
family GTPases have been demonstrated to bind the N-terminal region (the GBD and 
FH3 domain) of mDia1, including RhoB, RhoC (Rose et al. 2005a; Rose et al. 2005b), 
Rac1, and Rac2 (Lammers et al. 2005; Kühn and Geyer 2014). Experiments using 
mDia1 and RhoC indicated that binding to the formin GBD and the proximal FH3 
region (analogous to the FHOD1 DID) was mediated by the effector loop region that is 
conserved among Rho small GTPases (Rose et al. 2005a; Kühn and Geyer 2014). 
Whilst providing mechanistic insight into the steps involved in the steric displacement 
of the formin FH3/DID-DAD interaction, such a finding casts doubt as to the specificity 
of the interaction between the Rho family small GTPases and the formin GBD (Kühn 
and Geyer 2014). Insights into the mechanism of DRF activation have primarily 
stemmed from crystallographic and structural studies, which have suggested that Rho 
displaces the autoinhibitory DRF interaction between the FH3 and DAD domains in a 
two-step mechanism: first through weak binding of the GBD followed by stronger 
binding to the FH3 domain (Lammers et al. 2005; Kühn and Geyer 2014). RhoA 
binding to mDia1 has been directly attributed to activation of this formin since RhoA 




pyrene-actin assembly assays (Maiti et al. 2012). However, greater activation was 
achieved with the mDia1 variant lacking the C-terminal DAD, and even at relatively 
high concentrations of RhoA, only partial activation of mDia1 was achieved. Both of 
these factors suggest that further cues are required for full activation to occur. 
Regardless of the placement of the GBD of FHOD1, this also appears to be the case 
with the FHOD1 and Rac interaction. Although Rac has been suggested to recruit 
FHOD1 to the plasma membrane, the association of these two proteins did not appear to 
result in full FHOD1 activation as evidenced by a lack of stress fibre formation in cells 
(Gasteier et al. 2003; Schulte et al. 2008; Patel and Cote 2013). While some of the extra 
signals that contribute to the activation of mDia1 remain elusive, further insights have 
been gained with mDia2 and the FHOD proteins. mDia2 was shown to be 
phosphorylated by ROCK in two residues near the DAD, an event which resulted in 
activation of the formin (Staus et al. 2011b). FHOD1 and FHOD3 have also been shown 
to be activated by ROCK phosphorylation (Staus et al. 2011a; Iskratsch et al. 2013a).   
 
A number of studies have found that ROCK regulates the activity of FHOD1.  It has 
been demonstrated that ROCK directly phosphorylates Ser1131, Ser1138, and Thr1141 
in the DAD of FHOD1.  Site directed mutagenesis of these residues to Aspartates, 
which mimics phosphorylation, disrupted the intramolecular autoinhibitory interaction 
and activated FHOD1, as was evidenced by stress fibre formation (Takeya et al. 2008).  
Further experiments revealed that FHOD1 directly bound ROCK via the N-terminal part 
of its FH2 domain and that co-expression of the two proteins resulted in the formation 
of non-apoptotic plasma membrane blebs (Hannemann et al. 2008).  FHOD1 was also 
shown to function downstream of RhoA-ROCK signalling to promote SMC 
differentiation.  Downstream of ROCK phosphorylation, FHOD1 was shown to induce 
expression of SMC-specific genes.  This induction of gene expression was dependent on 
the actin regulating activity of FHOD1, which ultimately influenced myocardin-related 
transcription factor (MRTF) localisation to the nucleus by altering the cytoplasmic ratio 
of F-actin to G-actin (Staus et al. 2011).  Furthermore, FHOD1 was shown to function 
downstream of ROCK phosphorylation in platelets, where it might participate in the 
formation of thrombin induced stress fibres (Thomas et al. 2011).  Phosphorylation by 
ROCK may represent the primary mechanism by which FHOD1 is activated, rather than 





But where does this leave the notion of a possible physical association between Rho 
family small GTPases and FHOD1? None of the commonly studied Rho family GTPase 
members bind the GBD of FHOD1 but studies have shown they certainly could play a 
role in influencing the subcellular localization of FHOD1. The initial studies examining 
the FHOD1-Rac interaction revealed that overexpression of constitutively active Rac1 
or treatment with platelet-derived growth factor (PDGF), a Rac activator, resulted in 
greater association of endogenous FHOD1 with F-actin in NIH3T3 cells (Gasteier et al. 
2003). FHOD1 was specifically recruited to plasma membrane ruffles, lamellipodia, and 
actin fibres. Importantly, FHOD1 co-localised with Rac at these subcellular locations. 
Overexpression of constitutively active Rho or Cdc42 did not result in notable changes 
in the localization of endogenous FHOD1. This same study also highlighted the 
involvement of FHOD1 in the formation of Rac-induced lamellipodia (Gasteier et al. 
2003). Rac1 has also been shown to mediate targeting of FHOD1 to actin tails, where 
FHOD1 participates in actin tail initiation and elongation in HeLa cells infected with the 
WR strain of vaccinia virus (Alvarez and Agaisse 2013). While it is questionable 
whether Rac1 directly contributed to the activation of FHOD1 in this study, the 
depletion of Rac in cells resulted in reduced targeting of FHOD1 to actin tails, 
suggesting that Rac1 is partly responsible for the targeting of this formin. Thus, while 
the extent of activation that is achieved upon association of FHOD1 and Rac is 
debatable, the cross-talk between these two proteins seems to contribute to the 
regulation of certain F-actin-based structures. 
 
Src has also been shown to regulate FHOD1.  Apart from mediating FHOD1 induced 
transcription from the SRE, Src has also been shown to regulate the subcellular 
localisation of FHOD1.  Studies have found that Src activity was required to mediate 
FHOD1 targeting to lamellipodia (Koka et al. 2005) and to non-apoptotic plasma 
membrane blebs (Hannemann et al. 2008).  The association of FHOD1 and ROCK was 
also found to be dependent on Src activity as was evidenced in co-immunoprecipitation 
experiments using Src inhibitors (Hannemann et al. 2008).  Further work by Iskratsch et 
al. 2013 revealed that the direct interaction between FHOD1 and the SFKs was required 
for targeting of FHOD1 to early integrin clusters, where it was able to participate in 
actin polymerisation during cell spreading and migration. Binding of the SFKs to the 
polyproline motif on FHOD1 resulted in phosphorylation of FHOD1 by the SFKs at the 




This phosphorylation event did not necessarily disrupt the autoinhibitory interaction of 
FHOD1 but more-likely contributed to the targeting of FHOD1 since the constitutive 
inactive FHOD1 3A mutant still localized to adhesions (Iskratsch et al. 2013b). 
1.12.5 Additional Kinases that Phosphorylate FHOD1 
 
Protein phosphorylation is a recognized mechanism by which cellular function can be 
modulated downstream of physiological stimuli. One notable example is the 
involvement of protein phosphorylation during myocardial contraction, namely the 
phosphorylation of myosin light chain and the resulting interaction between actin and 
myosin required for cross-bridge cycling (Rapundalo 1998).  There have been examples 
of formins influencing the physiology of certain cell types by facilitating the 
propagation of signalling cascades involving phosphorylation of key proteins. For 
example, mDia1, which binds to the intracellular domain of the receptor for advanced 
glycation endproducts (RAGE), was required for RAGE induced oxidative stress 
generation, which culminated in Akt and glycogen synthase kinase (GSK3) 
phosphorylation followed by SMC migration in a model of neoinitimal hyperplasia 
(Toure et al. 2012). As discussed above, it has also become apparent that certain 
formins, including FHOD1, are directly regulated by phosphorylation (Takeya et al. 
2008; Staus et al. 2011b; Iskratsch et al. 2013a).  
 
Another study with FHOD1 have also found through co-immunoprecipitation 
experiments and in vitro kinase assays that PKGI binds and phosphorylates FHOD1 and 
that this interaction is disrupted by the presence of cGMP.  This raises the possibility 
that FHOD1 may regulate VSMC migration and vascular tone (Wang et al. 2004). 
Another study looked at Aurora-B, a mitotic kinase, and found that it phosphorylates 
FHOD1 (Floyd et al. 2013). This phosphorylation event was thought to contribute to 
cytoskeletal organization since a non-phoshophorylatable version of FHOD1 was 
impaired in its ability to organise stress fibres and microtubules. Overall, the interplay 
between FHOD1 and Aurora-B could implicate FHOD1 in mediating cytoskeletal 
rearrangements in dividing cells. Thus, FHOD1 could be phosphorylated by different 
kinases in various cell types but further work with these proteins will be required to 





1.12.6 Further Insights into FHOD1 Function from other Interacting 
Partners 
 
A number of binding proteins have been described for FHOD1, with binding spanning 
different regions of the FHOD1 molecule. Figure 1.14 represents a comprehensive map 
of the different proteins that have been shown to bind FHOD1. Figure 1.15 represents a 
map of the cell and highlights the subcellular compartments where FHOD1 has been 
noted to co-localise with its binding proteins. Characterisation of some of the FHOD1's 
interacting proteins has also shed some light on its function.  As expected, FHOD1 was 
found to interact with profilin, more specifically profilin IIa (Tojo et al. 2003).  
Subsequent studies revealed a wide array of FHOD1 binding partners.  The C-terminal 
portion of the protein was found to interact with protein kinase C binding protein 1 
(PRKCBP1), cyclophilin B, and WISHB.  The interaction with WISHB revealed a 
possible inhibitory regulatory mechanism since its association disrupted FHOD1 
induced stress fibre formation (Figure 1.15 Part II) (Westendorf and Koka 2004). 
FHOD1 was also found to bind insulin responsive aminopeptidase, which suggested a 
scaffolding role for the protein by tethering GLUT4 containing vesicles to the 
cytoskeleton (Figure 1.15 Part I)   (Tojo et al. 2003).  In human B cells lacking CD19, 
the interaction between FHOD1 and CD21 was found to participate in receptor 














 Figure 1.14: Schematic of FHOD1 Regions of Binding for Identified Interaction Partners (Part I). Schematic 
of FHOD1 and regions of binding by other proteins identified in the scientific literature. Tables describe the 
interaction by summarising the following: name of FHOD1 binding protein and region of protein involved in 
interaction; corresponding amino acids of FHOD1 involved in the interaction (for both the long and short FHOD1 






Figure 1.14: Schematic of FHOD1 Regions of Binding for Identified Interaction Partners (Part II). 
Schematic of FHOD1 and regions of binding by other proteins identified in the scientific literature. Tables 
describe the interaction by summarising the following: name of FHOD1 binding protein and region of protein 
involved in interaction; corresponding amino acids of FHOD1 involved in the interaction (for both the short and 
long FHOD1 variant); experimental procedures used to ascertain the interaction and the corresponding source of 






FHOD1 was also found to interact with nesprin-2 giant (nesprin-2G) and using yeast 
two-hybrid, GST pull-down, and co-immunoprecipitation assays, the interaction was 
mapped to the FHOD1 N-terminus (GBD-DID) and to the spectrin repeats (SRs) 11-12, 
which are unique to nesprin-2G (Figure 1.14 Part II) (Kutscheidt et al. 2014). In this 
study FHOD1 was found to be required for the formation of TAN lines, arrays of 
nesprin and actin cables that are found across the nucleus (Figure 1.15 Part I). Actin 
cables are bundles of actin filaments that localize to the cell cortex which play roles in 
particle transport and can mediate cell polarity. TAN lines are required to position the 
nucleus at the rear of the cell. Rearward movement of the nucleus is achieved by 
coupling dorsal actin cables with nesprin-2G (outer nuclear lamina) and SUN proteins 
(inner nuclear lamina). In migrating fibroblasts, rearward movement of the nucleus is 
required for placement of the centrosome at the leading edge of the cell (Chang et al. 
2013). Positioning of the centrosome at the leading edge is an important step since 
centrosomes dictate the arrangement of microtubules, which are required for migration 
(Tang and Marshall 2012). Interestingly, while FHOD1 was required for TAN line 
formation, it was found to be dispensable for the formation of actin cables (Kutscheidt 
et al. 2014). This study this highlighted the potential anchoring role of FHOD1 in 
linking nesprin-2G to actin cables. The function of FHOD1 may thus vary according to 













Figure 1.15: Schematic of Subcellular Localisations of FHOD1 Interactions (Part I). A 
multitude of interactions have been described for FHOD1. These interactions were noted to take 






Figure 1.15: Schematic of Subcellular Localisations of FHOD1 Interactions (Part II). A 
multitude of interactions have been described for FHOD1. These interactions were noted to take 
place in specific subcellular compartments. 
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Although a variety of FHOD1 binding partners have been described, it is somewhat 
difficult to extrapolate a unified view of FHOD1’s function from the available literature. 
This partly stems from the fact that different cell types have been used to characterise 
the functional significance of these interactions. Furthermore, many of the FHOD1 
interacting proteins localize to distinct subcellular compartments. Consequently, the 
association of FHOD1 with a number of its individual interacting partners seem to play 
non-overlapping roles. While FHOD1 co-localises with Raf-1 and MEK at lamellipodia 
and stress fibres (Boehm et al. 2005), respectively (Figure 1.15 Part I), the functional 
significance of this co-localisation is not clear. Raf-1 and MEK may provide a link 
between the actin cytoskeleton and the nucleus by facilitating the transcriptional effects 
of FHOD1 on the SRE by signalling through ERK in NIH 3T3 cells. However, work in 
SMCs indicated that the transcriptional activity of FHOD1 is mediated by the actin-
sensitive MRTF-SRF pathway, and occurs downstream of the Rho-ROCK pathway 
(Staus et al. 2011a). While there is potential for cross-talk between ROCK and MEK, 
given that they can be found at stress fibres with FHOD1, it is difficult to speculate as to 
what the functional relevance would be. A similar case can be made for Raf-1 and Rac-
1. Rac-1 recruits FHOD1 to lamellipodia (Figure 1.15 Part I), which is also incidentally 
the site where FHOD1 associates with Raf-1. Until the relevance of the interactions 
between FHOD1, Raf-1, and MEK are fully elucidated, one can only speculate as to 
how these molecules could function together, thus, their proximity within specific 
cellular compartments can only be described as incidental. A similar argument can be 
made for the FHOD1 interactions that take place at/near the plasma membrane, as was 
the case with ROCK at plasma membrane blebs (Hannemann et al. 2008), the CD21 
receptor aggregation event following EBV attachment (Gill et al. 2004), and the 
transport of GLUT4-containing vesicles towards the plasma membrane via actin cables 
(Tojo et al. 2003) (Figure 1.15 Part I). These interactions occur in distinct cell types; 
therefore it would be difficult to speculate as to how they are linked, although a 
theoretical example could be the possible recruitment of FHOD1 to these sites by Rac-
1. 
 
A more-likely possibility of cross-talk among the FHOD1 binding proteins could take 
place between the SFKs and ROCK. Not only is FHOD1 recruited to plasma membrane 
blebs by ROCK, but this process is also dependent on Src activity (Hannemann et al. 
2008). Furthermore, FHOD1 targeting to early integrin clusters is mediated by Src and 
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likely occurs upstream of ROCK phosphorylation (Iskratsch et al. 2013b). Src 
phosphorylation and binding of FHOD1 could serve as a means to recruit FHOD1 to the 
plasma membrane, where FHOD1 is subsequently activated by ROCK. A similar 
argument can be made for Rac-mediated targeting of FHOD1 to the plasma membrane. 
Interestingly, Rac is activated downstream of Src during instances of integrin-mediated 
signalling events (Huveneers and Danen 2009) and could serve as another mediator for 
FHOD1 targeting to adhesion sites. Overall, the study of FHOD1’s binding partners has 
painted a complex picture of this formin in cells, with multiple interacting partners and 
localisations identified.  Nevertheless, FHOD1 has been shown to be an important 
regulator of the actin cytoskeleton in a variety of cell types, although, its role in striated 
muscle has yet to be examined.  The role  of its closest relative, the formin homology 
protein FHOD3 has provided some additional insight into the possible function of 




1.13.1 The Formin Homology Protein, FHOD3 
 
Formin homology 2 domain containing protein 3 (FHOD3), formerly known as FHOS2, 
is another DRF of the FHOD subclass.  It was identified as a paralogue of FHOD1, 
bearing 52.1% amino acid homology, and is found on chromosome 18q12.2.  Initial in 
silico characterisation predicted it to be 1,439 amino acids long.  The human FHOD3 
gene is comprised of a 4,964 ORF with an 119bp 5' UTR and an 525bp 3' UTR. 
Sequence comparison to other formins found that FHOD3 is comprised of a similar 
modular structure.  FHOD3 was predicted to encode at least 3 different isoforms due to 
alternative splicing of the exon skipping type (Katoh 2004).  Bioinformatic analysis has 
found that it undergoes alternative splicing between exons 11-13.  Studies with the 
mouse variant have found mFhod3 to be abundant in the heart, kidney, and to a lesser 
extent in the brain.  More importantly, it exhibited isoform specific distribution. A 
larger FHOD3 1,578 amino acid isoform exhibited predominantly cardiac specific 
expression whereas another smaller 1,422 amino acid isoform was restricted to 
expression in the kidney and brain (Kanaya et al. 2005). 
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FHOD3 has also been found to regulate actin dynamics. Initial transfection experiments 
in HeLa cells found that C-terminal truncation mutants of FHOD3 lead to stress fibre 
formation and that FHOD3 was targeted to these actin-based structures to some extent. 
Fluorescence microscopy also revealed that FHOD3 associates with nestin filaments in 
H9C2 and COS7 cells (Kanaya et al. 2005).  More recent work on FHOD3 has 
highlighted the importance of formins in striated muscle. 
 
 
1.13.2 Preliminary Work with FHOD3 – Motivation for Work with 
FHOD1 in Striated Muscle  
 
Characterisation of FHOD3 has revealed that the protein plays a crucial role in 
regulating cardiac muscle cell biology.  It was shown that FHOD3 is required for 
myofibrillar maintenance in cultured cardiomyocytes by disrupting expression of the 
protein using siRNA (Taniguchi et al. 2009).  This was concurrently confirmed by 
Iskratsch et al. 2010 using a more elegant vector based siRNA approach to knock down 
FHOD3 in cultured cardiomyocytes.  Depletion of FHOD3 led to fragmentation of 
myofibrils thus highlighting the requirement of the formin in myofibrillar maintenance.  
Myofibril recovery experiments following Latrunculin B treatment also revealed that 
FHOD3 was able to more efficiently induce recovery of myofibrils compared to mDia1, 
highlighting the possibility that formin homology proteins are key players in the 
maintenance of the myofibrillar apparatus (Iskratsch et al. 2010; Dwyer et al. 2012).    
 
The localisation of FHOD3 has also been studied in cardiac muscle.  Cultured neonatal 
rat cardiomyocytes revealed that FHOD3 associated with thin filaments and also 
exhibited a doublet localisation for FHOD3 around the area of the A-band (Taniguchi et 
al. 2009; Iskratsch et al. 2010; Kan-o et al. 2012b).  There are still some discrepancies 
regarding the localisation of FHOD3 in adult cardiac muscle.  Iskratsch et al. 2010 
reported FHOD3 at the Z-disk in adult heart muscle (Iskratsch et al. 2010) whereas 
Kan-o et al. 2012 reported that the localisation of FHOD3 in adult cardiac muscle is 
relatively unchanged compared to that seen in neonatal rat cardiomyocytes and can be 
found near the centre of the sarcomere as a pair of doublet bands (Kan-o et al. 2012b).  
This work was further elaborated on and it was revealed that FHOD3 is 
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developmentally regulated in both its expression levels and myofibrillar targeting.  The 
likely localisation of FHOD3 in the mature myofibril is at the Z-disk (Iskratsch et al. 
2013a).  
 
Iskratsch et al. 2010 additionally cloned a novel striated muscle specific variant of 
FHOD3 that is phosphorylated by CK2.  CK2 phosphorylation was found to govern the 
subcellular localisation and turnover of muscle FHOD3 (Iskratsch et al. 2010).  This 
notion was subsequently confirmed in CK2alpha knockout mice in which FHOD3 had 
lost its defined myofibrillar targeting (Iskratsch et al. 2013a).  Overall, FHOD3 has been 
found to play an important role in cardiac muscle as evidenced by experiments looking 
at its expression, localisation, function, and regulation.  The importance of this formin 
homology protein indicates that FHOD1 may also play an important role in striated 
muscle. 
 
1.14 Formins in Disease 
 
As mentioned previously, a number of formins have been directly implicated in disease 
processes. For instance, mDia1 has been implicated in a form of non-syndromic 
deafness in a kindred in Costa Rica. The disease was associated with a truncated variant 
of mDia1 that arose from a four base pair insertion, resulting in the generation of a 
premature STOP codon (Lynch et al. 1997; DeWard et al. 2010). Disruptions in the 
gene encoding mDia3 (DIAPH2) have been linked to premature ovarian failure (Bione 
et al. 1998; DeWard et al. 2010). Other formins have been reported to be expressed at 
differential levels in disease states. Although it has yet to be directly linked to mediating 
a disease process, increased levels of FHOD1 have been reported in an oral squamous 
cell cancer line (Gardberg et al. 2013). Furthermore, FHOD1 was also found to enhance 
cell migration when overexpressed in human melanoma cells and has allowed for the 
proposal of a role of FHOD1 in metastasis (Koka et al. 2003). With respect to the 
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1.14.1 Formins in Cardiac Disease 
 
Among the formin homology proteins, FHOD3 has been the best documented to display 
altered expression levels during instances of cardiac disease.  FHOD3 has been shown 
to be downregulated in human cardiomyopathy samples associated with heart failure 
(Iskratsch et al. 2010).  In this study, different samples of human myocardial tissue were 
examined for levels of FHOD3 and covered a broad range of aetiologies of heart failure 
such as idiopathic dilated cardiomyopathy (DCM), ventricular DCM, familial DCM, 
ischemic heart disease, and perinatal DCM. Regardless of the aetiology accounting for 
the cardiomyopathy, levels of FHOD3 were found to be down-regulated. This notion 
was also supported by immunofluorescence experiments, which revealed fainter 
staining for FHOD3 in failing heart tissue sections (Iskratsch et al. 2010). Certain 
FHOD3 variants have also been found to be closely associated with hypertrophic 
cardiomyopathy (HCM) (Wooten et al. 2012). Although two variants were identified to 
be closely associated with HCM, one variant in particular, FHOD3 V1151I, displayed a 
stronger association with the HCM phenotype in humans. Furthermore, analysis of 
HCM septal myectomy samples by quantitative polymerase chain reaction (PCR) and 
Western blotting revealed increased levels of FHOD3 at the transcript and protein level, 
respectively (Wooten et al. 2012). FHOD3 could thus be downregulated during 
instances of DCM and upregulated during instances of HCM. 
 
The above findings concerning FHOD3 in cardiac disease could mean this formin could 
play a role in pathological states that often result in heart failure in humans. Cardiac 
hypertrophy, an increase in heart mass, is a leading cause of mortality associated with 
cardiovascular disease (Wooten et al. 2012).  Cardiac hypertrophy (Figure 1.16 B) can 
be triggered as a response to ischaemic insults or to hypertension.  The increase in 
cardiomyocyte size associated with hypertrophy initially functions as a compensatory 
response to preserve cardiac function.  It is even possible for the heart to remodel itself 
back to its previous state (Figure 1.16 A).  However, it is often the case that adverse 
remodelling events take place with negative consequences.  Increased ventricular mass 
often precedes the onset of heart failure, a state in which the dilated heart fails to 
adequately meet the energetic demands of the myocardium in order to pump blood 
systemically (Paul et al. 2006).  Such a state is usually characterised by a heart with 
distended ventricular cavities and thinning walls (Figure 1.16 C). The transition to heart 
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failure can be explained partly by increased levels of myocyte apoptosis and necrosis 
due to greater levels of oxidative stress (Hingtgen et al. 2006).  Cardiac hypertrophy 
also predisposes individuals to ischaemia and arrhythmias therefore it is also a major 
risk factor for sudden cardiac death (Hilfiker-Kleiner et al. 2006).  The precise 
mechanisms underlying the remodelling events that are characteristic of cardiac 
hypertrophy have yet to be fully explained.  In both humans and animal models, 
mutations in cytoskeletal regulatory proteins, such as muscle lim protein (MLP), are 
associated with hypertrophic and dilated cardiomyopathy (Buyandelger et al. 2011).  So 









1.14.2 Insights from MLP deficient mice 
 
 
Figure 1.16: Cardiac Disease.  Schematic representation of hypertrophic and dilated hearts.  
A) Normal heart. B) Heart exhibiting left ventricular hypertrophy, as shown by an increase in 
the size of the myocardium (dark red).  Cardiac hypertrophy can be pathological and often 
progresses to a dilated phenotype followed by heart failure.  Cardiac hypertrophy can result 
from chronic pressure overload (i.e. hypertension).  This schematic is also representative of 
HCM, which is often inherited.  C) Dilated heart exhibiting left ventricular dilatation and 
thinning of the ventricular wall.  This dilated phenotype is often associated with heart failure.  
This schematic is also representative of the DCM phenotype, which is also often inherited. 
HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy. White arrows indicate 
site of hypertrophy or dilation. 
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Work using an animal model of DCM, the MLP
-/-
 mouse (Arber et al. 1997), has also 
indicated the possible involvement of FHOD3 in cardiac disease. MLP deficient mice 
have been reported to display a number of alterations in cardiomyocyte structure.  
Although overall structure of sarcomeres remains unchanged, MLP deficient mice 
display a number of abnormalities at the level of the intercalated disk.  The most notable 
feature is widening of the intercalated disk, which has been attributed to greater 
convolution of the structure (Ehler et al. 2001). Analysis of FHOD3 expression in MLP
-
/-
 mice revealed that there was a downregulation in FHOD3 expression and a switch to 
the non-muscle FHOD3 isoform. Furthermore, the Z-disk and intercalated disk 
associations of FHOD3 were lost and instead the formin was found distributing as weak 
striations around the M-band or in p62 containing autophagosomes (Iskratsch et al. 
2010). 
 
MLP was initially identified by Arber et al. (Arber et al. 1994) and is a striated muscle 
specific cytoskeletal regulator that is found at the Z-disk (Knöll et al. 2010) and the 
nucleus (Knöll et al. 2002a; Knöll et al. 2002b; Boateng et al. 2009).  It has a number of 
binding partners and has importantly been shown to form a ternary complex with -
actinin and nebulin related anchoring protein (NRAP), an actin binding protein that has 
been shown to play a role in myofibril assembly (Carroll et al. 2001; Carroll et al. 2004; 
Dhume et al. 2006).  It is not fully understood how MLP depletion results in a 
hypertrophic and DCM phenotype but work using a mutant variant of MLP associated 
with DCM in humans has shed some light on the issue.  Gehmlich et al. 2004 showed 
that a DCM mutant variant of MLP (C58G) is more susceptible to proteolysis due to 
improper zinc coordination and misfolding of one of its LIM domains.  It was also 
shown that the MLP--actinin-NRAP interaction decreased with the DCM causing 
mutation.  The decrease in MLP was thought to be partly compensated for by an 
increase in NRAP expression (Ehler et al. 2001), which was thought to account for the 
myofibrillar disarray phenotype (Gehmlich et al. 2004).  However, it is not entirely clear 
if an upregulation in NRAP was responsible for the alterations seen in DCM mice since 
NRAP overexpression in mice led to right ventricular dysfunction but no perturbation of 
the intercalated disks (Lu et al. 2011). However, there was not substantial accumulation 
of NRAP at the intercalated disks of NRAP-overexpressing mice compared to wild-type 
mice, which may explain the lack of intercalated disk perturbation. It should also be 
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noted that NRAP-overexpressing mice exhibited only modest cardiac hypertrophy 
which may have explained why the intercalated disks had not widened.  
 
The role of MLP in cardiomyopathy is being revealed to be increasingly complex.  
Work exploring a different MLP missense mutation (W4R) that is associated with DCM 
in humans was shown to cause hypertrophic cardiomyopathy (HCM) in knock-in mice.  
Decreased levels of MLP mRNA and protein were also associated with this mutation as 
well as a heart failure phenotype in mice (Knöll et al. 2010).  These cardiomyopathic 
changes have been partially attributed to a decreased interaction between MLP and 
telethonin, resulting in impaired mechanosensing (Knöll et al. 2002a; Knöll et al. 
2002b; Knöll et al. 2010).  MLP seems to be relevant in both HCM and DCM.  
Although HCM and DCM are distinguished as separate cardiomyopathies (Figure 1.16), 
overlaps in features occur and 10-20% of HCM patients develop DCM later in life 
(Konno et al. 2003; Knöll et al. 2010).  Alterations in MLP have also been noted in 
human heart failure samples (Zolk et al. 2000) and rats that underwent aortic banding or 
myocardial infarction.  Increased levels of total MLP were noted in these models of 
heart failure but it was found that MLP accumulated in the nucleus and decreased 
substantially in the cytosol.  Accumulation of nuclear MLP was also associated with 
increased synthesis of S6 ribosomal protein and may have indicated enhanced rates of 
protein synthesis, thus partly accounting for some of the cellular changes associated 
with the hypertrophic response (Boateng et al. 2007).  The role of MLP thus varies 
depending on the pathological stimulus applied to hearts. In summary, studying the role 
of MLP in the heart has furthered our understanding of some of the changes involved in 
cardiomyopathy and insights from cardiomyopathic MLP
-/-
 mice have highlighted a 
possible involvement of formins in this devastating group of diseases. 
1.15 Conclusion 
 
Muscle contraction is brought about by the sliding of myofilaments past each other.  
The basic contractile apparatus of striated muscle is organised into thin and thick 
filaments.  The thin filaments are made of polymerised actin and are decorated and 
bound by a number of other proteins that confer stability and regulate their function.  A 
number of actin regulatory proteins have been described to modulate the polymerisation 
of actin via a number of mechanisms including capping, severing, and processive 
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elongation.  There is little known about the polymerisation and regulation of thin 
filaments in muscle but previous work has highlighted the role of diaphanous related 
formins in their regulation, especially the formin homology protein FHOD3.  FHOD1, 
another formin homology protein, is a close relative of FHOD3 bearing considerable 
sequence homology.  FHOD1 is a well-established regulator of cytoskeletal dynamics 
and has been shown to induce formation of actin-based structures, including stress 
fibres downstream of RhoA-ROCK signalling.  
1.16 Hypothesis and Aims 
 
The purpose of the present study was to investigate if FHOD1 played a role in striated 
muscle. Previous work suggested that FHOD3 was a crucial regulator of cardiac cell 
architecture and that this was due to the ability of FHOD3 to directly contribute to 
myofibrillar regulation at the level of actin. A growing body of evidence would indicate 
that FHOD1 is an important regulator of cytoskeletal dynamics, particularly at the level 
of actin, in a variety of cell types. Given the importance of formin homology proteins 
and of actin in muscle cells, we hypothesised that FHOD1 was involved in regulation of 
the myofibrillar apparatus and cytoskeleton in striated muscle and thus set out to 
characterise it. Characterisation of FHOD1 involved looking at different facets of 
protein biology including expression and localisation, function, regulation, and 
interactions with other proteins.  The aims for each chapter are summarised below: 
 
1) Expression and Localisation of FHOD1 – Since there have been conflicting 
reports on the expression pattern of FHOD1 in muscle, we sought to investigate 
the expression of FHOD1 at the protein level in cardiac and skeletal muscle 
samples.  As has been the case for FHOD3 and other actin binding proteins in 
muscle, the localisation of proteins can provide insight into their roles; therefore 
we investigated the localisation of endogenous FHOD1 in different muscle 
samples using a number of commercially available anti-FHOD1 antibodies. We 
also attempted to complement the antibody studies with overexpression studies 
using full-length epitope-tagged FHOD1 constructs in order to clarify its 
subcellular localisation. Different modules on FHOD1 have previously been 
shown to contribute to its targeting, therefore we also overexpressed individual 
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epitope-tagged FHOD1 domains and truncation mutants to deduce how FHOD1 
is targeted in cardiac muscle cells 
 
2) Functional Characterisation of FHOD1 – Studies so far have suggested that 
FHOD1 is regulated by an autoinhibitory intramolecular interaction and that it 
primarily exerts its effects on the actin cytoskeleton after activation. Therefore, a 
number of gain-of-function studies were performed in cultured cardiac cells to 
gauge the effects of FHOD1 activation.  In order to further probe the functional 
significance of FHOD1 in muscle cells, additional loss-of-function studies were 
performed, in which shRNA constructs were designed to knock down 
endogenous FHOD1 in cultured cardiac and skeletal muscle cells.  The general 
role of formins was also investigated in cultured cardiomyocytes in experiments 
using a general inhibitor of formin mediated actin assembly.  
 
3) Regulation of FHOD1 – With the regulation of FHOD1 by the Rho family small 
GTPases a possibility, a number of binding assays were performed.  This work 
also examined the downstream effector of the Rho pathway, ROCK. While none 
of these effector molecules have been shown to bind the GBD of FHOD1, work 
with Rac and ROCK-I has suggested that binding of a Rho family small GTPase 
or effector molecule can occur outside of the FHOD1 GBD and can contribute to 
the regulation of this formin. Previous studies have only addressed the smaller 
FHOD1 variant, lacking the alternatively spliced exons 12-13; therefore we 
performed binding assays with an FHOD1 construct containing the alternatively 
spliced exons to test if they could mediate binding with any of the above 
putative regulatory proteins. Src is also being increasingly highlighted as a 
regulator of FHOD1; therefore we performed binding assays between FHOD1 
and Src to test the possibility that regulation could occur by a direct binding. 
 
4) Novel Protein-Protein Interactions – Many actin regulatory proteins interact with 
other factors that modify or enhance their activity in some way. We additionally 
aimed to identify new binding partners for FHOD1 by performing cDNA library 
screens using a yeast two-hybrid system with different FHOD1 fragments. In 
order to gain a view of the potential FHOD1 interacting partners that may occur 
in muscle, a human cardiac cDNA library was employed.  































Adult male C57/BL6 wild-type and MLP
-/-
 mice were used for tissues in Western Blot 
analysis and immunofluorescence studies. Mice were fed a normal dry chow diet and 
kept on a light/dark cycle (12/12h) at 22°C receiving food and water ad libitum. MLP
-/-
 
mice were described in Arber et al. 1997 and generated through targeted disruption of 
the MLP gene (Arber et al. 1997). Experiments were performed in accordance with the 
Guidance on the Operation of Animals (Scientific Procedures) Act, 1986 (UK). Prior to 
harvesting tissue, mice were sacrificed by cervical dislocation. Tissues were then kept in 
PBS before methylbutane treatment for 1 min. in liquid nitrogen or snap frozen in liquid 
nitrogen for storage at -80°C. 
2.1.2 Murine Samples 
 
Tissues samples were frozen in liquid nitrogen, pulverised, and lysed in 100μl of SDS 
lysis buffer (130mM Tris, 190mM SDS, 3.69M urea, 0.06% NP40, 0.17%β-
mercaptoethanol, 3.85% glycerol and 0.01% bromophenol blue at pH 6.8).  For 
immunofluorescence staining, tissues (heart) were cut on a Leica CM1950 cryostat 
(Leica, Wetzlar, Germany) into 12μm sections, mounted on poly-L-lysine coated 
microscope slides, fixed with pre-cooled acetone (-20°C) for 5min at -20°C and stained 
as described below (See 2.11.2), or stored at -80°C until further use. 
2.1.3 COS-1 Cells 
 
COS-1 cells were washed in PBS and lysed in 100μl of SDS lysis buffer using a rubber 
policeman, then boiled for 2min and stored at -20°C until further use.  For pull-down 
assays, COS-1 cells were washed in ice cold PBS and lysed in 100l of pull-down lysis 
buffer (150 mM NaCl, 20 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.2% (v/v) NP-40, 1 
mM Dithiothreitol DTT) and 1x protease inhibitor (complete mini, Roche applied 
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science, Mannheim, Germany) for 10min on ice, the lysates collected with a cell 
scraper, centrifuged at 16,000 x g and 4°C for 15min, the supernatant transferred to a 
new tube for another round of centrifugation at 16,000 x g and 4°C for 15min, and the 
supernatant collected and stored at -80°C until further use.  
2.1.4 Yeast 
 
For expression tests, Saccharomyces cerevisiae yeast (L40 strain) were transformed 
with the relevant FHOD1 bait constructs and cultured in 0.5ml SD-drop out medium 
lacking Tryptophan (MP Biomedical, Santa Ana, California) at 30°C shaking at 
200rpm.  Liquid cultures were spun down for 30sec at 15,000 x g for 1min.  Yeast were 
then re-suspended in 25ml TE buffer (0.1M Tris-HCl, 10mM EDTA, pH7.5, sterile by 
filtration) with 1x protease inhibitor (complete mini, Roche applied science, Mannheim, 
Germany).  Glass beads were added to the mixture which was then vortexed for 10sec.  
100l of yeast lysis buffer (8M Urea, 2% NP40, 1% TritonX100 5%, glycerol-BPB, 5% 
β-mercaptoethanol,  5% SDS, 0.1M Tris-HCl pH6.7) were then added to samples which 
were mixed by vortexing for 2min.  Samples were then boiled for 5min spun down 
briefly and the supernatant was then transferred to a new tube.  Samples were stored at -
20°C until further use. 
2.2 Cell Culture 
2.2.1 Neonatal Rat Cardiomyocytes 
 
Neonatal rat cardiomyocytes (NRCs) were isolated from day 1 newborn Wistar rat pups.  
NRCs were isolated using the Worthington Neonatal Cardiomyocyte Isolation System 
(Worthington Biochemical Corporation, Lakewood, NJ, USA) according to the 
manufacturer’s instructions. The following protocol describes isolation for one litter of 
rat pups (approximately 10-12 rat pups per litter). All reagents/supplies were provided 
by Worthington Biochemical Corporation unless otherwise stated.  Wister rat pups were 
sacrificed by decapitation with sterile straight scissors and the hearts were excised, 
chopped into smaller pieces and stored on ice in 30ml Hank's Balanced Salt Solution 
(HBSS) containing 20 mM 2,3-Butanedione monoxime (BDM). BDM, a reversible 
potassium and L-type calcium channel and myosin ATPase inhibitor was added to 
protect cells during the isolation procedure and improves cell-yield and viability (Ehler 
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et al. 2013). Heart pieces were transferred to a petri dish on ice in a sterile hood, HBSS 
was removed and the tissue pieces were minced using curved scissors. 20 ml of HBSS + 
20 mM BDM containing 1 mg trypsin were then added to the petri dish. Samples were 
then subjected to an overnight trypsin digest at 4°C without agitation. The next morning 
the tissue suspension was transferred to a sterile 50ml centrifugation tube on ice. The 
trypsinisation reaction was subsequently stopped by the addition of 2 mg of trypsin 
inhibitor (reconstituted in 1 ml of HBSS + 20 mM BDM). After oxygenation of the 
tissue suspension by bubbling it with a pipette for 30sec, the vial was then warmed in a 
37°C water bath for 15 min and then subjected to collagenase digestion. 1500 units of 
lyophilised Worthington Purified Collagenase, which contains less than 50 UI/mg 
caseinase and is composed of two separable but very similar collagenases, were 
reconstituted in 5 ml of 5 ml Leibovitz L-15 media + 20mM BDM. The collagenase 
solution was added to the centrifugation tube, which was placed in a shaking incubator 
(2-4 rpm) at 37°C and incubated for 30min. The tissue suspension was then triturated 
with a standard 10 ml plastic serological pipet about 10 times to release cells. Cells 
were then transferred into a new 50 ml centrifugation tube by filtering through a cell 
strainer that was pre-rinsed with 2 ml of Leibovitz L-15 media + 20mM BDM. After the 
solution containing the cells was filtered through, the cell strainer was once again rinsed 
with 2 ml of Leibovitz L-15 media + 20mM BDM in order to wash through residual 
cells. The solution was then oxygenated for 1min by bubbling it with a pipette before 
centrifugation at 70 x g for 5min at room temperature. Pelleted cells were suspended in 
30 ml of plating medium (66% DMEM, 16.5% M199, 10% horse serum, 5% fetal calf 
serum, 4mM Glutamine, 1% penicillin/streptomycin), distributed between three 90mm 
dishes and left to incubate at 37°C for 3hrs to allow fibroblasts to attach. After this pre-
plating step, cardiomyocytes, which would still be in suspension since they take much 
longer to attach to cell culture plastic, were rinsed off, seeded onto PureCol® purified 
bovine collagen solution (Advanced BioMatrix, San Diego, CA, USA) coated 30mm 
dishes in NRC plating medium and left at 37°C in 5% CO2 for 24 hr. After 24 hr, cells 
that were to be transfected were placed into transfection medium (20% M199, 75% 
DBSSK, 4% horse serum, 4mM Glutamine; DBSS-K: 6.8 g/l NaCl, 0.14mM NaH2PO4, 
0.2 mM CaCl2, 0.2mM MgSO4, 1mM dextrose, 2.7mM NaHCO3)  . Cells not used for 
transfection were transferred into NRC maintenance medium (75% DMEM, 20% 
M199, 4% horse serum, 4 mM Glutamine, 1% penicillin/streptomycin, 0.1 mM 
phenylephrine, 10 M cytosine-B-D-arabino-furanoside hydrochloride [AraC]). 
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2.2.2 Adult Rat Cardiomyocytes 
 
Adult rat cardiomyocytes (ARCs) were isolated by Dr. Shiney Reji from Langendorff 
perfused adult male Wister rats (250-300g body weight).  Cells were seeded onto 
PureCol® purified bovine collagen solution (Advanced BioMatrix, San Diego, CA, 
USA) coated 30mm dishes with COS maintenance medium (10% fetal calf serum, 1% 
penicillin/streptomycin and 4 mM Glutamine in DMEM) at 37°C in 5% CO2. 
2.2.3 COS-1 Cells 
 
COS-1 cells (Gluzman 1981) were cultured in COS maintenance medium at 37°C in 5% 
CO2. Cells were passaged at 70-80% confluency by trypsinisation.  For passaging, cells 
were treated with 2ml trypsin/EDTA solution (Sigma, St. Louis, MO, USA) for 5min at 
37°C, before stopping the trypsin digest by addition of COS maintenance medium. For 
transfection, cells were plated onto 30mm dishes and grown to 50-70% confluency. 
2.2.4 C2C12 Cells 
 
C2C12 cells (Yaffe and Saxel 1977) were cultured in C2C12 maintenance medium 
(20% fetal calf serum 1% penicillin/streptomycin and 4mM Glutamine in DMEM) at 
37°C in 5% CO2. Cells were passaged with standard trypsinisation (See 2.2.3) and 
plated at 1x10
5
 cells onto collagen coated 30mm dishes. Cells were changed into C2C12 
differentiation medium (2% horse serum 1% penicillin/streptomycin and 4 mM 
Glutamine in DMEM) and left to differentiate over a time course of 14 days at 37°C in 
5% CO2 
2.2.5 HeLa Cells 
 
HeLa cells (Scherer et al. 1953) were cultured in COS maintenance medium at 37°C in 
5% CO2. Cells were passaged at 70-80% confluency by trypsinisation (See 2.2.3).  For 
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2.2.6 Latrunculin B Treatment 
 
NRCs were transfected and cultured in transfection medium as described in 2.10.1.  
Cells were grown for 5 days in transfection medium containing 1μg/ml verapamil.  
Actin depolymerisation took place by treatment with 20μM latrunculin B (VWR 
International) in transfection medium containing verapamil (1μg/ml) overnight.  The 
Latrunculin B was subsequently washed out and replaced with NRC maintenance 
medium containing verapamil (1μg/ml) for 1hr.  Cells were then fixed in 
paraformaldehyde and stained as described below (See 2.11.1). (Iskratsch et al. 2010) 
 
The Latrunculins bind actin monomers in a 1:1 complex thereby inhibiting actin 
polymerization.  They are heterocyclic marine toxins that were initially derived from the 
Red Sea sponge Latrunculia magnifica.  Latrunculin A is characterised by a 16-member 
ring and Latrunculin B is characterised by a 14-member ring.  Both compounds contain 
a rare 2-thiazolidinone moiety. Initial experiments using these compounds revealed that 
they had a profound impact on cell morphology, an effect attributed to their action on 
actin but not on microtubules (Spector et al. 1983).  While the effects of both 
Latrunculin A and B are reversible, Latrunculin A is the more potent of the two 
compounds and its effects on cell morphology are less transient than those of latrunculin 
B (Spector et al. 1989).  The more transient effects on cell morphology noted with 
Latrunculin B was one of the reasons for selection of this agent over Latrunculin A, 
especially considering that thin filament recovery following depolymerisation was being 
investigated.  Furthermore, Latrunculin A was not used in this assay because it has been 
suggested that myofibrils are stable in the presence of Latrunculin A (Wang et al. 2005; 
Ono 2010). Although cytochalasin, a fungal toxin that prevents actin assembly 
(Goddette and Frieden 1986), seemingly represented an option to induce thin filament 
disruption, we selected Latrunculin B over cytochalasin (i.e., cytochalasin D) for the 
following reason: while the thin filaments of isolated cardiomyocytes are susceptible to 
inhibition by cytochalasin D during plating, mature thin filaments seemingly become 
resistant to cytochalasin D treatment after they have adapted to culture conditions 
(Rothen-Rutishauser et al. 1998).    
 
The concentration of Latrunculin B used in this experiment was previously optimised in 
our laboratory in similar experiments using NRCs (Iskratsch et al. 2010).  The 
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seemingly high working concentration of Latrunculin B used may have been partially 
influenced by the presence of serum in the medium required to culture NRCs.  It has 
been suggested that the effects of Latrunculin B are dampened by the presence of serum 
since previous studies have described how the presence of serum shifted the working 
range of latrunculin B concentrations upward as much as ten-fold (Wakatsuki et al. 
2001).  However, serum in the NRC medium was essential in order to promote cell 
viability and adequate expression of the transfection constructs and has been a 
longstanding and integral component of NRC growth mediums that have been 
previously described (Chlopcikova et al. 2001).  
 
The addition of verapamil was also required for the disassembly of thin filaments in 
NRCs.  Verapamil is an L-type calcium channel blocker that inhibits cross-bridge 
cycling in cardiomyocytes and is used as a rate-controlling anti-hypertensive drug in 
humans due to its cardiac-specific negative inotropic effects.  Previous attempts to 
disassemble the thin filaments of NRCs with Latrunculin B were unsuccessful but the 
addition of verapamil facilitated disassembly of thin filaments, a side effect attributed to 
destabilisation of the sarcomeric Z-disks.   
 
Previous optimization efforts in our laboratory revealed that overnight treatment with 
Latrunculin B was required for a complete effect to be seen (Iskratsch et al. 2010).  
After latrunculin B wash out, NRC maintenance medium containing phenylephrine was 
added to cells.  Phenylephrine, an alpha-1 adrenergic agonist was included in the NRC 
maintenance medium to promote thin filament recovery, since phenylephrine has been 
shown to promote sarcomere assembly and increase cell size, although this response 
varies according to the substrate that cells are plated on (e.g., laminin versus collagen) 
(Taylor et al. 2000).  Verapamil was included in the NRC maintenance medium after 
wash out as previously indicated (Iskratsch et al. 2010). One discrepancy that arose in 
this protocol regarded the antagonistic effects that phenylephrine and verapamil have on 
myofibrillar contractility. While phenylephrine increases intracellular Ca
2+
 
concentration and stimulates cardiac contractility, verapamil blocks intracellular Ca
2+
 
transients and beating. Through these antagonistic effects, verapamil has been shown to 
partially inhibit phenylephrine induced hypertrophy and sarcomere assembly in NRCs 
(Eble et al. 1998). Nevertheless, the present conditions were sufficient to induce 
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depolymerisation of F-actin and myofibrils, although future experiments may require 
optimisation in order to address the outlined discrepancies. 
 
2.2.7 SMIFH2 Treatment 
 
The formin inhibitor 1-(3-bromophenyl)-5-(2-furylmethylene)-2-thioxodihydro-
4,6(1H,5H)-pyrimidinedione (ID#5992446, ChemBridge™), here referred to as 
SMIFH2 was purchased from Chembridge Corporation (San Diego, CA, USA). 
SMIFH2 lyophilised powder was reconstituted in DMSO as described by Rizvi et 
al.2009 and stored at -80°C (Rizvi et al. 2009). NRCs were treated with 30μM SMIFH2 
in 2ml of culture medium over a time course of 2, 4, and 8hr. 
 
SMIFH2, is an inhibitor of formin mediated actin assembly.  It was found to inhibit 
actin polymerisation by formins at the level of nucleation, elongation, and association 
with the barbed end of filaments.  The effects of the inhibitor have been attributed to its 
targeting the conserved FH2 domain, although binding by the small molecule has never 
been shown (Rizvi et al. 2009). Moreover, it was shown to specifically inhibit formins 
and not any other actin polymerising proteins such as Arp2/3. However, there are still a 
number of uncertainties regarding how it exerts its effects. While SMIFH2 is thought to 
inhibit formin mediated actin polymerisation by targeting the conserved FH2 domain, 
initial characterisation efforts have been limited to investigating only a handful of 
formins: mDia1, mDia2, and Cdc12. Further characterisation of SMIFH2 will be 
required in order to establish if it indeed acts on all members of the formin family of 
proteins, whether its effects on individual formins occur at specific concentrations, and 
whether it can inhibit other activities attributed to formins, such as actin bundling. 
2.3 Antibodies 
 
Experimental procedures involving Western blotting and immunofluorescence required 
the use of antibodies to identify specific proteins.  An account of the primary antibodies 
and their appropriate dilutions is given in Table 2.1.  The Polyclonal Rabbit anti-
sarcomeric α-actinin was kindly donated by Prof. Dieter Fürst.  The Polyclonal Rabbit 
anti-all Myosin Binding Protein C was produced by Prof. Mathias Gautel.  The 
Monoclonal Mouse anti- Myomesin B4 hybridoma supernatant was produced by Dr. 
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Elisabeth Ehler.  The Polyclonal Rabbit anti-NRAP antibody was specially generated by 
immunisation of rabbits with a peptide portion of NRAP by Bioscience (Göttingen, 
Germany) and donated by Dr. Elisabeth Ehler.  All Cy conjugated secondary antibodies 
were purchased from Jackson Immuno Research (West Grove, PA, USA).  All 
secondary antibodies employed in this study were of “multi-labelling” quality, i.e. had 
been tested for a lack of cross-reaction between the relevant species (mouse, rat and 
rabbit). These secondary antibodies were used in combination successfully in the past 
and no cross-reaction was ever seen e.g. (Nosal et al. 1992; Ehler et al. 1999; Lange et 
al. 2002; Ahuja et al. 2004; Ehler et al. 2004; Ahuja et al. 2006; Ahuja et al. 2007; 
Hirschy et al. 2010; Iskratsch et al. 2010; Iskratsch et al. 2013a; Dwyer et al. 2014). The 
mouse and rat HRP conjugated secondary antibodies were purchased from DAKO 
(Glostrup, Denmark) and the goat and rabbit HRP conjugated secondary antibodies 
were purchased from Chemicon (CA, USA).  Counterstains were also used to visualise 
specific subcellular compartments.  An account of the secondary antibodies, 


























































Table 2.1: List of Primary Antibodies used for Western Blotting and 
Immunofluorescence Studies.  Names of primary antibodies are given with the species of 
animal they were raised in.  The companies and individuals where antibodies were acquired 
from are given as the source.  Dilutions for antibodies are listed for western blotting and 
immunofluorescence. WeB, western blotting; IF, immunofluorescence; N/A, not applicable; 
HA, haemagglutinin; GFP, green fluorescent protein; GST, glutathione S-transferase. 














Table 2.2: List of Secondary Antibodies and Counterstains used for Western Blotting 
and Immunofluorescence Studies.  Names of HRP and fluorophore conjugated secondary 
antibodies are given with the species of animal they were raised in and which species they 
recognised.  DAPI was used to visualise nuclei and Alexa fluor conjugated Phalloidin was 
used to visualise F-actin.  The companies where antibodies and counterstains were acquired 
from are given as the source.  Dilutions for antibodies and counterstains are listed for 
western blotting and immunofluorescence. WeB, western blotting; IF, immunofluorescence; 
Cy, cyanine fluor; HRP, horse radish peroxidase; DAPI, 4',6diamidino2phenylindole; N/A, 
not applicable. 
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2.3.1 Validation of Novel Antibodies 
 
We attempted to characterise the specificity of the 5 commercially available anti-
FHOD1 antibodies that were presently used for Western blot and Immunofluorescence 
studies. Validation efforts took place by testing the antibodies against human FHOD1 
and FHOD3 expression constructs in Western blot and immunofluorescence studies. 
Validation efforts for the antibodies recognising total FHOD1 (polyclonal goat anti-
FHOD1 C14 [Santa Cruz], polyclonal goat anti-FHOD1 C20 [Santa Cruz], polyclonal 
mouse anti-FHOD1 [Abcam], polyclonal mouse anti-FHOD1 [ECM Biosciences]) can 
be found in section 3.1. Validation efforts for the polyclonal rabbit anti-
PhosphoThreonine1141 FHOD1 antibody can be found in section 4.2.  
 
2.4 Preparation of Transfection Constructs 
2.4.1 First Strand cDNA Synthesis with Reverse Transcriptase 
 
Human skeletal muscle cDNA was generated for use as a template in PCR.  2μg total 
RNA from adult human skeletal muscle were mixed with 0.5μg d(T)18 and 0.5μg 
d(N)10 Primers.  Nuclease free water was added to make a final volume of 15μl.  The 
mix was incubated at 75°C for 5min and subsequently cooled on ice. Then 5μl of 5x RT 
buffer, 1.5μl of 10 mM dNTPs, 0.5μl RNasin (RNase Inhibitor), 2μl nuclease free water 
and 100U of M-MLV reverse transcriptase (Promega, Madison, WI, USA) were added 
to the mixture. The reaction was incubated at 42°C for 90min. Finally the reverse 
transcriptase enzyme was denatured by incubating at 75°C for 10min. 
2.4.2 PCR 
 
The full-length long variant of FHOD1[1-1191] was amplified from 0.5l human 
skeletal muscle cDNA (See 2.4.1), using LaTaq polymerase (TaKaRa Bio, Shiga, 
Japan) and 0.02nmol sense and antisense primers (synthesized by Eurofins MWG 
Operon, Ebersberg, Germany).  FHOD1 DAD [1-1096] was later amplified using 
0.2l of the GFP-tagged full-length FHOD1 [1-1191] construct DNA as a template.  
50μl total reaction volume contained 25μl 2x GC buffer 1, 80nmol dNTPs, and 2.5U 
LaTaq DNA polymerase. PCRs were performed on a Techne TC-512 thermal cycler 
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(Techne, Chelmsford, UK).   Products were amplified using a touchdown approach (for 
improved product yield), implementing a denaturation temperature of 98°C for 1.5min 
during all cycles. For the first 5 cycles an annealing temperature of 65°C was 
implemented for 2min. For the next 30 cycles the annealing temperature was lowered to 
62°C for 2min. The elongation temperature used throughout the touchdown procedure 
remained at 72°C for 1.5min. 
 
FHOD1 domain constructs (FH2, GBD-DID, GBD, and DID) were amplified using 
0.2l of the full-length FHOD1 [1-1191] construct DNA as a template.  Amplifications 
were performed using 20pmol sense and antisense primers (Eurofins MWG Operon, 
Ebersberg, Germany).  50μl total reaction volume contained 5μl 10x HF buffer, 10nmol 
dNTPs, and 0.8U Phusion-High Fidelity DNA polymerase (Finnzymes, Espoo, 
Finland).  PCRs were performed on a TC-512 thermal cycler.  After hot start and initial 
denaturation at 98°C (1.5min) fragments were amplified with touchdown procedure 
conditions listed above but reducing the extension time to 1min due to the smaller 






















DNA fragments amplified from PCR (See 2.4.2) were cloned into the pEGFP-C1 and 
pEGFP-C2 (Clontech/TaKaRa Bio, Shiga, Japan) vectors for eventual expression as N-
terminally-tagged green fluorescent fusion proteins. Insert DNA was cloned into the 
vector through the EcoRI and KpnI sites. Digests were performed under standard 
conditions with EcoRI (12U/μl Promega, USA) and KpnI (10U/μl, Promega, USA) at 
Table 2.3: List of PCR Primers Used to Amplify FHOD1 Constructs.  Construct names are 
given in the left hand column with the name of the vector used for cloning into, followed by the 
portion of FHOD1 that was amplified.  The middle column lists the primer pairs used for PCR 
reactions and their orientation.  5’3’ indicates sense direction and 3’5’ indicates antisense 
direction.  The right hand column lists the restriction enzymes used and which primer sequence 
they correspond to.  FW, indicates forward primer; RV, indicates reverse primer; L, FHOD1 
long variant; pEGFP C1, green fluorescent protein (GFP) expression vector frame1; pEGFP 
C1, green fluorescent protein (GFP) expression vector frame 2. 
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37°C with subsequent purification with the WizardR SV Gel and PCR Clean-Up 
System (Promega, USA). Inserts were ligated into the vector using a 3:1 insert to vector 
ratio using 1μl of 10x T4 DNA ligase buffer (Promega, USA), 0.5μl of T4 DNA ligase 
(3u/μl, Promega, Madison, WI, USA) in a 10μl reaction. Constructs were transformed 
into competent Escherichia coli (XL1 blue strain) and plated onto LB agar plates 
(Thermo Fisher Scientific Waltham, MA) containing 50μg/ml kanamycin. Colonies 
were selected, cultured overnight in 5ml LB broth liquid cultures (Thermo Fisher 
Scientific Waltham, MA) containing 50μg/ml kanamycin, and the plasmid constructs 
were subsequently purified using the PureYield™ Plasmid Miniprep System (Promega, 
USA).  Refer to Appendix Figure 8.1 for maps of all the FHOD1 expression constructs. 
2.4.4 Sequencing 
 
All sequencing was performed with Eurofins MWG Operon (Ebersberg, Germany).  50-
100ng/l purified plasmid DNA (diluted in 12l H20) were sequenced with 2pmol/l of 
the appropriate sequencing primer.  GFP-tagged constructs were sequenced with the 
GFP forward and SV40 reverse primers specified by MWG.   
2.4.5 Constructs 
 
The following constructs were outsourced. The GFP-FHOD1 full-length short variant 
[1-1164], GST-FHOD1 [1-513], GST-FHOD1 GBD-DID [1-340], LEXA-FHOD1 
[340-585], and LEXA-FHOD1 GBD-DID [1-340] were cloned by the Randall Protein 
Production Facility.  The HA-DLG [1395-1919] was cloned in our laboratory by Nadine 
Lohmann. GFP-FHOD3 FH1 [941-1079] and GFP-FHOD3 CTS [1065-1622] were 
cloned in our laboratory by Dr. Thomas Iskratsch. The TOMATO-FHOD1 [1-1191] and 
the GFP-FHOD1 3A, 3D, GBD, and V228E constructs were kindly donated by Dr. 
Thomas Iskratsch (Columbia University, New York, USA).  The NRAP (SR5-6, SR5-7, 
SR4, r01-r10, LIM) constructs were kindly donated by Dr. Katja Gehmlich (University 
of Oxford, Oxford, UK).  The Rho family small GTPase (CA Rac1 G12V, CA Cdc42 
G12V) and the ROCK (CA ROCK-I 1 and WT ROCK-II) constructs were kindly 
donated by the lab of Prof. Anne Ridley (King’s College London, UK).  The Src (WT, 
CA, DA) constructs were donated by the lab of Dr. Michael Way (LRI, London, UK). 
The remainder of the constructs were made in-house by myself. These included the 
following constructs: GFP-FHOD1 [1-1191], GFP-FHOD1 DAD [1-1128], GFP-
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FHOD1 GBD [1-116], GFP-FHOD1 DID [117-340], GFP-FHOD1 GBD-DID [1-340], 
GFP-FHOD1 FH2 [642-1031], 1095 shRNA construct, 2375 shRNA construct, and the 
2635 shRNA construct. 
2.4.6 Validation of Expression Constructs 
 
Expression constructs were validated by testing their expression in COS-1 cells. COS-1 
cells were transfected (See 2.10.2), cultured to 2 days, and subsequently lysed in SDS 
lysis buffer. Samples were resolved on SDS-PAGE gels with subsequent Western 
blotting (See 2.9.1). This was performed to see if constructs expressed at the correct size 
in cells. 
2.5 RNA Interference 
 
A vector-based shRNA approach was used to deplete FHOD1 in cultured cells.  
Oligonucleotides were designed to target 22 nucleotide sequences of FHOD1 in Rattus 
norvegicus and Mus musculus.  Three sets of sense and antisense 64mer DNA 
oligonucleotides were designed against separate portions of FHOD1 (Table 2.4) and 
were referred to by the section of the FHOD1 coding sequence they corresponded to. 
Oligonucleotides were obtained from Sigma-Genosys (Poole, UK) in 0.05μM scale and 
dissolved to a final concentration of 1mM. 2nmol of forward and reverse 
oligonucleotides were diluted in 50μl of annealing buffer (30 mM HEPES, 100 mM 
potassium acetate and 2mM magnesium acetate at pH 7.4) and incubated for 4min at 
98°C, 10min at 70°C and then slowly cooled down to 4°C.  Annealed oligonucleotides 
were ligated into the BglII and XhoI restriction sites of a modified cDNA 3.1 vector 
(H1GFP vector), which was constructed by Dr. Stephan Lange by inserting the H1 
expression cassette from pSUPER.  The vector functions under the control of the 
polymerase III H1-RNA gene promoter thereby transcribing small RNA transcripts 
which are further processed to siRNAs that target homologous cellular RNA for 
degradation. The vector additionally expresses GFP under control of the CMV 
promoter.  The system is described in   Brummelkamp et al. 2002 (Brummelkamp et al. 
2002). The vector underwent restriction digest by BglII (10U/μl, Promega) and XhoI 
(10U/μl, Promega) and the unphosphorylated DNA oligonucleotides were then ligated 
into the vector and cloned using Escherichia coli (XL1 blue strain) as described above 
(See 2.1.3).  Transformed bacteria were plated onto LB agar plates containing 
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ampicillin 50μg/ml. Colonies were selected, cultured overnight in 5ml LB broth liquid 
cultures with ampicillin 50μg/ml, and the plasmid constructs purified as described 











2.6 Library Screens and Interactions Assays using the Yeast Two-
Hybrid System 
 
The FHOD1 GBD-DID [1-340] and FHOD1 [340-585] fragments were cloned into the 
pLEXA C vector (Dualsystems Biotech, Schlieren, CH) by the Randall Protein 
Production Facility using the EcoRI and KpnI restriction sites.  For yeast 
transformations, plasmid DNA was mixed with denatured salmon sperm DNA 
(Dualsystems Biotech, Schlieren, CH) (~ 20 x plasmid DNA amount), Saccharomyces 
cerevisiae (L40 strain) (initially washed twice in yeast buffer A (10mM Tris-HCl, 1mM 
EDTA, and 100mM LiOAc at pH 7.5)), yeast buffer B (40% PEG 4000, 10mM Tris-
Table 2.4: List of Oligonucleotides Used to Design RNAi Constructs.  Construct names are 
given in the left hand column with the name of the vector used for cloning into.  
Oligonucleotide names incorporate the starting base pair of the target sequence.  The right hand 
column lists the sequence of the 64mer oligonucleotides and their orientation. FW, indicates 
forward primer; RV, indicates reverse primer; H1GFP, RNAi vector functioning under the H1 
promoter that additionally expressed green fluorescent protein (GFP). 
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HCl, 1mM EDTA, and 100mM LiOAc at pH 7.5), and incubated for 20min at 30°C. 
After addition of DMSO to a final concentration of 6%, yeast were heat shocked at 
42°C for 15min, spun down, re-suspended in sterile water and plated on selection plates 
lacking Tryptophan. For library screening, overnight cultures of yeast, already 
transformed with bait construct (FHOD1 GBD-DID [1-340] or FHOD1 [340-585] were 
transformed with pACT2 human cardiac muscle library (Clontech/TaKaRa Bio, Shiga, 
Japan) (kindly donated by Dr. Katja Gehmlich and amplified by Dr. Ay Lin Kho) as 
described above.  After heat shocking, yeast were spun down, re-suspended in 2xYPD 
(Lab M, Lancashire, UK) medium and incubated for 90min at 30°C, spun down again 
and re-suspended in water.  Transformants were screened by plating on selection plates 
lacking the amino acids Histidine, Tryptophan and Leucine. For β-galactosidase 
reporter assays, clones were transferred to Hybond N+ nylon membranes (GE 
Healthcare, Amersham Place, UK) on selection plates, lacking the amino acids 
Tryptophan and Leucine and grown for 3 days at 30°C. Membranes were frozen in 
liquid nitrogen, thawed, transferred to filter paper, pre-soaked with Z-buffer (60mM 
Na2HPO4, 40mM NaH2PO4, 10mM KCl, 1mM MgSO4 and 50mM β-mercaptoethanol 
+ 20μl 2% X-Gal in dimethylformamide) and incubated at 30°C for several hours. 
Library plasmids from positive clones were isolated using the QIAprep miniprep kit 
(Qiagen, Crawley, UK), following the manufacturer’s instructions. Isolated plasmids 
were transformed into Escherichia coli (XL1 blue strain) for amplification. Plasmids 
were sequenced with a Gal4 AD sequencing primer (5’ TAC CAC TAC AAT GGA TG 
3’).  For further verification of the interaction, identified clones were re-transformed 
into the yeast together with the empty pLEXA plasmid or the corresponding FHOD1 
pLEXA  constructs and grown on selection plates lacking Histidine, Tryptophan and 
Leucine and containing 2.5mM 3-amino-1,2,4-triazole.  The NRAP SR5-6 and SR5-7 
were cloned into the pACT2 vector by Dr. Atsushi Fukuzawa and used for the yeast 
two-hybrid assays. 
 
2.7 Protein Expression 
 
For protein expression, constructs were cloned into a pGEX-2TK vector (GE-
Healthcare, Amersham Place, UK), including a GST-tag followed by a thrombin 
consensus sequence on the 5’ end of the insert.  Cloning of the FHOD1 [1-513] GST 
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construct and the FHOD1 GBD-DID [1-340] GST construct was performed by the 
Randall Protein Production Facility.  After amplification of the plasmids in Escherichia 
coli (XL1 blue strain), plasmids were transformed into competent Escherichia coli 
(BL21-RIL strain), which were plated on LB-agar, containing ampicillin (100μg/ml). 
Colonies were picked, transferred into 50ml LB broth liquid cultures containing 
ampicillin (100μg/ml) and grown at 37°C while shaking at 150rpm until OD600 reached 
0.6. Protein expression was then induced by addition of isopropyl β-D-1-
thiogalactopyranoside (IPTG) to a final concentration of 0.4mM. Protein was expressed 
overnight at 18°C with cultures shaking at 150rpm. For lysis, cell suspensions were 
spun down and the pellet was re-suspended in pull-down lysis buffer with 1x protease 
inhibitor cocktail before addition of lysozyme. Cell suspensions were incubated for 1hr 
on ice while shaking before sonication (Jencons, Lutterworth, UK) and centrifugation at 
5000 x g and 4°C for 30min. For GST-fusion proteins, glutathione sepharose 4 fast flow 
beads (GE Healthcare, Amersham Place, UK) at ~100μl/100ml initial culture volume 
were added to the lysates and incubated for 90min at 4°C on a rotating wheel. After 
incubation, beads were separated by centrifugation (3000 rpm, 4°C, 5min) and washed 3 
times with pull-down lysis buffer. Overexpression and purification of GST-fusion 
proteins were confirmed by Western blotting (See 2.9.1) and Coomassie staining (2.9.2) 
as described below. 
 
2.8 GST Pull-down Assay 
 
The amount of GST-fusion protein bound to glutathione beads utilised for the GST-pull 
down assays was estimated by standardisation using SDS-PAGE (See 2.9.1) and 
Coomassie staining (See 2.9.2). Prior to commencing pull-down assays, 10% of the 
target protein lysates were taken as an input control. The cell lysates were incubated 
with the beads overnight on a rotating wheel at 4°C. Pull-down assays yielding a 
positive interaction were repeated by incubating cell lysates with the beads for 1 hr on a 
rotating wheel at 4°C. Three wash steps in pull-down lysis buffer using 10 times of the 
used bead volume were carried out for 1 min with gentle rotation on ice. After the first 
spinning at 4,000 rpm for 30 sec, 10% of the supernatant was taken as a second control. 
SDS lysis buffer was added to the final pellet in a ratio of 1:1 followed by boiling for 5 
min, SDS-PAGE, and Western Blotting as described (See 2.9.1).  




Although the pull-down lysis buffer was sufficient for extraction of the majority of the 
target proteins used for pull-down assays, the conditions in the buffer were not 
optimised for each of the interactions being tested. The lack of optimisation was 
reflected by the absence of positive controls for many seemingly negative interactions; 
therefore a number of the pull-down assays were inconclusive.  
2.9 Resolution of Protein Samples by Gel Electrophoresis 
2.9.1 SDS-PAGE and Western Blotting 
 
Samples were electrophoretically separated on polyacrylamide minigels (Mini-Protean 
Electrophoresis System, Biorad, Hercules, Ca, USA).  Tissue SDS samples were run on 
7.5% SDS gels and other lysates were run on 10-12% SDS gels for Western Blotting. 
Gels were run at 200mV.  A rainbow marker (Novex marker, Invitrogen, Carlsbad, CA, 
USA) was included for size standardisation. The gel containing the samples was then 
blotted onto a nitrocellulose membrane (Amersham, UK) in a wet Western blot 
apparatus and left to transfer in blotting buffer (25mM Tris-Base pH 8.3, 192mM 
Glycine, 0.01% SDS, and 20% methanol) overnight at 60mA.  Membranes were stained 
with Ponceau red stain (Sigma, St. Louis, MO, USA) to confirm transfer and equal 
loading of protein samples. Blocking and destaining took place in 5% non-fat milk in 
low salt buffer (0.9% NaCl, 0.1% Tween-20, 9mM Tris Base pH7.4).  Membranes were 
incubated with primary and secondary antibodies for 1hr at room temperature with three 
5min washing steps in between.  Protein bands were then visualised by enhanced 
chemiluminescence with 1min incubation of membranes in ECL solution (7.5ml H2O, 
1ml 10x Luminol (250 mg Luminol in 50ml H2O), 1ml 10x Iodophenol (55mg 
Iodophenol in 50ml DMSO), 0.5ml 1M Tris pH 7.5, 5l H2O2).  Luminol was 
purchased from Sigma (Sigma, St. Louis, MO, USA) and Iodophenol from Fluka 
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2.9.2 Quantification of Western Blots 
 
Quantification of the relative expression levels of FHOD1 in murine tissues on Western 
blots was performed with ImageJ software. The ImageJ software measurement tool was 
used to quantify the level of intensity within each region of interest (ROI) (i.e., band) in 
images converted to grayscale. The measurement tool was set to quantify mean grey 
value and area. The rectangle tool was used to capture each ROI and measurement areas 
were fitted to capture individual ROI. Background measurements of Western blots were 
also captured by taking measurements outside the ROI. Measurements were all adjusted 
to the rectangular area used around each ROI; this essentially calculated intensity per 
unit area of measurement. Background measurements were then subtracted from 
measurements of each band on the same blot. Quantification of relative FHOD1 levels 
in muscle tissue lysates was performed by normalising measurements to sarcomeric α-
actinin levels. The present methodology is exemplified in the following flow of 
equations: 
 
𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑅𝑒𝑎𝑑𝑖𝑛𝑔 = (
𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡 𝑂𝑢𝑡𝑠𝑖𝑑𝑒 𝑅𝑂𝐼





𝐴𝑟𝑒𝑎 𝑜𝑓 𝑅𝑒𝑐𝑡𝑎𝑛𝑔𝑙𝑒 𝑢𝑠𝑒𝑑 𝑡𝑜 𝑀𝑒𝑎𝑠𝑢𝑟𝑒 𝑅𝑂𝐼 
− 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑅𝑒𝑎𝑑𝑖𝑛𝑔 
 
 − 𝑎𝑐𝑡𝑖𝑛𝑖𝑛 𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡 =
𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡 𝑜𝑓 𝑅𝑂𝐼
𝐴𝑟𝑒𝑎 𝑜𝑓 𝑟𝑒𝑐𝑡𝑎𝑛𝑔𝑙𝑒 𝑢𝑠𝑒𝑑 𝑡𝑜 𝑚𝑒𝑎𝑠𝑢𝑟𝑒 𝑅𝑂𝐼 
− 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑅𝑒𝑎𝑑𝑖𝑛𝑔 
 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐸𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝐿𝑒𝑣𝑒𝑙 =  
𝐹𝐻𝑂𝐷1 𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡
 − 𝑎𝑐𝑡𝑖𝑛𝑖𝑛 𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡
 
 
The quantification of Western blots was potentially restricted by the innate drawbacks 
of the technique and particularly the attainment of the linear range desired for accurate 
quantification. Enhanced chemiluminescence is limited by the characteristics of the X-
ray film used: a minimal threshold for silver activation and the finite amount of silver 
grain available to detect signals can result in the non-linear response of X-ray film to 
weak or strong signals. Very faint signals, resulting from low light emission, may be 
underrepresented on X-ray films due to improper activation of the silver on the 
membrane. The amount of silver present on the film also represents a limiting substrate 
in detection of the chemiluminescence reaction. Oversaturation of the X-ray film can 
occur in the presence of a strong signal. In this situation, further signal cannot be 
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detected, the optical density of the band will plateau, and subsequent measurements will 
be underrepresented. The desirable linear range for quantification can thus be obtained 
when the density of the band on the film is proportional to the exposure time. Therefore, 
upon underexposure or oversaturation of protein signals on Western blots, a non-linear 
relationship between the amount of protein and the observed signal occurs and will 
skew quantification.  
 
2.9.2.1 Statistical Analysis used for Quantification of Western Blots 
 
The quantification of FHOD1 expression relative to -actinin effectively compared the 
average levels of expression across different tissues. Three Western blots using samples 
from two C57/BL6 mice were quantified for this purpose and allowed for basic 
statistical analysis to be performed. In order to see if levels of expression were 
significantly different between two tissues, we employed an unpaired, two-tailed 
student’s t-test. The student’s t-test was deemed appropriate for this analysis since the 
means were being compared between 2 samples under the same condition (i.e., different 
treatment arms were not employed that would necessitate implementation of ANOVA 
analysis). Independent samples (e.g., murine heart, soleus, and tibialis anterior) were 
used for analysis of expression levels; therefore the t-test was unpaired. Since 
expression levels for a given sample could theoretically be higher or lower than the 
comparator sample, a two-tailed approach was used to test significance in both 
directions. A value of P <0.05 was considered significant. The level of variability in 
expression levels was calculated using standard error of the mean (SEM) 
2.9.3 Coomassie Staining 
 
Polyacrylamide gels were stained with boiling 0.1% Coomassie Brilliant Blue R250 in 
40% methanol and 10% acidic acid for 30min and subsequently destained for 30min in 
boiling 10% acidic acid. 
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2.10 Transient Expression Studies 
2.10.1 Transient Transfection of Neonatal Rat Cardiomyocytes 
 
NRCs were isolated as described above (See 2.2.1) and 1d after plating were transferred 
to transfection medium and transfected with approximately 1μg of plasmid DNA per 
30mm plate using 3l Escort III transfection reagent (Sigma, St. Louis, MO, USA). 
After 6hr, medium was replaced with NRC maintenance medium for short term 
transfections (up to 48hr) and subsequently replaced with transfection medium for long 
term transfections (> 48hr). Unless otherwise stated, cells were cultured for 48 h at 
37°C in 10% CO2.  
2.10.2 Transient Transfection of COS-1 Cells 
 
COS-1 cells were cultured as described above (See 2.2.3). Cells were transfected with 
approximately 1μg of plasmid DNA per 30mm plate, using Escort IV, following 
supplier’s instructions (Sigma, St. Louis, MO, USA). After 48hr of maintenance at 37°C 
in 5% CO2, cells were either fixed with 4% paraformaldehyde/PBS for 10min and 
examined by fluorescence microscopy, lysed with SDS lysis buffer for SDS-PAGE and 
western blotting, or lysed with pull-down assay lysis buffer. 
2.10.3 Transient Transfection of C2C12 Cells 
 
C2C12 cells were cultured as described above (See 2.2.4). Cells were transfected with 
approximately 1μg of plasmid DNA per 30mm plate, using Lipofectamine LTX with 
Plus reagent (Invitrogen, Carlsbad, CA, USA), following supplier’s instructions.  After 
24hr of culture cells were then changed into C2C12 differentiation medium. 
2.10.4 Transient Transfection of HeLa Cells 
 
HeLa cells were cultured as described above (See 2.2.5). Cells were transfected with 
approximately 1μg of plasmid DNA per 30mm plate, using Lipofectamine LTX with 
Plus reagent (Invitrogen, Carlsbad, CA, USA), following supplier’s instructions. After 
24hr in maintenance medium at 37°C in 5% CO2, cells were then changed into 
starvation medium (0.1% foetal calf serum, 1% penicillin–streptomycin, and 4mM 
Glutamine in DMEM) for 24hr prior to being fixed with paraformaldehyde. 




2.11.1 Staining of Cultured Cells 
 
NRCs, ARCs, COS-1, C2C12, and HeLa cells were fixed prior to staining. Cells were 
fixed with 4% paraformaldehyde/PBS for 10min or with pre-cooled methanol (-20°C) 
for 5min at -20°C.  When staining for endogenous FHOD1 in cells we compared 
paraformaldehyde and methanol fixation and their effect on the signals produced by the 
commercially available anti-FHOD1 antibodies.  Paraformaldehyde fixation gave a 
consistently stronger and clearer signal for FHOD1, therefore it was used for all of the 
antibody localisation studies.  Furthermore, localisation of the FHOD1 signal was not 
dependent on the fixation method.  Permeabilisation took place using 0.2% Triton X-
100/PBS for 2 min for COS-1, C2C12, and HeLa cells and 5min for NRCs and ARCs.  
Primary antibodies were diluted in Gold buffer (20 mM Tris, 155 mM NaCl, 2 mM 
EGTA, 2 mM MgCl2 at pH 7.5), as listed in Table 2.1. For triple-immunofluorescence 
staining Cy2/Alexa Fluor 488, Cy3 and Cy5/Alexa Fluor 633 conjugated secondary 
antibodies and Phalloidin (Invitrogen, Renfrew, UK), as well as 4',6-diamidino-2-
phenylindole (DAPI, Sigma, St. Louis, MO, USA) were used. For double labelling of 
primary mouse antibodies together with monoclonal rat anti-HA, cross adsorbed anti-
mouse and anti-rat antibodies were used. Secondary antibodies were diluted as listed in 
Table 2.2.  Antibody incubations took place for 1hr at room temperature in a humid 
chamber. After each step, cells were washed 3 times for 5min with PBS.  Finally, cells 
were mounted in Lisbeth’s medium (0.1 M Tris-HCl/glycerol (3:7) and 50 mg/ml n-
propylgallate at pH 9.5) with a glass coverslip (Messerli et al. 1993).  Where cells where 
transfected with TOMATO-tagged constructs, dishes were mounted in Cherry mounting 
medium (See 2.13).  




 mouse hearts were frozen down in methylbutane, which was 
chilled in liquid nitrogen immediately after dissection and stored at -80°C until 
sectioning (See 2.1.2). Tissue sections were blocked in 5% horse or goat serum in Gold 
buffer for 20min.  Staining took place using the same procedure with cultured cells (See 
2.11.1). 
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2.11.3 Confocal Microscopy 
 
All confocal microscopy was performed on a LSM510 laser scanning confocal 
microscope (Carl Zeiss MicroImaging GmbH, Jena, Germany) with solid state (diode) 
laser excitation at 405 nm and emission at 420-480 nm, Ar-laser excitation at 488 nm 
and emission at 505-530 nm or He-Ne-laser excitation at 546 and 633 nm and emission 
at 560-615 nm and > 650 nm, respectively,  using a Plan-Apochromat 63x/1.4 oil 
objective, Plan-Neofluar 40x/0.9 oil objective, or a LCI Plan-Neofluar 25x/0.8 oil 
objective. An optical slice of 284 nm was used to acquire images. Sequential scans were 
used to acquire images in order to avoid bleedthrough. Visual inspection/cross-checking 
of individual channels was also performed prior to scanning images in order to partly 
gain a sense of bleedthrough between channels and possible background.  
2.11.4 Quantification of F-actin Staining 
 
Transfected HeLa cells were stained with Phalloidin as described above (2.11.1).  
Levels of F-actin were quantified from confocal images using ImageJ.  10 views were 
used for each construct per experiment using the Plan-Neofluar 40x/0.9oil objective. 1-5 
transfected cells and 3-6 untransfected cells were present per view. In each view the 
Phalloidin pixel intensity was measured individually in transfected and untransfected 
cells.  Values were obtained by normalising the average Phalloidin pixel intensities in 
transfected cells to untransfected cells. However, since the experiment was only 
performed once, it did not allow for an adequate sample size for statistical analysis to 
ensue. Instead, variability of the F-actin ratio measured for each construct was 
represented with standard deviation.  
 
One caveat that applied to the measurement of the F-actin signal in HeLa related to the 
possibility that measurements may not have been captured within the desired linear 
range for quantification. Although fluorescence exhibits a fairly broad linear range, 
measurements may be skewed in the presence of a very bright signal. In this assay, the 
presence of F-actin stress fibres, with relatively bright staining for F-actin, may have 
been a source of error in the measurement of the Phalloidin pixel intensity. When 
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measurements are performed in the presence of an oversaturated F-actin signal, the 
relationship between the level of F-actin and the present signal is no longer linear.  
2.11.5 Scoring of Myofibrillar Integrity for F-actin/Myofibril 
Depolymerisation Assay 
 
The integrity of myofibrils was judged by looking at the distribution of -actinin and F-
actin, namely if they were incorporated into myofibrils and regained their striated 
appearance. Staining for F-actin was used to visualise myofibrils. Organisation at the 
level of the sarcomere was assessed by staining for the Z-disk marker, -actinin.  
Transfected cells were counted and grouped according to whether they had poor, 
intermediate, or excellent myofibrillar integrity. Cells deemed to exhibit poor 
myofibrillar integrity were devoid of myofibrils and displayed patchy and irregular -
actinin staining. Cells deemed to exhibit intermediate myofibrillar integrity displayed 
evidence of filamentous F-actin-based structures with -actinin distributing along them, 
although the spacing of -actinin was irregular and hence indicated improper formation 
of the Z-disks. Cells deemed to have excellent myofibrillar integrity displayed well-
formed myofibrils with regularly spaced Z-disks. Due to the fairly heterogeneous 
response seen with Latrunculin B treatments, baseline measurements were taken in 
untransfected cells as a comparison.  
 
2.11.6 Calculation of Fusion Index in Differentiating C2C12 Cells 
 
For RNAi experiments, a fusion index was calculated for day 7 C2C12 cells transfected 
with the shRNA constructs and the empty shRNA vector. Cells were stained with DAPI 
for enumeration of nuclei. Transfected cells were identified by their GFP signal, since 
the shRNA vectors additionally express GFP. The fusion index was calculated by taking 
the number of nuclei in transfected cells and dividing it by the total number of 
transfected cells.  This essentially calculated the number of nuclei per cell. The values 
were represented as the average fusion index for the 70-100 cells that were counted for 
each construct. However, since the experiment was only performed once, it did not 
allow for an adequate sample size for statistical analysis to ensue. Instead, variability of 
the fusion indices measured for each construct was represented with standard deviation. 
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2.12 Sequence Alignment 
2.12.1 Amino Acid Sequence Alignment 
 
Sequence alignment was performed with clustalw2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Alignment was performed using the 
amino acid sequence of FHOD1 from human (Homo sapiens; NCBI Reference 
Sequence: NP_037373.2), rat (Rattus norvegicus; NCBI Reference Sequence: 
NP_001178529.1), and mouse (Mus musculus; NCBI Reference Sequence: 
NP_808367.2). This was performed to look at the extent of sequence similarity between 
human and rodent FHOD1.  
2.12.2 Nucleic Acid Sequence Alignment 
 
Alignment of the shRNA target sequences used for RNAi experiments was performed 
with Mega5 (Tamura et al. 2011). Alignment was performed using the DNA sequence 
of FHOD1 from human (Homo sapiens; Accession No: NM_013241.2), rat (Rattus 
norvegicus; Accession No: NM_001191600.1), and mouse (Mus musculus; Accession 
No: NM_177699.4). This was performed to confirm that the shRNA target sequences 
were matched to the corresponding sequence on rodent fhod1 and to highlight 

















  Materials and Methods 
132 
 
Table 2.5: List of Buffers, Solutions, and Media Used in all Experimental Procedures.  
Alphabetised list describing the contents of the buffers, solutions, and media used in all 
molecular, biochemical, and cell biological experimental procedures.  


























3. Expression and Localisation of 
FHOD1 
 
3.1 Validation of Commercially Available Anti-FHOD1 Antibodies 
 
In order to investigate the expression and localisation of FHOD1 at the tissue level, we 
performed Western blot and immunofluorescence studies with FHOD1 specific 
antibodies. We only used commercially available antibodies, however, due to the high 
levels of homology between formin family members and based on potential cross-
reactivity of polyclonal antisera with other muscle proteins, we attempted to validate the 
specificity of our reagents.  4 different commercially available anti-FHOD1 antibodies 
were used to examine FHOD1.  The 4 antibodies designed to recognise total levels of 
endogenous FHOD1 included the following: Polyclonal goat C14 anti-FHOD1 (Santa 
Cruz); Polyclonal goat C20 anti-FHOD1 (Santa Cruz); Polyclonal mouse anti-FHOD1 
(Abcam); Polyclonal mouse anti-FHOD1 (ECM Biosciences).  The polyclonal goat C14 
anti-FHOD1 was raised against a peptide within an internal region of human FHOD1 
whereas the C20 antibody was raised against a peptide near the C-terminus of human 
FHOD1. The polyclonal mouse anti-FHOD1 antibodies were raised against full-length 
human FHOD1. 
 
The specificity of these 4 commercially available anti-FHOD1 antibodies was first 
tested against epitope tagged FHOD1 constructs, comprised of full-length variants of 
the protein as well as fragments. The expression constructs were transfected into COS-1 
cells prior to harvest and visualization by Western blotting with the 4 anti-FHOD1 
antibodies. The following constructs were used (Figure 3.1): GFP-tagged long variant of 
full-length FHOD1 comprising the alternatively spliced exons 12-13 [1-1191] (Figure 
3.1 A); GFP-tagged short variant of FHOD1 lacking the alternatively spliced exons 12-
13 [1-1164] (Figure 3.1 B); GFP-tagged truncation mutant of the long FHOD1 variant 
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lacking the C-terminal diaphanous autoregulatory domain (FHOD1 DAD [1-1228]) 
(Figure 3.1 C); GFP-tagged truncation mutant of the long variant lacking the N-terminal 
GTPase binding domain (FHOD1 GBD [117-1191]) (Figure 3.1 D); GFP-tagged 
FHOD1 [1-340], the N-terminus comprised of the GBD and diaphanous inhibitory 
domain (DID) (Figure 3.1 E); GFP-tagged GBD [1-116] (Figure 3.1 F); GFP-tagged 
DID (Figure 3.1 G); GFP-tagged formin homology 2 (FH2) domain [642-1031] (Figure 
3.1 H); HA-tagged FHOD1 C-terminus [641-1191/616-1164] (Figure 3.1 I).  















The following expression experiments describe qualitative results since the exact 
protein concentration was not determined before loading (Figure 3.2). In these 
experiments, some degradation of the longer FHOD1 constructs was apparent as 
evidenced by lower running faint bands. Western blot analysis revealed the portions of 
FHOD1 recognised by the commercially obtained antibodies. The polyclonal mouse 
FHOD1 antibodies from ECM Biosciences (Figure 3.2 A) and Abcam (Figure 3.3 B) 
recognised all of the variants and fragments of FHOD1. These antibodies therefore 
seemingly recognise multiple epitopes on FHOD1 within the N and C-termini. One 
Figure 3.1: Maps of FHOD1 Expression Constructs used for Antibody Validation.  
Schematic representation of the different human FHOD1 expression constructs used 
throughout experimental procedures.  A) GFP-tagged full-length long variant [1-1191] 
containing the alternatively spliced exons (E12-13). B) GFP-tagged full-length short variant 
[1-1164] lacking the alternatively spliced exons (E12-13). C) GFP-tagged full-length long 
variant truncation mutant containing the alternatively spliced exons (E12-13) and lacking the 
GBD [117-1191]. D) GFP-tagged full-length long variant truncation mutant containing the 
alternatively spliced exons (E12-13) and lacking the DAD [1-1128].  E) GFP-tagged GBD-
DID [1-340]. F) GFP-tagged GBD [1-116]. G) GFP-tagged DID [117-340]. H) GFP-tagged 
FH2 [642-1031]. I) HA-tagged C-terminal construct of FHOD1 [641-1191/616-1164]. Amino 
acid length is given in brackets []. GBD, GTPase binding domain; DID, diaphanous 
inhibitory domain; FH, formin homology; DAD, diaphanous autoregulatory domain. 
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limitation of this experiments was that we were unable to ascertain whether the 
antibodies recognized portions of FHOD1 found within amino acids 341 to 641 on the 
long variant of FHOD1 containing the alternatively spliced exons or amino acids 341 to 
615 on the short variant of FHOD1 lacking the alternatively spliced exons. These 
regions corresponded to the linker region and FH1 domain of FHOD1. While the 
seemingly indiscriminate recognition of multiple epitopes could call into question the 
specificity of the polyclonal mouse antibodies, this finding was in line with the fact that 
these antibodies were raised against the full-length FHOD1 molecule; therefore it is 
conceivable that they recognised multiple epitopes on the protein. The polyclonal goat 
antibodies recognised the full-length long and short variant of FHOD1 as well as the 
truncation mutants lacking either the GBD or DAD (Figure 3.2 C-D). Unlike the 
polyclonal mouse antibodies, the polyclonal goat antibodies specifically recognised the 
FH2 domain and the FHOD1 C-terminal construct, out of the FHOD1 fragments tested 
and did not show any reaction with GBD and/or DID. This is as expected considering 
that the polyclonal goat C14 and C20 antibodies were raised against an internal portion 
and a C-terminal portion of FHOD1, respectively. However, the caveat applies that we 
were unable to test for the specificity of the polyclonal goat antibodies against the 
portion of FHOD1 comprised of the linker region and FH1 region. 
 
Overall, we demonstrated that the 4 antibodies could recognise human FHOD1 
constructs on Western blots. In the case of the polyclonal mouse antibodies, these 
recognized multiple fragments of FHOD1 whereas the polyclonal goat antibodies 
recognized the C-terminus of FHOD1 but did not recognize the FHOD1 N-terminus, 
despite adequate expression of the GFP-tagged FHOD1 N-terminal fragments (Figure 
3.2 E). It is unclear whether the polyclonal goat antibodies preferentially recognized the 
FH2 domain or the sequence of FHOD1 that lies downstream of the FH2 domain since 
the HA-tagged C-terminal FHOD1 construct also comprised the FH2 domain. Overall, 
the antibodies recognized the full-length human FHOD1 constructs and this was not 
mediated by the presence of the GFP tag, which was included on gels as a control.  





































Figure 3.2: Validation of anti-FHOD1 Antibodies against FHOD1 Constructs.  COS-1 
cells were transfected with the following epitope tagged FHOD1 constructs: GFP-tagged full-
length long variant [1-1191] containing the alternatively spliced exons (E12-13); GFP-tagged 
full-length short variant [1-1164] lacking the alternatively spliced exons (E12-13); GFP-tagged 
full-length long variant truncation mutant containing the alternatively spliced exons (E12-13) 
and lacking the GBD [117-1191]; GFP-tagged full-length long variant truncation mutant 
containing the alternatively spliced exons (E12-13) and lacking the DAD [1-1128].; GFP-
tagged GBD-DID [1-340]; GFP-tagged GBD [1-116]; GFP-tagged DID [117-340]. H) GFP-
tagged FH2 [642-1031]; HA-tagged C-terminal construct of FHOD1 [641-1191/616-1164].  
Cells were cultured to day two prior to lysis and resolution by SDS-PAGE followed by 
Western blotting.  Blots were tested with the commercially available anti-FHOD1 antibodies in 
order to gauge the specificity of each antibody.  Blots were incubated with the following anti-
FHOD1 antibodies: A) Polyclonal Mouse (ECM Biosciences); B) Polyclonal Mouse (abcam); 
C) Polyclonal goat C20 (Santa Cruz); D) Polyclonal goat C14 (Santa Cruz). E) Expression of 
the GFP-tagged constructs was confirmed by incubating blots the with the anti-GFP antibody. 
F) Expression of the HA-tagged FHOD1 C-terminal construct was confirmed using the anti-
HA antibody. Relative molecular weight marker is shown on the left hand side of blots. Amino 
acid length is given in brackets []. Some degradation was apparent for the longer FHOD1 
constructs. GBD, GTPase binding domain; DID, diaphanous inhibitory domain; FH, formin 
homology; DAD, diaphanous autoregulatory domain. N=3 
 




In order to rule out cross-reactivity with FHOD1’s sister homolog, FHOD3, we 
performed Western blot and immunofluorescence studies using COS-1 cells that were 
transiently transfected by the full-length long variant of FHOD1 [1-1191], HA-tagged 
FHOD3, or the empty GFP vector. Cross-reactivity with FHOD3 could have 
represented an issue since human FHOD1 and FHOD3 bear 52.1% amino acid 
similarity. While the anti-FHOD1 antibodies recognised GFP-tagged FHOD1 as a band 
running around 156kDa, none of the anti-FHOD1 antibodies displayed evidence of 
cross-reactivity with FHOD3 on Western blots (Figure 3.3 A-D) despite the presence of 
HA-tagged FHOD3 in the lanes (Figure 3.3 F), which resolved as a band running at 
approximately 160kDa. While the lower running bands in the lanes of lysates with GFP-
tagged FHOD1 most likely represented degradation products, the band running near the 
128kDa marker produced by the polyclonal goat anti-FHOD1 antibodies in all three 
lanes likely represented recognition of endogenous FHOD1 in COS-1 cells. However, in 
the absence of an antigen competition assay, it was not possible to determine with 
certainty that this band corresponded to endogenous FHOD1. Overall, the present 
Western blot studies indicated that the anti-FHOD1 antibodies recognised human 







































Figure 3.3: Assessment of Cross-Reactivity against FHOD3 with the anti-FHOD1 
Antibodies by Western Blotting.  COS-1 cells were transfected with the GFP-tagged full-
length long variant of FHOD1 containing the alternatively spliced exons (E12-13) or the HA-
tagged full-length long variant of FHOD3.  Cells were cultured to day two prior to lysis and 
resolution by SDS-PAGE followed by Western blotting.  Blots were tested with the 
commercially available anti-FHOD1 antibodies in order to gauge the specificity of each 
antibody and to rule out any cross-reactivity with FHOD3.  Blots were incubated with the 
following anti-FHOD1 antibodies: A) Polyclonal Goat C14 (Santa Cruz), B) Polyclonal Goat 
C20 (Santa Cruz), C) Polyclonal Mouse (abcam), D) Polyclonal Mouse (ECM Biosciences), E) 
Phospho-Thr1141 (ECM Biosciences). E) Blots were visualised using the anti-GFP antibody to 
confirm the presence of GFP-tagged FHOD1. F) Blots were visualised with the anti-HA 
antibody to confirm the presence of HA-tagged FHOD3, especially in the absence of cross-
reactivity with the anti-FHOD1 antibodies.  Lane 1, lysates of COS-1 cells transfected with 
GFP-FHOD1; Lane 2, lysates of COS-1 cells transfected with HA-FHOD3; Lane 3, lysates 
from untransfected COS-1 cells. Relative molecular weight marker is shown on the left hand 
side of blots. Some degradation was apparent with the FHOD1 construct. GFP, green 
fluorescent protein. HA, haemagglutinin. N=2 
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Results from immunofluorescence studies resonated those found via Western blotting. 
The anti-FHOD1 antibodies recognised GFP-tagged FHOD1 when overexpressed in 
COS-1 cells (Figure 3.4). With the exception of the polyclonal goat C14 antibody, 
which produced a signal for FHOD1 that only displayed minimal co-localisation with 
GFP-tagged FHOD1 (Figure 3.4 A), the remainder of the anti-FHOD1 antibodies 
produced a signal that displayed abundant co-localisation with GFP-tagged FHOD1 
throughout the cytoplasm of cells (Figure 3.4 B-D). Control cells, transfected with the 
empty GFP vector and thus expressing just the GFP tag, were also stained with the anti-
FHOD1 antibodies (Figure 3.5). No substantial co-localisation was noted between the 
antibody signal and the GFP tag. In COS-1 cells transfected with HA-tagged FHOD3 
(Figure 3.6), no co-localisation was noted between the signal produced by the anti-
FHOD1 antibodies and the HA signal, indicating that the antibodies did not recognise 
human FHOD3. While we were able to rule out cross-reactivity of the anti-FHOD1 
antibodies with human FHOD3, we were unable to do so with certainty for rodent 
FHOD3. However, similarly to human FHOD1 and FHOD3, which bear 52.1% amino 
acid similarity, human FHOD1 bears 56% amino acid similarity to rat and mouse 
FHOD3. This comparable level of homology was not associated with cross-reactivity of 
the anti-FHOD1 antibodies when human FHOD3 constructs were concerned and 
suggest that it would be a similar case for rodent FHOD3, however, such findings are 
merely suggestive that no cross-reactivity would occur and do not substitute for 





















Figure 3.4: Validation of anti-FHOD1 Antibodies with Full-length FHOD1 by 
Fluorescence Confocal Microscopy.  COS-1 cells were transfected with GFP-tagged full-
length long variant of FHOD1 containing the alternatively spliced exons (E12-13), cultured to 
day two, fixed, and stained with the commercially available anti-FHOD1 antibodies.  This 
was performed in order to gauge the specificity of each antibody in immunofluorescence 
specimens.  COS-1 cells were stained with the following anti-FHOD1 antibodies: A) 
Polyclonal goat C14 (Santa Cruz), B) Polyclonal goat C20 (Santa Cruz), C) Polyclonal 
mouse (Abcam), D) Polyclonal mouse (ECM Biosciences). GFP-FHOD1 is seen in green, 
anti-FHOD1 antibodies in red, F-actin in blue.  Scale bar represents 10m. N=2 










Figure 3.5: Assessing the Reactivity of the anti-FHOD1 Antibodies against GFP by 
Fluorescence Confocal Microscopy.  COS-1 cells were transfected with the empty GFP 
vector, cultured to day two, fixed, and stained with the commercially available anti-FHOD1 
antibodies.  This was performed in order to gauge the specificity of each antibody in 
immunofluorescence specimens.  COS-1 cells were stained with the following anti-FHOD1 
antibodies: A) Polyclonal goat C14 (Santa Cruz), B) Polyclonal goat C20 (Santa Cruz), C) 
Polyclonal mouse (Abcam), D) Polyclonal mouse (ECM Biosciences). GFP-FHOD1 is seen 
in green, anti-FHOD1 antibodies in red, F-actin in blue.  Scale bar represents 10m. N=2 
























Figure 3.6: Validation of anti-FHOD1 Antibodies with Full-length FHOD3 by 
Fluorescence Confocal Microscopy.  COS-1 cells were transfected with the HA-tagged full-
length long variant of FHOD3, cultured to day two, fixed, and stained with the commercially 
available anti-FHOD1 antibodies.  This was performed in order to gauge the specificity of each 
antibody in immunofluorescence specimens and to rule out any cross-reactivity with FHOD3.  
COS-1 cells were stained with the following anti-FHOD1 antibodies: A) Polyclonal goat C14 
(Santa Cruz), B) Polyclonal goat C20 (Santa Cruz), C) Polyclonal mouse (Abcam), D) 
Polyclonal mouse (ECM Biosciences). HA-FHOD3 is seen in green, anti-FHOD1 antibodies in 
red, F-actin in blue.  Scale bar represents 10m. N=2 
 




While the above studies addressed the specificity of the FHOD1 antibodies against the 
human FHOD1 protein, they do not clarify whether the antibodies were sensitive 
enough to recognise FHOD1 in mouse and rat tissues. In the absence of rodent FHOD1 
constructs, we performed an amino acid sequence comparison of the short variant of 
human FHOD1 with rat and mouse FHOD1 (Figure 3.7). The overall sequence identity 
between human FHOD1 and rat FHOD1 was 86%. Homology between the human 
FHOD1 N-terminus [1-357] and the rat FHOD1 N-terminus [1-360] was 94%. 
Homology between the human FHOD1 internal portion [358-626] and the rat FHOD1 
internal portion [361-619] was 73%. Homology between the human FHOD1 C-terminus 
[627-1164] and the rat FHOD1 C-terminus [620-1138] was 86%. The overall sequence 
identity between human FHOD1 and mouse FHOD1 was 91%. Homology between the 
human FHOD1 N-terminus [1-357] and the mouse FHOD1 N-terminus [1-360] was 
94%. Homology between the human FHOD1 internal portion [358-626] and the mouse 
FHOD1 internal portion [361-619] was 75%. Homology between the human FHOD1 C-
terminus [627-1164] and the mouse FHOD1 C-terminus [620-1138] was 91%. This 
sequence comparison suggested that human FHOD1 bears considerable homology to rat 
and mouse FHOD1, particularly within the N and C-termini. We demonstrated via 
Western blot analysis that the polyclonal mouse antibodies recognised portions of the 
FHOD1 N and C-termini. Furthermore, we demonstrated that the polyclonal goat 
antibodies recognised portions of the FHOD1 C-terminus. Therefore, the commercially 
available anti-FHOD1 antibodies could conceivably have possessed sufficient 
sensitivity to recognize rodent FHOD1 at the tissue and cellular level. However, such 
findings are only suggestive of sensitivity and do not substitute biochemical verification 
of antibody sensitivity against rodent FHOD1 constructs.  
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3.2 Expression of FHOD1 in Muscle 
 
The characterisation of FHOD1 was initiated by examining the expression pattern of the 
FHOD1 protein in murine muscle samples.  Currently there are few studies describing 
the expression of FHOD1 in muscle.  FHOD1 mRNA has been found in lymphatic 
tissue but also in skeletal muscle, cardiac muscle, lung, kidney, and colon (Gill et al. 
2004).  Originally, FHOD1 was found to be abundantly expressed in the spleen 
(Westendorf et al. 1999).  FHOD1 protein was previously described as being expressed 
in the aortic and coronary vasculature, bladder, lung, testis, stomach, and skeletal 
muscle (Wang et al. 2004).  However, the protein expression profile of FHOD1 is not in 
complete agreement with the reported mRNA expression profile, since FHOD1 
expression has been reported as absent in murine myocardial lysates (Staus et al. 
2011a). However, a more-recent study reported FHOD1 expression at the mRNA 
transcript and protein level in human cardiac and skeletal muscle (Krainer et al. 2013).  
Presently, expression levels of FHOD1 were examined in mouse skeletal muscle 
(tibialis anterior and soleus) and mouse cardiac muscle. 
 
Western blot analysis of FHOD1 protein was performed using lysates from murine 
muscle tissue and out of the 4 antibodies, only the polyclonal mouse anti-FHOD1 
antibody (abcam) produced a discernible signal for the protein when visualised by 
enhanced chemiluminescence. While the other anti-FHOD1 antibodies should 
theoretically have recognised FHOD1 in murine heart lysates, they may not have done 
so because the method of sample preparation (i.e., subjection to denaturing conditions 
such as boiling), which may have comprised the epitope site they would have otherwise 
recognised in rodent tissue.  Expression was present in the heart, tibialis anterior (TA), 
and soleus (Figure 3.8 A).  A band for FHOD1 could be identified as running above the 
123 kDa marker, which is consistent with the predicted molecular weight of murine 
FHOD1, approximately 129kDa.  Since high FHOD1 expression has been reported in 
the spleen (Westendorf et al. 1999), spleen lysates were also loaded as a positive 
control, where a strong signal for FHOD1 could be seen at the same molecular weight.  
To gauge the relative expression levels of FHOD1 in the different muscle samples, 
densitometric analysis of Western blots was performed.  The intensity of the single 
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FHOD1 band was measured in each sample and normalised to levels of sarcomeric -
actinin, which was used to visualise the loading of the protein samples (Figure 3.8 B-C).  
Highest FHOD1 expression was observed in the heart with levels in the heart 2.66 times 
greater than that seen in the TA (P=0.0077) and 4.9 times greater than that seen in the 
soleus (P=0.0023).  Levels of FHOD1 in the TA were 1.85 times greater than that seen 
in the soleus (P=0.0417).  Lowest levels of FHOD1 expression occurred in soleus 
samples. Overall, these results suggest that significantly greater expression of FHOD1 
occurs in cardiac and fast twitch skeletal muscle, rather than slow twitch skeletal 
muscle. However, it is important to note that this experiment only provides information 
on the relative levels of expression of FHOD1 between murine tissues since the total 
protein concentration of the tissue lysate preparations was not measured. While the SDS 
lysis buffer used for all experiments was optimised for extraction of cytoskeletal 
proteins, the concentrations of the urea, -mercaptoethanol, and SDS used in the buffer 
interfere with most protein assays (e.g., bicinchoninic acid [BCA] assay). Furthermore, 
in the absence of an antigen competition assay, we could not conclude with certainty 







































Figure 3.8: Expression of FHOD1 in Striated Muscle.  Western blot of murine tissue 
lysates from heart, TA, soleus, and spleen. A) Western blot probed with the polyclonal 
mouse anti-FHOD1 antibody (Abcam).  Spleen samples were loaded as a positive control. 
B) Western blot probed against sarcomeric -actinin. C) Bar chart displaying relative 
expression levels of FHOD1 in striated muscle.  Relative levels were obtained by 
performing densitometric analysis on bands visualised by Western blotting.  The relative 
intensity of FHOD1 bands were normalised to that of the -actinin bands.  Relative 
expression is expressed as arbitrary units. TA, tibialis anterior; kDa, kilodaltons. An 
unpaired, two-tailed student’s t-test was used to test for statistical significance. *P<0.05. 
Error bars represent standard error mean. N=3 repetitions of Western blots with 2 sets of 
samples.  
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3.3 Localisation Studies in Heart Muscle 
 
After potentially establishing that FHOD1 was expressed in striated muscle we set out 
to investigate the subcellular localisation of the formin protein in cardiac muscle.  A 
number of localisations have previously been reported for FHOD1 including 
distribution within the cytoplasm (Westendorf et al. 1999) and at the plasma  membrane 
(Westendorf 2001; Gill et al. 2004; Hannemann et al. 2008).  FHOD1 has also been 
found to be targeted to a number of structures that contain actin such as stress fibres and 
membrane ruffles (Koka et al. 2003).  It has also been suggested that the protein can 
translocate to the nucleus in instances of apoptosis (Menard et al. 2006).  The consensus 
reached by most studies is that FHOD1 is targeted to F-actin based structures, especially 
after activation (Gasteier et al. 2003).  Such studies looking at FHOD1 have mainly 
investigated targeting of the protein in cultured cells by overexpression studies.  
However, there is little published data reporting the localisation of endogenous FHOD1 
protein.  Localisation of endogenous FHOD1 was examined in Co396 cells (a vascular 
smooth muscle cell line), where the protein was found to distribute within the cytoplasm 
and in the perinuclear region of cells (Wang et al. 2004).  A more recent study 
examining FHOD1 localisation in Caenorhabditis elegans found that FHOD1 was 
localised near the equivalent of the sarcomeric Z-disks in striated body wall muscles 
(Mi-Mi et al. 2012).  We performed a number of localisation studies by staining against 
endogenous FHOD1 with the commercially available anti-FHOD1 antibodies.  To build 
a picture of where FHOD1 was localised in heart muscle we stained for FHOD1 in 
neonatal rat cardiomyocytes (NRCs), adult rat cardiomyocytes (ARCs), and mouse 
heart tissue sections.  Localisation was visualised by confocal microscopy. 
 
Prior to commencing localisation studies, we sought to confirm the presence of 
endogenous FHOD1 at the protein level via Western blotting in NRCs and ARCs. The 
following experiments describe qualitative results since the exact protein concentration 
was not determined before loading; we merely sought to confirm the presence of 
endogenous FHOD1. The 4 commercially available anti-FHOD1 antibodies were tested 
for their reactivity against day 3 NRCs and day 0 freshly isolated ARCs lysates. The 
GFP-tagged long variant of FHOD1 was loaded as a positive control to demonstrate that 
the antibodies were functioning in the possible absence of a signal in the cultured 
cardiomyocyte lysates. All 4 anti-FHOD1 antibodies produced a signal for the protein 
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as a band migrating at approximately 128kDa in NRC lysates (Figure 3.9 A-D). 
Furthermore, the band for FHOD1 in ARCs as visualised by the polyclonal mouse 
(Abcam) antibody ran at a slightly higher molecular weight than that seen in NRCs, and 
could indicate the presence of a different FHOD1 isoform. However, this size shift was 
not apparent with the polyclonal goat C20 antibody. While the polyclonal mouse 
(Abcam) and the polyclonal goat C20 antibodies produced a signal in ARCs, the 
polyclonal mouse (ECM Biosciences) and the polyclonal goat C14 antibodies did not 
produce a discernible signal for FHOD1 in ARCs. Levels of –actinin were also 
visualised as a loading control in order to confirm the presence of protein and the 
integrity of the cultured cardiomyocyte samples (Figure 3.9 E). Overall, while all 4 anti-
FHOD1 antibodies were in agreement with the notion that the protein could be detected 
































3.3.1 Localisation of Endogenous FHOD1 in Neonatal Rat 
Cardiomyocytes 
 
The relative localisation of FHOD1 in cardiac muscle samples was partially delineated 
by counterstaining against well-known subcellular markers as a reference.  NRCs were 
stained with four of the commercially available anti-FHOD1 antibodies.  All 4 of the 
anti-FHOD1 antibodies produced a signal when visualised by immunofluorescence.  
When staining for endogenous FHOD1, it became apparent that the protein was 
distributing along myofibrils and in a striated manner (Figure 3.10 A-D).  Such a 
distribution would indicate targeting of the protein somewhere within the sarcomere. 
Cardiomyocytes were counterstained with the A-band protein Myosin Binding Protein 
C (MyBP-C) to discern the relative localisation of FHOD1 in the sarcomere.  
Figure 3.9: Expression of FHOD1 in Cultured Neonatal Rat and Adult Rat 
Cardiomyocytes.  Western blot of lysates of day 3 cultured NRCs and day 0 freshly 
isolated ARCs to confirm the presence of rat Fhod1 at the protein level. COS-1 cells were 
transfected with the GFP-tagged full-length long variant of FHOD1 containing the 
alternatively spliced exons (E12-13); these lysates functioned as a positive control in the 
possible absence of a signal in the lysates of cultured cardiomyocytes. Blots were 
incubated with the following anti-FHOD1 antibodies: A) Polyclonal Goat C14 (Santa 
Cruz), B) Polyclonal Goat C20 (Santa Cruz), C) Polyclonal Mouse (abcam), D) 
Polyclonal Mouse (ECM Biosciences), E Western blot probed against sarcomeric -
actinin.  N=2 
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Counterstaining with this sarcomeric marker indicated that each antibody produced a 
unique staining pattern for FHOD1.  The polyclonal goat C14 anti-FHOD1 antibody 
revealed FHOD1 distributing along myofibrils (Figure 3.10 A). Prominent bands for 
FHOD1 were found at the lateral portions of the sarcomere, as gauged by staining for 
MyBP-C (Figure 3.10, Zoom). Some concentrated FHOD1 staining was also found at 
the peripheries of the cells, one of the proposed sites of myofibril assembly in 
cardiomyocytes.  The polyclonal goat C20 antibody revealed FHOD1 distributing along 
myofibrils, but its striated appearance was dramatically different in that it consisted of 
thick doublet bands (Figure 3.10 B).  These bands overlapped with the MyBP-C signal 


























Staining with the two polyclonal mouse anti-FHOD1 antibodies (Figure 3.10 C-D) also 
produced a striated pattern for FHOD1, again indicating some localisation within the 
sarcomere.  The polyclonal mouse anti-FHOD1 antibody (ECM Biosciences) gave well 
defined and broadly spaced striations (Figure 3.10 C).  These striations were found 
within the central region of the sarcomere, although there was some overlap with the 
Figure 3.10: Localisation of Endogenous FHOD1 in Neonatal Rat Cardiomyocytes. Day 3 
NRCs were cultured in maintenance medium.  Cells were stained with the commercially 
available anti-FHOD1 antibodies and MyBP-C.  The following anti-FHOD1 antibodies were 
used: A) Polyclonal goat C14 (Santa Cruz), B) Polyclonal goat C20 (Santa Cruz), C) 
Polyclonal mouse (ECM Biosciences), D) Polyclonal mouse (abcam).  FHOD1 is seen in red, 
MyBP-C in green, and DAPI/nuclei in blue.  NRC, neonatal rat cardiomyocytes; MyBP-C, 
myosin binding protein-C. White boxes show zoomed selections of merged images. Scale bars 
represent 10m. N=3 
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signal for MyBP-C, indicating the possibility of some distribution along the region of 
the thick filaments.  The other polyclonal mouse anti-FHOD1 antibody (Abcam) 
revealed FHOD1 distributing along myofibrils, with striations also being occasionally 
discerned (Figure 3.10 D).  FHOD1 striations were visible as alternating bright and faint 
bands.  The brighter bands were found near the lateral portions of the sarcomere and the 
fainter bands near the centre.   
 
While these staining experiments suggest that endogenous FHOD1 is targeted to 
myofibrils and might concentrate in particular regions of the sarcomere, such disparate 
results between the 4 antibodies could indicate a number of issues. One likely 
possibility is that the antibodies were actually detecting other sarcomeric proteins, 
which have been shown to be problematic in antibody studies (Wang et al. 2012). In the 
absence of an antigen competition assay, it was not possible to rule out cross-reactivity 
of the 4 anti-FHOD1 antibodies with other sarcomeric proteins. Another possibility was 
the potential for cross-reactivity of the fluorophore labelled secondary antibodies to the 
incorrect primary antibody, although we strove to avoid this issue by only employing 
multi-labelling quality antibodies. However, in the absence of single staining controls 
using just the FHOD1 antibodies, cross-reactivity between the secondary antibodies 
cannot be ruled out. It is therefore difficult to draw any definitive conclusions regarding 
the localisation of endogenous FHOD1 in NRCs until these issues are resolved.. 
 
3.3.2 Localisation of Endogenous FHOD1 in Adult Rat 
Cardiomyocytes 
 
As heart muscle grows and remodels over time, the expression and localisation of 
certain proteins are altered.  For example, the formin homology protein FHOD3 was 
shown to localise to the region of the A-bands in NRCs (Iskratsch et al. 2010) but was 
found at the Z-disk in freshly isolated ARCs (Iskratsch et al. 2013a).  FHOD1 was 
therefore stained against in freshly isolated adult rat cardiomyocytes to look for any 
alterations in localisation when compared to the localisation patterns seen in NRCs.  
Out of the 4 commercially available antibodies recognising endogenous FHOD1, only 
three of the antibodies produced a signal for the protein in ARCs when visualised by 
immunofluorescence.  




Localisation of each anti-FHOD1antibody in ARCs was similar to that seen in NRCs 
(Figure 3.3 A-C).  Similarly to NRCs, the signal for FHOD1 was again found 
distributing along myofibrils and could be occasionally be visualised as striations.  The 
polyclonal goat C14 antibody produced fairly weak staining for FHOD1 that consisted 
of a predominantly filamentous signal, although the signal was also occasionally visible 
as faint striations within the lateral regions of the sarcomeres, as gauged by an 
alternating pattern with the M-band marker, myomesin (Figure 3.11 A, Zoom).  The 
polyclonal goat C20 antibody revealed a myofibrillar signal for FHOD1, which resolved 
as thick doublet bands that localised either side of the Z-disks, as gauged by –actinin 
staining, emanating towards the centre of the sarcomere (Figure 3.11 B, Zoom).  The 
polyclonal mouse antibody (Abcam) revealed endogenous FHOD1 distributing in a 
striated manner. Counterstaining with MyBP-C revealed that prominent FHOD1 bands 
were consistently resolved in between the A-bands, near the centre of the sarcomere 
(Figure 3.11 C, Zoom). Fainter targeting to lateral portions of the sarcomere could 
occasionally be discerned. However, the same caveats apply here as in the above 
antibody staining studies using NRCs. In the absence of an antigen competition assay 
and single staining controls for FHOD1, we cannot rule out the possibility of cross-
reactivity of the anti-FHOD1 antibodies with other sarcomeric proteins and with the 
other antibodies used in the staining procedures. Although it was difficult to detect any 
dramatic alterations in FHOD1 localisation between NRCs and ARCs due to limits in 
resolution, results with the polyclonal mouse (Abcam) could suggest redistribution of 
FHOD1 from the lateral portions of the sarcomere in NRCs, where it displayed 
prominent striations, to the central portion of the sarcomere in ARCs.  . 
 













3.3.3 Localisation of Endogenous FHOD1 in Adult Mouse Heart Tissue 
Sections 
 
In order to visualise the localisation of endogenous FHOD1 in situ, we stained for the 
protein in frozen heart sections from adult mice.  Proteins can alter their localisation in 
cultured cells under two-dimensional culture conditions therefore tissue sections allow 
one to study the localisation of a protein in its native environment. Out of the 4 
commercial anti-FHOD1 antibodies tested in heart sections, only the two polyclonal 
goat anti-FHOD1 antibodies (Santa Cruz) produced a signal for the protein when 
visualised by immunofluorescence. 
 
Figure 3.11: Localisation of Endogenous FHOD1 in Adult Rat Cardiomyocytes.  
Freshly isolated ARCs were fixed and stained with the commercially available anti-FHOD1 
antibodies as well as other sarcomeric markers and F-actin, with subsequent visualisation by 
confocal microscopy.  The following anti-FHOD1 antibodies were used: A) Polyclonal goat 
C14 (Santa Cruz), B) Polyclonal goat C20 (Santa Cruz), C) Polyclonal mouse (Abcam).  
FHOD1 is seen in red, myomesin/-actinin/MyBP-C are seen in green, and F-actin seen in 
blue.  ARC, adult rat cardiomyocytes; MyBP-C, myosin binding protein-C.  Scale bars 
represent 10m. White boxes show zoomed selections of merged images. N=2 
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 FHOD1 localisation was visualised in both transverse and longitudinal heart sections to 
discern whether the protein was localising to the sarcomere and/or the sarcoplasmic 
reticulum.  Low magnification images of transverse sections taken through myofibrils 
with both the polyclonal goat C14 (Figure 3.12 A) and C20 (Figure 3.13 A) antibodies 
revealed FHOD1 distributing within myofibrils although some membrane targeting was 
apparent.  Low magnification images of longitudinal sections also revealed FHOD1 
distributing in cardiomyocytes in a filamentous manner (Figure 3.12 B, 3.13 B).  Most 
notably, FHOD1 was also found as a bright signal at the intercalated disk, the 
specialised electro-mechanical junction between neighbouring cardiomyocytes. 
 
High magnification images of longitudinal sections confirmed a strong signal for 
FHOD1 in cardiomyocytes and revealed that FHOD1 was concentrated at the 
intercalated disks. Staining also revealed that FHOD1 was occasionally distributing in a 
striated manner, once again indicating some sarcomeric localisation. Counterstaining 
with the M-band marker, myomesin revealed an alternating pattern with FHOD1 which 
would suggest that FHOD1 may have been present in the lateral portions of the 
sarcomeres, near the Z-disks (Figure 3.12 C, Zoom; Figure 3.13 C, Zoom). Some 
staining for FHOD1 was also noted in the interstitial spaces between cardiomyocytes, 
indicating that it could have also been expressed in cardiac fibroblasts, one of the more 
numerous cell types in the heart that play roles in maintaining the structural, 
electrochemical, and biochemical properties of the heart (Camelliti et al. 2005). Indeed, 
FHOD1 expression has been reported in fibroblasts (Iskratsch et al. 2013b) therefore it 
is entirely conceivable that it was also found in cardiac fibroblasts in our 
immunofluorescence samples. However, we were unable to confirm FHOD1 expression 
in this cell type. Counterstaining tissue sections against vimentin would allow for 
cardiac fibroblasts to be spatially delineated and would facilitate the confirmation 
FHOD1 expression in this cell type.   
    
In the absence of an antigen competition assay or single staining controls with the anti-
FHOD1 antibodies alone, we were unable to determine if the signal for FHOD1 was 
bona fide or a product of cross-reactivity with other myocardial proteins. However, we 
were able to examine the effects of the fluorophore coupled secondary antibodies on 
any non-specific localisation (Figure 3.14). The Cy3-coupled donkey anti-goat 
antibody, which was used to detect the goat anti-FHOD1 antibodies, displayed co-
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localisation with myofibrils in both transverse (Figure 3.14 A) and longitudinal sections 
(Figure 3.14 B) but did not stain the intercalated disks nor did it produce the distinct 
cross striations seen with the anti-FHOD1 antibodies. The Cy2-coupled donkey anti-
mouse antibody, used to detect the mouse anti-myomesin antibody, produced some 
background staining along myofibrils and at cell boundaries, although this background 
staining disappeared when staining was performed with the appropriate primary 
antibody. Although the caveat remained regarding the specificity of the anti-FHOD1 
antibodies in these experiments, we were able to exclude the effects of any extraneous 

























Figure 3.12: Localisation of Endogenous FHOD1 with the Polyclonal Goat C14 
Antibody in Murine Hearts.  Frozen heart sections of 1 year old male adult C57/BL6 
mice were stained with the anti-FHOD1 goat C14 antibody (Santa Cruz), myomesin, 
and visualised by confocal microscopy.  Images represent portions of A) low 
magnification transverse sections, B) low magnification longitudinal sections, and C) 
high magnification longitudinal sections.  FHOD1 is seen in red, myomesin is seen in 
green, and DAPI/nuclei are seen in blue.  Arrowheads indicate an intercalated disk.  
Scale bars represent 10m. White box shows zoomed selection of merged images. N=3 
 
 
















Figure 3.13: Localisation of Endogenous FHOD1 with the Polyclonal Goat C20 
Antibody in Murine Hearts.  Frozen heart sections of 1 year old male adult C57/BL6 mice 
were stained with the anti-FHOD1 goat C20 antibody (Santa Cruz) and), myomesin, and 
visualised by confocal microscopy.  Images represent portions of A) low magnification 
transverse sections, B) low magnification longitudinal sections, and C) high magnification 
longitudinal sections.  FHOD1 is seen in red, myomesin is seen in green, and DAPI/nuclei  
are seen in blue.  Arrowheads indicate an intercalated disk.  Scale bars represent 10m. 
White box shows zoomed selection of merged images. N=3 
 
 

















3.4 Expression and Localisation of FHOD1 in Differentiating C2C12 
Myoblasts 
 
C2C12 myoblasts are a murine cell line of skeletal muscle lineage.  They represent a 
model that can be used to study myofibrillogenesis and myogenic differentiation under 
culture conditions (Berry et al. 2001), as they recapitulate some of the events in 
formation of skeletal muscle (Burattini et al. 2004).  C2C12 cells begin as proliferative 
myoblasts, muscle precursor cells.  When cultured under low serum conditions they 
begin the differentiation process into skeletal muscle cells.  In the early stages of 
differentiation, C2C12 myoblasts will fuse with neighbouring cells.  Fused cells will 
then elongate and become morphologically distinct myotubes.  During the later stages 
of differentiation, fused cells complete the process of assembling their sarcomeres and 
eventually become skeletal muscle cells, which are sometimes seen to contract in 
Figure 3.14: Negative Control for Fluorophore Coupled Secondary Antibodies.  In order 
to assess the extent of background staining produced by the secondary antibodies used for 
localisation studies in tissue sections, frozen heart sections of 1 year old male adult C57/BL6 
mice were stained with the Cy3-coupled donkey anti-goat antibody, which was used to detect 
the goat anti-FHOD1 antibodies and the Cy2-coupled donkey anti-mouse antibody, which 
was used to detect the mouse anti-myomesin antibody and visualised by confocal 
microscopy.  Images represent portions of A) low magnification transverse sections and B) 
low magnification longitudinal sections. Cy3-coupled donkey anti-goat is seen in red, Cy2-
coupled donkey anti-mouse is seen in green, and DAPI/nuclei are seen in blue. Scale bars 
represent 10m. N=1   
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syncytium.  C2C12 differentiation requires a number of cytoskeletal remodelling 
events, especially at the level of F-actin (Malone et al. 2011).  We therefore chose to 
look at FHOD1 expression and localisation through Western blot and antibody 
localisation studies, respectively in differentiating C2C12 cells at different time points. 
 
3.4.1 Expression of FHOD1 in Differentiating C2C12 Myoblasts 
 
Prior to initiating localisation studies, we sought to confirm expression of FHOD1 at the 
protein level in differentiating C2C12 cells. FHOD1 expression was examined in 
differentiating C2C12 cells, with harvesting of protein samples occurring every two 
days, after culture in low serum conditions (Figure 3.15).  The earliest time point was 
day 0, when progenitor cells were seeded into dishes coated with collagen but were kept 
in proliferation medium. The following expression experiments describe qualitative 
results since the exact protein concentration was not determined before loading. 
Initially, the 4 commercially available anti-FHOD1 antibodies were tested for their 
reactivity against C2C12 protein lysates.  Out of the 4 antibodies, only the polyclonal 
goat C14 anti-FHOD1 antibody produced a discernible signal for the FHOD1 protein 
when visualised by enhanced chemiluminescence (Figure 3.15 A).  Lysates were also 
blotted against sarcomeric –actinin (Figure 3.15 C) and desmin (Figure 3.15 D), to 
confirm the differentiation status of cultured cells over time. An increased signal for –
actinin and desmin after switching cells into low serum conditions was consistent with 
the reported upregulation of these proteins during the differentiation process (Kislinger 



















Western Blot studies with the polyclonal goat C14 anti-FHOD1 antibody resolved one 
distinct band associated with FHOD1 at each time point (Figure 3.15 A).  In day 0 
undifferentiated C2C12 myoblasts, FHOD1 expression was visible as a faster migrating, 
smaller molecular weight band between the 123 kDa and 78 kDa protein markers.  In all 
of the subsequent time points, a band for FHOD1 was resolved as a slower running, 
therefore higher molecular weight band just above the 123 kDa protein marker. The 
higher molecular weight band was consistent with the predicted molecular weight of 
129kDa for mouse FHOD1.  Human FHOD1 has been previously found to undergo 
differential splicing with a longer mRNA transcript for FHOD1 with a 78bp insert 
having been described by Tojo et al. 2003. From day 2 through day 14, the FHOD1 
signal in differentiating cells, likely corresponded to the 1,197 amino acid variant 
reported in mice.  Currently, there is only one definite FHOD1 isoform in mice and no 
smaller isoforms have been documented. In our model of differentiating C2C12 
myoblasts, the band in day zero lysates may have corresponded to an unreported 
FHOD1 splice variant.  These data may indicate an isoform switch in FHOD1 
expression during skeletal muscle development. However, in the absence of an antigen 
competition assay, we could not rule out the possibility of the polyclonal Goat C14 
antibody cross-reacting with other murine skeletal myoblast/myotube proteins, which 
could particularly explain the band at day 0 that was found to migrate at an unexpected 
Figure 3.15: Expression of FHOD1 in Differentiating C2C12 Myoblasts.  Western blots 
of differentiating C2C12 myoblasts at different time points A) Western blot probed with the 
polyclonal goat C14 anti-FHOD1 antibody (Santa Cruz).  B) Western blot probed against 
sarcomeric -actinin.  A signal for the protein is seen as a single band around 100 kDa. C) 
Western blot probed against desmin.  A signal for the protein is seen as a single band around 
54 kDa. kDa, kilodaltons. N=2 repetitions of Western blots from 2 rounds of cell 
culture/C2C12 differentiation. 
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molecular weight. Further confirmation should take place by examining the expression 
of FHOD1 at the mRNA transcript level in differentiating C2C12 cells in order to 
resolve discrepancies regarding the presence of a faster migrating species in day 0 
lysates. 
 
3.4.2 Localisation of Endogenous FHOD1 in Differentiating C2C12 
Myoblasts 
 
With the possibility in mind that FHOD1 was expressed in C2C12 cells, we 
subsequently stained for endogenous FHOD1 in differentiating C2C12 cells to examine 
the localisation of FHOD1 over time.  C2C12 cells were fixed at four different time 
points starting from freshly seeded day zero myoblasts to day 14 myotubes.  Out of the 
4 commercially available antibodies raised against FHOD1, only three of the antibodies 
produced a signal for FHOD1 when visualised by immunofluorescence.  Each antibody 
produced a distinct localisation pattern for FHOD1 in differentiating C2C12 cells.  
In day 0 myoblasts, staining for FHOD1 with the polyclonal goat C14 antibody 
produced a predominantly diffuse cytoplasmic signal (Figure 3.16 A).  FHOD1 was also 
visualised as cytoplasmic speckles.  There was no co-localisation with the F-actin 
network.  At day 3, when cells began to elongate and fuse, the signal for FHOD1 
became more diffuse and was sometimes concentrated along F-actin stress fibres 
(Figure 3.16 B).  At day 7, when myotubes began to enlarge and lay down sarcomeres, 
the signal for FHOD1 was mostly diffuse throughout the cytoplasm of cells (Figure 3.16 
C).  At day 14, when myotubes had laid down mature sarcomeres, FHOD1 still 
distributed in a diffuse cytoplasmic manner although some localisation along myofibrils 
was apparent (Figure 3.16 D). However, there was little visible evidence to support that 
FHOD1 was distributing in a cross striated manner. Overall, the polyclonal C14 
antibody primarily revealed FHOD1 distributing in a diffuse cytoplasmic manner 
although some myofibrillar targeting was noted in mature myotubes.  
 
 
























Figure 3.16: Localisation of Endogenous FHOD1 with the Polyclonal Goat C14 
Antibody in Differentiating C2C12 Myoblasts.  C2C12 myoblasts were differentiated 
from day 0 myoblasts to day 14 myotubes.  Cells were fixed at multiple time points prior to 
staining with the anti-FHOD1 polyclonal goat C14 antibody (Santa Cruz) as well as other 
myofibrillar and cellular markers.  Stained cells were visualised by confocal microscopy.  
Images represent cells at separate stages of differentiation at A) day 0, B) day 3, C) day 7, 
and D) day 14.  FHOD1 is seen in red, F-actin/myomesin in green, and DAPI/nuclei/F-actin 
in blue.  Scale bars represent 10m. White box shows zoomed selection of merged images. 
N=2 
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When staining with the polyclonal goat C20 antibody, the signal for FHOD1 was 
comparatively stronger than that for the polyclonal goat C14 or polyclonal mouse 
antibodies (ECM Biosciences) (Figure 3.17).  In day 0 myoblasts, FHOD1 was again 
visible as speckles, albeit distributing in a more concentrated manner within the 
cytoplasm (Figure 3.17 A).  At day 3, the signal for FHOD1 became more diffuse with 
some occasional localisation along F-actin stress fibres (Figure 3.17 B).  At day 7, it 
was apparent that FHOD1 was already distributing along newly formed myofibrils and 
was even producing a striated signal (Figure 3.17 C, Zoom).  FHOD1 striations were 
present as doublet bands found either side of myomesin, and could have indicated some 
distribution of the endogenous protein along the length of the thick filaments.  At day 
14, the doublet FHOD1 striations became more prominent (Figure 3.17 D, Zoom).  
Unlike the staining found in NRCs and ARCs, the spacing of these doublets were 































Figure 3.17: Localisation of Endogenous FHOD1 with the Polyclonal Goat C20 
Antibody in Differentiating C2C12 Myoblasts.  C2C12 myoblasts were differentiated 
from day 0 myoblasts to day 14 myotubes.  Cells were fixed at multiple time points prior 
to staining with the anti-FHOD1 polyclonal goat C20 antibody (Santa Cruz) as well as 
other myofibrillar and cellular markers.  Stained cells were visualised by confocal 
microscopy.  Images represent cells at separate stages of differentiation at A) day 0, B) 
day 3, C) day 7, and D) day 14.  FHOD1 is seen in red, F-actin/myomesin in green, and 
DAPI/nuclei/F-actin in blue.  Scale bars represent 10m. White box shows zoomed 
selection of merged images. N=2 
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The polyclonal mouse anti-FHOD1 antibody (ECM Biosciences) produced a distinct 
signal for FHOD1 in day 0 undifferentiated myoblasts (Figure 3.18 A) when compared 
to the other anti-FHOD1 antibodies.  Although the signal was primarily diffuse and 
cytoplasmic, it was apparent that FHOD1 was occasionally distributing in a faint 
filamentous manner.  In day 3 cells, the FHOD1 signal was diffuse throughout the 
cytoplasm of cells, although there were some hints of targeting along F-actin stress 
fibres (Figure 3.18 B).  The distribution of the protein remained relatively unchanged at 
day 7 (Figure 3.18 C).  In day 14 mature myotubes, the FHOD1 signal was 
predominantly diffuse throughout the cytoplasm although some targeting to myofibrils 
and faint striations could occasionally be discerned (Figure 3.18 D, Zoom).  However, it 
was not possible to discern the precise spacing of the FHOD1 striations. There was 
some evidence that a prominent FHOD1 band alternated with the signal for MyBP-C, 
although the resolution currently achieved in this experiment did not allow us to gain a 
clear idea of FHOD1 distribution within the sarcomere.    
 
























Figure 3.18: Localisation of Endogenous FHOD1 with the Polyclonal Mouse 
Antibody in Differentiating C2C12 Myoblasts.  C2C12 myoblasts were differentiated 
from day 0 myoblasts to day 14 myotubes.  Cells were fixed at multiple time points prior 
to staining with the anti-FHOD1 polyclonal mouse antibody (ECM Biosciences) as well as 
other myofibrillar and cellular markers.  Stained cells were visualised by confocal 
microscopy.  Images represent cells at separate stages of differentiation at A) day 0, B) 
day 3, C) day 7, and D) day 14.  FHOD1 is seen in red, F-actin/MyBP-C in green, and 
DAPI/nuclei/F-actin in blue.  Scale bars represent 10m. White box shows zoomed 
selection of merged images. N=2 
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The localisation studies performed in C2C12 cells would indicate that endogenous 
FHOD1 is initially found in the cytoplasm of C2C12 cells, although it was occasionally 
found at the membrane edge.  As cells began to elongate and fuse, the FHOD1 signal 
became dispersed throughout the cytoplasm of differentiating myotubes and there was 
some occasional co-localisation with F-actin stress fibres.  In mature myotubes, while 
the FHOD1 signal was primarily that of a diffuse cytoplasmic nature, we did note some 
occasional targeting to myofibrils and concentration within the sarcomere as striations. 
However, a number of caveats apply when interpreting the present results. In the 
absence of an antigen competition assay, we were unable to determine the level of non-
specific staining with the anti-FHOD1 antibodies. Furthermore, while Western blot 
studies suggested the presence of FHOD1 at the protein level throughout the C2C12 
differentiation process (Figure 3.15 A), we were only able to do this using the 
polyclonal goat C14 antibody, which casted doubt as to whether we were visualising 
FHOD1 in C2C12 cells with the polyclonal goat C20 and polyclonal mouse (ECM 
Biosciences) antibodies. However, the lack of detection on Western blots could be 
explained by the loss of the epitope the antibodies recognise due to the denaturing 
conditions used in our sample preparation and for SDS-PAGE. 
 
Overall, we described the expression and localisation of endogenous FHOD1 using 4 
commercially available anti-FHOD1 antibodies in a number of tissue and cell types of 
cardiac and skeletal muscle origin (Table 3.1). The antibodies were not always in 
agreement with each other regarding the localisation of endogenous FHOD1, a factor 
which did not bode well for the validity of these staining experiments. However, they 
could likely be resolved by further characterisation of antibody specificity and 
sensitivity through antigen competition assays and biochemical validation using rodent 
FHOD1 constructs, respectively. 
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Table 3.1: Summary of Antibody Studies.  Table summarising the localisation of 
endogenous FHOD1 using the 4 commercial antibodies recognising total FHOD1 
levels in different muscle specimens. A summary of the reactivity against FHOD1 
via Western blotting is also given.  NRC, neonatal rat cardiomyocytes; ARC, adult 
rat cardiomyocytes; ICD, intercalated disk; Y, yes (reactivity was noted); N, no 
(reactivity was not noted). 
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3.5 Overexpression of Full-length FHOD1 in Neonatal Rat 
Cardiomyocytes 
 
In addition to antibody localisation studies, a number of transient expression studies 
were performed in cultured cardiomyocytes to explore the targeting of different epitope 
tagged FHOD1 constructs.  GFP and TOMATO-tagged variants of full-length FHOD1 
were transiently transfected into NRCs to visualise the subcellular targeting of full-
length FHOD1.  There are currently two full-length variants of human FHOD1 that 
have been described.  The shorter version of the protein was the variant that was 
described in the initial characterisation of FHOD1 (Westendorf et al. 1999) and the 
longer version, which contains a 78bp insertion (Tojo et al. 2003) that represent the 
alternatively spliced exons 12-13.  We compared targeting of the short and long FHOD1 
isoforms to assess if there was any differential targeting between the splice variants in 
cells and to see if FHOD1 overexpression induced any changes in the F-actin network 
or cell morphology. 
 
Prior to commencing overexpression studies in NRCs, we sought to confirm that the 
GFP and TOMATO-tagged expression constructs were capable of expression in 
mammalian cells and that they were expressed at the expected molecular weight. COS-1 
cells were used for this purpose because of the substantially higher transfection 
efficiency that can be achieved with this cell line. Although NRC transfection by Escort 
III transfection reagent resulted in comparably better transfection efficiency and cell 
viability than other non-viral methods of transfection (results not shown), it still resulted 
in a relatively low transfection efficiency (approximately <5%). While results from one 
cell line cannot be directly translated into a completely valid interpretation in primary 
cells, the low transfection efficiency with NRCs restricted their use to 
immunofluorescence studies when implementation of expression constructs was 
concerned. The following expression experiments describe qualitative results because of 
their extrapolation in significance to another cell type and since the exact protein 
concentration was not determined before loading. Expression tests of the GFP-tagged 
constructs in transiently transfected COS-1 cells followed by Western blotting revealed 
that GFP fusion proteins of the expected molecular weight were generated (Figure 3.19 
A-B). The long and short variant of FHOD1 ran near the 154kDa marker, consistent 
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with their expected combined molecular weight with GFP (Figure 3.19 D). Although 
there is a slight size difference of approximately 2kDa between these two constructs, we 
were unable to resolve the difference in size on SDS-PAGE gels but confirmed the 
identity of each construct by DNA sequencing. The full-length long variant of FHOD1 
tagged with TOMATO protein also ran at its expected molecular weight (Figure 3.19 D) 














Figure 3.19: Expression Test of Different FHOD1 Constructs in COS-1 Cells. 
A) Western blot with anti-GFP antibody of SDS samples from COS-1 cells that 
were transiently transfected with the different FHOD1 constructs. 12% SDS-PAGE. 
B) Western blot with anti-dsRed antibody of SDS samples from COS-1 cells that 
were transiently transfected with the different FHOD1 constructs. 12% SDS-PAGE. 
C) 7.5% SDS-PAGE gel with anti-GFP antibody to better resolve size difference 
between full-length FHOD1 and the GBD construct. D) Table of expected 
molecular weights of constructs. Constructs of the expected molecular weight were 
observed in all samples. Untransfected COS-1 cells were used as a negative control. 
E12-13, alternatively spliced exons 12-13 found on the long FHOD1 splice variant. 
N=3 
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3.5.1 Targeting of the Full-Length FHOD1 in Neonatal Rat 
Cardiomyocytes 
 
GFP-tagged version of the shorter FHOD1 variant (spanned from amino acids 1 to 
1164; Figure 3.2 A), lacking exons 12-13, and the GFP-tagged longer FHOD1 variant 
(spanned from amino acids 1-1191; Figure 3.2 B), containing the alternatively spliced 
exons 12-13, were overexpressed in NRCs to compare their targeting. Both the short 
(Figure 3.20 C) and long (Figure 3.20 D) FHOD1 variants displayed a predominant 
localisation at the periphery of the cells. In addition, there was a lot of diffuse 
cytoplasmic signal. Counterstaining with F-actin, to visualise the I-bands of sarcomeres 
and the actin cytoskeleton revealed that the full-length FHOD1 construct displayed 
some targeting along myofibrils, but this was accompanied by little evidence of well-
defined cross-striations. However, the longer construct had a slightly more striated 
appearance than that seen with the shorter construct. There was no considerable co-
localisation between FHOD1 and F-actin in transfected cells. Furthermore, no increased 
signal was seen at the cell-cell contacts between NRCs. Despite FHOD1 having the 
reported ability to reorganise the cytoskeleton into structures like stress fibres (Takeya 
et al. 2008), we did not note the appearance of any new F-actin based structures or any 
morphological changes in transfected cells.  Such an observation would be consistent 
with the fact that full-length FHOD1 is maintained in a closed inactive conformation. 
Overall, there was no marked difference in the targeting between the GFP-tagged long 
and short FHOD1 variants. These data would suggest that the alternatively spliced 
exons do not confer a specific subcellular localisation to full-length FHOD1 or govern 
its targeting.  
 
As a control for both the long and short GFP-tagged full-length FHOD1 constructs, we 
also transfected NRCs with the empty GFP vector in order to examine if FHOD1 
localisation was mediated by the GFP tag (Figure 3.20 E). Untagged GFP co-localised 
with F-actin throughout cells and was also found to accumulate in the nuclei of cells. 
While we found FHOD1 distributing along myofibrils, we did not note substantial co-
localisation with F-actin. Furthermore, GFP-tagged full-length FHOD1 was excluded 
from the nucleus. While use of other epitope tagged constructs is required and would 
avoid the issue of GFP stickiness, we were fairly confident that the localisation of the 
GFP-tagged FHOD1 constructs were not mediated by the GFP tag.   




A TOMATO-tagged version of the long variant was also transiently transfected in 
NRCs (Figure 3.21 A-B).  Unlike cells overexpressing the GFP-tagged variants of 
FHOD1, FHOD1-TOMATO transfected cells had a slightly elongated morphology.  
Transfected cells presented with extended plasma membrane processes, to which 
FHOD1 localised to.  In these cells, FHOD1 was occasionally found along myofibrils, 
although this was likely mediated by the TOMATO tag, which displayed similar co-
localisation with myofibrils (Figure 3.21 C).  The cellular phenotype induced by 
FHOD1-TOMATO might have been due to activation of the protein.  This could have 
conceivably been due to the fact that the TOMATO tag (54 kDa) is larger than the GFP 
tag (28 kDa), and may have interrupted the autoinhibitory intramolecular interaction 
that maintains FHOD1 in a closed inactive state.  Cells transfected with the empty 
TOMATO vector were identical to untransfected cells in their appearance (Figure 3.21 
C), therefore indicated that the morphological changes noted in cells were not solely due 
to the TOMATO tag. Overall, results using the TOMATO tag proved to be inconclusive 
since the large size of the tag may have interfered with FHOD1’s autoregulatory 
conformation and since the TOMATO tag may have mediated the subcellular targeting 

































Figure 3.20: Overexpression of Full-length GFP-tagged FHOD1 in Neonatal Rat 
Cardiomyocytes.  NRCs were transfected with different full-length fluorescent tagged 
FHOD1 constructs and cultured to day 4.  Cells were stained against -actinin, F-actin, and 
DAPI.  Stained cells were visualised by confocal microscopy.  GFP-tagged expression 
constructs were generated for A) the short variant of FHOD1 [1-1164], lacking the 
alternatively spliced exons 12-13 and B) the long variant of FHOD1 [1-1191], containing the 
alternatively spliced exons 12-13. Cells were transfected with the following constructs: C) 
the shorter variant of GFP-tagged full-length FHOD1 [1-1164], D) the longer variant of GFP-
tagged full-length FHOD1 [1-1191], E) the empty GFP vector.  -actinin is seen in red, GFP-
FHOD1 in green, and F-actin/DAPI in blue. GFP, green fluorescent protein. E12-13, 
alternatively spliced exons 12-13 found on the long FHOD1 splice variant.  Scale bars 
represent 10m. White boxes show zoomed selections of merged images. N=3 
 
















3.6 Subcellular Targeting of FHOD1 Domains in Neonatal Rat 
Cardiomyocytes 
 
FHOD1 is composed of a modular domain structure typically found among the 
diaphanous related formins.  The first half of the protein is composed of a GTPase 
binding domain (GBD) and a diaphanous inhibitory domain (DID).  The second half is 
composed of two formin homology domains (FH1 and FH2) and a diaphanous 
autoregulatory domain (DAD).  Having established the targeting of full-length FHOD1, 
the next step was to discern whether a particular portion of the protein was responsible 
for its targeting.  We mapped the targeting of FHOD1 via overexpression of individual 
GFP-tagged fragments of the protein. The following FHOD1 constructs were examined 
in NRCs: the FH2 domain [642-1031]; the GBD-DID portion of the N-terminus [1-
Figure 3.21: Overexpression of Full-length TOMATO-tagged FHOD1 in Neonatal Rat 
Cardiomyocytes.  NRCs were transfected with different full-length fluorescent tagged 
FHOD1 constructs and cultured to day 4.  Cells were stained against -actinin and F-actin.  
Stained cells were visualised by confocal microscopy.  A) A TOMATO-tagged expression 
construct was generated for the long variant of FHOD1, containing the alternatively spliced 
exons 12-13. Cells were transfected with the following constructs: B) the long variant of 
TOMATO-tagged full-length FHOD1 [1-1191], and C) the empty TOMATO tag vector 
TOMATO-FHOD1 is seen in red, -actinin in green, and F-actin in blue. E12-13, 
alternatively spliced exons 12-13 found on the long FHOD1 splice variant. Scale bars 
represent 10m. N=3 
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340]; the GBD [1-116]; the DID [117-340] and a version of the long variant of FHOD1 
lacking the GBD, termed FHOD1 GBD [117-1191]. 
 
Prior to initiating transfection studies, we sought to confirm that the expression 
constructs of the individual FHOD1 domains were expressed at the correct molecular 
weight (Figure 3.19). COS-1 cells were used for the expression tests because of the very 
low transfection efficiency we were able to achieve in NRCs of approximately less than 
5%. The following expression experiments describe qualitative results because of their 
extrapolation in significance to another cell type and because the exact protein 
concentration was not determined before loading. Expression tests of the GFP-tagged 
constructs in transiently transfected COS-1 cells followed by Western blotting revealed 
that the GFP fusion proteins expressed at the expected molecular weight. In order to 
confirm the correct size of the FHOD1 GBD construct (Figure 3.19 A,C), we ran 
samples on lower percentage SDS-PAGE gels in order to visualise the size shift 
(approximately 37kDa) between the long variant of FHOD1 and the FHOD1 GBD 
construct (Figure 3.19 C). 
 
3.6.1 Overexpression of the FH2 Domain [642-1031] 
 
Formin homology 2 (FH2) domains are the reported actin polymerising portion of 
formins (Chhabra and Higgs 2007).  We overexpressed the FH2 domain of FHOD1 
(amino acids 642 to 1031) on its own in NRCs (Figure 3.22 A).  Transfected cells were 
morphologically indistinguishable from untransfected neighbours.  The GFP-tagged 
FH2 domain distributed in a striated manner in cells.  The FH2 domain produced a 
strong signal at the Z-disk, as indicated by co-localisation with -actinin (Figure 3.22 B, 
Zoom) and an alternating signal with the M-band protein, myomesin (Figure 3.22 C).  
In line with the reported ability of FH2 domains to associate with F-actin (Higashida et 
al. 2004), co-localisation was noted between the FH2 domain of FHOD1 and F-actin at 
the peripheries of cells (Figure 3.22 C, Zoom).  Overall, the FH2 domain of FHOD1 
displayed targeting the Z-disks and F-actin in cardiomyocytes. Furthermore, in line with 
the capping and weak elongation activity of the FH2 domain (Schonichen et al. 2013), 
we observed a slight accumulation of F-actin in cells at sites where the FH2 domain and 
F-actin co-localised. 



















3.6.2 Overexpression of the GBD-DID [1-340] 
 
It has previously been suggested that the distinct subcellular targeting of formin proteins 
is governed by their N-termini (Seth et al. 2006; Ramalingam et al. 2010).  This is due 
partly to the fact that formins show greatest sequence and structural divergence within 
their N-termini (Schulte et al. 2008).  We overexpressed an FHOD1 N-terminal 
construct comprised of the GBD and the DID and spanning amino acids 1 to 340 in 
NRCs (Figure 3.23 A).  The GFP-tagged N-terminal fragment of FHOD1 mainly 
Figure 3.22: Overexpression of the FHOD1 FH2 Domain in Neonatal Rat 
Cardiomyocytes.  A) An FHOD1 FH2 domain [642-1031] expression construct was 
generated to assess its targeting in NRCs. NRCs were transfected with the GFP-tagged 
expression construct and cultured to day 4.  Cells were stained against B) sarcomeric -
actinin and F-actin or C) myomesin and F-actin.  Stained cells were visualised by confocal 
microscopy.  Myomesin/-actinin are seen in red, GFP-tagged FHOD1 expression construct 
in green, and F-actin in blue. GFP, green fluorescent protein; FH, formin homology.  White 
boxes show zoomed selections of merged images. Arrows denote sites of co-localisation. 
Scale bars represent 10m. N=3 
 
Expression and Localisation of FHOD1 
180 
 
distributed in a diffuse cytoplasmic manner, although there was some evidence of 
targeting to myofibrils.  Occasionally, some co-localisation with F-actin could be 
discerned along myofibrils (Figure 3.23 B, Zoom). This would have been consistent 
with reports that the N-terminus of FHOD1 is required for its F-actin binding activity 
(Takeya and Sumimoto 2003) and targeting to actin-based structures, particularly stress 
fibres (Schonichen et al. 2013).  Overall, the GBD-DID FHOD1 construct primarily 
distributed in a diffuse cytoplasmic manner although there was some evidence of 
























Figure 3.23: Overexpression of FHOD1 GBD-DID in Neonatal Rat Cardiomyocytes.  A) 
An FHOD1 GBD-DID [1-340] expression construct was generated to assess its targeting in 
NRCs. NRCs were transfected with the GFP-tagged expression construct and cultured to day 
4.  Cells were stained against B) myomesin and F-actin.  Stained cells were visualised by 
confocal microscopy.  Myomesin is seen in red, GFP-tagged FHOD1 expression construct in 
green, and F-actin in blue. GFP, green fluorescent protein; GBD, GTPase binding domain; 
DID, diaphanous inhibitory domain.  White box shows zoomed selection of merged images. 
Arrows denote sites of co-localisation. Scale bars represent 10m. N=3 
 
Expression and Localisation of FHOD1 
181 
 
3.6.3 Overexpression of the GBD [1-116]  
 
The GTPase binding domain (GBD) is typically thought to play a role in activation of 
DRFs.  DRFs are normally held in a closed inactive state until binding of a Rho family 
small GTPase in the GBD (Tominaga et al. 2000).  This partially relieves the 
autoinhibitory interaction between both ends of the protein and subsequently leads to 
activation when the functional formin homology domains are exposed.  With the N-
terminus of FHOD1 representing a likely portion of the protein responsible for 
mediating its targeting to myofibrils, we investigated the localisation of the GBD when 
overexpressed on its own in NRCs.  A GBD construct spanning from amino acids 1 to 
116 was used for this purpose (Figure 3.24 A).  When overexpressed in NRCs, the GFP-
tagged GBD distributed primarily in a diffuse cytoplasmic manner (Figure 3.24 B-C).  
There was some evidence of myofibrillar targeting and an occasional signal could be 
discerned at the Z-disk, as evidenced by co-localisation with –actinin (Figure 3.24 B, 
Zoom) and an alternating signal with myomesin (Figure 3.24 C, Zoom). Very faint co-
localisation with myomesin could occasionally be discerned, indicating the presence of 
the GBD at some of the M-bands. Overall, the FHOD1 GBD predominantly distributed 


















3.6.4 Overexpression of the DID [117-340] 
 
The Diaphanous inhibitory domain (DID) is involved in mediating the autoinhibitory 
interaction that maintains DRFs in a closed inactive state (Schonichen et al. 2006).  The 
DID (amino acids 117 to 340) of FHOD1 was overexpressed in NRCs in order to 
examine its targeting (Figure 3.25 A).  In contrast to the localisation of both the GBD 
and DID together, the GFP-tagged DID on its own distributed as aggregates or small 
vesicular structures throughout cells (Figure 3.25 B).  The DID is likely dispensable 
regarding targeting of FHOD1 to the sarcomere.  However, in the absence of an 
expression test in NRCs, we were unable to rule out whether the protein was unstable, a 
factor which may have accounted for its aberrant localisation.  
 
Figure 3.24: Overexpression of the FHOD1 GBD in Neonatal Rat Cardiomyocytes.  A) 
An FHOD1 GBD [1-116] expression construct was generated to assess its targeting in NRCs. 
NRCs were transfected with the GFP-tagged expression construct and cultured to day 4.  
Cells were stained against B) sarcomeric -actinin and F-actin or C) myomesin and F-actin.  
Stained cells were visualised by confocal microscopy.  Myomesin/-actinin are seen in red, 
GFP-tagged FHOD1 expression construct in green, and F-actin in blue. GFP, green 
fluorescent protein; GBD, GTPase binding domain.  White boxes show zoomed selections of 
merged images. Arrows denote sites of co-localisation. Scale bars represent 10m. N=3 
 















3.6.5 Overexpression of FHOD1 GBD [117-1191] 
 
In order to determine if the GBD was indeed playing a role in the targeting FHOD1 to 
myofibrils, we overexpressed an FHOD1 deletion construct lacking the N-terminal 
GBD (Figure 3.26 A).  This construct spanned from amino acids 117 to 1191 and 
included the alternatively spliced exons, and thus represented a truncation mutant of the 
long FHOD1 variant.  In contrast to the full-length FHOD1 construct , which 
accumulated in the peripheries of cells and was partially targeted to myofibrils (Figure 
3.20 D), FHOD1 GBD was instead distributing as aggregates or small vesicular like 
structures throughout cells (Figure 3.26 B).  However, similarly to the DID, due to the 
lack of expression controls on the protein level in NRCs for the GBD, we were unable 
to rule out if the aberrant localisation noted for the protein was merely due to its 
instability in NRCs. Overall, these experiments could suggest that the GBD domain of 
FHOD1 mediated the subcellular targeting that is observed for full-length FHOD1 in 
NRC. 
 
Figure 3.25: Overexpression of the FHOD1 DID in Neonatal Rat Cardiomyocytes.  A) 
An FHOD1 DID [117-340] expression construct was generated to assess its targeting in 
NRCs. NRCs were transfected with the GFP-tagged expression construct and cultured to day 
4.  Cells were stained against B) myomesin and F-actin.  Stained cells were visualised by 
confocal microscopy.  Myomesin is seen in red, GFP-tagged FHOD1 expression construct in 
green, and F-actin in blue. GFP, green fluorescent protein; DID, diaphanous inhibitory 
domain.  White box shows zoomed selection of merged images Scale bars represent 10m. 
N=3  
 















3.7.1 Expression of FHOD1 in Muscle Tissue 
 
We initiated our characterisation of FHOD1 by seeking to confirm expression in protein 
lysates of murine whole muscle samples.  As a positive control we loaded lysates from 
whole murine spleen samples where, as expected, a prominent band was seen running at 
the expected molecular weight of FHOD1 in Mus musculus (Westendorf et al. 1999; 
Tojo et al. 2003). Furthermore, a band of the same molecular weight was also detected 
in heart, as well as in fast and slow twitch skeletal muscle (Tibialis anterior, TA, and 
Soleus, respectively).Expression of sarcomeric -actinin was used as a loading control 
for quantification, which suggested that expression of FHOD1 is significantly higher in 
heart and fast twitch than in slow twitch muscle. The finding suggesting that slow 
twitch fibres appear to express lower levels of FHOD1 than either fast twitch fibres or 
the heart is in contrast to many other cytoskeletal proteins, which seem to be regulated 
in their expression in a similar way in ventricular and slow twitch muscle (Schiaffino 
Figure 3.26: Overexpression of FHOD1 GBD in Neonatal Rat Cardiomyocytes.  A) An 
FHOD1 GBD [117-1191] expression construct was generated to assess its targeting in 
NRCs. NRCs were transfected with the GFP-tagged expression construct and cultured to day 
4.  Cells were stained against B) myomesin and F-actin.  Stained cells were visualised by 
confocal microscopy.  Myomesin is seen in red, GFP-tagged FHOD1 expression construct in 
green, and F-actin in blue. GFP, green fluorescent protein; GBD, GTPase binding domain. 
E12-13, alternatively spliced exons 12-13 found on the long FHOD1 splice variant.  White 
box shows zoomed selection of merged images Scale bars represent 10m. N=3  
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and Reggiani 1996). However, although Western blots were performed three times for 
adequate quantification and basic statistical analysis to be performed, it must be noted 
that samples were derived from only two C57/BL6 mice. The results must therefore be 
interpreted with the caveat that they reflect findings from a relatively small sample size 
in an inbred strain of mice. Extrapolation of these findings to other mammalian systems, 
particularly to humans, must be done so with caution. However, our data in murine 
samples was in agreement with the expression profile of FHOD1 in human samples 
reported by one study that examined the expression profile of all 15 formins (Krainer et 
al. 2013). Here it was found that FHOD1 expression was higher in cardiac muscle than 
skeletal muscle on both the mRNA transcript level, as ascertained by real-time PCR, 
and the protein level, as confirmed by Western blotting.   
 
Previous studies suggested expression of FHOD1 on the mRNA transcript level in both 
cardiac and skeletal muscle (See Table 3.2 for previous expression data) (Westendorf et 
al. 1999; Tojo et al. 2003; Gill et al. 2004).  However, other reports implementing 
antibody studies suggested that FHOD1 was not expressed in hearts at the protein level 
(Staus et al. 2011).  Staus et al. 2011 reported no expression of FHOD1 in murine hearts 
whereas we found a signal for FHOD1 in hearts as well as confirming expression in 
skeletal muscle.  This discrepancy was most likely due to the fact that these profiles 
were ascertained using different anti-FHOD1 antibodies, since both studies were 
performed using C57/BL6 mice.  Whereas our study was able to produce a signal for 
FHOD1 in the heart with the polyclonal mouse anti-FHOD1 antibody (Abcam), Staus et 
al. 2011 was unable to do so using the polyclonal mouse anti-FHOD1 antibody (ECM 
Biosciences).  During our validation experiments for the polyclonal mouse anti-FHOD1 
antibody (ECM Biosciences), there was no observed signal for FHOD1 in either cardiac 
or skeletal muscle lysates (results not shown), unlike the previous study that revealed a 
signal for FHOD1 in skeletal muscle (Staus et al. 2011).  These conflicting results 
regarding the same antibody may have been accounted for by differences in sample 
preparation or even by the quality of different antibody batches.   Taking into account 
microscopy data, the notion that FHOD1 protein is found in cardiac muscle was 
supported by the observed signal for the protein in immunofluorescence samples of 
cultured cardiac cells and heart sections with several different antibodies. 
   





Table 3.2: Expression Profile of FHOD1 in Mammalian Tissues.  Summary of the expression patterns exhibited by FHOD1 in a 
number of tissues as described by previous studies.  The mRNA expression profiles were ascertained by Northern blot experiments and 
Multiple Tissue Expression Arrays using human tissues.  The protein expression profile was ascertained through Western blot studies 
using murine tissues.  The studies that described each expression profile are found in the left hand column. x, denotes expression in tissue; 
-, denotes absence of expression in tissue; N/A, not applicable since expression was not explored in tissue. 




Unlike its expression in cardiac muscle, FHOD1 expression has been confirmed in 
skeletal muscle by many of the relevant studies (Tojo et al. 2003; Gill et al. 2004; Staus 
et al. 2011a; Krainer et al. 2013), however, the present characterisation effort is the first 
to report differences in protein levels of this formin in fast versus slow skeletal muscle.  
Although weaker than that seen in cardiac muscle, a strong signal for FHOD1 was noted 
in samples from mouse tibialis anterior (TA).  TA muscle is primarily composed of fast 
twitch skeletal muscle fibres.  Fainter FHOD1 expression was observed in mouse soleus 
samples, a muscle composed primarily of slow twitch skeletal muscle fibres.  The 
reasons behind this observed difference in protein levels can only be speculated upon 
but they may be explained by rates of protein turnover in these muscle types.  Muscle 
proteins are continuously being turned over but rates vary according to the type of 
muscle.  The average half-lives in rat adult slow twitch and fast twitch skeletal muscles 
are 12.1 and 18.3 days, respectively (Lewis et al. 1984; Goldspink 1991).  The lower 
expression levels of FHOD1 in soleus could have therefore been explained by the 
higher rate of protein turnover, resulting in less accumulation of FHOD1 in slow twitch 
skeletal muscle.  Different levels of FHOD1 in each tissue may have also been 
indicative of specific requirements for the protein in various types of striated muscle.    
 
One discrepancy that arose in the study of FHOD1 expression in different tissues was 
the observation that only one antibody produced a discernible signal for FHOD1. This 
raised the point as to whether the polyclonal mouse anti-FHOD1 antibody (Abcam) was 
actually recognising FHOD1 in lysates. Antibody validation using full-length constructs 
and different fragments of FHOD1 suggested that all 4 of the commercial antibodies 
recognised the human FHOD1 constructs, albeit with varying specificity considering 
that the polyclonal goat antibodies seem to preferentially recognise the FHOD1 C-
terminus, at least in terms of all the constructs tested. Alignment of the human and 
mouse FHOD1 amino acid sequences suggested relatively high levels of sequence 
similarity among the regions of FHOD1 that the antibodies recognised on Western 
blots. This would suggest that recognition of mouse FHOD1 could have been possible, 
although sequence alignment cannot substitute for direct biochemical verification using 
mouse FHOD1 constructs. We also demonstrated that the anti-FHOD1 antibodies 
preferentially recognised the human FHOD1 construct and did not cross-react with 
human FHOD3 constructs on Western blots or in immunofluorescence samples of COS 
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cells overexpressing FHOD1 or FHOD3. This was a particularly important point to 
address since human FHOD1 and FHOD3 bear 52.1% amino acid similarity. Although, 
direct biochemical verification was lacking in terms of cross-reactivity using a mouse 
FHOD3 construct, the similar level of divergence noted between human FHOD1 and 
mouse FHOD3 (56% sequence similarity) could have been an indicator that cross-
reactivity was not occurring on blots. One likely explanation behind the lack of signal 
with the other anti-FHOD1 antibodies in murine tissue could be loss of the epitope the 
antibodies preferentially recognise, since samples are subjected to denaturing 
conditions. One way of addressing this potential issue could involve the use of milder 
sample preparation methods (e.g., lysis in RIPA buffer) and/or the inclusion of protease 
inhibitors in the lysis buffer.  
 
However, one major caveat that was not addressed involved the potential of antibody 
cross-reactivity with other proteins. Antigen competition assays were not performed, 
therefore we cannot conclude with certainty that we were truly visualising FHOD1 on 
Western blots. Even if the observed molecular weight of the bands attributed to FHOD1 
in tissue lysates were in agreement with the expected molecular weight, there are other 
proteins with similar molecular weight. Furthermore, a band at the correct expected 
molecular weight is not proof enough of protein identity since proteins can often 
migrate at unexpected observed molecular weights on one-dimensional gels.   
 
3.7.2 Localisation of Endogenous FHOD1 in Muscle Samples 
 
Aside from examining the expression of total FHOD1 protein, we looked at the 
localisation of the endogenous protein using the 4 commercial anti-FHOD1 antibodies 
in various muscle samples: NRCs, ARCs, mouse heart sections, and differentiating 
C2C12 skeletal muscle cells. The present localisation studies were complemented by 
Western blot studies, which sought to confirm reactivity against FHOD1 at the protein 
level. We were able to show reactivity with at least one antibody across all the different 
muscle samples. However, the caveat remained that we were unable to rule out non-
specific recognition of other proteins in the absence of an antigen competition assay 
with each sample. This was the case for both Western blot and immunofluorescence 
studies. Furthermore, as was the case for mouse FHOD1, we were unable to confirm the 
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sensitivity of the commercial anti-FHOD1 antibodies in biochemical verification 
experiments using rat FHOD1 constructs.  
 
Experiments in NRCs using the different antibodies revealed that FHOD1 could be 
found distributing along myofibrils and that it could also be visualised as striations, 
indicating that FHOD1 could be partly found distributing within specific compartments 
of the sarcomere. However, comparison between the antibodies revealed inconsistencies 
when the localisation of FHOD1 within the sarcomere was concerned (Table 3.1), 
therefore casting doubt as to the validity of these staining experiments. The multitude of 
FHOD1 localisations was highly suggestive that the antibodies were not recognising 
their designated target. A similar situation was noted for ARCs. While we noted 
myofibrillar targeting and some sarcomeric distribution for endogenous FHOD1 in 
ARCs, the results presented for the antibodies that demonstrated reactivity for FHOD1 
in immunofluorescence samples produced inconsistent results when they were 
compared among each other. It is therefore difficult to draw meaningful conclusions 
regarding the precise localisation of endogenous FHOD1 in NRCs and ARCs. 
 
We also investigated the subcellular localisation of FHOD1 in frozen sections of mouse 
heart. With two different FHOD1 antibodies (polyclonal goat C14 and C20) that are 
directed against two different epitopes along the molecule, a strong signal was seen in 
cardiomyocytes, which was mainly concentrated at the specific sites of cell-cell contact 
in heart, the intercalated discs. We also observed staining in the interstitial spaces 
between cardiomyocytes, which could have suggested that some FHOD1 expression 
occurred in cardiac fibroblasts. Occasionally a cross-striated pattern was seen in 
cardiomyocytes, suggesting the presence of FHOD1 within myofibrils. Counterstaining 
for the M-band marker myomesin revealed alternating striations and indicates that 
FHOD1 may be present in some of the Z-disks, although counterstaining with the Z-
disk marker –actinin must be performed in order to confirm this. Interestingly this 
localisation pattern may be evolutionally conserved; in C. elegans FHOD1 is also found 
as bright puncta at the muscle cell edges with faint striations at the dense bodies, the 
equivalent of the Z-disk (Mi-Mi et al. 2012). While we were able to rule out any 
background staining mediated by the secondary antibodies, we were not able to directly 
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demonstrate a lack of cross-reactivity of the antibody conjugates, although only multi-
labelling quality antibodies were employed. 
 
While we did not present the localisation of FHOD1 in skeletal muscle sections, we did 
explore its expression and localisation over the differentiation process that C2C12 cells 
undergo when they are subjected to low serum conditions, in concurrent Western 
blotting and immunofluorescence experiments. We showed reactivity with the 
polyclonal goat C14 antibody in C2C12 samples via Western blots throughout the entire 
differentiation process. However, the caveat applies that the identity of this signal was 
not confirmed in the absence of an antigen competition assay. We confirmed that cells 
were differentiating on Western blots by showing a more-prominent signal for –actinin 
and desmin at day 2. The differentiation process was also confirmed visually, as cells 
were seen to elongate, fuse into myotubes, and occasionally twitch. At day 0 we did 
however note a band for FHOD1 migrating at a lower molecular weight than expected. 
Currently, there is only one  reported FHOD1 isoform in mice, a large 1,197 amino acid 
variant (predicted molecular weight 128 kDa). This unidentified band may have 
represented non-specific recognition of another protein, although only the performance 
of an antigen competition assay would be able to truly clarify this. 
 
In undifferentiated myoblasts, FHOD1 exhibited predominantly cytoplasmic 
distribution. Originally, FHOD1 was found to be a cytoplasmic protein as determined 
by immunofluorescence staining in HeLa and also since it was found in the cytoplasmic 
fraction in cell fractionation experiments (Westendorf et al. 1999).  Furthermore, during 
the investigation of the localisation of endogenous FHOD1 in Co396 cells, a novel 
antibody was raised against FHOD1 and staining for the protein revealed that it 
distributed in a cytoplasmic manner and accumulated in the perinuclear region of cells 
(Wang et al. 2004).  In C2C12 cells, FHOD1 remained diffuse throughout the 
cytoplasm when cells began to elongate and fuse, but FHOD1 was occasionally 
visualised along F-actin stress fibres.  In differentiated cells that had assembled 
sarcomeres, FHOD1 could occasionally be discerned along myofibrils, but any evidence 
of sarcomeric targeting was not clear, except for the polyclonal goat C20 antibody. The 
goat C20 anti-FHOD1 antibody consistently produced doublet banding pattern for 
FHOD1 in cultured cells of myogenic origin. Once again, discrepancies in the 
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localisation of endogenous FHOD1 occurred between the antibodies, therefore it is 
difficult to draw any meaningful conclusions until we can determine with certainty that 
the anti-FHOD1 antibodies are only recognising their designated epitope and not 
another protein. 
 
3.7.3 Overexpression of FHOD1 in NRCs   
 
In addition to investigating the expression and localisation of endogenous FHOD1 in 
muscle samples, we performed transient expression studies using epitope tagged full-
length FHOD1 and fragments therefore in cultured NRCs. One of the issues we sought 
to address was the potential for differential targeting between the short and long 
FHOD1 isoforms found in human. Differential splicing of FHOD1 had been previously 
noted when a larger FHOD1 isoform was described in skeletal muscle (Tojo et al. 
2003).  Apart from the 1,164 amino acid variant, two additional FHOD1 isoforms have 
been identified in humans: the larger skeletal muscle variant containing a 78bp (26 
amino acid) insertion and a truncated variant with a 24bp insertion, containing an in-
frame stop codon at the same site as the 78bp insertion.  The 78 bp insertion represents 
two alternatively spliced exons (exons 12-13).  Previous analysis of the mRNA 
expression pattern of the FHOD1 variants revealed that the larger variant was 
preferentially expressed in heart, skeletal muscle, and prostate samples whereas the 
original isoform exhibited a more ubiquitous expression profile. Furthermore, the larger 
variant was abundantly expressed in skeletal muscle and faintly in the heart whereas the 
original isoform was abundantly expressed in the heart and faintly expressed in skeletal 
muscle (Tojo et al. 2003).  
 
Overexpression of both the long and short GFP-tagged FHOD1 constructs in NRC 
revealed a mainly diffuse signal with major intensities at the periphery of the cells. 
However, in contrast to the observed localisation for FHOD1 at the intercalated disk in 
heart tissue, we did not detect a consistently increased signal for GFP-tagged FHOD1 at 
the cell-cell contacts between NRCs. This was also the case for endogenous FHOD1, 
which was visualised with the commercially available anti-FHOD1 antibodies. These 
contacts between NRCs are often termed intercalated disk-like structures since, despite 
containing the classical intercalated disk components such as desmosomal proteins and 
gap junction proteins, one major difference is that they do not necessarily require end-
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on insertion of myofibrils but can also occur in parallel to myofibrils (Hirschy et al. 
2006). Analysis of FHOD1 expression during embryonic heart development and 
comparison of its localisation with established intercalated disk anatomy will be 
required to determine, whether FHOD1 is only a late addition and characterizes mature 
intercalated disks in the three-dimensional environment in situ. 
 
It was noted that the GFP-tagged full-length FHOD1 constructs were well tolerated in 
cells and did not induce any changes in their cytoarchitecture, as gauged by staining for 
the Z-disk marker, -actinin. This observation was consistent with previous 
overexpression studies in cultured cells that indicated full-length FHOD1 was 
maintained in a closed inactive state and could therefore not induce changes in cell 
morphology (Westendorf 2001; Gasteier et al. 2003; Koka et al. 2003; Takeya and 
Sumimoto 2003; Boehm et al. 2005; Gasteier et al. 2005).  However, the TOMATO-
tagged long variant of full-length FHOD1 induced mild cell elongation and the 
formation of membrane extensions, to which FHOD1 was targeted to.  This would be in 
line with the cell elongation phenotype observed in full-length FHOD1 overexpressing 
NIH3T3 and WM35 cells (Koka et al. 2003).  One can only speculate as to why the 
TOMATO-tagged FHOD1 construct induced a change in cardiomyocyte morphology 
whereas the full-length GFP-tagged constructs did not.  We propose that the TOMATO-
tagged long variant of full-length FHOD1 may have been rendered in a partially active 
confirmation, due to steric displacement of the formin autoinhibitory interaction by the 
larger size of the TOMATO tag. These potentially undesirable characteristics of the 
TOMATO tag highlight that it is not a suitable epitope tag for localisation studies as it 
could alter the native properties of the protein. Furthermore, we observed nearly 
identical distribution along myofibrils for the TOMATO tag on its own, indicating that 
the observed localisation for TOMATO-tagged FHOD1 along myofibrils may have 
been mediated by the tag. While stickiness of the GFP molecule posed a potential 
caveat in this study, we found GFP restricted to the I-bands and nuclei of NRCs while 
the GFP-tagged FHOD1 constructs displayed comparatively different targeting.    
 
Interestingly, targeting of full-length FHOD1 differed from that previously noted with 
full-length FHOD3, which distributed along myofibrils but was found near the A-bands 
of  sarcomeres when overexpressed in NRCs (Iskratsch et al. 2010).  Perhaps distinct 
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subcellular localisations for the two closely related formins indicate a specialised 
function for each protein. However, one drawback of overexpressing human protein in 
rat cardiac cells is that it is not fully representative of the protein’s native environment. 
Although the FHOD1 and FHOD3 amino acid sequences are fairly highly conserved 
between human and rat, further overexpression experiments using rat FHOD1 should be 
performed in order to see if targeting of rat and human FHOD1 differs.   
 
The subcellular targeting of formins is often mediated by their N-terminus (Seth et al. 
2006; Ramalingam et al. 2010), which also tends to be the part of the molecule with the 
highest divergence in its sequence and even in its structure (Schulte et al. 2008). We 
created GFP-tagged expression constructs that only encoded for subdomains of FHOD1 
and analysed their subcellular targeting in NRC. The FH2 domain of FHOD1 on its own 
displayed a strong signal at the Z-disk, as indicated by its alternation with signal for the 
M-band protein myomesin and co-localisation with the Z-disk marker -actinin. The 
FH2 domain also co-localised with F-actin near the cell peripheries and may have led to 
a slight increase in F-actin levels at their sites of overlap. This may have been consistent 
with the capping, mild elongation, or bundling activity that the FHOD1 FH2 domain 
may possess (Schonichen et al. 2013).  Constructs encoding the GBD-DID domain or 
even only the GBD domain on its own showed mainly diffuse cytoplasmic localisation 
with some evidence for myofibrillar and sarcomeric localisation. The DID alone as well 
as an N-terminal deletion construct lacking the GBD domain either showed aggregates 
or small vesicular-like structures. These experiments would suggest that the GBD 
domain of FHOD1 could mediate the subcellular targeting that is observed for full-
length FHOD1 in NRC.  
 
Initial reports suggested that the C-terminus of FHOD1 was responsible for mediating 
its subcellular localisation (Westendorf 2001).  The current work and that of others 
would however have indicated otherwise.  The current data indicated that the GBD of 
FHOD1 may have mediated the targeting of the full-length GFP-tagged 
FHOD1construct in NRCs.  This would be in line with a previous study that suggested 
that the GBD of FHOD1 is essential for its activity.  One study overexpressed different 
active and inactive FHOD1 GBD constructs in NIH3T3 cells to study the role of the 
GBD.  The construct lacking the GBD but in its uninhibited confirmation (FHOD1 
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GBDDAD) was unable to promote the formation of stress fibres whereas the active 
construct containing the GBD (FHOD1 DAD) was able to promote stress fibres 
formation and localised to these sites (Schulte et al. 2008).  It has also been noted that 
FHOD1 mediated stress fibre formation was dependent on the targeting of the protein to 
these sites (Gasteier et al. 2003).  A more-recent study found that wild-type FHOD1 and 
an N-terminal construct of FHOD1 (amino acids 1-573; FHOD1 short variant) co-
localised with actin arcs and stress fibres whereas a truncation mutant of FHOD1, 
lacking the N-terminus but retaining the FH2 domain, did not (Schonichen et al. 
2013).The possibility that the GBD in particular is required for the targeting of FHOD1 
poses interesting biological questions.  Perhaps a Rho family small GTPase is required 
to mediate the targeting of FHOD1 by way of binding to the GBD.  However, no studies 
have demonstrated binding of a Rho family small GTPase to the FHOD1 N-terminus 
(Westendorf 2001; Schulte et al. 2008). There is also currently little known about the 
expression pattern of the Rho family GTPases in cardiac muscle.  Furthermore, while 
there is some evidence for the association between the Rho family GTPases and 
myofibrils (Ahuja et al. 2007), this remains to be fully elucidated; therefore there is 
little room for speculation.   
 
However, the targeting of the FH2 domain to the Z-disks and to F-actin would suggest 
that the FH2 domain might also contribute to the targeting of FHOD1. Interestingly, 
also the FH2 domain of FHOD3 targets to Z-disks when expressed on its own (Iskratsch 
and Ehler, personal communication), so it may be a more general feature of FHOD 
formins. There are other possible explanations behind the apparent change in 
localisation of the FHOD1 GBD construct in NRCs. This construct still contains the 
regulatory DID and DAD regions, therefore FHOD1 could have still been conceivably 
held in its autoinhibited state thus masking the FH2 domain, which could mediate 
targeting to the Z-disks and F-actin. The GBD could therefore mediate the subcellular 
targeting of FHOD1 in its autoinhibited state whereas the Z-disk targeting requires the 
protein in its open conformation. This notion would need to be confirmed by 
performing overexpression studies with FHOD1 constructs lacking the both the GBD 
and DID, the GBD and DAD, or the GBD, DID, and DAD. Constructs lacking the FH2 
domain will also be necessary to investigate this hypothesis. 
 
 





In summary, we have demonstrated possible reactivity against FHOD1 in cultured 
muscle cells and whole muscle samples via Western blot and immunofluorescence 
studies. Furthermore, we have also unearthed potentially significant differences in 
expression levels of FHOD1 across murine muscle samples, which were in line with the 
expression pattern reported in a recent study in humans (Krainer et al. 2013). Since we 
reported a number of localisations for endogenous FHOD1 in immunofluorescence 
samples, we were not able to conclude with certainty the precise subcellular localisation 
of the protein in rat and mouse muscle samples. This was due to the technical 
limitations of the study, especially the lack of antigen competition assay control 
experiments. We also reported the effects of full-length human FHOD1 expression in 
NRCs, where the protein was found to primarily concentrate in the cell peripheries and 
distribute within the cytoplasm. Analysis of FHOD1 subdomains suggested that the 
GBD domain may play a role in mediating the localisation we noted for the full-length 
overexpressed protein, although the FH2 domain might also influence this. We 
hypothesise that the influence of the GBD and FH2 on the targeting of FHOD1 might 
differ according to the activation status of the protein. 
 
3.7.5 Future Directions 
 
While we were able to demonstrate that the anti-FHOD1 antibodies specifically 
recognised the human FHOD1 constructs and not FHOD3, one of the major oversights 
in these experiments was the uncertainty as to whether FHOD1 was cross-reacting with 
any other proteins on Western blots and immunofluorescence samples. Antigen 
competition assays will be required to address this issue. The commercial anti-FHOD1 
antibodies would need to be incubated with FHOD1 antigen prior to Western blotting or 
staining experiments in order to see if the previously noted signal for FHOD1 remains. 
Similarly, biochemical verification with rodent constructs will be required to prove with 
certainty that the antibodies recognise rodent FHOD1. Furthermore, single staining 
controls will be required in order to rule out any cross-reactivity with the other 
antibodies employed in the staining experiments, particularly if an overlapping signal 
was shown. Eventually, antibody studies should culminate in the generation of our own 
anti-FHOD1 serum from immunised rabbits. 




In terms of the overexpression studies, further confirmation will be required as to 
whether the GBD is indeed responsible for mediating the subcellular localisation of 
FHOD1, using the constructs outlined above. Furthermore, it must be noted that 
experiments with NRCs were performed in the presence of phenylephrine, a stimulator 
of myocardial contraction and hypertrophy. While it is common practice to add 
phenylephrine to our NRC maintenance medium as it promotes greater expression of 
epitope tagged expression constructs, future experiments must also be done in the 
absence of hypertrophic stimuli as these can potentially affect the localisation of the 
epitope tagged and endogenous protein in question. A further oversight of the 
overexpression studies was a lack of presentation of overexpression data in the absence 
of any other antibody staining. While we strove to avoid bleedthrough in our 
microscopy method by capturing individual channels with sequential scans, the 
possibility of bleedthrough can only be ruled out by omitting the inclusion of other 
fluorophore containing compounds.  
 
One important drawback relating to the analysis of FHOD1 expression concerned the 
methods used to quantify Western blots. Since protein assays were not performed, we 
were restricted to measuring levels of FHOD1 relative to the levels of -actinin. 
Furthermore, the quantification of Western blots was potentially restricted by the innate 
drawbacks of this technique, particularly the attainment of the linear range desired for 
accurate quantification. Upon saturation of protein signals on Western blots, a non-
linear relationship between the amount of protein and the observed signal occurs and 
will skew quantification. However, we strove to quantify blots within the linear range. 
Overall, chemiluminescence has a fairly narrow range compared to fluorescence 
detection systems, which have a wider linear range. Future efforts should focus on 
determining the levels of FHOD1 using protein assays and more-sensitive detection 
systems, namely fluorescence detection systems or charge-coupled device (CCD) 
















































4. Functional Characterisation of 
FHOD1 
4.1 Overexpression of FHOD1 Mutant Constructs in Neonatal Rat 
Cardiomyocytes 
 
In the current study, the localisation and expression of endogenous FHOD1 was 
explored in striated muscle.  Although the discrepancies in the staining pattern for 
FHOD1 with the 4 commercially available antibodies made it difficult to draw any 
meaningful conclusions regarding localisation of endogenous FHOD1 in cultured cells, 
antibody studies in frozen sections of mouse hearts suggested concentration of FHOD1 
at the intercalated disks between neighbouring cardiomyocytes, although some 
myofibrillar and sarcomeric localisation was also apparent. Transient expression studies 
in neonatal rat cardiomyocytes (NRCs) revealed that GFP-tagged full-length FHOD1 
distributed in a diffuse cytoplasmic manner, although it also produced major intensities 
at the peripheries of cells.  However, targeting of full-length FHOD1 was only explored 
in its supposedly inactive form.  Previous work on formins has suggested that full-
length formins are maintained in a closed inactive state.  In the case of FHOD1, the DID 
has been shown to directly bind the DAD and this interaction is thought to render 
FHOD1 inactive (Schonichen et al. 2006).  Indeed, FHOD1 constructs in their full-
length inactive form have mostly been reported to distribute in a diffuse cytoplasmic 
manner and generally do not induce significant morphological changes in cells (Takeya 
and Sumimoto 2003; Gasteier et al. 2005; Menard et al. 2006).  Only upon disruption of 
the DID-DAD interaction, such as in FHOD1 constructs lacking the DAD, is FHOD1 
associated with mediating cytoskeletal changes, particularly the appearance of stress 
fibres (Koka et al. 2003; Takeya and Sumimoto 2003; Gasteier et al. 2005; Schulte et al. 
2008; Schonichen et al. 2013).  Binding of a Rho family small GTPase to the N-
terminus of formins is often required for activation (Rose et al. 2005a).  While no small 
GTPase has been found to definitively bind and activate FHOD1, it has been established 
that FHOD1 is rendered partially active after it undergoes phosphorylation in its C-
  Functional Characterisation of FHOD1 
200 
 
terminus by the Rho family effector ROCK (Takeya et al. 2008).  On-going work would 
indicate that ROCK is a crucial regulator of FHOD1 activity (Thomas et al. 2011; Staus 
et al. 2011a) as well as FHOD3 activity (Iskratsch et al. 2013a).  Since a number of 
FHOD1 truncation and phosphomimetic mutants have been reported to render FHOD1 
active, they were currently implemented to explore the effects of FHOD1 activation in 
cultured cardiomyocytes.  We embarked on our functional characterisation of FHOD1 
by overexpression of inactive and constitutively active mutant and truncation constructs 
of the longer FHOD1 variant, containing the alternatively spliced exons, since FHOD1 
mutants lacking the exons where unavailable.  
 
Prior to initiating transfection studies, we sought to confirm that the expression 
constructs of the individual FHOD1 variants were expressed at the correct molecular 
weight (Figure 4.1). COS-1 cells were used for the expression tests because of the very 
low transfection efficiency we were able to achieve in NRCs of approximately less than 
5%. The following expression experiments describe qualitative results because of their 
extrapolation in significance to another cell type and because the exact protein 
concentration was not determined before loading. Expression tests of the GFP-tagged 
constructs in transiently transfected COS cells followed by Western blotting revealed 
that the GFP fusion proteins expressed at the expected molecular weight (approximately 
157 kDa for the full-length constructs). All of the following FHOD1 constructs were 
based on the long variant of FHOD1 containing the alternatively spliced exons 12-13. 
The FHOD1 DAD represents a truncation mutant of FHOD1, with a difference in 
molecular weight of roughly 6kDa. A slight shift in molecular weight can be seen, with 
the FHOD1 DAD migrating slightly faster than the full-length FHOD1 constructs. 
This size difference is better exemplified in Figure 4.6, A. The FHOD1 mutations for 
the V288E and the phosphomimetic constructs were confirmed by DNA sequencing. 
 












4.1.1 Overexpression of FHOD1 3A [1-1191] and FHOD1 3D [1-1191] 
Phosphomutants 
 
ROCK has been shown to phosphorylate FHOD1 at the C-terminal residues Ser1131, 
Ser1137, and Thr1141 on the short variant of FHOD1 lacking the alternatively spliced 
exons (Takeya et al. 2008; Staus et al. 2011a).  Phosphorylation of these residues has 
been associated with activation of FHOD1, which lead to the formation of stress fibres 
(Takeya et al. 2008) and the promotion of vascular smooth muscle cell differentiation 
(Staus et al. 2011a).  Two GFP-tagged FHOD1 constructs were created in which these 
three residues were mutated to either Alanine (FHOD1 3A) or Aspartic acid (FHOD1 
3D) residues. 
Figure 4.1: Expression Test of Different FHOD1 Constructs in COS-1 cells. A) Western 
blot with anti-GFP antibody of SDS samples from COS-1 cells that were transiently 
transfected with the different FHOD1 constructs. 12% SDS-PAGE. Cells were transfected 
with the following constructs: the FHOD1 DAD truncation mutant lacking the C-terminal 
DAD [1-1128], the FHOD1 3A mutant with the three ROCK phosphorylation sites mutated 
to Alanine residues [1-1191], the FHOD1 3D mutant with the three ROCK phosphorylation 
sites mutated to Aspartic acid residues [1-1191], and the FHOD1 V228E mutant with Valine 
residue at position 228 mutated to a Glutamic acid residue [1-1191]. Wild-type full-length 
FHOD1 containing the alternatively spliced exons 12-13 [1-1191] (FLL) was loaded as a 
comparator. GFP was loaded as a positive control. Untransfected COS-1 cells were used as a 
negative control. N=2. 




The FHOD1 3A construct represents a situation in which the three ROCK 
phosphorylation sites are unable to be phosphorylated.  Thus, the protein is thought to 
be maintained in its closed inactive state (Figure 4.2 A).  The FHOD1 3A construct was 
overexpressed in NRCs (Figure 4.2 B).  Transfected cells were morphologically 
indistinguishable from their untransfected neighbours.  The GFP-tagged FHOD1 3A 
mutant protein was found to accumulate at the peripheries of cells near the plasma 
membrane, as was noted previously with the GFP-tagged full-length wild-type FHOD1 
constructs.  The construct also distributed in a partly diffuse manner in cells. 
Occasionally some myofibrillar targeting was noted, since a faint cross-striated 
appearance could sometimes be resolved.  No co-localisation was noted between 
FHOD1 and F-actin. The construct was also well tolerated and had no impact on the 
levels of organisation of -actinin.  As expected, the FHOD1 3A construct behaved 






















The FHOD1 3D construct is a phosphomimetic variant of full-length FHOD1 designed 
to resonate the effects of ROCK phosphorylation in the C-terminus (Figure 4.2 A).  The 
3D mutation in the FHOD1 DAD thus represented a situation where FHOD1 is rendered 
constitutively active.  The FHOD1 3D construct was overexpressed in NRCs (Figure 
4.2 C) to assess the effects of constitutive FHOD1 activation in cardiomyocytes.  
Overexpression of the FHOD 3D construct did not seem to affect the organisation of 
myofibrils, as indicated by the levels and periodicity of the sarcomeric -actinin signal. 
Figure 4.2: Overexpression of FHOD1 Phosphomutant Constructs in Neonatal Rat 
Cardiomyocytes.  NRCs were transfected with different mutant variants of the longer 
version of GFP-tagged FHOD1 constructs and cultured to day 4.  Cells were transfected with 
the following constructs: A) the FHOD1 3A mutant with the three ROCK phosphorylation 
sites mutated to Alanine residues [1-1191] and the FHOD1 3D mutant with the three ROCK 
phosphorylation sites mutated to Aspartic acid residues [1-1191]. Cells were stained against 
sarcomeric -actinin, F-actin, and visualised by confocal microscopy. B) NRC transfected 
with the FHOD1 3A mutant. C) NRC transfected with the FHOD1 3D mutant (see D for 
zoomed image).  -actinin is seen in red, the GFP-FHOD1 mutants in green, and F-actin in 
blue.  GFP, green fluorescent protein. Scale bars represent 10m. White box shows zoomed 
selection of merged images. Arrow denotes site of co-localisation between FHOD1 and F-
actin. E12-13, denotes the alternatively spliced exons 12-13. N=2. 
 
  Functional Characterisation of FHOD1 
204 
 
There was some evidence for increased F-actin at the periphery of the cells and along 
myofibrils. Overexpression of the FHOD1 3D construct also resulted in a more 
elongated appearance compared to neighbouring untransfected control NRCs. 
Furthermore, the construct co-localised with F-actin near the plasma membrane (Figure 
4.2 C, Zoom) and in within extended plasma membrane processes, an observation 
which we did not note with the FHOD1 3A or wild-type constructs.  The FHOD1 3D 
construct also displayed some targeting to myofibrils, where it sometimes exhibited a 
faint cross-striated appearance, the spacing of which seemed to be irregular with the Z-
disk marker -actinin. The FHOD1 3D ROCK phosphomimetic mutant thus induced 
morphological changes and displayed some evidence of co-localisation with F-actin 
when compared to the FHOD1 3A inactive mutant in NRCs.  
4.1.2 Overexpression of FHOD1 DAD [1-1128] and FHOD1 V228E 
[1-1191] 
 
The Diaphanous autoregulatory domain (DAD) is not necessarily a discrete domain but 
a stretch of 20-30 amino acids found downstream of the FH2 domain.  It is involved in 
maintaining DRFs in their closed inactive state via an interaction with the N-terminal 
DID.  In formins, DAD truncation often results in activation, as has been shown in the 
case of mDia1 (Maiti et al. 2012) and FHOD1 (Koka et al. 2003; Gasteier et al. 2005; 
Schulte et al. 2008; Staus et al. 2011a).  The effects of FHOD1 activation in 
cardiomyocytes were further investigated by overexpressing a GFP-tagged FHOD1 
mutant lacking the DAD (FHOD1 DAD) (Figure 4.3 A).  Overexpression of the 
FHOD1 DAD construct resulted in a slightly elongated appearance in NRCs (Figure 
4.3 B).  Furthermore, FHOD1 DAD also led to the formation of F-actin bundles, 
where FHOD1 DAD was found to co-localise with F-actin (Figure 4.3 B, Zoom). 
Some myofibrillar targeting was also apparent, with occasional striations also resolved. 
However, the spacing of these striations were not always consistent.  Overall, truncation 
of the DAD of FHOD1 induced the formation of actin bundles, where FHOD1 co-
localised with F-actin, and displayed some targeting to myofibrils.  












Upon characterisation of the FHOD1 autoinhibitory mechanism it was found that the 
interaction between the N-terminal DID and the C-terminal DAD was dependent on the 
presence of a Valine residue at position 228 (Schulte et al. 2008) (Figure 4.4 A).  When 
this residue was mutated to a Glutamic acid it led to activation of FHOD1 in NIH3T3 
cells, as evidenced by formation of thick stress fibres and abrogated binding between 
the FHOD1 N-terminus and the DAD in GST pull-down experiments (Schulte et al. 
2008).  We overexpressed this constitutively active FHOD1 variant in NRCs to further 
investigate the effects of FHOD1 activation in cardiomyocytes (Figure 4.4 B).  
Overexpression of GFP-tagged FHOD1 V228E seemingly had a more-profound effect 
on NRC morphology than the other FHOD1 constitutively active mutant constructs.  
Cells displayed an elongated morphology and a number of thick stress fibres, which 
were arranged along the long axis of the cells.  The FHOD1 V228E mutant was targeted 
to stress fibres where it co-localised with F-actin.  Some myofibrillar targeting of the 
FHOD1 V228E construct was also apparent. The construct partly distributed in a faint 
cross-striated manner, but similarly to the other constitutively active constructs, the 
Figure 4.3: Overexpression of the FHOD1 DAD Construct in Neonatal Rat 
Cardiomyocytes.  NRCs were transfected with different mutant variants of the longer 
version of GFP-tagged FHOD1 constructs and cultured to day 4.  Cells were transfected with 
the A) FHOD1 DAD truncation mutant lacking the C-terminal DAD [1-1128]. Cells were 
stained against sarcomeric -actinin, F-actin, and visualised by confocal microscopy. B) 
NRC transfected with the FHOD1 DAD truncation mutant. -actinin is seen in red, the 
GFP-FHOD1 mutants in green, and F-actin in blue.  GFP, green fluorescent protein; DAD, 
diaphanous autoregulatory domain. Scale bars represent 10m. White box shows zoomed 
selection of merged images. Arrow denotes site of co-localisation between FHOD1 and F-
actin. E12-13, denotes the alternatively spliced exons 12-13. N=3.  
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spacing of these striations were irregular with respect to -actinin. The FHOD1 V228E 
constitutively active mutant thus induced rearrangement of the F-actin network into 











Overall, overexpression of the constitutively active FHOD1 variants seemingly had an 
impact on the F-actin network of NRCs, as evidenced by increased staining for F-actin 
in the peripheries of cells or the appearance of F-actin bundles and stress fibres. 
However, constitutive FHOD1 activation had little effect on myofibrillar organisation, 
since the characteristic Z-disk localisation of -actinin was mostly retained in 
transfected cells. Furthermore, we noted co-localisation between the constitutively 
active FHOD1variants and F-actin, an observation that was not seen with the full-length 
wild-type or the FHOD1 3A mutant. While the possible increase in F-actin staining in 
NRCs transfected with constitutively active FHOD1 variants may have implied greater 
levels of actin filament assembly, this remains to be seen, especially in light of recent 
reports that constitutively active FHOD1 caps actin and can only mildly elongate 
filaments in the presence of profilin (Schonichen et al. 2013). The present results would 
Figure 4.4: Overexpression of the FHOD1 V228E Construct in Neonatal Rat 
Cardiomyocytes.  NRCs were transfected with different mutant variants of the longer 
version of GFP-tagged FHOD1 constructs and cultured to day 4.  Cells were transfected with 
the A) FHOD1 V228E mutant with Valine residue at position 228 mutated to a Glutamic 
acid residue [1-1191].Cells were stained against sarcomeric -actinin, F-actin, and 
visualised by confocal microscopy. B) NRC transfected with the FHOD1 V mutant. -
actinin is seen in red, the GFP-FHOD1 mutants in green, and F-actin in blue.  GFP, green 
fluorescent protein. Scale bars represent 10m. Arrow denotes site of co-localisation 
between FHOD1 and F-actin. E12-13, denotes the alternatively spliced exons 12-13. N=2. 
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also suggest that the constitutively active FHOD1 variants may have exhibited some 
construct specific effects, suggesting that they not might have all represented reliable 
reporters of FHOD1 activation. Comparable effects were noted upon expression of the 
FHOD1 DAD and FHOD1 V228E variants, whereas we did not note substantial 
formation of bundled F-actin structures with the FHOD1 3D construct. Such an 
observation could indicate that phosphorylation in the DAD does not necessarily equate 
to full activation of FHOD1 when overexpressed in NRCs.  
 
4.2 Localisation of Phosphorylated FHOD1 in Heart Sections 
 
After addressing the function of FHOD1 in NRCs through overexpression of the 
different constitutively active constructs, we set out to investigate the localisation of 
phosphorylated endogenous FHOD1 in situ. For this purpose we stained frozen heart 
sections of adult mice with the anti-FHOD1 phospho-Threonine1141 antibody (ECM 
Biosciences). The anti-FHOD1 phospho-Threonine1141 antibody was raised against a 
synthetic peptide, which included the phosphorylated Threonine residue and 
corresponding amino acid residues that surround it in human FHOD1. The Threonine 
residue corresponds to one of the three that is phosphorylated by ROCK and therefore 
may represent FHOD1 in its active state (Takeya et al. 2008). The ROCK-I 
phosphorylation consensus motif, comprised of the two Serines and the Threonine 
residues, is conserved among rodent species (Figure 4.5), meaning that detection in 




















Characterisation of the phospho-Threonine1141 antibody’s specificity took place via 
Western blot and immunofluorescence studies. The following expression experiments 
describe qualitative results since the exact protein concentration was not determined 
before loading. Initial characterisation revealed that the phospho-Threonine1141  
antibody was able to detect GFP-tagged full-length FHOD1 when overexpressed in 
COS-1 cells (Figure 4.6 A, GFP-FHOD1 lane), which may have indicated that some 
basal phosphorylation of the construct was present in COS-1 cells. However, the 
phospho-Threonine1141 antibody was unable to detect the GFP-tagged FHOD1 3A and 
FHOD1 DAD constructs when overexpressed in COS-1 cells (Figure 4.6 A), despite 
the expression of these FHOD1 variants at comparable levels, as evidenced by detection 
with the anti-GFP antibody (Figure 4.6 B). These two constructs lacked the Serine and 
Threonine residues that are phosphorylated by ROCK-I in the DAD, therefore 
supporting the notion that the phospho-Threonine1141 antibody specifically recognised 
phosphorylation of FHOD1 within the ROCK-I consensus motif. The basal 
phosphorylation of the full-length FHOD1 construct may be due to serum in the culture 
medium.  
 
Immunofluorescence experiments in cultured NRCs, overexpressing full-length FHOD1 
and FHOD1 DAD, were also in agreement with the notion of the antibody’s 
specificity. While the phospho-Threonine1141 antibody recognised full-length FHOD1 
(Figure 4.7 A), as evidenced by partial co-localisation, it did not recognise the FHOD1 
Figure 4.5: C-terminal Sequence Comparison between Human and Rodent FHOD1.  
Alignment of the human FHOD1 C-terminal sequence amino acid sequence with the 
corresponding portions of mouse and rat FHOD1. The top reference sequence represents the 
Rattus norvegicus sequence (NCBI Reference Sequence: NP_001178529.1) [1-1138]. The 
middle reference sequence represents the Mus musculus sequence (NCBI Reference 
Sequence: NP_808367.2) [1-1197]. The bottom reference sequence represents the Homo 
sapiens sequence (NCBI Reference Sequence: NP_037373.2) [1-1164]. Sequence alignment 
was performed with clustalw2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/). Black boxes 
denote conserved serine and threonine residues. 
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DAD construct. Neighbouring untransfected NRCs showed no staining with the 
phospho-Threonine1141 antibody above background. Lack of recognition of the 
FHOD1 DAD construct was also evidence that recognition of the full-length construct 








Figure 4.6: Validation of anti-FHOD1 Phospho-Threonine1141 Antibody via Western 
Blot Studies.  A) and B) Western blot of SDS lysates of COS-1 cells transfected with one of 
the following GFP-tagged FHOD1 constructs: wild-type full-length FHOD1 containing the 
alternatively spliced exons 12-13 [1-1191], the FHOD1 3A mutant with the three ROCK 
phosphorylation sites mutated to Alanine residues [1-1191], and the FHOD1 DAD 
truncation mutant lacking the C-terminal DAD [1-1128]. A) Western blots probed with the 
FHOD1 phospho-Threonine1141 antibody. B) Western blots probed with the anti-GFP 
antibody. C), D), and E) Western blot of SDS lysates of COS-1 cells transfected with either 
GFP-tagged wild-type full-length FHOD1 containing the alternatively spliced exons 12-13 
[1-1191] or the HA-tagged full-length long variant of FHOD3. C) Western blot probed with 
FHOD1 phospho-Threonine1141 antibody. D) Western blots probed with the anti-GFP 
antibody. E) Western blot probed with the anti-HA antibody. GFP, green fluorescent 
protein; HA, haemagglutinin. N=2. 















Since the ROCK-I phosphorylation consensus motif is also conserved for FHOD3 
(Iskratsch et al. 2013a), we looked for evidence of cross-reactivity with FHOD1’s sister 
homolog. Western blots comparing GFP-tagged full-length FHOD1 and HA-tagged 
full-length FHOD3 overexpressed in COS-1 cells showed no signal with the phospho-
Threonine1141 antibody at the molecular weight expected for HA-tagged FHOD3 (180 
kDa; Figure 4.6 C). This observation was supported by immunofluorescence 
experiments in COS-1 cells expressing either full-length FHOD1 or FHOD3 which also 
Figure 4.7: Validation of the Anti-FHOD1 PhosphoThr1141 Antibody in Neonatal Rat 
Cardiomyocytes by Fluorescence Microscopy. NRCs were transfected with versions of the 
longer GFP-tagged FHOD1 variant and cultured to day 4. Cells were stained with the anti-
FHOD1 phosphoThr1141 antibody and for myomesin. Confocal micrographs of NRC 
transfected either with A) GFP-tagged full-length FHOD1 (left column) or B) DAD 
FHOD1 (right column). The GFP-tagged FHOD1 constructs are seen in green, 
phosphoThr1141 FHOD1 is seen in red, and myomesin in blue. Scale bar is equivalent to 10 
m. GFP, green fluorescent protein. N=3.  
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revealed no cross-reactivity (Figure 4.8). The phospho-Threonine1141 antibody 
partially recognised GFP-tagged FHOD1, as evidenced by co-localisation between the 
signal for the phospho-Threonine1141 antibody and the GFP-tagged FHOD1 signals 
within aggregates visualised throughout cells (Figure 4.8 A, Zoom), whereas there was 
no visual evidence of co-localisation between the phospho-Threonine1141 antibody 
signal and FHOD3 (Figure 4.8 C). Cells were also transfected with the empty GFP 
vector to rule out the possibility of the phospho-Threonine1141 antibody recognising 
the GFP tag on FHOD1 (Figure 4.8 B). Apart from background fluorescence in the 
nuclei of COS-1 cells, where the GFP tag on its own readily accumulates, we did not 
note co-localisation to the extent seen with FHOD1. Although the phospho-
Threonine1141 antibody might detect phosphorylated FHOD3 based on sequence 
homology, the present validation efforts suggest that this might be minimal. However, 
since the extent of FHOD3 phosphorylation was not determined in these assays, we 
cannot totally exclude cross-reactivity. Furthermore, the present characterisation efforts 
were performed with human FHOD1 and FHOD3 constructs; therefore it cannot be 
concluded with certainty whether they can be translated fully into the context of the 
rodent variants thereof.       
 












Nevertheless, with the caveat in mind that recognition of phosphorylated FHOD3 may 
have been a possibility, we stained mouse heart sections with the phospho-
Threonine1141 antibody (Figure 4.9). Staining with the antibody gave a very similar 
staining pattern to that noted previously with the polyclonal goat C14 and C20 anti-
FHOD1 antibodies, designed to recognise total levels of the protein. A strong signal was 
visualised at the intercalated disks. While there was a lot of diffuse staining in cells, 
occasional localisation along myofibrils was also noted. There was also some evidence 
Figure 4.8: Validation of the Phospho-Thr1141 FHOD1 Antibody in COS-1 Cells by 
Fluorescence Microscopy. COS-1 cells were transfected with A) GFP-tagged full-length 
long variant of FHOD1 containing the alternatively spliced exons (E12-13), B) the empty 
GFP vector, C) and HA-tagged full-length long variant of FHOD3. Cells were cultured to 
day two, fixed, and stained with the phosphoThr1141 FHOD1 antibody. Cells were also 
counterstained with Phalloidin to visualise F-actin.  This was performed in order to gauge 
the specificity of each antibody in immunofluorescence specimens and assess any possible 
cross-reactivity against FHOD3. GFP-tagged FHOD1 and HA-tagged FHOD3 are seen in 
green, phospho-Thr1141 FHOD1 is seen in red, and F-actin in blue. Scale bar is equivalent 
to 10 m. GFP, green fluorescent protein; HA, haemagglutinin. Arrow denotes site of co-
localisation. White box shows zoomed selection of merged images. N=2.  
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of the phosphorylated protein distributing in a striated manner.  An alternating pattern 
with the M-band marker myomesin indicated that the phosphorylated FHOD1 signal 
was partially found at the lateral portions of the sarcomere, near the Z-disks. Although 
the localisation of phosphorylated endogenous FHOD1 with the phospho-
Threonine1141 antibody was consistent with that seen with polyclonal goat anti-
FHOD1 antibodies, in the absence of an antigen competition assay, we cannot conclude 
with certainty that the signal for phosphorylated FHOD1 was genuine. This is especially 
the case because of the potential for cross-reactivity with FHOD3, which also contains 









4.3 F-actin Regulating Activity of FHOD1 
 
Overexpression of the constitutively active FHOD1 mutants in NRCs indicated the 
capacity of FHOD1 to rearrange the F-actin cytoskeleton and induce the appearance of 
F-actin based structures such as stress fibres and bundles.  We attempted to quantify the 
extent of formation of F-actin based structures with some of our available FHOD1 
constructs by performing in cyto F-actin formation assays. Due to the poor transfection 
efficiency we consistently achieved in NRCs, we opted to use HeLa cells as was done 
previously in the characterisation of the F-actin regulatory activity of FHOD3 in our 
laboratory (Iskratsch et al. 2010). We selected HeLa over COS-1 cells since HeLa cells 
Figure 4.9: Localisation of Phosphorylated FHOD1 in Murine Hearts.  Frozen heart 
sections of 1 year old male adult C57/BL6 mice were stained with the anti-FHOD1 
Phospho-Thr1141 antibody (ECM Biosciences), myomesin, and visualised by confocal 
microscopy.  Images represent portions of high magnification longitudinal sections.  
FHOD1 is seen in red, myomesin is seen in green, and DAPI/nuclei seen in blue.  
Arrowhead indicates an intercalated disk.  Scale bar represents 10m. White boxes show 
zoomed selections of merged images. N=2. 
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have an F-actin cytoskeleton that is better organised and hence more-amenable to 
imaging/quantification.   HeLa cells were transfected with the wild-type, constitutively 
inactive, and constitutively active mutant FHOD1 constructs.  Transiently transfected 
HeLa cells were subsequently stained with Phalloidin to measure the intensity of F-actin 
staining.  The Phalloidin pixel intensity was measured in both transfected and 
neighbouring untransfected cells and the ratio taken between them was used to measure 
differences in F-actin staining associated with the FHOD1 expression constructs (Figure 
4.10).  The activities of the empty GFP and TOMATO vectors were also quantified and 
provided baseline measurements, as they functioned as controls.  Both vectors did not 
have substantial actin polymerising activity since overexpression of the empty GFP 
vector resulted in an average Phalloidin pixel intensity ratio of 0.930 and the empty 
TOMATO vector produced a slightly elevated average ratio of 1.16.  A Phalloidin pixel 
intensity ratio of 1 would indicate equal amounts of F-actin in transfected and 
untransfected cells.  Cells expressing the GFP tag alone (Figure 4.11 A) and the 
TOMATO tag alone (Figure 4.11 I) were also morphologically indistinguishable from 
their untransfected neighbours.  The tags also distributed within the cytoplasm and 
nuclei of HeLa cells.  The negligible increases in Phalloidin pixel intensities suggested 
that the tags used for the assay were not responsible for any changes in F-actin staining.






                                      
Figure 4.10: Quantification of the Actin Regulating Activity of FHOD1 in HeLa Cells.  Bar chart depicting F-actin content in the presence of 
the FHOD1 constructs.  HeLa cells were transfected with different FHOD1 constructs and were subsequently fixed and stained for F-actin with 
Phalloidin.  The Phalloidin pixel intensity was measured in all cells and the ratio taken between transfected and untransfected cells.  The ratios of 
Phalloidin pixel intensities are expressed as arbitrary units.   GFP, green fluorescent protein empty vector; GFP-tagged long variant of full-length 
FHOD1[1-1191]; GFP-tagged short variant of full-length FHOD1 [1-1164]; FH2, GFP-tagged formin homology 2 domain [642-1031]; 3A, GFP-
tagged FHOD1 ROCK consensus site triple Alanine mutant [1-1191]; 3D, GFP-tagged FHOD1 ROCK consensus site triple Aspartic acid mutant 
[1-1191]; DAD, GFP-tagged FHOD1 truncation mutant lacking the diaphanous autoinhibitory domain [1-1128]; VE, GFP-tagged FHOD1 Valine 
228 to Glutamic acid mutant [1-1191]; TOMATO empty vector; TOMATO-tagged long variant of full-length FHOD1[1-1191].  Values represent 
cells seen in 10 views per dish: 1-5 transfected cells per view and 3-6 untransfected cells per view. Error bars represent standard deviation 
(STDEV). Values are provided in the accompanying table. N=1. 











Overexpression of both the long and short full-length GFP-tagged FHOD1 variants 
similarly induced an increase in the Phalloidin pixel intensity above the levels induced 
by the empty GFP vector (Figure 4.10).  Both constructs did not display evidence of 
Figure 4.11: Actin Regulating Activity of FHOD1 in HeLa Cells.  Representative images of 
HeLa cells transfected with the FHOD1 constructs.  HeLa cells were transfected with the 
FHOD1 constructs, fixed, and stained for F-actin, using Phalloidin.  Cells were transfected 
with the following constructs: A)  The empty GFP tag vector, B) GFP-tagged long variant of 
full-length FHOD1 [1-1191], C) GFP-tagged short variant of full-length FHOD [1-1164], D) 
GFP-tagged FH2 domain [642-1031] E) GFP-tagged FHOD1 ROCK consensus site triple 
Alanine mutant (3A) [1-1191], F) GFP-tagged FHOD1 ROCK consensus site triple Aspartic 
acid mutant (3D) [1-1191], G) GFP-tagged FHOD1 truncation mutant lacking the diaphanous 
autoinhibitory domain (DAD) [1-1128], H) GFP-tagged FHOD1 Valine 228 to Glutamic 
acid mutant (V228E) [1-1191], I) TOMATO tag empty vector, J) TOMAT -tagged long 
variant of full-length FHOD1 [1-1191]. GFP, green fluorescent protein; FH, formin homology.  
The FHOD1 constructs and their associated epitope tags are seen in green and F-actin in red.    
DAPI/nuclei are seen in blue.  Scal bars represent 10m. N=1. 
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significant co-localisation with the F-actin network in HeLa cells and distributed in a 
diffuse cytoplasmic manner (Figure 4.11 B-C).  The full-length TOMATO-tagged 
FHOD1 construct (Figure 4.11 J) was associated with more F-actin staining in 
transfected cells than the empty TOMATO vector, although the full-length TOMATO-
tagged FHOD1 construct exhibited a notable degree of variability in its capacity to alter 
F-actin staining (Figure 4.10). TOMATO-tagged FHOD1 was also associated with the 
appearance of stress fibres in some cells, indicating that it might have been partially 
rendered active. 
 
The F-actin regulating activity of the FHOD1 FH2 domain was also explored since the 
FH2 domains of formins have been shown to be sufficient to create actin filaments, as 
was exemplified with Bni1p (Pruyne et al. 2002).  Overexpression of the GFP-tagged 
FHOD1 FH2 domain on its own displayed a variable response in its capacity to alter 
staining for F-actin; therefore it was not possible to conclude whether the FH2 domain 
had an effect on the F-actin content of cells (Figure 4.10).  The formation of stress fibres 
was not noted and transfected cells were indistinguishable from untransfected 
neighbours.  Furthermore, the FH2 domain did not exhibit substantial co-localisation 
with the F-actin network and was targeted to cytoplasmic blebs (Figure 4 11.D). 
 
When the FHOD1 mutants were overexpressed in HeLa cells they were associated with 
greater staining for F-actin than the wild-type FHOD1 constructs (Figure 4.10).  This 
was strangely the case also with the supposedly inactive GFP-tagged FHOD1 3A 
construct, which exhibited a strong response: the average level of F-actin staining in 
transfected versus untransfected cells was greater than the GFP-tagged wild-type 
FHOD1 constructs. While the FHOD1 3D construct was associated with increases in F-
actin staining above the wild-type constructs, it did so to extremely varying degrees. 
The GFP-tagged FHOD1 DAD construct also increased F-actin staining in transfected 
cells, although it too exhibited a considerably variable response.  The GFP-tagged 
FHOD1 V228E construct seemingly increased F-actin staining in transfected cells to the 
greatest extent among the constitutively active constructs, but similarly to the other 
constitutively active construct, it also exhibited a variable response.  Cells transfected 
with the FHOD1 mutant constructs often displayed numerous stress fibres, to which 
they were partially targeted to (Figure 4.11 E-H).   
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The present experiment suggested that FHOD1 possessed the ability to induce the 
reorganisation and/or the accumulation of F-actin in HeLa cells. This may have 
occurred to a greater extent under instances of constitutive activation of FHOD1. 
However, it is difficult to speculate as to why the FHOD1 3A construct resulted in 
greater F-actin staining in transfected cells versus their untransfected neighbours, but it 
could indicate that phosphorylation in the DAD may not be a reliable reporter for 
activation. Furthermore, we noted a high degree of variability in the responses of the 
constitutively active FHOD1 constructs. While this is a reflection that further 
experiments will be required to validate these findings, it could also be indicative of 
other factors. We did not check levels of expression of the FHOD1 constructs in HeLa 
cells by Western blotting; therefore we could not rule out the possibility that certain 
constructs exhibited differential degrees of stability within HeLa cells. Furthermore, 
measurements may have been skewed in the presence of saturated F-actin signals found 
at stress fibres. While fluorescence has a wider linear range than chemiluminescence, 
very bright staining for F-actin could have resulted in measurements that were not 
performed in the linear range and may partly account for the variability in the responses 
we observed for many of the constructs. While the present experiment did not 
distinguish between the ability of FHOD1 to polymerise or reorganise actin, recent 
studies have indicated the latter. Even in its constitutively active confirmation, FHOD1 
was shown to cap actin filaments rather than elongate them and was also shown to 
possess a potent actin bundling activity (Schonichen et al. 2013). In addition, a region 
N-terminal to the FH1 domain of FHOD1 was characterised, which binds F-actin and 
mediates bundling (Schonichen et al. 2013). It is therefore possible, that the results that 
were seen for the FHOD1 3A construct reflect not so much an activation of 
polymerisation activity but more a bundling activity of FHOD1. 
 
4.4 Myofibril/F-actin Depolymerisation Assay 
 
Upon overexpression, activation of FHOD1 was partly associated with reorganisation of 
the F-actin network in cardiomyocytes and potential increases in F-actin staining in 
HeLa cells.  Transient expression studies were then performed to see if FHOD1 was 
involved in the regulation of thin filaments in cardiomyocytes. FHOD1 constructs were 
overexpressed in NRCs, which were subjected to depolymerisation of their myofibrils 
and all cellular F-actin through overnight Latrunculin B treatment.  FHOD1 transfected 
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NRCs were subsequently allowed to recover in wash-out experiments.  Transiently 
transfected cells were then scored on the integrity of their myofibrils and compared to 
cells transfected with the empty GFP and TOMATO vectors (Table 4.1). The integrity 
of myofibrils was judged by looking at the distribution of -actinin and F-actin, namely 
if they were incorporated into myofibrils and regained their striated appearance. 
Staining for F-actin was used to visualise myofibrils. Organisation at the level of the 
sarcomere was assessed by staining of the Z-disk marker, -actinin.  Transfected cells 
were counted and grouped according to whether they had poor, intermediate, or 
excellent myofibrillar integrity. Cells deemed to exhibit poor myofibrillar integrity were 
devoid of myofibrils and displayed patchy and irregular -actinin staining. Cells 
deemed to exhibit intermediate myofibrillar integrity displayed evidence of filamentous 
F-actin-based structures, although the spacing of the -actinin signal was irregular and 
hence indicated improper formation of the Z-disks. Cells deemed to have excellent 
myofibrillar integrity displayed well-formed myofibrils with regularly spaced Z-disks. 
Due to the fairly heterogeneous response seen with Latrunculin B treatment, baseline 
measurements were taken in untransfected cells. At baseline, the majority of 
untransfected cells (64%) displayed poor myofibrillar integrity. However, 
approximately a third of untransfected cells still displayed a moderate or excellent 
degree of myofibrillar integrity, indicating that the conditions may have required further 
































Both the GFP and TOMATO empty vectors were transfected into NRCs as negative 
controls and to test if they had any ability to influence the integrity of myofibrils after 
latrunculin B treatment with subsequent wash-out.  The GFP tag on its own was enough 
to promote myofibrillar integrity above baseline measurements, but the majority of cells 
(48%) still displayed poor myofibrillar integrity (Table 4.1).  Most cells displayed with 
a lacerated appearance and lacked organised myofibrils with sarcomeres (Figure 4.12 
A).  On the other hand, the TOMATO tag was enough to confer a notable degree of 
myofibrillar integrity in most cells, since 49% of transfected cells displayed 
intermediate myofibrillar integrity (Table 4.1).  The majority of TOMATO transfected 
cells had well-defined myofibrils, although they were not fully mature since the striated 
appearance of -actinin was not regular (Figure 4.12 E).  Both the GFP and TOMATO 
Table 4.1: Quantification of Myofibril Integrity in FHOD1 Transfected Neonatal Rat 
Cardiomyocytes.  NRCs were transfected with the different FHOD1 constructs prior to 
overnight treatment with Latrunculin B.  Promotion of myofibril recovery was promoted by 
washing out the Latrunculin B and replacing it with maintenance medium.  Cells were stained 
for -actinin, F-actin, visualised by confocal microscopy, and scored on their ability to 
recover their myofibrils.  Cells were grouped as having poor (+), intermediate (++), or 
excellent (+++) myofibrillar integrity. The following constructs were tested: GFP, green 
fluorescent protein empty vector; GFP-tagged long variant of full-length FHOD1 [1-1191]; 
GFP-tagged short variant of full-length FHOD1 [1-1164]; GFP-tagged formin homology 2 
(FH2) domain [642-1031]; GFP-tagged FHOD1 ROCK consensus site triple Alanine (3A) 
mutant [1-1191]; GFP-tagged FHOD1 ROCK consensus site triple Aspartic acid (3D) mutant 
[1-1191]; GFP-tagged FHOD1 truncation mutant lacking the diaphanous autoinhibitory 
domain (DAD) [1-1128]; GFP-tagged FHOD1 Valine 228 to Glutamic acid (V228E)  mutant 
[1-1191]; TOMATO empty vector; TOMATO-tagged long variant of full-length FHOD1 [1-
1191]; NRC, neonatal rat cardiomyocytes. N=1. 
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tags displayed diffuse cytoplasmic signals and nuclear targeting.  Although the GFP and 
TOMATO tags displayed the capacity to increase myofibrillar integrity with respect to 
untransfected cells after latrunculin B treatment, they did so to a lesser extent than most 



















The short and long variants of GFP-tagged full-length FHOD1 both promoted 
myofibrillar integrity in NRCs to a notable degree.  When they were overexpressed in 
Figure 4.12: Myofibril Recovery Assay in FHOD1-Transfected Neonatal Rat 
Cardiomyocytes.  Representative images of transfected NRCs subjected to Latrunculin B 
treatment with subsequent myofibril recovery.   Cells were stained with -actinin and F-
actin to visualise the extent of recovery.  Cells were transfected with the following 
constructs:  A)  the empty GFP tag vector, B) GFP-tagged long variant of full-length 
FHOD1 [1-1191], C) GFP-tagged short variant of full-length FHOD [1-1164], D) GFP-
tagged FH2 domain [642-1031],  E) TOMATO tag empty vector, F) TOMATO-tagged long 
variant of full-length FHOD1 [1-1191].  In the GFP transfected cells FHOD1 is seen as 
green and -actinin in red.  In the TOMATO transfected cells FHOD1 is seen as red and -
actinin in green.  F-actin is seen in blue.  NRC, n onatal rat cardiomyocytes; GFP, gr en 
fluorescent protein; FH, formin homology.  Scale bars represent 10m. White boxes show 
zoomed selections of merged images. Arrows denote sites of co-localisation with F-actin. 
N=1. 
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NRCs, a large proportion of transfected cells displayed excellent myofibrillar integrity 
when compared to the empty GFP vector.  The longer variant displayed a greater 
response with 62% of cells displaying well-formed myofibrils with regular –actinin 
staining (Figure 4.12 B).  47% of cells expressing the shorter variant displayed excellent 
myofibrillar integrity (Table 4.1) and presented with a similar appearance to cells 
transfected with the long GFP-tagged FHOD1 variant (Figure 4.12 C). The full-length 
FHOD1 constructs distributed along myofibrils but was sometimes found to concentrate 
with F-actin in round foci near the plasma membrane and at the ends of myofibrils, 
although the latter mainly applied to the shorter FHOD1 variant (Figure 4.12 B-C, 
Zoom). The TOMATO-tagged long variant of full-length FHOD1 was also 
overexpressed in NRCs.  This construct promoted excellent myofibrillar integrity in 
more cells than the empty TOMATO vector.  However, in a similar manner to the 
empty TOMATO vector, the majority of cells (47%) only displayed intermediate 
myofibrillar integrity (Table 4.1).  TOMATO-tagged FHOD1 predominantly distributed 
along myofibrils where it sometimes co-localised with both -actinin and F-actin 
(Figure 4.12 F, Zoom).  The FH2 domain on its own was also overexpressed in NRCs 
and was found to have an inhibitory effect on myofibril integrity when compared to the 
full-length FHOD1 variants.  NRCs overexpressing the GFP-tagged FHOD1 FH2 
domain promoted poor myofibrillar integrity, with 82% of transfected cells essentially 
devoid of any discernible myofibrils (Table 4.1).  Like the majority of untransfected 
cells, FH2 domain-transfected cells had a poorly organised F-actin network (Figure 4.12 
D).  The FHOD1 FH2 domain was also noted to co-localise with F-actin (Figure 4.12 D, 
Zoom).  Thus, experiments employing overexpression of full-length wild-type FHOD1 
suggested that it promoted myofibrillar integrity in the majority of NRCs after 
Latrunculin B treatment whereas the isolated FH2 domain seemed to have a negative 
effect on myofibrillar integrity. 
 
The FHOD1 mutant constructs were also tested for their capacity to regulate 
myofibrillar integrity in cardiomyocytes that were subjected to Latrunculin B treatment.  
The GFP-tagged FHOD1 3A construct promoted a relatively high degree of myofibrillar 
integrity, with 37% of cells displaying well-formed myofibrils with mature Z-disks 
(Table 4.1).  In these cells, FHOD1 3A distributed along myofibrils and occasionally 
co-localised with F-actin and -actinin (Figure 4.13 A, Zoom).  On the other hand, the 
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phosphomimetic FHOD1 3D construct enhanced myofibrillar integrity to a greater 
extent than the 3A construct, with 46% of cells displaying excellent myofibrillar 
integrity (Table 4.1).  In these cells FHOD1 also distributed along myofibrils, where it 
sometimes co-localised with F-actin and -actinin (Figure 4.13 B, Zoom), and exhibited 













The GFP-tagged FHOD1 DAD construct seemed to have a modest effect on the 
integrity of myofibrils compared to other constructs, with 54% of cells displaying 
Figure 4.13: Myofibril Recovery Assay in Mutant FHOD1-Transfected Neonatal Rat 
Cardiomyocytes.  Representative images of transfected NRCs subjected to Latrunculin B 
treatment with subsequent myofibril recovery.   Cells were stained with -actinin and F-
actin to visualise the extent of recovery.  Cells were transfected with the following FHOD1 
mutant constructs:  A) GFP-tagged FHOD1 ROCK consensus site triple Alanine mutant 
(3A) [1-1191], B) GFP-tagged FHOD1 ROCK consensus site triple Aspartic acid mutant 
(3D) [1-1191], C) GFP-tagged FHOD1 truncation mutant lacking the diaphanous 
autoinhibitory domain (DAD) [1-1128], D) GFP-tagged FHOD1 Valine 228 to Glutamic 
acid mutant (V228E) [1-1191].  GFP-tagged FHOD1 mutant constructs are seen in green, -
actinin in red, and F-actin in blue.  NRC, neonatal rat cardiomyocytes;  GFP, green 
fluorescent protein.  Scale bars represent 10m. White boxes show zoomed selections of 
merged images. Arrows denote sites of co-localisation with F-actin. N=1. 
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intermediate myofibrillar integrity (Table 4.1).  The construct distributed along less 
mature myofibrils where it co-localised with F-actin and -actinin (Figure 4.6 C, 
Zoom).  The GFP-tagged FHOD1 V228E mutant had a profound effect on myofibrillar 
integrity, with 46% of cells displaying well-formed myofibrils (Table 4.1).  This 
construct exhibited a unique localisation pattern compared to the other FHOD1 
constructs (Figure 4.6 D).  The FHOD1 V228E construct was found as small blebs that 
distributed along myofibrils.  Perinuclear accumulation of the construct was also 
present.  The FHOD1 V228E construct exhibited some co-localisation with F-actin 
throughout transfected cells (Figure 4.6 D, Zoom).   
 
Although myofibril/F-actin depolymerisation experiments suggested that FHOD1 may 
have a role in the regulation of myofibrillar integrity, it was impossible to distinguish 
between the FHOD1 expression constructs facilitating recovery of myofibrils (i.e., 
promoting de novo myofibrillogenesis) or preventing disassembly of myofibrils. 
Comparison of the wild-type and mutant FHOD1 constructs indicated that myofibrillar 
integrity was generally increased regardless of the activation status of FHOD1. Taken 
together these observations might point at slightly different subcellular roles for the 
closely related FHOD3 and FHOD1 in cardiomyocytes. While results for FHOD3 were 
clear-cut and related to its activation status (Iskratsch et al., 2010), results for FHOD1 
were more ambiguous. FHOD3 is consistently associated with myofibrils, at least in its 
muscle isoform, while FHOD1 may mainly be localised in the cellular periphery, 
meaning that it may aid myofibrils integrity but not as strongly and consistently as 
FHOD3. Interestingly, the FH2 domain of FHOD1 seemed to reduce myofibrillar 
integrity in this assay, suggesting that it may have facilitated disassembly of myofibrils 
and/or inhibited the assembly of thin filaments after Latrunculin B wash-out. While the 
FH2 domains of some formins have been shown to be sufficient for thin filament 
assembly, this does not seem to be the case for FHOD1. FH2 domain-containing 
FHOD1 constructs have been shown to preferentially cap filaments rather than elongate 
them (Schonichen et al. 2013). If the isolated FHOD1 FH2 domain possessed any actin 
polymerising activity, we may have expected a greater degree of myofibrillar integrity 
than that seen in untransfected NRCs. The GFP-tagged full-length FHOD1 constructs 
containing the FH2 domain did however promote myofibrillar integrity, which could 
mean that elements that lie outside of the FH2 domain were partly responsible. The 
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FHOD1 N-terminus has been shown to possess actin bundling activity (Schonichen et 
al. 2013) and could conceivably play a role in promoting myofibrillar stability in the 
presence of Latrunculin B. These factors would suggest that the full-length and active 
FHOD1 constructs prevented myofibrillar/F-actin disassembly rather than promoted de 
novo filament assembly. However, this remains to be confirmed by performing this 
assay with other FHOD1 subunits and deletion constructs. 
4.5 RNAi Mediated Knockdown Studies 
 
In addition to the transient expression studies with the FHOD1 expression constructs, a 
number of loss-of-function experiments were also performed.  These took place through 
vector based RNAi mediated knockdown of FHOD1 in cultured cells.  Vector based 
RNAi approaches have certain advantages over direct treatment with naked siRNA.  
Direct addition of siRNA to cells is associated with increased toxicity.  Furthermore, 
vector based shRNA approaches have been found to have fewer off-target effects (Rao 
et al. 2009).  The RNA interference approach used in this study functions on the basis 
that the H1 RNA polymerase III promoter stimulates the transcription of a RNA strand 
from the cloned target coding sequence of the gene in question (Brummelkamp et al. 
2002).  The vector produces short hairpin RNAs (shRNAs) which are further processed 
into small inhibitory RNAs (siRNAs) by the enzyme Dicer.  The resulting siRNAs 
target the specified portion of mRNA for eventual degradation.  The siRNA and the 
complementary mRNA are then incorporated into the RNA-induced silencing complex 
(RISC), a multi-enzyme complex with an RNAase component responsible for cleaving 
the target sequence (Rao et al. 2009).  Since our initial analysis of FHOD1’s expression 
pattern through Western blot studies suggested that there were reasonably high levels of 
FHOD1 in both cardiac and skeletal muscle, it was decided to knock down FHOD1 in 
cultured NRCs and differentiating C2C12 cells.  Three shRNA constructs were 
designed to deplete FHOD1 in mouse and rat cells.  Constructs were named according 
to the coding sequence of rat FHOD1 that they were designed to target: 1095, 2375, and 
2635.  The shRNA vector, which is based on pSUPER, also separately expresses GFP 
and confers the additional advantage over naked siRNA molecules of allowing 
transfected cells to be visualised. 
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4.5.1 Design and Validation of shRNA Constructs 
 
The three shRNA constructs were designed to knockdown FHOD1 in rat and mouse 
cells (Figure 4.14). The 2635 shRNA was also designed to target the human FHOD1 
sequence, whereas the 1095 shRNA and the 2375 shRNA contained 3 and 1 
mismatched base pairs with respect to the corresponding sequence on human FHOD1, 
respectively.  The three constructs were designed to target all of the reported FHOD1 
isoforms in rat and mice.  Basic Local Alignment Search Tool (BLAST) queries were 
performed to confirm the constructs would specifically target FHOD1 and no other 










Prior to performing knockdown studies in cultured cells, the RNAi system was first 
assessed for its ability to inhibit FHOD1 expression.  As mentioned above, the 2635 
shRNA construct was not only designed to target the rodent sequence of FHOD1, but 
also the human sequence.  Via transfection studies in COS-1 cells, we looked at the 
extent of knockdown of the human FHOD1 construct by the 2635 shRNA construct.  
COS-1 cells were co-transfected with the long variant of TOMATO-tagged human 
Figure 4.14: Sequence Alignment of the FHOD1 shRNA Constructs with Human and 
Rodent FHOD1 DNA Sequence. Target DNA sequence of the three shRNA constructs 
designed to disrupt expression of FHOD1. A) Alignment for the 1095 shRNA construct. B) 
Alignment for the 2635 shRNA construct. C) Alignment for the 2375 shRNA construct. 
Alignments were included for the Homo sapiens (Accession No: NM_013241.2), Rattus 
norvegicus (Accession No: NM_001191600.1) and Mus musculus (Accession No: 
NM_177699.4) sequences. Black boxes denote areas of base pair mismatch with the human 
sequence. Alignment was performed with Mega5 (Tamura et al. 2011). 
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FHOD1 as well as the 2635 shRNA construct.  Cells were lysed and protein levels were 
visualised by Western blotting (Figure 4.15 A).  TOMATO-tagged FHOD1, with an 
expected molecular weight of 182 kDa, expressed as a high running band above the 128 
kDa marker.  In cells cotransfected with the 2635 shRNA construct and TOMATO-
tagged FHOD1, the band associated with TOMATO-tagged FHOD1 was reduced to 
undetectable levels.  This indicated that expression of the human FHOD1 construct was 
efficiently being disrupted.  The empty shRNA vector did not have an effect on levels 
of the FHOD1 construct and, similarly, the 2635 shRNA construct was unable to knock 
down the expression of the TOMATO tag.  Lysates were also blotted for GFP as a 
loading control (Figure 4.15 B), indicating that loading was similar between the samples 
in direct comparison to each other (e.g., lane of COS-1 cells co-transfected with the 
empty shRNA vector and TOMATO-tagged FHOD1 versus lane of COS-1 cells co-
transfected with the 2635 shRNA construct and TOMATO-tagged FHOD1) and thus 























Further validation of the RNAi approach took place via immunofluorescence 
experiments to confirm the disruption of expression of the FHOD1 construct that was 
seen in Western blot experiments.  COS-1 cells were co-transfected with TOMATO-
tagged FHOD1 and the 2635 shRNA construct.  If the previous experiment using 
Western blot analysis to visualise knockdown of FHOD1 proved accurate, an attenuated 
signal for TOMATO FHOD1 would be noted in double transfected cells.  The resulting 
data resonated that seen with the Western blot studies.  The empty shRNA vector was 
unable to knock down the expression of the TOMATO tag (Figure 4.16 A) and neither 
was the 2635 shRNA construct (Figure 4.16 B).  The empty shRNA vector was also 
Figure 4.15: Validation of RNAi Technique by Western Blotting.  Western blots from 
lysates of COS-1 cells.  Cells were transfected with a combination of constructs to assess the 
ability of the 2635 shRNA construct to knock down FHOD1 expression.  In the first lane on the 
left hand side, cells were double transfected with the empty shRNA vector (H1 GFP) and the 
empty TOMATO vector (TOM).  In the second lane cells were double transfected with the 
empty shRNA vector and the TOMATO-tagged long variant of full-length FHOD1 (FlL TOM) 
[1-1191].  In the third lane cells were double transfected with the 2635 shRNA construct and 
the empty TOMATO vector.  In the fourth lane on the right, cells were double transfected with 
the 2635 shRNA construct and TOMATO-tagged long variant of full-length FHOD1 [1-1191].  
Single transfected samples of each construct are also shown on the gel. Untransfected COS-1 
lysates were loaded as a negative control. A) COS-1 lysates probed with the dsRed antibody to 
visualise the TOMATO signal. B) COS-1 lysates probed with the GFP antibody.  Arrow 
indicates band corresponding to the TOMATO-tagged long variant of full-length FHOD1 and 
to TOMATO.  GFP, green fluorescent protein. N=3. 
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unable to knock down TOMATO FHOD1 (Figure 4.16 C).  The 2635 shRNA construct 
disrupted expression of TOMATO-tagged FHOD1 since co-transfected cells displayed a 
weak signal for TOMATO-tagged FHOD1 (Figure 4.16 D).  These data would indicate 
that the RNAi approach used in this study could be specific for FHOD1 and was 
capable of disrupting expression of the human construct. However, while these results 
provide proof-of-concept evidence for the RNAi approach used, they cannot be fully 
extrapolated as evidence for the capacity to disrupt expression of endogenous FHOD1. 
This was especially the case since these experiments were limited to validation of only 
one shRNA construct. Better proof-of-concept may have been gained by testing the 
capacity of the shRNA constructs to disrupt expression of rat and mouse FHOD1 
constructs while concurrently demonstrating knockdown of endogenous FHOD1 in the 


























Figure 4.16: Validation of RNAi Technique by Fluorescence Confocal Microscopy.  COS-
1 cells were transfected with different combinations of constructs to validate knockdown of 
FHOD1 by RNAi.  COS-1 cells were stained for F-actin prior to visualisation by confocal 
microscopy.  Cells were transfected with a combination of constructs to assess knockdown of 
FHOD1 expression: A) cells were double transfected with the empty shRNA vector and the 
empty TOMATO vector, B) cells were double transfected with the empty shRNA vector and 
the TOMATO-tagged long variant of full-length FHOD1 [1-1191], C) cells were double 
transfected with the 2635 shRNA construct and the empty TOMATO vector, D) cells were 
double transfected with the 2635 shRNA construct and TOMATO-tagged long variant of full-
length FHOD1 [1-1191]. GFP is seen in green, TOMATO in red, and F-actin in blue.  GFP, 
green fluorescent protein.  Scale bars represent 10m. N=1. 
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4.5.2 Knockdown of FHOD1 in Neonatal Rat Cardiomyocytes 
 
The three different shRNA constructs designed to target the rodent fhod1 mRNA were 
transfected into cultured NRCs.  The effects of the shRNA constructs were examined at 
different time points to assess the potentially cumulative effects of knockdown.  Cells 
were fixed at days 3, 5 and 8.  In the absence of a means to definitively show that 
expression of endogenous FHOD1 was disrupted at the transcript level, we qualitatively 
assessed the possibility of FHOD1 knockdown by staining for well-established 
myofibrillar, sarcomeric, and cell-cell contact markers. In the hopes of visualising 
knockdown of FHOD1 the protein level, we stained NRCs with the polyclonal mouse 
anti-FHOD1 antibody (Abcam).  
 
Day 3 (Figure 4.17) and day 5 (Figure 4.18) FHOD1 shRNA-transfected NRCs were 
indistinguishable from NRCs transfected with the empty shRNA vector.  A phenotype 
associated with the transfection of the shRNA constructs designed to knock down 
endogenous rat FHOD1 was not seen until day 8. In the case of the gene paralogue of 
FHOD1, FHOD3, the full effects of RNAi mediated knockdown were also not seen 
until day 8 (Iskratsch et al. 2010) and might reflect slow turnover of these proteins in 
myofibrils.     







Figure 4.17: The Effects of the FHOD1 shRNAs in Neonatal Rat Cardiomyocytes at 
Day 3.  NRCs were transfected with three different shRNA constructs designed to 
knockdown FHOD1.  NRCs were cultured until day 3 in long term/transfection medium.  
Cells were stained for FHOD1, F-actin, and visualised by confocal microscopy.  Transfected 
cells are seen in green since the shRNA vector separately expresses GFP.  NRCs were 
transfected with the following constructs: A) the empty shRNA vector, B) the 1095 shRNA 
construct, C) the 2375 shRNA construct, D) the 2635 shRNA construct. GFP is seen in 
green, FHOD1 in red, and F-actin in blue. GFP, green fluorescent protein.  Scale bars 
represent 10m. N=3. 
 
















Figure 4.18: The Effects of the FHOD1 shRNAs in Neonatal Rat Cardiomyocytes at 
Day 5.  NRCs were transfected with three different shRNA constructs designed to 
knockdown FHOD1.  NRCs were cultured until day 5 in long term/transfection medium.  
Cells were stained for FHOD1, F-actin, and visualised by confocal microscopy.  Transfected 
cells are seen in green since the shRNA vector separately expresses GFP.  NRCs were 
transfected with the following constructs: A) the empty shRNA vector, B) the 1095 shRNA 
construct, C) the 2375 shRNA construct, D) the 2635 shRNA construct. GFP is seen in 
green, FHOD1 in red, and F-actin in blue. GFP, green fluorescent protein.  Scale bars 
represent 10m. N=3. 
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In control and untransfected cells, FHOD1 distributed in the manner seen previously in 
earlier cultures of NRCs at day 3 (Figure 4.19 A).  Cells transfected with the shRNA 
constructs displayed a decrease in FHOD1 staining (Figure 4.19 B-D).  Counterstaining 
with Phalloidin initially revealed that transfection with the shRNA constructs resulted in 
fragmentation of myofibrils.  In control and untransfected cells, F-actin was seen to 
distribute along myofibrils at the level of the I-bands (Figure 4.19 A).  Also in the 
shRNA transfected cells, there was a seemingly attenuated signal for F-actin, as 
suggested by weaker staining (Figure 4.19 B-D).  In knockdown cells, F-actin often 
distributed in a diffuse cytoplasmic manner.  This was especially the case with the 2635 
shRNA construct (Figure 4.9 D), which seemed to have the most profound effect on the 
F-actin network and cardiomyocyte morphology as a whole. 
 
 
   
 























Figure 4.19: The Effects of the FHOD1 shRNAs in Neonatal Rat Cardiomyocytes at 
Day 8.  NRCs were transfected with three different shRNA constructs designed to 
knockdown FHOD1.  NRCs were cultured until day 8 in long term/transfection medium.  
Cells were stained for FHOD1, F-actin, and visualised by confocal microscopy.  Transfected 
cells are seen in green since the shRNA vector separately expresses GFP.  NRCs were 
transfected with the following constructs: A) the empty shRNA vector, B) the 1095 shRNA 
construct, C) the 2375 shRNA construct, D) the 2635 shRNA construct. GFP is seen in 
green, FHOD1 in red, and F-actin in blue. GFP, green fluorescent protein.  Scale bars 
represent 10m. N=3. 
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The effects of the shRNA constructs were further investigated by staining 
cardiomyocytes against other myofibrillar markers.  Control and untransfected cells 
retained a normal flattened morphology as characterised by regular membrane edges 
and longitudinal myofibrils that ran along the edge of cells and emanated from within 
the cell peripheries (Figure 4.20 A).  In cells transfected with the shRNAs designed to 
knock down FHOD1, it became apparent that myofibrils were absent or had been 
disrupted (Figure 4.20 B-D).  It was also noted that FHOD1 shRNA-transfected cells 
displayed with irregular plasma membrane edges and appeared to have a more lacerated 
morphology.  In control and untransfected cells -actinin distributed in its typical 
pattern at the Z-disk (Figure 4.20 A).  In cells transfected with the FHOD1 shRNAs, the 
distribution of -actinin became more patchy, although it was still seen to localise to the 
Z-disk on the truncated portions of myofibrils (Figure 4.20 B-D).  In the case of MyBP-
C, the protein was seen to localise to the A-bands in control and untransfected cells.  In 
knockdown cells, MyBP-C became diffusely distributed throughout cells, although it 
was still found to be partially targeted to the remaining portions of myofibrils (Figure 
4.20 B-D).  In the case of myomesin, the protein was found at the M-band in control 
and untransfected cells (Figure 4.21 A) but staining for the protein was seemingly 
reduced in shRNA-transfected cells, as suggested by fewer M-band striations and an 
overall attenuation in the myomesin signal (Figure 4.21 B-D).   



















Figure 4.20: The Effects of the FHOD1 shRNAs on the Z-disk and the A-band.  NRCs 
were transfected with three different shRNA constructs designed to knockdown FHOD1.  
NRCs were cultured until day 8 in long term/transfection medium.  Cells were stained for -
actinin and MyBP-C to visualise the effect of knockdown on myofibrils and visualised by 
confocal microscopy.  Transfected cells are seen in green since the shRNA vector separately 
expresses GFP.  NRCs were transfected with the following constructs: A) the empty shRNA 
vector, B) the 1095 shRNA construct, C) the 2375 shRNA construct, D) the 2635 shRNA 
construct. GFP is seen in green, -actinin in red, and MyBP-C in blue.  MyBP-C, myosin 
binding protein C; GFP, green fluorescent protein.  Scale bars represent 10m. N=3. 
 




Transfection with the shRNA constructs was also associated with a number of 
alterations at the level of the intercalated disk.  Control and untransfected cells 
displayed normal cell-cell contacts with -catenin distributing along the intercalated 
disk (Figure 4.21 A).  Normally, -catenin forms part of the cadherin-catenin complex 
involved in mediating cell-cell adhesion at the intercalated disk (Masuelli et al. 2003).   
FHOD1 shRNA-transfected cells displayed an increase in the numbers of cell-cell 
contacts, which were present as thin plasma membrane projections.  Fluorescent 
staining for -catenin in transfected cells revealed a decreased signal for the protein at 
the intercalated disk (Figure 4.21 B-D).  Instead, it was often found concentrated 





















Figure 4.21: The Effects of the FHOD1 shRNAs on the M-band and the Intercalated 
Disk.  NRCs were transfected with three different shRNA constructs designed to 
knockdown FHOD1.  NRCs were cultured until day 8 in long term/transfection medium.  
Cells were stained for the intercalated disk protein -catenin and the sarcomeric protein 
myomesin to visualise the effect of knockdown on the cell-cell contacts and myofibrils.  
Cells were visualised by confocal microscopy.  Transfected cells are seen in green since the 
shRNA vector separately expresses GFP.  NRCs were transfected with the following 
constructs: A) the empty shRNA vector, B) the 1095 shRNA construct, C) the 2375 shRNA 
construct, D) the 2635 shRNA construct. GFP is seen in green, myomesin in red, and -
catenin in blue.  GFP, green fluorescent protein.  Scale bars represent 10m. N=3. 
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Overall, transfection with the shRNA constructs designed to knock down endogenous 
FHOD1 was associated with alterations in cardiomyocyte morphology, particularly at 
the level of myofibrillar organisation/integrity and the appearance of cell-cell contacts. 
However, we were not able to fully attribute this phenotype to depletion of FHOD1, 
since this was neither confirmed at the mRNA transcript or protein level. A reduction in 
FHOD1 at the mRNA transcript level could not be demonstrated for any of the shRNA 
constructs because of the low transfection efficiency we achieved in cultured NRCs. 
While staining of NRCs with the polyclonal mouse anti-FHOD1 antibody (Abcam) may 
have suggested reduced staining for FHOD1, this notion was only tested using one 
antibody. Furthermore, in the absence of an antigen competition assay, we could not be 
certain of the specificity, and hence utility, of the presently employed polyclonal mouse 
anti-FHOD1 antibody.  Furthermore, although we demonstrated that the 2635 shRNA 
construct could disrupt expression of the human FHOD1 construct in COS-1 cells, such 
proof-of-concept data cannot be extended to the other shRNA constructs or knockdown 
of rodent FHOD1. Therefore, it cannot be concluded with certainty that the observed 
phenotypes were not due to off-target effects rather than FHOD1 depletion.  
 
4.5.3 RNAi Rescue Experiments in Neonatal Rat Cardiomyocytes 
 
As an additional control for the knockdown experiments in cultured cardiomyocytes, 
rescue experiments were performed to begin to address if the effects of the shRNA 
constructs were due to depletion of FHOD1 (Figure 4.22).  NRCs were co-transfected 
with the TOMATO-tagged long variant of full-length FHOD1 and the 1095 shRNA 
construct.  The rescue experiment functioned on the basis that the 1095 shRNA 
construct could not knock down the TOMATO FHOD1 construct: it was not designed 
for targeted degradation of any portion of the human FHOD1 gene since it contained 
three mismatched base pairs with respect to its corresponding sequence on the human 
gene (Figure 4.14).  Instead, overexpression of the TOMATO-tagged FHOD1 construct 
would restore normal cardiomyocyte morphology.  When the empty TOMATO vector 
and the empty shRNA vector were co-transfected, there was no change in 
cardiomyocyte morphology or the appearance of myofibrils at day 8 (Figure 4.22 A).  
When the TOMATO-tagged FHOD1 construct was co-transfected with the empty 
shRNA vector, cells displayed an elongated morphology, with FHOD1 distributing 
along myofibrils and at the peripheries of cells (Figure 4.22 B).  When co-transfected 
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with the empty TOMATO vector, the 1095 shRNA construct resulted in disrupted 
cardiomyocyte morphology and compromised myofibrillar integrity (Figure 4.22 C).  
When co-transfected with TOMATO-tagged FHOD1, the effects of the 1095 shRNA 
vector were no longer visible (Figure 4.22 D).  Under these conditions, cardiomyocytes 
retained their normal morphology, with fully formed myofibrils and mature sarcomeres.  
Overexpression of FHOD1 in shRNA knockdown cells therefore seemingly rescued the 
phenotype associated with transfection of the 1095 shRNA construct.  These data would 
indicate that the effects of the 1095 shRNA may have been due to FHOD1 depletion 
and not due to off-target effects. However, the same cannot be said for the other two 
shRNA constructs. In order to extrapolate these conclusions to the other shRNA 

























Figure 4.22: Rescue of RNAi Mediated Effects by FHOD1 Overexpression.   NRCs 
were transfected with different combinations of constructs to assess if the effects associated 
with the RNAI mediated knockdown could be rescued by FHOD1 overexpression.  NRCs 
were cultured to day 8 and stained for -actinin prior to visualisation by confocal 
microscopy.  shRNA transfected cells are seen in green since the shRNA vector also 
expresses GFP.  Cells were transfected with a combination of constructs: A) cells were 
double transfected with the empty shRNA vector and the empty TOMATO vector, B) cells 
were double transfected with the empty shRNA vector and the TOMATO-tagged long 
variant of full-length FHOD1 [1-1191], C) cells were double transfected with the 1095 
shRNA construct and the empty TOMATO vector, D) cells were double transfected with 
the 1095 shRNA construct and TOMATO-tagged long variant of full-length FHOD1 [1-
1191]. GFP is seen in green, TOMATO in red, and -actinin in blue.  GFP, green 
fluorescent protein.  Scale bars represent 10m. N=1. 
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4.5.4 Knockdown of FHOD1 in Day 3 C2C12 Cells 
 
In addition to knockdown experiments in cardiac cells, RNAi experiments were 
performed in differentiating C2C12 skeletal muscle myoblasts, a murine cell line.  
C2C12 cells were transfected with the three FHOD1 shRNA constructs and the empty 
shRNA vector.  Cells were then induced to differentiate and were visualised by confocal 
microscopy at days 3 and 7.  At day 3, a phenotype associated with transfection of the 
shRNA constructs designed to knock down FHOD1 was noted (Figure 4.23).  Cells 
transfected with the empty shRNA vector retained their normal morphology (Figure 
4.23 A).  At this time point, control and untransfected cells exhibited an elongated 
appearance and displayed numerous stress fibres, as visualised by Phalloidin staining 
for F-actin.  Transfection with the three shRNA constructs was associated with 
disruption of the F-actin network.  In examining the three different shRNA constructs it 
became apparent that there were a number of construct-specific effects.  In the case of 
the 1095 shRNA construct, cells had lost the stress fibres associated with this time 
point.  Instead, they displayed a perturbed F-actin cytoskeleton consisting of diffuse 
staining for F-actin (Figure 4.23 B).  Cells transfected with the 2375 shRNA construct 
displayed seemingly reduced levels of F-actin as suggested by a weaker signal.  These 
cells also displayed a less organised F-actin cytoskeleton compared to untransfected 
neighbours (Figure 4.23 C).  Transfection with the 2635 shRNA construct also resulted 
in disruption of the F-actin cytoskeleton, with complete absence of stress fibres and F-
actin distributing in a punctate manner throughout cells (Figure 4.23 D).  The different 
effects produced by the three constructs may have reflected different degrees of FHOD1 
knockdown.  However, we were unable to confirm knockdown of endogenous FHOD1 
in C2C12 cells at the mRNA transcript or the protein level, therefore the differences 
between the constructs could have indicated the presence of off-target effects (i.e. 
knockdown of another gene). Alternatively, the construct-specific effects may have 
been due to transfection toxicity. While staining for DAPI did not reveal fragmented 
nuclei, and therefore suggested against the possibility of cell toxicity by potentially 
ruling out apoptosis, the performance of cytotoxicity assays by other methods (e.g. 
TUNEL or caspase-3 staining) might better resolve this issue,  
 


















Figure 4.23: The Effects of the  FHOD1 shRNAs in Day 3 C2C12 Cells.  C2C12 cells were 
transfected with the three shRNA constructs designed to knockdown FHOD1.  C2C12 cells 
were cultured until day 3 in differentiation medium, stained for F-actin, and were visualised by 
confocal microscopy.  Transfected cells are seen in green since the shRNA vector separately 
expresses GFP.  C2C12 cells were transfected with the following constructs: A) the empty 
shRNA vector, B) the 1095 shRNA construct, C) the 2375 shRNA construct, D) the 2635 
shRNA construct. GFP is seen in green, F-actin in red, and DAPI/nuclei in blue.  GFP, green 
fluorescent protein.  Scale bars represent 10m. N=2. 
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The effects of the shRNA constructs designed to knock down endogenous FHOD1 were 
also examined in day 7 differentiating C2C12 cells (Figure 4.24).  Control cells, 
transfected with the empty shRNA vector, had a normal elongated morphology and 
were present as multi-nucleate myotubes (Figure 4.24 A).  shRNA-transfected 
myotubes were indistinguishable from control cells and untransfected neighbours 
(Figure 4.24 B-D).  We also looked to see if there were alterations in the rates of 
myoblast cell fusion into myotubes.  A fusion index was calculated for cells transfected 
with the shRNA constructs and the empty vector (Figure 4.25) by taking the number of 
nuclei in the transfected cells and dividing it by the total number of transfected cells.  
This essentially calculated the number of nuclei per cell.  The average cell fusion index 
was comparable across the constructs and the control vector. However, substantial 
variability in fusion indices was noted with the FHOD1 shRNA constructs and may 
have indicated that further experiments were required in order to see if they had an 
impact on C2C12 fusion. Overall, results with the FHOD1 shRNAs suggested there was 
no disruption of the F-actin cytoskeleton, morphological ultrastructure, or the cell fusion 
index in day 7 shRNA transfected C2C12 cells. However, as was the case with day 3 
C2C12 cells, confirmation of reduced FHOD1 expression was not performed in day 7 
C2C12 cells. The lack of treatment effect at this time point could therefore have been 
the result of a lack of knockdown. It may also be due to a dilution of the plasmid 


















Figure 4.24: The Effects of the FHOD1 shRNAs in Day 7 C2C12 Cells.  C2C12 cells were 
transfected with the three different shRNA constructs designed to knockdown FHOD1.  
C2C12 cells were cultured until day 7 in differentiation medium, stained for F-actin, and 
visualised by confocal microscopy.  Transfected cells are seen in green since the shRNA 
vector separately expresses GFP.  C2C12 cells were transfected with the following 
constructs: A) the empty shRNA vector, B) the 1095 shRNA construct, C) the 2375 shRNA 
construct, D) the 2635 shRNA construct. GFP is seen in green, F-actin in red, and 
DAPI/nuclei in blue.  GFP, green fluorescent protein.  Scale bars represent 10m. N=2. 
 














4.6 Treatment with the Formin Inhibitor SMIFH2 
 
 
In order to more generally dissect the function of formins in the heart, NRCs were 
treated with a general formin inhibitor.  SMIFH2, is an inhibitor of formin mediated 
actin assembly.  It was found to inhibit actin polymerisation by formins at the level of 
nucleation, elongation, and association with the barbed end of filaments.  The effects of 
the inhibitor have been attributed to its targeting the conserved FH2 domain, although 
binding by the small molecule has never been shown (Rizvi et al. 2009).  Cells were 
treated with 30M SMIFH2 for 2, 4, and 8 hours and then stained for a number of 
Figure 4.25: Fusion Index in Day 7 FHOD1 shRNA-transfected C2C12 Cells.  Bar chart 
displaying fusion index values in day 7 C2C12 cells transfected with the different shRNA 
constructs.  Cells were stained for DAPI to identify nuclei and were visualised by confocal 
microscopy for counting.  The fusion index was calculated by counting the number of nuclei 
in transfected cells in one view and dividing that number by the amount of transfected cells.  
The fusion index represents an average of nuclei per cell.  The first column on the left rep*-
resents the value for the empty shRNA vector (H1 GFP).  The three different shRNA 
constructs are shown in the following columns.  Results represent average values for 70-100 
cells for each construct. Error bars represent standard deviation (STDEV). N=1. 
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myofibrillar proteins and subcellular markers to visualise the effects of formin 
inhibition. 
 
The effects of formin inhibition on cardiomyocytes resulted in a number of cellular 
abnormalities.  Treatment with the vehicle control, DMSO, had no effect on the 
appearance of NRCs during either of the time points (Figure 4.26 A and Figure 4.27 A), 
and therefore excluded any off-target effects of the vehicle.  The effects of treatment 
with SMIFH2 could be seen after 2 hours (Figure 4.26 and 4.27).  Affected cells had 
decreased staining for F-actin and Z-disk striations became less defined, as visualised 
by -actinin staining.  MyBP-C displayed somewhat weaker staining than DMSO-
treated cells and was sometimes found to distribute in a diffuse cytoplasmic manner, 
although it was still predominantly found at the A-bands (Figure 4.26 B).  Also at 2 
hours, it was noted that myomesin staining was sometimes visualised as irregular in its 
spacing and patchy in its appearance.  Staining for the intercalated disk protein, -
catenin revealed that there was a small degree of intercalated disk retraction, as cell-cell 
contacts appeared to be stretched (Figure 4.27 B).  At 4 hours, the effects of the 
inhibitor intensified, with many cells presenting with myofibrillar disruption and weaker 
staining for F-actin and MyBP-C (Figure 4.26 C).  Cell-cell contacts became even more 
stretched, suggesting further damage to the intercalated disk (Figure 4.27 C).  At 8 
hours, the myocardial cytoskeleton and myofibrils appeared to recover to an extent 
since -actinin and MyBP-C redistributed in their characteristic striated pattern, 
although some diffuse cytoplasmic staining of MyBP-C was still noted.  Many cells 
displayed numerous cell-cell contacts that were present as extended membrane 
protrusions, with an increased signal for -actinin and F-actin at these sites (Figure 4.26 
D).  Whereas the effects of the inhibitor on myofibrils seemed to be transient, the effects 
on the intercalated disk appeared to be cumulative.  By 8 hours, the intercalated disks 
appeared broader and more convoluted (Figure 4.27 D).  Overall, inhibition of formin 
mediated actin regulation in NRCs resulted in a number of abnormalities at the level of 



















Figure 4.26: Effects of the Formin Inhibitor SMIFH2 on Myofibrils and the Sarcomere.  
Day 4 NRCs were cultured in maintenance medium prior to treatment with 30M SMIFH2 
or DMSO vehicle control.  Cells were treated for 2, 4, and 8 hours and stained for -actinin 
and MyBP-C prior to visualisation by confocal microscopy.  Images represent: A) DMSO 
treated NRCs at 8 hours and SMIFH2 treated NRCs at B) 2, C) 4, and D) 8 hours.  F-actin is 
seen in red, -actinin in green, and MyBP-C in blue. NRC, neonatal rat cardiomyocytes; 
MyBP-C, myosin binding protein C.  Scale bars represent 10m. N=2. 
 


















Figure 4.27: Effects of the Formin Inhibitor SMIFH2 on the M-band and the 
Intercalated Disk.  Day 4 NRCs were cultured in maintenance medium prior to treatment 
with 30M SMIFH2 or DMSO vehicle control.  Cells were treated for 2, 4, and 8 hours and 
stained for myomesin and -catenin prior to visualisation by confocal microscopy.  Images 
represent: A) DMSO treated NRCs at 8 hours and SMIFH2 treated NRCs at B) 2, C) 4, and 
D) 8 hours.  F-actin is seen in red, Myomesin in green, and -catenin in blue. NRC, neonatal 
rat cardiomyocytes; MyBP-C, myosin binding protein C.  Scale bars represent 10m. N=2. 
 




4.7.1 Mapping the Functional Layout of FHOD1 in Cardiomyocytes 
 
Presently, we explored the functional implications of FHOD1 overexpression by 
transiently expressing a number of inactive and constitutively active FHOD1 mutant 
constructs in NRCs.  Overexpression studies using the different constitutively active 
FHOD1 mutants revealed that FHOD1 induced rearrangement of the F-actin 
cytoskeleton in NRCs.  While all of the constitutively active mutant constructs induced 
cell elongation and F-actin rearrangement, they did so to varying degrees.   
 
Overexpression of the FHOD1 3D ROCK phosphomimetic mutant induced an 
elongated cell phenotype.  NRCs were shown to extend long processes. There was also 
some enrichment of FHOD1 and F-actin at the plasma membrane and along myofibrils, 
although not to the extent seen with the FHOD1 DAD and V228E constructs. The 
FHOD1 3A construct, containing the kinase insensitive Alanine mutations, exhibited 
similar behaviour to the wild-type FHOD1 constructs when overexpressed in NRCs. 
The FHOD1 3A construct was found to accumulate in the peripheries of cells and did 
not result in any significant changes in cell morphology. This finding would be 
consistent with previous work indicating that phosphorylation of the Serine and 
Threonine residues in the FHOD1 DAD relieves the autoinhibitory interaction between 
the FHOD1 N-terminus and C-terminus (Takeya et al. 2008). GST pull-down assays 
between the FHOD1 N-terminus and a DAD fragment containing the triple Aspartate 
mutations abrogated binding between these two regions, whereas the DAD containing 
the triple Alanine mutations had no effect. Work exploring the functional effects of 
ROCK phosphorylation on FHOD1 had previously noted the formation of stress fibres 
and an elongated phenotype in HeLa cells (Takeya et al. 2008). The FHOD1 3D 
construct was also previously found to stimulate expression of vascular smooth muscle 
cell (VSMC)-specific genes to a greater capacity than the full-length construct (Staus et 
al. 2011a). Furthermore, this was attributed to FHOD1’s capacity to regulate F-actin, 
since treatment with Latrunculin B inhibited the capacity of the FHOD1 3D construct to 
stimulate SM22 promoter activity.  
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The FHOD1 DAD truncation mutant also induced cell elongation and displayed strong 
targeting to newly formed actin bundles.  Studies first using FHOD1 C-terminal 
truncation mutants observed formation of stress fibres in NIH3T3 (Gasteier et al. 2003; 
Gasteier et al. 2005) and WM35 cells (Koka et al. 2003).  Cell elongation and stress 
fibre formation was also induced in a similar manner to that seen with mDia by 
overexpressing a C-terminal truncation mutant in HeLa cells (Takeya and Sumimoto 
2003).  Overexpression of the FHOD1 V228E mutant had the most profound effect on 
the morphology of NRCs, which displayed an elongated appearance and thick stress 
fibres oriented along the long axis of the cell.  The Valine at position 228 in the FHOD1 
DID was previously found to be a crucial residue mediating the autoinhibitory 
interaction between the DID and DAD of FHOD1.  When this mutant variant (FHOD1 
V228E) was overexpressed in NIH3T3 cells it led to the formation of stress fibres in a 
similar manner to a C-terminal truncation mutant (Schulte et al. 2008).  The differences 
between the FHOD1 DAD and FHOD1 V228E constructs in NRCs could be explained 
by the fact that FHOD1 may have required the DAD for its biological activity.  
 
While the FHOD1 DAD and FHOD1 V228E mutants were associated with the 
appearance of actin bundles and stress fibres, respectively, we did not note the 
appearance of such structures with the FHOD1 3D construct. This may indicate that 
other cues beside phosphorylation in the DAD are needed for full activation of the 
protein to occur in NRCs. Indeed, previous comparison of the FHOD1 3D and the 
FHOD1 DAD mutant revealed that the FHOD1 3D mutant did not stimulate VSMC-
specific transcription as strongly (Staus et al. 2011a). Therefore, phosphorylation in the 
FHOD1 DAD might not represent a reliable marker of full FHOD1 activation.   
 
Overall, overexpression data in NRCs would be in line with previous observations of 
FHOD1 activation inducing cell elongation (Koka et al. 2003; Takeya and Sumimoto 
2003).  More importantly, our findings are in agreement with the notion that FHOD1 
has the capacity to reorganise F-actin into different structures, namely bundle them into 
stress fibres (Schonichen et al. 2013). Similar reorganisation of the F-actin cytoskeleton 
was also noted after overexpression of different FHOD3 mutants in cardiomyocytes.  
An FHOD3 3D ROCK phosphomimetic mutant and an FHOD3 DAD truncation 
mutant were overexpressed in NRCs and led to the formation of small actin bundles 
  Functional Characterisation of FHOD1 
254 
 
(referred to as actin cables) (Iskratsch et al. 2013a).  Although the effects of 
overexpression of the FHOD3 active mutants were not as profound as those produced 
by FHOD1, FHOD3 was found to increase staining for F-actin in FHOD3 
overexpressing NRCs (Iskratsch et al. 2013a), a possible indicator that F-actin assembly 
was increased.  
 
However, the present study attempted to extrapolate the function of human FHOD1 
constructs in rat cardiomyocytes, therefore the relevance of such experiments remains to 
be determined until similar experiments are performed with constitutively active rat 
FHOD1 constructs. While the human and rat FHOD1 variants bear high sequence 
similarity, comparison with constitutively active rat FHOD1 in NRCs will be necessary 
to establish whether the effects of human FHOD1 are conserved in NRCs or whether 
the present findings only represent an artefact of ectopically overexpressing a human 
protein in its non-native environment.       
 
While the functional implications of DAD truncation and the equivalent V228E 
mutation have not been explored with the rodent FHOD1 variants, phosphorylation in 
the DAD could be a common feature between human and rodent FHOD1. Indeed, the 
Serine and Threonine residues that are associated with phosphorylation by ROCK are 
conserved between human and rodent FHOD1. The antibody that recognises the 
phosphorylated Threonine1141 antibody on human FHOD1 was used to stain mouse 
heart sections and revealed similar staining to that seen previously with the antibodies 
designed to recognise total FHOD1. A strong signal for phosphorylated FHOD1 was 
noted at the intercalated disks as well as some myofibrillar and possible Z-disk 
localisation. The similarity in staining between phosphorylated and total FHOD1 could 
be taken as an indicator that the previously noted localisation of endogenous FHOD1 
may be representative of its activated or partially activated state. Co-staining of total 
and phosphorylated FHOD1 would be required to confirm this. However, the full-length 
wild-type FHOD1 construct, which did not result in overt effects on NRC morphology, 
was recognised by the anti-FHOD1 phospho-Threonine1141 antibody in NRCs, 
suggesting that phosphorylation of the construct was present. While these observations 
could be explained by incomplete phosphorylation of all three of the relevant residues in 
the DAD, it could be indicative that further cues are required for full activation of 
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FHOD1 to occur. The full extent of phosphorylation in the FHOD1 DAD in mouse 
sections also needs clarification: the other two Serine residues in cells may not have 
been phosphorylated. Therefore the relevance of phosphorylated FHOD1 in situ remains 
to be explored.  
 
While validation experiments using the FHOD1 3A and FHOD1 DAD constructs 
indicated that the antibody specifically recognised the phosphorylated residue in the 
FHOD1 DAD, we were not able to definitively rule out cross-reactivity with FHOD3 or 
other proteins. Western blot studies and immunofluorescence studies in COS-1 
suggested minimal levels of cross-reactivity. However, the extent of phosphorylation of 
the FHOD3 construct in COS-1 cells was not determined; therefore it cannot be 
excluded that there is some cross-reactivity between the phospho-Threonine1141 
antibody and FHOD3. Indeed, cross-reactivity with FHOD3 in this instance may have 
been a possibility since the ROCK-I phosphorylation consensus motif is highly 
conserved between FHOD1 and FHOD3 (Iskratsch et al. 2013a) and because total 
FHOD3 has been noted to exhibit a similar localisation pattern in wild-type C57/BL6 
mice (Iskratsch et al. 2010). In the absence of an antigen competition assay, it was also 
not possible to rule out cross-reactivity with other proteins.   
 
4.7.2 The F-actin Regulatory Activity of FHOD1 
 
Work in HeLa cells provided further insight into the potential actin regulating activity 
of FHOD1 by examining the effects of different FHOD1 constructs. While all studies, 
including the current one, support the idea that FHOD1 stimulates the formation of F-
actin bundles and stress fibres, it has been debated as to whether this is merely due to 
the ability of FHOD1 to reorganise F-actin or to polymerise it as well.  We attempted to 
quantify changes in Phalloidin pixel intensity in FHOD1-overexpressing HeLa cells in 
order to further dissect the protein’s F-actin regulatory activity.  Results suggested that 
FHOD1 increased staining for F-actin. The long and short GFP-tagged wild-type 
FHOD1 variants were able to increase levels of F-actin above the levels produced by the 
empty vector in a manner reminiscent of the full-length wild-type FHOD3 long and 
short variants in HeLa cells (Iskratsch et al. 2010). As expected, the localisations of the 
full-length inactive constructs were predominantly diffuse and cytoplasmic and they did 
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induce the formation of stress fibres or other actin-based structures.  The TOMATO-
tagged long FHOD1 variant may have displayed the capacity to increase F-actin 
staining above the GFP-tagged full-length FHOD1 variants, although its response was 
substantially variable. Overall, HeLa cells transfected with TOMATO-tagged FHOD1 
displayed some degree of stress fibre formation and this may have been explained by 
partial activation of the construct due to the large size of the TOMATO tag. This 
phenomenon regarding the TOMATO tag was observed earlier in NRCs and may have 
indicated that this construct was not suitable for studies looking at the function or 
targeting of full-length wild-type FHOD1.   
 
Examination of the effects of the FHOD1 FH2 domain in HeLa cells revealed no 
discernible effect on the F-actin content of cells. This was in contrast to a study which 
looked at the FH2 domain of mDia1, which was overexpressed in NIH3T3 cells and 
was enough to promote accumulation of F-actin (Copeland and Treisman 2002). 
However, previous reports suggested that FHOD1 caps actin filaments via its FH2 
domain (Schonichen et al. 2013). While the FH2 domain of mDia induced actin 
polymerisation in in vitro pyrene assays, constitutively active FHOD1 FH2-domain 
containing constructs inhibited actin polymerisation, suggesting a capping activity for 
FHOD1. Presently, the FH2 domain distributed throughout cells as small blebs.  This 
may have been indicative of the ability of the FHOD1 FH2 domain to self-associate 
(Takeya and Sumimoto 2003) hence concentrate as blebs within the cytoplasm of cells 
or may have just reflected the inactive nature of the construct in HeLa cells. The 
functional contribution of the FH2 domain to F-actin content in cyto remains to be 
determined using FHOD1 constructs lacking the FH2 domain. 
 
Overexpression of the constitutively active FHOD1 variants suggested increases in F-
actin staining greater than that seen with the GFP-tagged wild-type FHOD1 constructs 
in HeLa cells.  Cells transfected with the constitutively active FHOD1 constructs were 
also associated with the appearance of more-prominent F-actin stress fibres. 
Furthermore, the constitutively active FHOD1 variants were found to partially co-
localise with stress fibres, consistent with previous work performed in HeLa cells 
(Takeya and Sumimoto 2003; Gasteier et al. 2005).  However, a discrepancy arose in 
this assay regarding the FHOD1 3A construct.  FHOD1 3A-overexpressing HeLa cells 
displayed an increase in F-actin staining when compared to the full-length FHOD1 
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wild-type constructs.  FHOD1 3A transfected cells were also associated with the 
appearance of stress fibres.  This finding contrasted greatly to the effects of 
overexpression of the FHOD1 3A construct in NRCs. In NRCs, the FHOD1 3A 
construct behaved in a similar manner to the wild-type FHOD1 constructs: it 
accumulated in the peripheries of cells, did not co-localise with F-actin, and it did not 
result in changes in cell morphology. The present results are also in contrast to similar 
experiments performed with FHOD3. In HeLa cells, overexpression of the FHOD3 3D 
and 3A mutants resulted in similar F-actin staining as the wild-type FHOD3 construct 
(Iskratsch et al. 2010). However, the FHOD3 DAD construct was associated with 
greater F-actin staining than the wild-type constructs. While the present results may 
suggest a divergence in function between FHOD1 and FHOD3, they raise questions as 
to what may be the most reliable marker of FHOD1 activation. However, these findings 
may stem from improper characterisation of the different FHOD1 constructs in HeLa 
cells; therefore, further experiments are required to determine if these construct-specific 
effects were extraneous occurrences or issues that merit further investigation.   
 
In order to further investigate the activity of FHOD1, experiments were performed in 
primary cultures of cardiomyocytes to probe the involvement of FHOD1 in the 
regulation of thin filaments. We subjected FHOD1-overexpressing NRCs to Latrunculin 
B treatment.  Latrunculin B treatment depolymerises all cellular F-actin and results in 
the disruption of the thin filaments of cardiomyocytes (McElhinny et al. 2005), which 
can subsequently recover their myofibrils after removal of Latrunculin B (Iskratsch et 
al. 2010).  Overexpression of full-length FHOD1 and the constitutively active FHOD1 
variants partially rescued the phenotype produced by Latrunculin B treatment, with 
FHOD1 transfected cells displaying a greater degree of myofibrillar integrity compared 
to GFP-transfected or untransfected cells.  Interestingly, the GFP-tagged full-length 
wild-type variants of FHOD1 were associated with the greatest degree of myofibrillar 
integrity. Previously, overexpression of full-length FHOD3 in cardiomyocytes was also 
found to rescue the phenotype produced by Latrunculin B treatment (Iskratsch et al. 
2010). The FHOD1 DAD construct only exhibited an intermediate response in terms 
of myofibril recovery and this may have reflected the fact that the DAD could be 
required for the full biological activity of FHOD1. Whereas the remaining constitutively 
active FHOD1 constructs promoted thin filament recovery, they did so to a similar or 
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lower extent than that induced by the GFP-tagged wild-type FHOD1 constructs.  
Although further experiments are required for confirmation of this effect, the present 
data indicated that the promotion of myofibril integrity may have occurred irrespective 
of FHOD1’s activation status.     
 
While the present experiment may have indicated a role for FHOD1 in regulation of the 
cardiac thin filaments, it did not differentiate between FHOD1 promoting de novo 
myofibrillogenesis or preventing thin filament disassembly. Further studies will be 
required to investigate the mechanism by which FHOD1 exerts its effect on myofibrils 
in the context of Latrunculin B treatment with subsequent wash-out. Furthermore, the 
present methodology used to characterise the extent of myofibril integrity will likely 
require optimisation in order to dissect the effects of the different FHOD1 constructs in 
a more granular fashion. A more reliable approach to quantify the extent of myofibril 
integrity could involve counting of sarcomeres in NRCs. However, such an approach 
would create a bias towards measuring a response in the cells which were deemed to 
exhibit a higher degree of myofibrillar integrity after Latrunculin B treatment. A 
combination of the qualitative assessment presently employed and sarcomere counting 
may be able to further elucidate the effects of FHOD1’s activation status on thin 
filament integrity after Latrunculin B treatment. 
 
With the present experiments looking at FHOD1’s actin regulatory activity in HeLa 
cells and NRCs in mind, the question remains: does FHOD1 merely reorganise F-actin 
into stress fibres or does it exhibit a degree of functionally relevant actin 
polymerisation? As discussed above, one line of thinking regarding FHOD1’s actin 
regulatory activity is that it caps actin filaments via its dimeric FH2 domain, thus 
preventing both polymerisation and depolymerisation, whereas the region N-terminal to 
the FH1 is thought to be responsible for its bundling activity (Schonichen et al. 2013; 
Kühn and Geyer 2014; Schulze et al. 2014). However, other studies have suggested that 
the actin polymerising activity of FHOD1 may be central to some of its functions in 
cells. One study exploring the events following early adhesion formation in cells 
highlighted FHOD1 as a potential actin nucleation/elongation factor (Iskratsch et al. 
2013b). Knockdown of FHOD1 in mouse embryonic fibroblasts (MEFs) on RGD-
supported membranes was associated with reduced actin polymerisation from RGD-
integrin clusters and reduced cluster growth. The notion that FHOD1 possesses 
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bundling activity was also supported in this study because FHOD1 was required for 
organisation of actin.   
 
Other studies have suggested that FHOD1 displayed the capacity to polymerise actin in 
cyto (Watanabe et al. 1999; Gasteier et al. 2003; Koka et al. 2003; Gasteier et al. 2005). 
In one study using NIH3T3 cells, overexpression of wild-type FHOD1 did not result in 
an increase in F-actin staining, whereas a constitutively active FHOD1 construct lacking 
the C-terminus resulted in an approximate two-fold increase in F-actin staining 
(Gasteier et al. 2003). Regardless of the appearance of stress fibres, an increase in actin 
polymerisation was still claimed. Taken with the present data, it is conceivable that 
FHOD1 partly exhibits its effects in cells by polymerising actin.  After activation, 
FHOD1 may associate with pre-existing actin filaments or may induce the formation of 
new filaments de novo.  The association of FHOD1 and actin is reportedly increased 
after activation and this is likely due to direct binding.  FHOD1 has been suggested to 
directly bind actin via a number of biochemical experiments.  HA-tagged full-length 
FHOD1 was shown to co-immunoprecipitate with G-actin (Koka et al. 2003)  and the 
actin binding portion of FHOD1 was subsequently mapped to the N-terminus of the 
protein, since an N-terminal FHOD1 construct was shown to bind F-actin in co-
sedimentation assays (Takeya and Sumimoto 2003).  The current findings supported the 
data from previous studies since co-localisation between FHOD1 and F-actin may have 
increased after activation of this formin in both cardiomyocytes and HeLa cells. 
Nevertheless, co-localisation does not necessarily equate to association between two 
proteins. This issue would require clarification through the implementation of actin 
binding deficient FHOD1 constructs, one possible example being an FHOD1 construct 
lacking the FH2 domain.   
 
4.7.3 Loss-of-Function Studies in Muscle Cells 
 
The role of FHOD1 in striated muscle was further investigated by performing a number 
of loss-of-function studies.  Three shRNAs were designed to knock down FHOD1 in 
rodent cells.  In cultured cardiomyocytes, transfection with the shRNA constructs 
resulted in disruption of myofibrils.  Transfected NRCs were either completely devoid 
of myofibrils or presented with truncated myofibrils.  Those myofibrils that were 
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present were also misaligned.  Cells were characterised by reduced staining for F-actin 
and irregular distribution of other sarcomeric proteins such as -actinin, MyBP-C, and 
myomesin. shRNA-transfected cardiomyocytes also exhibited a distorted morphology 
as they presented with an irregular plasma membrane edge, perhaps indicating 
disruption of the plasma membrane cytoskeleton.  Interestingly, transfection with the 
shRNA constructs designed to knock down endogenous FHOD1 also resulted in 
perturbation of the intercalated disks.  Under these circumstances, these specialised 
junctions between cells were reduced to multiple thin projections.  It was also apparent 
that the distribution of -catenin had been altered. Instead of distributing along the 
intercalated disk, -catenin had become mislocalised and redistributed within the 
cytoplasm in a punctate or diffuse manner, although some -catenin staining was still 
present at cell-cell contacts.  This was somewhat reminiscent of what had been 
previously noted in NRCs depleted of emerin, another cytoskeletal regulator.  
Knockdown of emerin in NRCs led to mislocalisation of -catenin, which redistributed 
to sites that did not participate in cell-cell adhesion (Wheeler et al. 2010).  Similar 
perturbation of cell-cell junctions were also seen in embryonic cardiomyocytes isolated 
from mice that had undergone targeted disruption of the formin Dishevelled-associated 
activator of morphogenesis 1 (DAAM-1).  DAAM-1 depleted cardiomyocytes displayed 
aberrant adherens junctions with prominent plaques and misalignment along the plasma 
membrane.  Furthermore, -catenin and N-cadherin became mislocalised from the 
plasma membrane, despite normal levels of expression (Li et al. 2011).   
 
Transfection of the shRNA constructs designed to knock down endogenous FHOD1 in 
C2C12 cells also resulted in cytoskeletal abnormalities.  In a manner similar to NRCs, 
Day 3 C2C12 cells transfected with the FHOD1 shRNA constructs displayed what 
seemed to be a reduction in staining for F-actin.  Control cells and untransfected 
neighbours had an elongated appearance with numerous stress fibres whereas shRNA-
transfected cells presented with an irregular morphology and disrupted F-actin 
cytoskeleton.  Interestingly, there were no cellular defects associated with shRNA 
constructs in later time points of C2C12 differentiation as determined by cellular 
morphology and calculation of the cell fusion index. If FHOD1 depletion was indeed 
achieved in cells, perhaps FHOD1 is crucial in day 3 C2C12 cells for the formation 
and/or alignment of stress fibres.  Any cytoskeletal defects in day 7 cells may have also 
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been compensated for by other actin regulatory proteins.  Overall, previous work 
exploring knockdown of FHOD1 would be in excellent agreement with the above 
findings.  Knockdown of FHOD1 blocked the formation of stress fibres in in Human 
Pulmonary Artery Endothelial Cells (HPAEC) (Takeya et al. 2008) and smooth muscle 
cells (Staus et al. 2011a).  Knockdown of FHOD1 was also associated with altered 
levels of G-actin to F-actin, suggesting decreased levels of F-actin hence, possibly less 
actin polymerisation or stabilisation of F-actin filaments (Staus et al. 2011a).  
Furthermore, silencing of FHOD1 in breast cancer cells also led to a loss of stress 
fibres, less cell elongation, and a diminished metastatic potential (Jurmeister et al. 
2012).   
 
Although we presently report phenotypes associated with the shRNA constructs 
designed to knock down endogenous FHOD1 in rodent cells, we were not able to 
definitively show that this was the result of FHOD1 depletion. The differences between 
the shRNA constructs also raises doubt as to the specificity of the RNAi approach used, 
although these may have been due to varying degrees of FHOD1 knockdown. The time 
point-specific effects of the shRNA constructs in different cell types is also an issue that 
requires elucidation. While we noted a phenotype associated with the shRNA constructs 
at day 8 in NRCs, a phenotype was only seen in C2C12 cells at day 3 and not at day 7. 
There is the possibility that the amounts of available shRNA construct were diluted 
when the transfected C2C12 myoblasts fused with untransfected C2C12 myoblasts to 
myotubes. While we did not see dramatic differences in the GFP intensity between d3 
and d7 C2C12 cells, this is not a quantitative way to assess availability of shRNA. If the 
effects were indeed due to FHOD1 disruption, they may reflect differences in turnover 
of FHOD1 in cardiac versus skeletal muscle or due to differences in maturation status. 
NRCs possess mature myofibrils at the time of isolation and it was shown previously 
that the dynamics of actin and its associated proteins is much lower in mature 
myofibrils than in assembling premyofibrils (Wang et al. 2014). Recently fused C2C12 
myotubes are only starting to assemble their myofibrils (i.e. at premyofibril stage) and a 
more mobile actin cytoskeleton can be expected. Closer investigations on the time 
course of expression and localisation of FHOD1 in differentiating C2C12 cells, 
potentially accompanied by FRAP experiments to assess protein dynamics will be 
required before conclusions of an effect of the shRNAs can be drawn.  
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Although we demonstrated the capacity of the 2375 construct to disrupt expression of 
the human FHOD1 construct in COS-1 cells, this does not substitute for verification of 
FHOD1 knockdown at the transcript and protein level with all three shRNA constructs 
in NRCs and C2C12 cells. While we noted a decreased signal for FHOD1 with the 
polyclonal mouse anti-FHOD1 antibody in NRCs transfected with the shRNAs, this was 
not sufficient to confirm knockdown of FHOD1 since the extent of potential cross-
reactivity against other proteins with the antibody has not been explored via antigen 
competition assays. Furthermore, we could not definitively confirm the presence of 
FHOD1 protein at the different time points due to improper characterisation of the anti-
FHOD1 antibodies. In the case of the 1095 shRNA construct in NRCs, however, the 
phenotype associated with this construct was apparently rescued by overexpression of 
TOMATO-tagged FHOD1, which was theoretically resistant to the effects of this 
shRNA construct. This could be perceived as evidence that the construct’s effect was 
due to FHOD1 depletion.  However, the possibility of off-target effects with the present 
methodology remains. 
 
If the effects of the FHOD1 shRNA constructs were indeed due to disruption of 
endogenous FHOD1, could they have been attributed to reductions in actin 
polymerisation?  In the present functional characterisation of FHOD1, we highlighted 
the possibility of this protein’s involvement in influencing the integrity of thin 
filaments, reorganisation of the myocardial cytoskeleton in NRCs, as well as the 
possible induction of accumulation of F-actin in the form of stress fibres in HeLa cells.  
Transfection of muscle cells with the FHOD1 shRNA constructs resulted in visibly less 
staining for F-actin and disruption of myofibrils and the cytoskeleton, possibly 
indicating that the actin polymerisation activity of FHOD1 may have been required for 
the maintenance of these structures.  Previous work with FHOD3 indicated that its 
effects in cardiomyocytes (i.e. myofibrillar maintenance and sarcomere organisation) 
were partly mediated by its actin polymerisation activity since an actin binding 
defective variant of FHOD3 was unable to promote sarcomere organisation (Taniguchi 
et al. 2009).  The requirement for FHOD1 in myofibrillar and cytoskeletal maintenance 
could therefore have been explained by the actin polymerising ability of this formin. 
Nevertheless, the reported capping activity of these formins in vitro (Taniguchi et al. 
2009; Schonichen et al. 2013) would argue against a polymerisation mechanism and the 
well-characterised bundling activities of FHOD1 (Schonichen et al. 2013; Schulze et al. 
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2014) could mean that the present results may be explained by its ability to regulate the 
organisation of actin-based structures. 
However, we cannot rule out the previously reported role of FHOD1 in mediating gene 
expression. FHOD1 has been implicated in signalling gene expression to the serum 
response element (SRE) via serum response factor (SRF) binding to the skeletal actin 
promoter (Boehm et al. 2005), factors which are also important in skeletal muscle 
differentiation (Kim et al. 2009) and the maintenance of the myofibrillar apparatus in 
cardiomyocytes (Balza and Misra 2006). Studies in smooth muscle revealed that 
FHOD1 was involved in the regulation of differentiation and that high levels of 
expression were required to maintain the expression of smooth muscle marker proteins 
(Staus et al. 2011a): knockdown of FHOD1 was associated with attenuation of markers 
of VSMC differentiation, including skeletal actin (Staus et al. 2011a). In VSMCs, the 
involvement of FHOD1 in the differentiation process may have also involved its actin 
polymerising or stabilising activity, which regulated the translocation of myocardin-
related transcription factor (MRTF) to the nucleus. Thus, FHOD1’s actin regulatory 
activity and/or its capacity to stimulate gene expression could be factors accounting for 
the phenotype observed in muscle cells transfected with the shRNA constructs designed 
to knock down FHOD1,  
 
If the observed phenotypes associated with the FHOD1 shRNA constructs were indeed 
due to FHOD1 depletion, the results from the current loss-of-function studies in cells 
would be in agreement with previous work looking at FHOD1 and other formins in 
muscle.  In Caenorhabditis elegans, overexpression of mutant variants of FHOD1 and 
CYK-1 resulted in defects relating to the development of the contractile lattice in the 
body wall muscles (BWM) of larvae (Mi-Mi et al. 2012).  Developing larvae 
overexpressing the mutant formin variants had smaller BWM compared to wild-type 
specimens.  These regions also displayed decreased staining for F-actin.  Sarcomere 
organisation was also adversely impacted in terms of the spacing and number of 
striations. These defects were also recapitulated by disrupting expression of endogenous 
FHOD1.  Knockdown of FHOD3 in cultured cardiomyocytes has also resulted in a 
severe myofibrillar phenotype (Taniguchi et al. 2009; Iskratsch et al. 2010).  Iskratsch et 
al. 2010 noted defects in myofibrils by day 5 of FHOD3 knockdown.  At this time point, 
FHOD3 depleted NRCs presented with shortened myofibrils and fewer mature 
sarcomeres.  By day 8, FHOD3 depletion resulted in exacerbation of the myofibrillar 
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phenotype (Iskratsch et al. 2010) and resembled that associated with the FHOD1 
shRNA constructs.  Overall, these data can be taken as evidence for formin homology 
proteins as crucial players in myofibrillar maintenance. 
4.7.4 Involvement of Formins in Regulation of the Myofibrillar 
Apparatus 
 
After having highlighted a potential role for FHOD1 in myofibrillar maintenance we 
aimed to further investigate the role of formins more generally in cardiomyocytes. 
SMIFH2 is an inhibitor of formin mediated actin assembly (Rizvi et al. 2009). It was 
found to inhibit actin polymerisation by formins at the level of nucleation, elongation, 
and association with the barbed ends of filaments. These effects were attributed to 
SMIFH2 targeting the conserved FH2 domain, although direct binding of the small 
molecule has never been shown.  Moreover, it was shown to specifically inhibit formins 
and not any other actin polymerising proteins such as Arp2/3. In NIH-3T3 cells, 
treatment with SMIFH2 resulted in a reduction in the number of F-actin bundles and a 
reduction in the size of focal adhesion plaques (Rizvi et al. 2009). In MEFs, treatment 
with SMIFH2 resulted in impaired cell spreading similarly to that seen in FHOD1 
depleted MEFs (Iskratsch et al. 2013b). Whereas the previous study demonstrated 
SMIFH2 to disrupt actin-based structures in yeast and cell lines, our study is the first to 
use the inhibitor in primary cells.  
 
Consistent with its reported effects, SMIFH2 disrupted the myocardial actin 
cytoskeleton and sarcomeric organisation. In contrast to our RNAi experiments, 
membrane deformation was far less than that seen in shRNA transfected cells.  Overall, 
inhibition of formin mediated actin assembly resulted in disruption of thin filaments and 
mislocalisation of sarcomeric proteins, which would be in agreement with previous 
studies that found that some formins are required for myofibrillar formation, 
maintenance, and organisation (Taniguchi et al. 2009; Iskratsch et al. 2010; Iskratsch 
and Ehler 2011; Li et al. 2011; Dwyer et al. 2012; Mi-Mi et al. 2012; Kan-o et al. 
2012a).  The effects of the inhibitor also seemed to be transient since cardiomyocytes 
exhibited a certain degree of recovery in terms of reintegration of their myofibrils.  
Reintegration of the cytoskeleton and sarcomere could partly be explained by the fact 
that there are other actin nucleators in muscle.  One potential nucleator accounting for 
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reintegration of myofibrils during treatment with SMIFH2 could have been Leiomodin-
2, an assembly factor competes with tropomodulin for binding at the pointed ends of 
thin filaments to promote elongation (Tsukada et al. 2010).  N-WASP could also be 
another potential nucleator/elongator in striated muscle. N-WASP and nebulin were 
shown to form a complex at the Z-disk and contribute to the formation of unbranched 
actin filaments in response to IGF-1 stimulation in skeletal muscle cells (Takano et al. 
2010), but whether their effects on thin filament assembly extend to cardiac muscle 
remains to be seen.  The presence of other actin polymerising proteins such as 
leiomodin or N-WASP may have thus accounted for the transient effect seen with the 
formin inhibitor.   
 
Treatment with the formin inhibitor seemed to have an irreversible impact on the 
intercalated disks.  SMIFH2 seemed to have a cumulative effect on cell-cell junctions 
which became increasingly widened and convoluted.  Could formins be indispensable in 
the integration of the F-actin network between neighbouring cells?  Transfection of 
NRCs with the shRNA designed to knock down endogenous FHOD1 resulted in 
disruption of the intercalated disk in cultured cardiomyocytes and DAAM (Li et al. 
2011) along with Formin1 (Zigmond 2004) were also found to be required for proper 
formation of adherens junctions. The potential localisation of FHOD1 and the 
confirmed localisation of FHOD3 (Iskratsch et al. 2010) at the intercalated disks in 
frozen sections of cardiomyocytes could also point to a role for formin homology 
proteins at this particular site in cardiomyocytes.  It is likely that formins and other actin 
regulatory proteins are required in specific muscle subcellular compartments at different 
times; therefore it would be of interest to establish a spatio-temporal expression profile 
of each formin in striated muscle. 
 
While the effects of treatment with SMIFH2 partly resonated with the findings seen in 
NRCs transfected with the FHOD1 shRNA constructs, they were very disparate to those 
noted with the FHOD1 3A construct. While the FHOD1 3A construct represents a 
kinase insensitive FHOD1 construct, this does not necessarily mean that it possesses a 
dominant-negative effect. In NRCs, the FHOD1 3A mutant behaved in a similar manner 
to the GFP-tagged wild-type FHOD1 constructs. Surprisingly, in HeLa cells, it became 
apparent that the FHOD3 3A construct was associated with the formation of stress 
fibres. However, it remains to be seen if this was an extraneous occurrence or if it is an 
  Functional Characterisation of FHOD1 
266 
 
effect of the construct that is specific to HeLa cells. Overexpression studies with the 
FHOD1 constitutively active mutants in NRCs would also suggest that phosphorylation 
in the FHOD1 DAD may not necessarily be a full marker of activation. Furthermore, 
the different full-length FHOD1 constructs, including the FHOD1 3A construct, were 
able to promote myofibrillar integrity after Latrunculin B treatment and wash-out 
regardless of activation status. Previous in vitro work has also demonstrated how full-
length, supposedly inactive FHOD1 can both cap and bind the sides of actin filaments 
(Schonichen et al. 2013). These factors could account for the disparity in the effects of 
the FHOD1 3A construct and the SMIFH2 inhibitor. However, the differences between 
FHOD1 3A and SMIFH2 could also suggest that different formins might make 
individual contributions to the maintenance of the cardiac cytoskeleton.  
 
While both the presently and previously reported effects of the pan-formin inhibitor 
SMIFH2 are somewhat in line with the canonical role of formin proteins (i.e., regulation 
of F-actin), there are still a number of uncertainties regarding how it exerts its effects. 
While SMIFH2 is thought to inhibit formin mediated actin polymerisation by targeting 
the conserved FH2 domain, initial characterisation efforts have been limited to 
investigating only a handful of formins: mDia1, mDia2, and Cdc12 (Rizvi et al. 2009). 
Further characterisation of SMIFH2 will be required in order to establish if it indeed 
acts on all members of the formin family of proteins and whether its effects on 
individual formins occur at specific concentrations. It also remains to be seen if 
SMIFH2 disrupts the other reported abilities of formins, such as actin bundling, since 
experiments have been restricted to looking at its effects on actin polymerisation in in 
vitro assays. If SMIFH2 does indeed inhibit actin assembly by formins via their FH2 
domain, one interesting experiment could involve treating constitutively active FHOD1-
overexpressing NRCs with the inhibitor to begin and dissect the contribution of 
FHOD1’s potential actin polymerising activity. 
4.7.5 Conclusion 
  
In summary, we attempted to gain insight into the functional relevance of FHOD1 with 
a mixture of gain-of-function and loss-of-function studies. Gain-of-function studies 
using constitutively active FHOD1 mutants suggested that this formin has the capacity 
to reorganise the F-actin cytoskeleton in cardiomyocytes, although the discrepancies 
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noted between the different constructs raised questions regarding the most-appropriate 
reporter of FHOD1 activation. Immunofluorescence samples of mouse heart sections 
stained with the antibody that recognises the phosphorylated Threonine-1141 residue on 
FHOD1 also may have indicated the localisation of endogenous FHOD1 may represent 
the formin in its active state, since near-identical staining was previously noted for 
endogenous FHOD1, although the full extent of phosphorylation could not be probed. 
However, in the absence of proper characterisation of the antibody, we were unable to 
rule out the possibility of cross-reactivity with other proteins, particularly FHOD3. We 
also attempted to highlight FHOD1’s actin regulatory activity with experiments in HeLa 
cells with multiple constructs, although discrepancies arose relating to the FHOD1 3A 
construct and an overall high degree of variability. Experiments in NRCs which were 
subjected to depolymerisation of F-actin and their myofibrils suggested that FHOD1 
possessed the capacity to confer myofibrillar integrity irrespective of its activation 
status. However, we were unable to differentiate between FHOD1 preventing 
depolymerisation and FHOD1 promoting de novo myofibrillogenesis. Loss-of-function 
experiments, by way of RNAi, revealed a phenotype in NRCs and C2C12 cells 
transfected with the shRNA constructs designed to knock down endogenous FHOD1. 
This phenotype was seemingly characterised by defects in myofibrillar and cytoskeletal 
maintenance. However, we were not able to definitively prove that this phenotype was 
due to FHOD1 depletion. Finally, treatment with the general formin inhibitor, SMIFH2, 
also resulted in perturbation of the myofibrillar apparatus and highlighted the potential 
importance of formin proteins in cardiac cells. 
4.7.6 Future Directions 
 
While overexpression of the constitutively active FHOD1 variants in NRCs may have 
provided some insight into the function of FHOD1, this was limited to the long variant 
of FHOD1, which contained the alternatively spliced exons 12-13. Similar experiments 
should be performed with the shorter variant of FHOD1 in order to probe the possibility 
of divergence in function between the different FHOD1 isoforms. Furthermore, the 
present overexpression experiments were performed in the presence of phenylephrine. 
Future studies examining the effects of constitutive activation of FHOD1 in NRCs 
should be performed in the presence and absence of hypertrophic stimuli, which could 
conceivably influence the function of the protein.   
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Staining for phosphorylated FHOD1 in mouse heart sections suggested a similar 
localisation pattern for phosphorylated FHOD1 and total FHOD1. However, we were 
not able to rule out cross-reactivity between the FHOD1 phospho-Threonine1141 
antibody and other proteins, particularly FHOD3. Antigen competition assays using 
both phosphorylated C-terminal fragments of FHOD1 and FHOD3 will be required to 
assess the extent of cross-reactivity with this antibody. 
 
While we reported a phenotype associated with cells transfected with the FHOD1 
shRNA constructs, future work should make it a priority to confirm that this was indeed 
due to depletion of endogenous FHOD1. In the absence of a well-characterised antibody 
that has been shown to definitively detect endogenous FHOD1 in the cells used in this 
study, it was not possible to definitively confirm knockdown on a single cell basis. 
Furthermore, due to the low transfection efficiency in both NRCs and C2C12 cells, it 
was not possible to confirm knockdown at the mRNA transcript level by RT-PCR. This 
could potentially be addressed by implementing a virally mediated gene transduction 
approach in order to achieve higher efficiency of gene transfer into cells. Furthermore, 
the phenotype associated with the FHOD1 shRNAs will require further characterisation 
via quantification of the extent of myofibrillar and cytoskeletal disruption. 
 
Since experiments using Latrunculin B in NRCs could not differentiate between 
FHOD1 preventing depolymerisation of myofibrils versus FHOD1 promoting de novo 
myofibrillogenesis, further experiments will be required. One approach could involve 
treating FHOD1-depleted cells with Latrunculin B with subsequent wash-out and 
myofibril recovery. Visualising the effects of FHOD1 overexpression in Latrunculin B-
treated NRCs at different time points could also provide insight into how FHOD1 exerts 
its effects on myofibrils. It will also be of interest to see if the effects of FHOD1 can be 
substituted for by other formins, especially its closest relative FHOD3. 
 
One caveat that applied to the experiments in HeLa cells related to the possibility that 
differences between the F-actin bundling activity and the potential actin polymerising 
activities of FHOD1 could not necessarily be dissected. Although an increase in total 
levels of F-actin would be suggestive of actin polymerisation, the more-concentrated 
staining for F-actin on resulting stress fibres may have offset measurements of the 
Phalloidin pixel intensity, therefore accurate measurements within the linear range of 
  Functional Characterisation of FHOD1 
269 
 
intensity may not have been captured. Such experiments need to be complimented by 
biochemical analysis in order to see if total levels of F-actin or if the ratio of G-actin to 
F-actin was altered in cells. While this would be feasible in HeLa cells, which exhibited 
a greater transfection efficiency, subsequent studies attempting to measure the F-actin 
regulatory activity of FHOD1 in NRCs may require the use of virally mediated gene 
transduction in order to achieve higher efficacy of gene transfer for biochemical 
































5. Regulation of FHOD1 
5.1 Regulation of FHOD1 by the Rho Family Small GTPases and their 
Effectors 
 
Rho family small GTPases represent a subset of the Ras superfamily of GTP-dependent 
enzymes.  Their ability to mediate cytoskeletal rearrangements and influence actin 
dynamics has been well documented (Hall 1998).  The Rho family small GTPases play 
important roles in a number of processes requiring cell polarisation (Fukata et al. 2003) 
such as division (Yoshizaki et al. 2003), spreading (Price et al. 1998), migration (Ridley 
2001), and adhesion (Braga 2002).  Most studies concerning this family of enzymes 
have focused on characterisation of three of around 22 members, RhoA, Rac1, and 
Cdc42.  The Rho GTPases regulate actin assembly via activation of the WASP proteins 
or the diaphanous related formins (DRFs) (Ridley 2006).  Activation of WASP proteins 
stimulates actin polymerisation via the Arp2/3 complex (Zalevsky et al. 2001).  Rho 
family GTPases are thought to activate formins by displacing the interaction between 
the N-terminal Diaphanous inhibitory domain (DID) and the C-terminal Diaphanous 
autoregulatory domain (DAD).  The small GTPases are thought to bind the N-terminal 
GTPase binding domain (GBD) therefore causing steric displacement of the interaction 
between the two ends of a DRF, hence resulting in exposure of the actin polymerising 
FH2 domains (Tominaga et al. 2000).  GTPases have been shown to regulate aspects of 
formin biology including activation and localisation.  We explored the potential 
interactions between the N-terminus of FHOD1 and some of the Rho family small 
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5.1.1 Validation of the N-Terminal GST-tagged FHOD1 Construct 
 
The presently employed GST-tagged FHOD1 construct spanned from amino acids 1 to 
513.  This construct was comprised of the GBD, DID, and contained the linker region 
which stopped just short of the FH1 domain (Figure 5.1 A).  The FH1 domain was not 
included as this represents a region with a different subset of already specified 
interactions, including profilin.  The novel aspect about the FHOD1 construct used in 
the studies here is that it included the alternatively spliced exons 12 and 13, which were 
described to be mainly expressed in striated muscle (Tojo et al. 2003). Interactions 
between FHOD1 and the Rho family small GTPases were not yet studied in the context 
of the alternatively spliced exons found in the longer FHOD1 variant (exons 12-13). 
Prior to commencing the GST pull-down studies, levels of expression and the size of the 
GST-tagged FHOD1 N-terminal construct were checked by SDS-PAGE followed by 
Western blotting. The N-terminal fragment of FHOD1 without the GST tag had a 
predicted molecular weight of 55kDa (Figure 5.1 B).  
 
Western blots probed with the anti-GST antibody revealed that the FHOD N-terminal 
construct was expressed at sufficient levels for biochemical experiments to be 
performed, although some degradation was present (Figure 5.1 C). Two prominent 
bands were resolved for the GST-tagged FHOD1 construct on SDS-PAGE gels: a larger 
species migrating beneath the 123kDa marker and a smaller species migrating around 
the 78kDa marker. The size of the smaller band was  in agreement with the expected 
molecular weight of the GST-tagged FHOD1 construct  (81 kDa) (Figure 5.1 B). One 
possible explanation behind the larger species could be that it was a product of protein 
oligomerisation; in this case a possible aggregate of the GST-tagged FHOD1 construct 
and a lighter peptide resulting from degradation. However, the denaturing conditions 
used for the SDS-PAGE make this highly unlikely. Alternatively, the unexplained band 
could have represented a contaminant in the protein preparation. The unwanted 
influence of another protein species would call into question the validity of any GST 
pull-down experiments performed. This would especially be the case in the context of a 
positive interaction; since it would not be clear which GST-tagged species was 
responsible for mediating the interaction. One method of validating the protein 
preparation in question would involve probing blots with an anti-FHOD1 antibody that 
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recognises the N-terminal region of the protein. Should the larger species prove not to 
be reactive to the anti-FHOD1 antibodies, one method of identifying it would be to 
excise the unidentified band, trypsinise it, and subject it to mass spectrometry. If the 
unidentified band did indeed represent a contaminating species, an extra purification 
step could be employed (e.g., size exclusion chromatography) in order to obtain the 
desired GST-tagged protein for biochemical assays. Nevertheless, GST pull down 
assays were performed using the protein preparations containing the multiple bands. 
Relative levels of loading between untagged GST protein and GST-tagged FHOD1 
were visually gauged on gels and subsequently adjusted to reflect comparable levels of 































5.1.2 Conditions used for GST Pull-Down Assays 
 
For the GST pull-down assays the following buffer was used for lysis, washing, and 
incubation of the GST-tagged and target proteins: 150 mM NaCl, 20 mM Tris-HCl pH 
7.6, 1 mM Ethylenediaminetetraacetic acid (EDTA), 0.2% (v/v) NP-40, 1 mM 
Dithiothreitol (DTT), and 1x protease inhibitor cocktail. The buffer used for GST pull-
downs was designed to partly mimic the conditions within a cellular environment whilst 
Figure 5.1: Expression Test for GST-FHOD1 [1-513].  A) The GST-tagged N-
terminal fragment of FHOD1 spanning from amino acid 1 to 513 and containing the 
alternatively spliced exons 12-13 was presently employed for interaction studies since 
the potential interactions with the Rho family small GTPases and their effector molecules 
have never been studied in this context of the alternatively spliced exons. B) The N-
terminal FHOD1 fragment had an expected molecular weight of 55kDa. Combined with 
the molecular weight of the GST tag (26kDa), the GST-tagged FHOD1 construct has an 
expected molecular weight of 81kDa. C) The GST-tagged FHOD1 construct and the 
GST tag alone were purified from bacterial lysates, resolved by SDS-PAGE, and 
visualised by enhanced chemiluminescence on Western blots incubated with the anti-
GST antibody. This was performed to gauge the relative size and expression levels of the 
protein. D) Representative blot from GST pull-down assays that shows the relative 
loading of the GST tag in the negative control lanes and of the GST-tagged FHOD1 
construct in the lanes testing for an interaction. Western blot was probed with the anti-
GST antibody to visualise unmodified GST and the GST-tagged N-terminal FHOD1 
fragment. GST, glutathione S-transferase. N=2. 
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maximising yield and promoting stability of the extracted target proteins. Addition of 
150 mM NaCl promoted an isotonic environment for cell lysis and corresponded to the 
ionic concentrations found in physiological conditions. Tris-HCl was added because it 
acts as a buffer that stabilises the pH within a narrow range. This is important because 
the lysis procedure can introduce rapid changes in pH, which could affect the stability 
of the target proteins. The 20mM Tris-HCl solution was titrated to pH 7.6, which is near 
to the intracellular cytosolic pH and should therefore have prevented pH dependent 
denaturation of the target proteins. EDTA, a metal chelator, was added to prevent 
oxidative damage of proteins and to prevent degradation by divalent cation dependent 
proteases. NP-40, a non-ionic and non-denaturing detergent, was added to improve 
solubilisation of cell membranes and improve lysis. We found that 0.2% (v/v) NP-40 
was sufficient to promote lysis of cells as gauged by a sufficient yield of target protein. 
1mM DTT, a reducing agent, was added to prevent oxidative damage of the proteins. 
The addition of protease inhibitors was necessary in order to prevent degradation of 
target proteins by proteases liberated/activated during lysis. The above buffer sufficed 
for isolation of all the target proteins, which were soluble and expressed to levels 
sufficient for biochemical experiments.  
 
COS-1 cells were used as a means to overexpress the target proteins due to the poor 
transfection efficiency we obtained with neonatal rat cardiomyocytes (NRCs). The use 
of COS-1 cells represented a drawback to this study since proteins could undergo 
diverse post-translational modifications in different cell types. Therefore, the present 
binding assays are not entirely representative of what could occur in muscle cells. While 
overnight incubation at 4°C between the GST-tagged FHOD1 protein and target 
proteins was initially performed for all experiments, experiments yielding a positive 
interaction were repeated with an incubation time of 1 hr at 4°C in order to rule out the 
potential of non-specific binding. A temperature of 4°C was selected for experiments in 
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5.1.3 Assessment of Binding of FHOD1 with the Rho family small 
GTPases and their Effectors  
 
 
In the current study we investigated the possibility of binding of the FHOD1 N-terminus 
with Rac1, Cdc42, and Rho associated protein kinase (ROCK) I and II.  Rac1 is a 
member of the Rho family small GTPases (Ridley and Hall 1992b) and has previously 
been shown to interact with FHOD1.  The FHOD1-Rac interaction has previously been 
mapped to the more C-terminal half of FHOD1, where the GBD was initially thought to 
lie (Gasteier et al. 2003). However, It has become apparent that like other DRFs, the 
GBD of FHOD1 lies in the N-terminus of the protein just upstream of the DID which 
questions the function of Rac binding in the FHOD1 C-terminus (Schulte et al. 2008). 
Nevertheless, Rac1 may contribute the targeting of FHOD1 in cells (Gasteier et al. 
2003; Alvarez and Agaisse 2013).   
 
Like the other GTPases, Cdc42 has been found to induce formation of membrane 
protrusions, namely filopodia (Nobes and Hall 1995). Although the interaction between 
Cdc42 and FHOD1 has not been thoroughly explored, it has been shown that Cdc42 is 
sometimes required for formin-mediated actin assembly.  In the absence of Cdc42, 
formin-dependent actin cable formation was not properly executed in yeast (Dong et al. 
2003).  Previous work indicated that neither full length FHOD1 nor a C-terminal 
truncation mutant of FHOD1 bound Cdc42 in GST pull-down assay analysis (Gasteier 
et al. 2003).    
 
ROCK-I is one of the major effector molecules that lies downstream the RhoA pathway 
(Ridley 2006). It has been shown that ROCK-I phosphorylates FHOD1 in the DAD to 
contribute to activation of this formin (Takeya et al. 2008).  Yeast two-hybrid studies 
also suggested that ROCK-I interacts with the N-terminal part of the FH2 domain 
(Hannemann et al. 2008). ROCK-II, which is closely related to ROCK-I  (65% amino 
acid similarity) (Riento et al. 2005), has not previously been linked to formin activity.  
Since regulation of FHOD1 by ROCK-I has been previously demonstrated, we also 
screened for the potential of an interaction between FHOD1 and ROCK-II.  
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While previous work has suggested that these effector molecules do not bind the 
FHOD1 N-terminus, they have not been studied in the context of the alternatively 
spliced exons 12-13 found on the long FHOD1 variant. Therefore we performed GST 
pull-down experiments with the FHOD1 construct described above. A pull-down with 
FLAG-tagged constitutively active Rac1 (Figure 5.2 A) was performed alongside a pull-
down with constitutively active Rac1 and the PBD portion of PAK (Figure 5.2 B). The 
PBD portion of PAK has been shown to bind both active Rac1 and Cdc42 (Sells et al. 
1997); this pull-down functioned as a positive control. Pull-downs were also performed 
with FLAG-tagged constitutively active Cdc42 (Figure 5.2 C), myc-tagged ROCK-I 
(Figure 5.3 A), and myc-tagged wild-type ROCK-II (Figure 5.3 B). The constitutively 
active Rac1 and Cdc42 constructs were created by mutating a Glycine residue at 
position 12 to a Valine (Ridley et al. 1992; Suzuki et al. 2000). The constitutively active 
ROCK-I 1 truncation mutant construct spanned amino acids 1-1080 (Chang et al. 
2006).   
 
The GST-tagged FHOD1 N-terminus was unable to pull down any of the currently 
addressed Rho family small GTPases (Figure 5.2) or ROCK-I and II (Figure 5.3) since 
there was no signal in the pellet portion for any of the pull-down assays. However, we 
could only conclude with some certainty that this was due to lack of binding in the case 
of Rac1, since a positive interaction in the control pull-down with PAK-PBD suggested 
optimised conditions for binding between FHOD1 and Rac1. The same cannot be said 
for the other proteins since no binding control was provided. Therefore, until positive 
binding controls are provided, the negative results seen in the pull-downs with Cdc42, 
ROCK-I, and ROCK-II cannot be concluded to hold any validity as they may have 






























Figure 5.2: Assessing the Interaction between the FHOD1 N-terminus with Members of 
the Rho Family Small GTPases.  Western blots depicting the results from GST pull-down 
assays.  The GST tagged N-terminus of FHOD1 [1-513] was used to pull down FLAG-tagged 
constitutively active variants of A) Rac1 and C) Cdc42 from COS-1 cell lysates.  Blots were 
probed with anti-FLAG antibody to visualise FLAG tagged constitutively active Rac1 and 
Cdc42. B) A positive control GST pull-down assay was performed for constitutively active 
Rac1. The GST-tagged PBD portion of PAK was used to pull down FLAG-tagged 
constitutively active Rac1 from COS-1 cell lysates. CA, constitutively active; GST, 
glutathione S-transferase. N=2. 
   











5.2 Regulation of FHOD1 by Src Kinase 
 
Src is a member of the Src family of non-receptor tyrosine kinases which has been 
shown to regulate FHOD1 activity.  Src was suggested to mediate targeting of FHOD1 
to lamellipodia and to bridge FHOD1 stimulated transcription from the SRE (Koka et 
al. 2005).  Src activity was also found to be crucial in mediating the association of 
FHOD1 with ROCK-I at the plasma membrane (Hannemann et al. 2008). During the 
time of the present study, Iskratsch et al. 2013b elaborated on the interaction between 
FHOD1 and the Src family kinases (SFKs). They demonstrated that the SFKs 
phosphorylated a conserved YEEI motif in the FHOD1 GBD (
99
YEEI) and that this was 
dependent on the SFKs binding the polyproline motifs in the FHOD1 FH1 domain 
(Iskratsch et al. 2013b). Overall, it was found that the direct interaction between 
FHOD1 and the SFKs was required for targeting of FHOD1 to early integrin clusters, 
where it was able to participate in actin polymerisation during cell spreading and 
migration. Prior to publication of the study by Iskratsch et al. 2013b, cross-talk between 
FHOD1 and Src had been well established but no direct binding between the two 
proteins had ever been shown. We had previously entertained the notion of a possible 
Figure 5.3: Assessing the Interaction between the FHOD1 N-terminus with Effectors of 
the Rho Family Small GTPases.  Western blots depicting the results from GST pull-down 
assays.  The GST tagged N-terminus of FHOD1 [1-513] was used to pull down myc-tagged 
constitutively active A) ROCK-I (ROCK-I 1) and B) wild type ROCK-II (full length) from 
COS-1 cell lysates.  Blots were probed with anti-myc antibody to visualise myc-tagged 
constitutively active ROCK-I and wild type ROCK-II. CA, constitutively active; WT, wild 
type; GST, glutathione S-transferase. N=2. 
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interaction between the FHOD1 N-terminus and Src and performed GST pull-down 
assays.   
 
5.2.1 Assessment of Binding of FHOD1 with Src 
 
GST pull-down assays were performed to assess whether there was any direct binding 
between the GST-tagged FHOD1 N-terminus (See Figure 5.1 for characterisation of 
construct) and Src (Figure 5.4 ). We also explored the possibility of binding in the 
context of the activation status of Src. For this purpose we used three GFP-tagged 
variants of Src: wild-type Src, constitutively active Src, and dominant-negative Src. The 
constitutively active Src construct represents a kinase active Src mutant. The dominant-
negative Src construct represents a kinase inactive variant of Src. Both constructs 
represent full-length variants of Src.  
 
GST-tagged FHOD1 fragment bound GFP-tagged wild-type Src, overexpressed in 
COS-1 cells, in this assay as there was a signal in the pellet portion of the pull-down 
(Figure 5.4 A). However, the GST-tagged FHOD1 fragment was unable to bind GFP-
tagged constitutively active Src (Figure 5.4 B) or dominant-negative Src (Figure 5.4 C). 
No signal was present in the pellet portion of the GST pull-down for constitutively 
active or dominant-negative Src, suggestive that the proteins do not bind. These 
findings would suggest that the FHOD1 N-terminus binds Src, but that this is could be 
dependent on the activation status of Src. However, due to the lack of positive binding 
controls performed with the constitutively active and dominant-negative Src constructs, 
we cannot conclude with certainty that this was the case. On the other hand, we were 
able to conclude with more certainty that FHOD1 could have at least bound wild-type 
Src, since we also demonstrated that the interaction was not mediated by the GFP tag 
(Figure 5.4 D). A GST pull-down assay was performed with the GST-tagged N-terminal 
fragment of FHOD1 and the GFP tag. There was no binding between the N-terminus of 
FHOD1 and GFP or between GST and GFP. Such a finding would be indicative of the 
specificity of binding between FHOD1 and wild-type Src. However, we cannot rule out 
that the unidentified species found in the protein preparation for the GST-tagged 
FHOD1 N-terminus (Figure 5.1 C) was responsible for the pull down and for a 
conclusive result the identity of this species has to be established first, respectively a 
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Figure 5.4: Assessing the Interaction between FHOD1 and Src.  Western blots depicting 
the results from GST pull-down assays. The GST-tagged N-terminus of FHOD1 [1-513] 
containing the alternatively spliced exons 12-13was used to pull down GFP-tagged variants 
of Src from COS-1 cell lysates.  Blots were probed with anti-GFP antibody to visualise GFP 
tagged Src variants. The following constructs were used for GST pull-down assays with the 
FHOD1 N-terminus: A) wild type (WT) Src, B) constitutively active (CA) Src, C) 
dominant-negative (DN) Src. D) A GST pull-down assay using untagged GFP was 
performed as a control to assess the potential for unspecific binding mediated by the GFP 
tag. GST, glutathione S-transferase; NRC, neonatal rat cardiomyocytes; GFP, green 
fluorescent protein.  N=3. 





5.3.1 Interaction between the FHOD1 N-terminus, the Rho Family 
Small GTPases, and their Effector Molecules 
 
DRF proteins are typically characterised as being regulated by the Rho family small 
GTPases.  In the assessment of the regulation of FHOD1, we looked at some of the 
common Rho family small GTPases and their effector molecules that have been 
previously shown to regulate DRFs. Our study used an N-terminal fragment of the 
longer variant of FHOD1 containing the alternatively spliced exons 12-13, which could 
have influenced potential binding to GTPases and had not been included in previous 
characterisation efforts.   
 
GST pull-down assays suggested that none of the currently addressed Rho family small 
GTPases, constitutively active variants of Rac1 and Cdc42, bound the FHOD1 N-
terminus including exons 12-13. However, this could only be concluded with a degree 
of certainty for the GST pull-downs with constitutively active Rac1. Consistent with 
previous reports, constitutively active Rac1 bound the PBD portion of PAK (Sells et al. 
1997). This positive control served as a means to confirm that constitutively active Rac1 
was being studied in a context in which it could possibly bind our GST-tagged FHOD1 
construct. Since no positive control was demonstrated for constitutively active Cdc42, 
we cannot conclude with certainty that the absence of interaction between the FHOD1 
N-terminus and Cdc42 was genuine or merely due to a lack of optimisation of the 
conditions required for binding. 
 
Previous characterisation efforts indicated that FHOD1 interacted directly with Rac.  It 
was shown that the full length short variant of FHOD1 interacted with Rac1 but not 
Cdc42, RhoA, Rac2, or Rac3 (Westendorf 2001; Gasteier et al. 2003).  Binding was 
also confirmed in vivo by co-immunoprecipitation assays using lysates from a breast 
carcinoma cell line (MDA-231 cells).  Rac1 and FHOD1 were also shown to co-localise 
in HeLa cells.  The interaction between FHOD1 and Rac1 was subsequently mapped 
between amino acids 422-717 of FHOD1 and the C-terminus of Rac1 (Gasteier et al. 
2003). However, the FHOD1-Rac interaction has been questioned for a number of 
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reasons.  Firstly, Rac has not been shown to bind the FHOD1 GBD, the quintessential 
GTPase interacting domain of formins. Secondly, Thomas et al. 2011 were unable to 
recapitulate binding between FHOD1 and Rac in co-immunoprecipitation experiments, 
although this may have just indicated that the proteins did not interact in platelets. 
While studies have found that Rac does not bind the FHOD1 GBD and therefore does 
not represent a possible means of activation like those noted previously with other 
formins, such as RhoA activation of mDia (Lammers et al. 2005; Lammers et al. 2008; 
Kühn and Geyer 2014), Rac could still influence the subcellular localisation and 
function of FHOD1. For example, Rac1 was shown to mediate targeting of FHOD1 to 
actin tails, where FHOD1 participates in actin tail initiation and elongation in HeLa 
cells infected with the WR strain of vaccinia virus (Alvarez and Agaisse 2013). Rac 
overexpression also promoted FHOD1 targeting to F-actin, membrane ruffles and the 
plasma membrane (Gasteier et al. 2003).  Other studies involving the FHOD1-Rac 
interaction also implied that Rac1 not only regulates the localisation of FHOD1 but also 
represses FHOD1 mediated transcription from the SRE (Westendorf 2001). Future 
efforts should also see if Rac represents a means of mediating the targeting of FHOD1 
in muscle cells.    
 
GST pull-down assays suggested that none of the currently addressed effector 
molecules that act downstream of Rho, constitutively active ROCK-I and wild-type 
ROCK-II, bound the FHOD1 N-terminus. However, we could not conclude with 
certainty that this was the case in the absence of positive binding controls for these 
proteins. Until binding is demonstrated between these target proteins and a previously 
reported interacting partner using the same conditions as in our GST pull-down assays 
with the FHOD1 N-terminus, we cannot rule out the possibility that our conditions were 
not optimised for binding. Conditions may vary for binding between different sets of 
proteins to occur; therefore our one-buffer-fits-all approach may not have been an 
appropriate method for the present binding experiments. 
 
Although FHOD1 regulation by Rac has become fairly well established, mounting 
evidence would suggest that a large part of FHOD1 regulation actually occurs 
downstream of RhoA signalling through the effector molecule ROCK.  ROCK has been 
shown to directly affect the activity of FHOD1 by phosphorylation.  Phosphorylation of 
FHOD1 by ROCK in three residues (Ser1131, Ser1137, and Thr1141) within the DAD 
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disrupted the diaphanous autoregulatory interaction and rendered FHOD1 active 
(Takeya et al. 2008).  Furthermore, FHOD1 has been shown to bind the central region 
of ROCK-I via the N-terminal part of its FH2 domain (Hannemann et al. 2008).  The 
functional importance of the Rho-ROCK cascade was further highlighted in 
experiments that demonstrated that ROCK phosphorylation of FHOD1 was essential in 
promoting smooth muscle differentiation (Staus et al. 2011a). Interestingly, activation 
by ROCK may be a conserved feature among DRFs, and especially formin homology 
proteins. mDia2 was shown to be phosphorylated by ROCK in two residues near the 
DAD, an event which resulted in activation of the formin (Staus et al. 2011b). FHOD3 
has also been shown to be activated by ROCK phosphorylation within the DAD (Staus 
et al. 2011a; Iskratsch et al. 2013a).  
 
5.3.2 Interaction between the FHOD1 N-terminus and Src 
 
In addition to the Rho family small GTPases and ROCK, Src has also been implicated 
in regulating the activity of FHOD1.  Src is frequently described as an important 
effector molecule in the context of cancer and tumour metastasis (Summy and Gallick 
2003).  One notable function of this kinase is that it phosphorylates focal adhesion 
kinase (FAK) to promote turnover of focal adhesions (Parsons 2003). Src has been 
shown to regulate FHOD1 in a number of studies.  It was initially found to regulate the 
localisation of FHOD1 in fibroblasts, since Src depletion resulted in mislocalisation of 
FHOD1 from lamellipodia.  However, Src was not required for FHOD1-induced stress 
fibres, which are more likely to be Rho-ROCK mediated.  Furthermore, Src was found 
to regulate the transcriptional activity of FHOD1 since Src inhibition blocked FHOD1 
induced transcription from the SRE (Koka et al. 2005).  Further work looking at the 
cross-talk between FHOD1 and Src revealed that Src activity was required for the 
formation of FHOD1-ROCK-I induced plasma membrane blebs.  Total and active Src 
also localised to plasma membrane blebs where FHOD1 and ROCK-I also co-localised 
(Hannemann et al. 2008).  This same study also found that binding between FHOD1 
and ROCK-I was dependent on Src activity, since binding was reduced in co-
immunoprecipitation experiments using Src inhibitors.  Generally, Src activity is 
required to mediate the transcriptional activity of FHOD1 and to promote its targeting to 
the plasma membrane (Koka et al. 2005; Hannemann et al. 2008).     




The concept of Src interacting with formins is not entirely new.  Src has been shown to 
bind the product of the limb deformity gene (Uetz et al. 1996) and mDia2 (Tominaga et 
al. 2000). Although cross-talk between FHOD1 and Src has been well established, 
binding assays between the two proteins had never previously been performed until 
publication of a study by Iskratsch et al. 2013, which was performed concurrently to the 
present study. The study by Iskratsch et al. 2013b suggested that a direct interaction 
between FHOD1 and the SFKs was required for targeting of FHOD1 to early integrin 
clusters, where FHOD1 was able to participate in actin regulation during cell spreading 
and migration. Binding of the SFKs to the polyproline motif in the FHOD1 FH1 domain 
resulted in phosphorylation of FHOD1 by the SFKs at the Y99 residue and 
consequently increased the interaction between FHOD1 and the SFKs. 
 
The present characterisation explored the possibility of binding between Src and the N-
terminus of FHOD1.  GST pull-down assays suggested that wild-type Src bound the 
FHOD1 N-terminus, whereas the constitutively active and dominant-negative variants 
of Src did not. We also demonstrated that binding between FHOD1 and wild-type Src 
was not mediated by the GFP tag on Src or the GST tag on FHOD1. However, in the 
absence of a positive binding control for the constitutively active and dominant-negative 
Src mutants, we were unable to conclude with certainty that they did not bind the 
FHOD1 N-terminus.  
 
Iskratsch et al. 2013b demonstrated that the polyproline motifs in the FHOD1 FH1 
domain were required for the SFKs to be co-immunoprecipitated with FHOD1. Src has 
also been shown to bind the Proline rich FH1 domain of mDia2 (Tominaga et al. 2000). 
However, the present experiments suggested that wild-type Src could bind the FHOD1 
N-terminus in the absence of the FH1 domain. There are a number of possible 
explanations behind this discrepancy. Our GST-tagged N-terminal FHOD1 construct 
retained the conserved YEEI motif in the GBD. This motif, when phosphorylated, 
constitutes a potential homology 2 (domain) (SH2) binding motif (Songyang et al. 1993; 
Iskratsch et al. 2013b). While the work by Iskratsch et al. 2013b suggested that binding 
of the SFKs preceded phosphorylation of the Y99 residue, the interaction between 
FHOD1 and the SFKs increased after phosphorylation of this motif (Iskratsch et al. 
2013b), suggesting some binding of the phosphorylated motif by the SFKs. We did not 
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investigate the phosphorylation status of the FHOD1 N-terminal construct, therefore it 
remains to be seen if phosphorylation of the Y99 residue was promoting any binding 
with wild-type Src. An alternative explanation could be that Src bound the FHOD1 N-
terminus via a region that was not previously addressed.    
 
Another discrepancy with the observed interaction with Src is related to its activation 
status. It is difficult to speculate as to why the wild-type form of Src bound the FHOD1 
N-terminus whereas the constitutively active and dominant-negative forms did not. 
Phosphorylation of the FHOD1 N-terminus by the SFKs enhances the interaction 
between these proteins (Iskratsch et al. 2013b), thereby suggesting that the kinase 
activity of the SFKs is essential in promoting their association. One might therefore 
expect an interaction between the FHOD1 N-terminus and constitutively active Src, but 
this was not the case in the present findings. Therefore the binding noted between 
FHOD1 and wild-type Src might be an extraneous occurrence. Indeed, the binding we 
noted with wild-type Src could have been mediated by the potentially contaminating 
high molecular weight protein species of unclear identity that we resolved in our protein 
preparations for the GST-tagged FHOD1 N-terminal construct. Nevertheless, the 
possibility of a physical interaction between FHOD1 and Src remains and could 




In summary, we assessed possible binding between the FHOD1 N-terminus with a 
number of known regulators of formin and FHOD1 function. The efforts were focused 
on an isoform of FHOD1 that contained the alternatively spliced exons 12-13 as 
previously described for striated muscle (Tojo et al. 2003) and which had not been 
included in previous studies. Although the binding experiments were not conclusive due 
to lack of positive binding controls for most of the putative interactions in question, they 
would suggest that that the constitutively active Rac1, constitutively active Cdc42, 
constitutively active ROCK-I, and wild-type ROCK-II do not bind to the FHOD1 N-
terminus containing the alternatively spliced exons. Furthermore we investigated 
binding between the FHOD1 N-terminus and Src. We found binding between FHOD1 
and wild-type Src but no binding with the constitutively active or dominant-negative 
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variants of Src. However, due to lack of a positive binding control for the constitutively 
active and dominant-negative Src constructs, we are unable to answer whether this 
result is indicative of a lack of interaction with the FHOD1 N-terminus. 
 
5.3.4 Future Directions 
 
In order to draw definitive conclusions from the present binding assays, positive binding 
controls will need to be performed for the experiments suggestive of a lack of binding 
with the FHOD1 N-terminus. This will be essential in order to confirm that the present 
results were not due to a lack of optimisation of the conditions required for binding with 
the target proteins in question.  
 
The potential binding between the FHOD1 N-terminus and Src will particularly have to 
be looked at more closely. It remains to be seen if binding was mediated by background 
phosphorylation of the Y99 residue, by an additional Src binding site, or if the binding 
was altogether an extraneous occurrence. The purity of the GST FHOD1 protein 
preparation must also be determined in order to rule out the possibility of any 
contaminating protein species, which could conceivably have been responsible for 
binding Src. It also remains to be seen if binding is influenced by the activation status of 
Src. This can partly be addressed by repeating the GST pull-downs between FHOD1 
and wild-type Src in the presence of well-established Src inhibitor, PP2. If the binding 
proves to be a plausible occurrence, further verification of the interaction should be 
performed by way of co-immunoprecipitation experiments and co-localisation studies 
using epitope-tagged Src and N-terminal FHOD1 constructs. 
 
In order to gain a more-complete picture of the potential cross-talk between FHOD1 and 
its established regulatory proteins in cardiac muscle, co-expression studies should be 
performed in cultured neonatal rat cardiomyocytes (NRCs). This would allow one to 
study where these proteins potentially interact in heart cells and to see if they have an 
impact on cardiac cytoarchitecture. This is also important to perform for proteins that 
might not directly bind FHOD1 since proteins that do not necessarily interact directly in 
vitro could cross-talk in vivo.   
 





























6. Novel Protein-Protein Interactions 
6.1 Yeast Two-Hybrid Screens with FHOD1 
 
Yeast two-hybrid assays provide a means by which novel protein-protein interactions 
can be screened for.  The functional basis underlying a yeast two-hybrid study is the 
confirmation of an interaction between two proteins via the activation of a reporter gene 
through a transcription factor (Figure 6.1).  The transcription factor is almost invariably 
split into two parts, made up of a DNA binding domain and an activation domain.  The 
‘bait’ protein used to perform the screen is usually tagged with the DNA binding 
domain of the transcription factor.  The ‘prey’ protein is usually tagged with the 
activation domain.  If the bait and prey protein interact this allows for association of the 
two parts of the hybrid transcription factor, resulting in activation of the chosen reporter 
gene.  This system can be used to directly test the interaction between two specified 
proteins or can alternatively be used to perform indiscriminate protein interaction 
screens against entire cDNA libraries.  In this study we performed interaction screens 
against a cDNA library using different portions of FHOD1 (Figure 6.2).  The yeast two-
hybrid platform used in this study utilised the LexA system, a binary transcription factor 
paradigm (Van Criekinge and Beyaert 1999).  LexA is based on a bacterial transcription 
factor that binds specific LexA operator systems to promote gene expression (Yagi et al. 
2010).  The different FHOD1 ‘bait’ constructs were cloned into the pLEXC vector and 
were therefore expressed with the LexA tag after transformation in yeast.  In this 
system, LexA functioned as the DNA binding domain of the hybrid transcription factor.  
The pLEXC vector also expressed the TRP1 gene for selection of transformed yeast 
growing on medium lacking Tryptophan.  The Gal4 activation domain portion of the 
transcription factor was expressed by the pACT2 vector.  Gal4 is a yeast transcriptional 
activator protein that binds upstream activation sequences (UAS) to stimulate gene 
transcription (Gietz 2006; Yagi et al. 2010).  The pACT2 vector also contains the LEU2 
gene which allows for selection of transformed yeast growing on medium lacking 
Leucine.  A human cardiac cDNA library was cloned into the pACT2 vector and was 
used for the novel protein interaction screens.  The FHOD1 bait constructs and the 
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cardiac cDNA library were transformed into the Saccharomyces cerevisiae strain L40.  
The L40 yeast strain contains two LexA inducible reporter genes, HIS3 and LacZ.  The 
HIS3 gene in yeast encodes for the protein Imidazoleglycerol-phosphate dehydratase, 
which is involved in Histidine biosynthesis. The LacZ gene encodes for -galactosidase, 
an enzyme involved in lactose metabolism.  Thus, a protein-protein interaction allowing 
for association of the hybrid transcription factor under the LexA system in L40 yeast 
would permit growth of yeast on medium lacking Histidine (Struhl and Davis 1981) and 
because of the activity of -galactosidase, would also produce blue yeast colonies upon 









Figure 6.1: Schematic Representation of the LexA/Gal4 Yeast Two-Hybrid System.  In 
the LexA/Gal4 yeast two-hybrid system the ‘bait’ protein is tagged with the LexA DNA 
binding domain and the ‘prey’ protein is tagged with the activation domain.  A) In the case of 
an interaction between the ‘bait’ and ‘prey’ protein, association of LexA and Gal4 will result 
in formation of a functional ‘hybrid’ transcription factor.  The LexA DNA binding domain 
binds the appropriate LexA inducible upstream promoter region of the relevant reporter gene.  
The Gal4 activation domain on the ‘bait’ protein participates in the induction of gene 
transcription by recruiting RNA polymerase II.  Thus, transcription of the reporter gene is 
stimulated.  In the illustrated example, transcription is stimulated from the LacZ reporter gene 
resulting in production of -galactosidase.  Upon incubation of yeast with X-gal, -
galactosidase will break down this substrate and result in the formation of blue yeast colonies.  
B) In the case of a lack of interaction (i.e. no binding/association of the bait and prey 
proteins), the LexA DNA binding domain will still bind the appropriate promoter region but 
the unbound Gal4 activation will be unable recruit RNA polymerase II.  Therefore no 
transcription of LacZ will take place, resulting in no -galactosidase.  In this situation, 
treatment with X-gal will result in pale/pink yeast colonies. (Van Criekinge and Beyaert 
1999) 













The purpose of the cDNA library screens was to identify novel interacting partners of 
FHOD1.  Many actin regulatory proteins interact with other factors that modify or 
enhance their activity in some way.  For instance N-WASP and Arp2/3 interact to 
enhance nucleation of actin filaments (Rohatgi et al. 1999; Suetsugu et al. 2001).  
Previous studies have performed yeast two-hybrid screens with different portions of 
FHOD1 and identified  a variety of interacting proteins. Some of these included protein 
kinase C binding protein 1 (PRKCBP1), cyclophilin B, an isoform of WASP-interacting 
SH3-domain protein/diaphanous-interacting protein 1 (WISH/DIP1), named WISH-B 
(Westendorf and Koka 2004), insulin-responsive aminopeptidase (IRAP), profilinIIa 
(Tojo et al. 2003), Cyclic GMP-dependent protein kinase I (PKGI) (Wang et al. 2004), 
and nesprin-2G (Kutscheidt et al. 2014).  These interactions have shed light onto some 
of the cellular functions of FHOD1.  While a number of FHOD1’s interacting partners 
have been mapped to interact with the more N-terminal part of the protein, the majority 
of studies have focused on interactions in the more C-terminal part of FHOD1. Formins 
are most divergent within their N-termini (Schulte et al. 2008).  It has been speculated 
that the N-termini of formins may confer targeting of formins to distinct subcellular 
compartments and this may be mediated through unique protein interactions.  We 
Figure 6.2: Map of FHOD1 Bait Constructs.  Schematic representations of the portions of 
FHOD1 used as ‘bait’ in the yeast two-hybrid assays.  Fragments of FHOD1 are shown with 
respect to A) the full length long variant of FHOD1, amino acids 1 to 1,1191. B) The FHOD1 
GBD-DID bait construct, spanned from amino acids 1 to 340. C) An internal portion of 
FHOD1 after the DID and stopped in the N-terminal portion of the FH2 domain was used as 
bait and spanned from amino acids 340 to 585. GBD, GTPase binding domain; DID, 
diaphanous inhibitory domain; FH, formin homology; DAD, diaphanous autoregulatory 
domain; E12-13, the alternatively spliced exons 12-13 found in the long FHOD1 variant. 
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therefore performed cDNA library screens via a yeast two-hybrid system with two 
different FHOD1 constructs that together covered the entirety of the FHOD1 N-
terminus. 
6.2 cDNA Library Screen with FHOD1 GBD-DID [1-340] 
 
The first FHOD1 bait construct comprised of the GTPase binding domain (GBD) and 
the Diaphanous inhibitory domain (DID) and spanned from amino acids 1 to 340 
(Figure 6.2 B).  Prior to performing the library screen, an expression test was done with 
the FHOD1 GBD-DID construct.  The construct was transformed into yeast, which 
were subsequently grown in culture and lysed.  Expression of the GBD-DID construct 
was checked by looking at the size of the protein product by Western blotting (Figure 
6.3).  Western blotting revealed a discrete band between the 78 kDa and the 54 kDa 
markers.  The predicted molecular weight of the FHOD1 GBD-DID was calculated to 
be 37 kDa.  The combined weight of the bait protein and LexA equalled 61 kDa.  
Therefore the band visualised by Western blotting most likely corresponded to the bait 
protein and LexA tag combined. However, an equally prominent band was seen running 
near the 27 kDa marker, which could not be accounted for. This may have represented a 
contaminating protein species, which could have potentially compromised the results 
from the screen performed in yeast. Other faint bands were also noted and possibly 
indicated some degradation of the bait protein. Alternatively, the extra bands may have 
represented a non-specific background signal produced by the anti-LexA antibody. In 
order to test this, the expression of the bait construct would need to be compared to 
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The FHOD1 GBD-DID construct was transformed into yeast with the pACT2 human 
cardiac cDNA library, resulting in a good transformation efficiency on SD-agar medium 
lacking Leucine, Tryptophan, and Histidine (-LWH) and on medium lacking Leucine 
and Tryptophan (-LW).  Initially, 200 clones were picked and were more stringently 
screened by checking for HIS3 and LacZ reporter gene activity (Results not shown).  25 
clones were subsequently selected for propagation.  The plasmids were isolated from 
the cultured yeast and then transformed into bacteria.  22 of the isolated plasmids were 
efficiently transformed into bacteria and grew well on plates containing ampicillin, to 
select for the pACT2 prey plasmids.  The prey construct plasmids were then isolated 
from the cultured bacteria and the clones were subsequently identified by DNA 













Figure 6.3: Validation of the FHOD1 GBD-
DID [1-340] Bait Construct.  Western blot 
showing expression of the FHOD1 GBD-DID 
bait protein [1-340].  The FHOD1 GBD-DID 
pLEXC bait construct was transformed into 
L40 yeast, which were then grown in culture 
and lysed.  Protein lysates were resolved on 
SDS-PAGE gels with subsequent visualisation 
by Western blotting.  The signal for the bait 
protein was visualised using the LexA 
antibody. N=1. 













6.2.1 Novel Interaction Partners with FHOD1 GBD-DID [1-340] 
 
The cDNA library screen performed with the FHOD1 GBD-DID construct yielded nine 
unique potential interacting partners (Table 6.1).  After sequencing, these interacting 
partners were found to be in the correct frame in the pACT2 vector and their sequence 
corresponded to the coding sequence of a specific gene.  The screen picked up a number 
of transcription factors: zinc finger and BTB domain containing 16 (ZBTB16), 
myeloid/lymphoid or mixed-lineage leukaemia protein (MLL), and hairy/enhancer-of-
split related with YRPW motif 2 (HEY2). Other proteins included the nuclear histone 
binding protein HIRIP3, the cell cycle regulator mono-methylase SETD8, and the 






Homo sapiens zinc finger and BTB domain 
containing 16 (ZBTB16),  
transcript variant 2 or 1 




Homo sapiens zinc finger and BTB domain 
containing 16 (ZBTB16),  
transcript variant 2 or 1 
In Frame Last 10 amino 
acids incorrect 
NM_013241.2 Homo sapiens formin homology 2 domain 
containing 1 (FHOD1) 
In Frame  
NM_001018011
.1 
Homo sapiens zinc finger and BTB domain 
containing 16 (ZBTB16),  
transcript variant 2 
In Frame Last 30 amino 
acids incorrect 
NM_004747.3 Homo sapiens discs, large homolog 5 
(Drosophila) (DLG5) 
In Frame  
NM_025135.2 Homo sapiens formin homology 2 domain 
containing 3 (FHOD3) 
In Frame  
NM_001197104
.1 
Homo sapiens myeloid/lymphoid or mixed-
lineage leukemia (trithorax 
homolog, Drosophila) (MLL), transcript 
variant 1 or 2 




Homo sapiens proteoglycan 4 (PRG4), 
transcript variant D (C,B,A) 
In Frame Last 10 amino 
acids incorrect 
NM_020382.3 Homo sapiens SET domain containing 
(lysine methyltransferase) 8 (SETD8) 
In Frame  
NM_003609.3 Homo sapiens HIRA interacting protein 3 
(HIRIP3) 
In Frame  
NM_012259.2 Homo sapiens hairy/enhancer-of-split 
related with YRPW motif 2 (HEY2) 
In Frame Last 10 amino 
acids incorrect 
 
Table 6.1: Results of cDNA Library Screen with FHOD1 GBD-DID [1-340].  The 
appropriate isolated yeast plasmid clones were transformed into bacteria prior to another 
round of plasmid isolation and identification by sequencing.  Table lists the NCBI accession 
number, name of gene found for protein in question, reading frame of isolated pACT2 prey 
construct, and any additional comments. Highlighted entries represent potential interacting 
partners that were further investigated. 
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proteoglycan PRG4. Although the potential interactions between FHOD1 and these 
proteins may have posed crucial biological implications, they would have been beyond 
the scope of this study namely due to the fact that they were mostly transcription 
factors. Although, FHOD1 has been found to possess transcriptional activity 
(Westendorf 2001), the mechanism by which it stimulated transcription from elements 
like the SRE was more likely due to having altered the cellular ratio of G-actin to F-
actin (Staus et al. 2011a), rather than directly associating with a transcription factor.  
Furthermore, FHOD1 is not necessarily a nuclear protein; therefore association with 
transcription factors in the nucleus would be unlikely.  Transcription factor proteins 
have been implicated in producing false positives in yeast two-hybrid screens since they 
often induce a high degree of auto-activation (Gietz 2006; Bruckner et al. 2009).  Zinc 
finger proteins are also reportedly notorious for their stickiness (Schmeichel and 
Beckerle 1994) and could create false hits in screens such as the present one.  PRG4 
was not further investigated due to lack of expression in the myocardium. 
 
The screen did however yield three potentially interesting interacting partners.  The 
cDNA library screen with the FHOD1 GBD-DID region revealed a potential interaction 
with another region of FHOD1.  The portion of FHOD1 identified by the screen 
corresponded to the C-terminal part of FHOD1, between amino acids 1018 to 1091 of 
the longer FHOD1 variant.  This region was comprised of part of the core FH2 domain 
and the DAD.  This interacting portion of FHOD1 that was picked up by sequencing 
may have represented the region that participates in the auto-inhibitory autoregulatory 
interaction between the N-terminus and the C-terminus of FHOD1 (Schonichen et al. 
2006).  Although not entirely novel, this interaction has never been previously picked 
up by a cDNA library screen using a yeast two-hybrid system.  
 
The screen also identified the closest relative of FHOD1, FHOD3.  Results from the 
screen indicated that FHOD1 GBD-DID interacted with amino acids 969 to 1253 of 
FHOD3.  This portion of FHOD3 corresponded to a region just upstream of the FH1 
domain and spanned towards the middle of the core FH2 domain.  The potential 
interaction between FHOD1 and FHOD3 may have been important from the perspective 
that the proteins could heterodimerise.  This would not be the first time formins have 
been suggested to work together since mDia1 and mDia2 have also been found to 
heterodimerise (Copeland et al. 2007).  FHOD3 expression has been confirmed in the 
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heart (Kanaya et al. 2005; Taniguchi et al. 2009) where it was found to participate in 
myofibrillar maintenance (Iskratsch et al. 2010) therefore an FHOD1-FHOD3 
interaction could pose noteworthy biological implications. 
 
The final potential interacting partner that was found in this screen was Discs large 
homolog 5 (DLG5).  DLG5 is a member of the membrane associated gyanylate kinases 
(MAGUKs) (Shah et al. 2002), which are thought to act as scaffold proteins in signal 
transduction networks (Nakamura et al. 1998).  The structure of DLG5 is characterized 
by an N-terminal coiled-coil-like domain, as well as four PDZ domains, a Src homology 
(SH) 3 domain, and a gyanylate kinase domain, which are conserved among the 
MAGUKs (Wakabayashi et al. 2003). The sequencing results from the screen with 
FHOD1 revealed that FHOD1 GBD-DID was interacting with the C-terminal part of the 
DLG5 protein, namely from amino acids 1362 to 1568. This region of DLG5 comprises 
a PDZ and a SH3 domain. Such modular domains have been known to contribute to 
protein interactions (Weng et al. 1994; Lee and Zheng 2010), therefore it is interesting 
that this portion of DLG5 surfaced in our cDNA library screen.  During initial 
characterization, the DLG5 gene was found to be expressed in both skeletal and cardiac 
muscle (Shah et al. 2002).  Apart from its expression profile in muscle, the possible 
interaction with DLG5 and FHOD1 may have been potentially interesting from the 
perspective that DLG5 may be a cytoskeletal regulator.  DLG5 has been proposed to 
mediate membrane trafficking of cadherins (Nechiporuk et al. 2007) and regulate 
expression of E-cadherin (Sezaki et al. 2012).  DLG5 has also been reported to interact 
with the microtubule binding protein cornetto (Bulgheresi et al. 2001; Giot et al. 2003). 
More-notably yet, DLG5 has been suggested a scaffolding role by interacting with 
vinexin and -catenin to form a ternary complex, which may play a role at cell-cell 
contacts (Wakabayashi et al. 2003).    
 
From the multiple potential interacting partners that came up in our screen, FHOD1, 
FHOD3, and DLG5 particularly caught our attention due to their expression in cardiac 
muscle and their reported roles as cytoskeletal regulators.  These potential interactions 
were further investigated by yeast two-hybrid assay analysis with the isolated prey 
plasmids. 
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6.2.2 Yeast Two-Hybrid assays with FHOD1 GBD-DID [1-340] 
 
Three of the interactions that came up in the screen with FHOD1 GBD-DID were 
selected for further investigation by performing additional yeast two-hybrid assays 
(Figure 6.4).  Yeast two-hybrid assays using the isolated prey plasmids allow one to 
confirm an interaction between two proteins found in an initial screen.  This was 
achieved by re-transforming the plasmid constructs isolated from the yeast and 
performing the gene reporter assays initially used for the library screen.  In these yeast 
two-hybrid assays, the FHOD1 GBD-DID pLEXC bait construct was co-transformed 
with the FHOD1, FHOD3, and DLG5 pACT2 prey constructs.  To test the specificity of 
the interactions for the bait construct, the prey constructs were also co-transformed with 
the empty pLEXC vector.  An additional control for auto-activation was performed by 
co-transforming the FHOD1 GBD-DID bait construct and the empty bait (pLEXC) with 
the prey plasmid (pACT2).  As expected, all of the combinations of co-transformations 
grew on SD-agar –LW (Figure 6.4 A).  A -galactosidase assay was performed to test 
for activation of the LacZ reporter gene.  Strong interactions were confirmed by bright 
blue yeast colonies co-transformed with the FHOD1 GBD-DID bait along with the 
FHOD1 and FHOD3 prey constructs (Figure 6.4 B).  Weak LacZ reporter gene activity 
was noted in yeast colonies co-transformed with the FHOD1 GBD-DID bait construct 
and the DLG5 prey construct, which was evidenced by very faint blue yeast colonies.  
In order to test for HIS3 reporter gene activity the co-transformed yeast were grown on 
SD-agar –LWH (Figure 6.4 C).  Colonies co-transformed with the FHOD1 GBD-DID 
bait and the three potential interacting prey constructs all grew on –LWH medium.  To 
test the strength of the interactions, co-transformed yeast were also grown on SD-agar –
LWH with 2.5mM 3-amino-1,2,4-triazole (3AT) (Figure 6.4 D). 3AT is a competitive 
inhibitor of the HIS3 gene product, imidazoleglycerol-phosphate dehydratase and can 
therefore be used to measure the strength of an interaction (Joung et al. 2000).  The 
yeast colonies co-transformed with the FHOD1 GBD-DID bait construct and all of the 
potential interacting prey constructs all grew on SD-agar –LWH + 3AT plates, 
indicating that the interactions were potentially strong. However, this was only 
performed with one concentration of 3AT. Future experiments should be performed 
with increasing concentrations of 3AT to further test the strength of the potential 
interactions. Furthermore, these interactions should have been tested in the context of 
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controls representative of previously reported positive and negative interactions in order 
to confirm the validity of the method. 
    
Nevertheless, the yeast two-hybrid assay indicated that the potential interactions 
between the FHOD1 GBD-DID bait and the relevant preys were specific since the prey 
constructs did not stimulate reporter gene activity when co-transformed with the empty 
bait plasmid.  No reporter gene activity was noted in colonies co-transformed with the 
FHOD1 GBD-DID bait construct and the empty pACT2 prey plasmid, therefore 
indicating that no auto-activation by the bait construct was present.  In this instance, the 
yeast two-hybrid assay supported the notion of an interaction between the FHOD1 
GBD-DID bait and the FHOD1 and FHOD3 prey.  Regarding the interaction between 
the FHOD1 GBD-DID bait and DLG5, an interaction between the proteins was either 











































Figure 6.4: Yeast Two-Hybrid Assay with the FHOD1 GBD-DID [1-340] Bait Construct.  
Photographs of co-transformed L40 yeast colonies in different reporter gene assays.  The 
FHOD1 GBD-DID bait was co-transformed with the three candidate prey interacting partners 
found in the initial screen.  The three prey proteins included FHOD1, FHOD3, and DLG5.  
Co-transformation between the prey proteins and the empty bait vector (pLEXC) were 
performed to ensure that the interactions were specific for FHOD1 GBD-DID and not the 
LexA tag.  Co-transformation of the FHOD1 GBD-DID bait and the empty pACT2 vector was 
performed to screen for autoactivation by the bait construct.  A) Yeast were grown on SD-agar 
–LW to ensure the co-transformations had been performed successfully. B) Yeast were grown 
on nitrocellulose membranes placed on SD-agar –LW medium prior to incubation with X-gal 
for a -galactosidase assay to test for LacZ reporter gene activity.  Yeast were grown on SD-
agar –LWH medium in the presence of C) no 3AT or D) 2.5mM 3AT to test for HIS3 reporter 
gene activity.  Bait, FHOD1 GBD-DID [1-340]; pLEX, empty pLEXC plasmid; pACT, empty 
pACT2 plasmid; L, Leucine; W, Tryptophan; H, Histidine; 3AT, 3-amino-1,2,4-triazole. N=2. 
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6.2.3 Validation of GST-tagged FHOD1 GBD-DID Construct 
 
The yeast two-hybrid assays highlighted a number of potential interactions with the 
FHOD1 GBD-DID region. In order to see if these interactions were the result of direct 
binding between the bait and prey proteins, we performed binding assays via GST pull-
down assays. For this purpose we used a GST-tagged FHOD1 GBD-DID construct. 
The presently employed GST-tagged construct spanned from amino acids 1 to 340.  
This construct was comprised of the GBD and DID (Figure 6.5 A). Prior to 
commencing the GST pull-down studies, levels of expression and the size of the GST-
tagged FHOD1 GBD-DID construct were checked by SDS-PAGE followed by Western 
blotting. The FHOD1 GBD-DID fragment without the GST tag had a predicted 
molecular weight of approximately 38kDa (Figure 6.5 B). The combined weight of the 
GST tag and the GBD-DID region was approximately 64kDa.    
 
Western blots probed with the anti-GST antibody revealed that the FHOD N-terminal 
GBD-DID construct was expressed at the correct size and at sufficient levels for 
biochemical experiments to be performed, although some degradation was present, as 
evidenced by faint lower running bands (Figure 6.5 C). Relative levels of loading 
between unmodified GST protein and GST-tagged FHOD1 were visually gauged on 
gels and subsequently adjusted to reflect comparable levels of protein for GST pull-
down assays (Figure 5.1 D). 
 
For the GST pull-down assay COS-1 cells were used as a means to overexpress the 
target proteins due to the poor transfection efficiency we obtained with neonatal rat 
cardiomyocytes (NRCs). The use of COS-1 cells represented a drawback of this study 
since proteins could undergo diverse post-translational modifications in different cell 
types. Therefore, the present binding assays are not entirely representative of what could 






























6.2.4 GST Pull-downs with FHOD1 GBD-DID [1-340] 
 
Results from the yeast two-hybrid assay indicated that FHOD1 GBD-DID interacted 
with amino acids 969 to 1253 of FHOD3. This portion of FHOD3 corresponded to a 
region just upstream of the FH1 domain and spanned towards the middle of the core 
FH2 domain. We assessed binding between the FHOD1 GBD-DID region and two 
fragments of FHOD3 that fell within the portion of FHOD3 identified in the screen: the 
Figure 6.5: Expression Test for GST-FHOD1 GBD-DID [1-340].  A) The 
GST-tagged GBD-DID fragment of FHOD1 spanning from amino acid 1 to 340 
was presently employed to validate the potential interactions found in the yeast 
two-hybrid assay using the FHOD1 GBD-DID fragment. B) The FHOD1 GBD-
DID fragment had an expected molecular weight of 38kDa. Combined with the 
molecular weight of the GST tag (26kDa), the GST-tagged FHOD1 construct has 
an expected molecular weight of 64kDa. C) The GST-tagged FHOD1 construct 
and the GST tag alone were purified from bacterial lysates, resolved by SDS-
PAGE, and visualised by enhanced chemiluminescence on Western blots 
incubated with the anti-GST antibody. This was performed to gauge the relative 
size and expression levels of the protein. D) Representative blot from GST pull-
down assays that shows the relative loading of the GST tag in the negative 
control lanes and of the GST-tagged FHOD1 construct in the lanes testing for an 
interaction. Western blot was probed with the anti-GST antibody to visualise 
unmodified GST and the GST-tagged FHOD1 GBD-DID fragment. GST, 
glutathione S-transferase. N=2. 
  Novel Protein-Protein Interactions 
302 
 
FH1 domain [941-1079] and the C-terminus of the short FHOD3 variant comprised of 
the FH2 domain and DAD [1065-1622]. This was performed in the hopes of mapping 
the interaction to a specific portion of FHOD3. The GST-tagged FHOD1 GBD-DID 
construct pulled down both the GFP-tagged FHOD3 C-terminus (Figure 6.6, A) and the 
GFP-tagged FHOD3 FH1 domain (Figure 6.6, B), as evidenced by a signal in the pellet 
portion of the pull-down assays. As a negative control, a pull-down was performed 
between the GST-tagged FHOD1 GBD-DID fragment and the GFP-tagged FHOD1 
DAD construct (Figure 6.6, C). As expected, no binding was noted between these 
portions of FHOD1, since it has been previously shown that the DAD is required for 
binding between the FHOD1 N and C-termini (Westendorf 2001). The lack of binding 
in the negative control experiment can also be taken as evidence that the positive 
interactions with FHOD3 were not mediated by the GFP tag, since the FHOD1 DAD 
construct was also GFP-tagged. A pull-down with the HA-tagged fragment of DLG5 
and GST-tagged FHOD1 GBD-DID suggested a lack of binding between these proteins. 
However, in the absence of a positive binding control for the DLG5 fragment, we were 
not able to conclude with certainty that the negative interaction was not due to 
insufficient optimisation of the conditions for the present binding assay. While we 
sought to validate the interaction with the FHOD1 C-terminus found in the library 
screen, the currently available HA-tagged FHOD1 C-terminal construct [641-1191] was 
not expressed at sufficient levels in COS-1 cells for GST pull-down assays to be 























Overall, a cDNA library screen performed in yeast with the FHOD1 GBD-DID region 
highlighted FHOD3 and DLG5 as possible interacting partners of FHOD1. Yeast two-
hybrid assays hinted at a potentially strong interaction between FHOD1 and FHOD3. 
Binding studies by way of GST pull-down assays suggested that FHOD1 bound the 
FH1 domain and the C-terminus of FHOD3. However, binding to multiple regions on 
FHOD3 may have indicated that the interaction was not specific, although this can only 
be confirmed by further testing via co-immunoprecipitation assays and co-localisation 
studies. Nevertheless, the possible FHOD1-FHOD3 binding interaction may have 
indicated the potential for these two formins to heterodimerise, as has been shown for 
other formins (Copeland et al. 2007). The possibility of an interaction between FHOD1 
and DLG5 was seemingly less likely than that for FHOD1 and FHOD3. Yeast two-
Figure 6.6: Assessing the Interaction between the FHOD1 GBD-DID fragment 
and Potential Interacting Partners.  Western blots depicting the results from GST 
pull-down assays.  The GST-tagged FHOD1 GBD-DID fragment [1-340] was used to 
pull down A) the GFP-tagged C-terminus of the short variant of FHOD3 [1065-
1622], B) the GFP-tagged FH1 domain of FHOD3 [941-1079], and C) the HA-tagged 
DLG-5 fragment [1395-1919] found in the library screen. The target proteins were 
overexpressed in COS-1 cell.  D) A negative control GST pull-down assay was 
performed using the GFP-tagged FHOD1 DAD construct. Blots were probed with 
anti-GFP and anti-HA antibodies to visualise GFP-tagged and HA-tagged proteins, 
respectively. GST, glutathione S-transferase; HA, haemagglutinin; FH, formin 
homology. N=2. 
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hybrid analysis provided less convincing evidence in support of an interaction between 
FHOD1 and DLG5. Furthermore, GST pull-down assays suggested that the FHOD1 
GBD-DID region did not bind the DLG5 fragment found in the cDNA library screen. 
However, in the absence of a binding control for the DLG5 fragment we could not 
conclude with certainty that the proteins did not bind.   
 
6.3 cDNA Library Screen with FHOD1 [340-585] 
 
Having covered the first part of the FHOD1 N-terminus (GBD-DID), another cDNA 
library screen was performed in yeast with a second part of the FHOD1 N-terminus.  
The second FHOD1 bait construct began at the end of the DID and ended in the region 
of the FH1 domain just upstream of the polyproline motifs.  This construct spanned 
from amino acids 340 to 585 (Figure 6.2 C).  This construct represented an internal 
fragment of the N-terminal half of the long variant of FHOD1, containing the 
alternatively spliced exons, exons 12 and 13.  Prior to performing the cDNA library 
screen, an expression test was done with the FHOD1 [340-585] construct.  The 
construct was transformed into yeast, which were subsequently grown in culture and 
lysed.  Expression of the FHOD1 [340-585] construct was checked by looking at the 
size of the protein product by Western blotting (Figure 6.7).  Western blotting revealed 
multiple bands running below the 78 kDa marker and around the level of the 54 kDa 
marker.  The predicted molecular weight of FHOD1 [340-585] was calculated to be 25 
kDa.  The molecular weight of the LexA tag is approximately 24 kDa.  The combined 
weight of the bait protein and LexA equalled 49 kDa.  A strong band was seen just 
below the 54 kDa marker and may have corresponded to FHOD1 [340-585].  However, 
in the presence of multiple bands of similar intensity, we could not definitively identify 
the band which corresponded to FHOD1. With the low probability that oligomerisation 
of the bait protein had occurred in the presence of denaturing conditions, the bands of 
unidentified origin may have represented contaminating protein species. If this was 
indeed the case, the validity of the present cDNA library screen may have been severely 
compromised, since potentially contaminating protein species could have mediated the 
interactions detected in the screen. An alternative explanation for the extra bands could 
be that the higher band actually represented the bait construct, possibly migrating at a 
higher molecular weight than expected, and the lower running bands represented 
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degradation products. This theory could be tested by repeating the experiment by 
including protease inhibitor in the yeast lysis buffer. The lysates could be tested for 
reactivity against an FHOD1 antibody to investigate the identity of the bands. 
Alternatively, the extra bands may have represented a non-specific background signal 
produced by the anti-LexA antibody. In order to test this, the expression of the bait 
construct would need to be compared to untransfected yeast lysates.   Nevertheless, with 
these caveats in mind we performed a cDNA library screen with the FHOD1 [340-585] 
bait construct.  
 
           
 
 
FHOD1 [340-585] was transformed into yeast with the human cardiac cDNA library, 
resulting in a good transformation efficiency on SD-agar medium lacking Leucine, 
Tryptophan, and Histidine (-LWH) and on medium lacking Leucine and Tryptophan (-
LW).  Initially, 50 clones were picked and were more stringently screened by checking 
for HIS3 and LacZ reporter gene activity (Results not shown).  32 clones were 
subsequently selected for propagation.  The plasmids were isolated from the cultured 
yeast and then transformed into bacteria.  Only 19 of the isolated plasmids were 
efficiently transformed into bacteria and grew well on plates containing ampicillin, to 
select for the pACT2 prey plasmids.  The prey construct plasmids were then isolated 
from the cultured bacteria and clones were subsequently identified by DNA sequencing 




Figure 6.7: Validation of the FHOD1 [340-
585] Bait Construct.  Western blot showing 
expression of the FHOD1 [340-585] bait 
protein.  The FHOD1 [340-585] pLEXC bait 
construct was transformed into L40 yeast, 
which were then grown in culture and lysed.  
Protein lysates were resolved on SDS-PAGE 
gels with subsequent visualisation by 
Western blotting.  The signal for the bait 
protein was visualised using the LexA 
antibody. N=1 











6.3.1 Novel Interaction Partners with FHOD1 [340-585] 
 
In comparison to the previous screen, the screen performed with the FHOD1 [340-585] 
construct revealed fewer potential interacting partners and a higher number of 
identifications corresponding to genomic DNA.  There were, however, four unique 
interacting partners that were in frame and corresponded to the coding sequence of a 
specific gene.  One of the potential interacting partners identified in the screen was the 
DNA binding protein X-ray repair complementing defective repair in Chinese hamster 
cells 6 (XRCC6). The screen also identified two transcription factors:  FLT3-interacting 
zinc finger 1 (FIZ1) and SRY (sex determining region Y)-box 10 (SOX10). Ku70, 
FIZ1, and SOX10 were not further investigated due to their roles as DNA binding 
proteins and transcription factors for the reasons outlined above.  
 
The other protein that came up in the screen was Nebulin-related anchoring protein 
(NRAP), transcript variant 1.  NRAP is an acting binding protein that was found to be 
exclusively expressed in striated muscle (Luo et al. 1997a; Luo et al. 1997b). It was 
found to be associated with the terminal ends of myofibrils and localised to the 
myotendinous junction in skeletal muscle and the intercalated disk in cardiac muscle 
Table 6.2: Results of cDNA Library Screen with FHOD1 [340-585].  The appropriate 
isolated yeast plasmid clones were transformed into bacteria prior to another round of plasmid 
isolation and identification by sequencing.  Table lists the NCBI accession number, name of 
gene found for protein in question, reading frame of isolated pACT2 prey construct, and any 
additional comments. Highlighted entries represent potential interacting partners that were 
further investigated. 
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(Zhang et al. 2001).    Furthermore, NRAP has been shown to play a role in myofibril 
assembly (Carroll et al. 2001; Carroll et al. 2004; Dhume et al. 2006).  Due to the 
reported roles of NRAP in myofibril assembly and a shared localisation at the 
intercalated disk, the potential interaction between FHOD1 and NRAP was further 
investigated. 
6.3.2 Binding between FHOD1 and NRAP 
 
With a number of NRAP fragment constructs available, GST pull-down assays were 
performed to see if there was any direct binding between FHOD1 and NRAP.  NRAP is 
composed of a LIM domain, a linker region (termed r01-r10), and 5 nebulin like super 
repeats (SRs) (Luo et al. 1997a; Gehmlich et al. 2004).  The following T7-tagged NRAP 
constructs were used: a short variant of SR5 (SR5-6); a long variant of SR5 (SR5-7); 
SR4; r01-r10; LIM domain (Figure 6.8).  The GST-tagged N-terminal fragment of 
FHOD1 was used for pull-down studies.  This construct spanned from amino acids 1 to 
513 and included the alternatively spliced exons, which were also included for the yeast 










GST pull-down assays were performed with the N-terminal fragment of FHOD1 and the 
available T7-tagged NRAP fragments (Figure 6.9).  Obtaining reasonable expression 
levels for the NRAP constructs was sometimes an issue during pull-down studies.  The 
LIM domain in particular achieved poor expression levels and was difficult to detect via 
Western blotting, therefore it was excluded from this study (results not shown).  Pull-
downs suggested the GST-tagged N-terminal fragment of FHOD1 was able to bind the 
T7-tagged SR5-6 construct when overexpressed in the lysates of COS-1 cells, as 
evidenced by a faint band detected in the pellet portion of the pull-down (Figure 6.9 A).  
The faint band may be indicative of a weak interaction between SR5-6 and FHOD1.  
Binding between FHOD1 and SR5-6 was consistently seen upon repetition of the pull-
Figure 6.8: Domain Map of NRAP.  Schematic representation of NRAP and its 
domains. SR, super repeats. 
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down.  Surprisingly, the GST-tagged FHOD1 N-terminal fragment was unable to pull 
down the T7-tagged SR5-7 fragment (Figure 6.9 B). This fragment represents a longer 
version of SR5-6 therefore it theoretically should have bound FHOD1. However, there 
is the possibility that the additional amino acid stretch in SR5-7 may have masked the 
interaction domain. The FHOD1 construct was also unable to pull down the SR4 
(Figure 6.9 C), and r01-r10 (Figure 6.9 D) fragments, as there was no detectable signals 
in the pellet portions of the pull-down assays. Therefore, it seemed that FHOD1 
preferentially bound the SR5-6 fragment. However, we could not conclude a lack of 
binding with the other NRAP fragments in the absence of a positive control for each 
fragment. Therefore we could not rule out that the absence of binding was due to lack of 
optimisation of the conditions used for the pull-downs. Furthermore, there were 
concerns about the validity of the protein preparations of the GST-tagged FHOD1 [1-
513] construct, which contained a higher molecular weight band of unidentified origin 

















6.3.3 Yeast Two-Hybrid Assays with FHOD1 [340-585] 
 
With the SR5 repeat a possible candidate for binding FHOD1, the potential interaction 
between FHOD1 and NRAP was further investigated by performing yeast two-hybrid 
assays (Figure 6.10).  The SR5-6 and SR5-7 constructs were obtained in the pACT2 
vector and co-transformed with the FHOD1 [340-585] bait construct in yeast to test for 
reporter gene activation.  The SR5 constructs were also co-transformed with the empty 
pLEXC plasmid to check the specificity of the interaction.  The FHOD1 [340-585] bait 
was also co-transformed with the empty pACT2 plasmid to check for auto-activation of 
reporter gene activity by the bait construct.  No activation of reporter gene activity was 
previously noted in yeast co-transformed with the empty pLEXC and empty pACT2 
plasmids (Figure 6.4).  As expected all the combinations of construct co-transformations 
in yeast grew on SD-agar –LW medium (Figure 6.10 A).  A -galactosidase assay to 
Figure 6.9: Binding between FHOD1 and NRAP.  Western blots depicting the results 
from GST pull-down assays.  The GST-tagged N-terminus of FHOD1 [1-513] was used to 
pull down the following T7-tagged NRAP fragments: A) SR5-6; B) SR5-7; C) SR4; D) 
r01-r10.  Blots were probed with anti-T7 antibody to visualise the T7-tagged NRAP 
constructs. N=3. 
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test LacZ reporter gene activity confirmed positive interactions between the FHOD1 
[340-585] bait and both SR5 constructs, as evidenced by blue yeast colonies (Figure 
6.10 B).  However, LacZ reporter gene activation was also seen in yeast co-transformed 
with the FHOD1 [340-585] bait and the empty pACT2 plasmid, which indicated that 
expression of the bait construct may have led to auto-activation of the reporter gene.  
HIS3 reporter gene activity was tested by growing the co-transformed yeast on SD-agar 
–LWH medium (Figure 6.10 C).  In this instance, yeast co-transformed with the 
FHOD1 [340-585] bait and the SR5-6 construct exhibited the most growth.  Notable 
growth was noted in yeast co-transformed with the FHOD1 [340-585] bait and the SR5-
7 construct.  A degree of auto-activation by the FHOD1 [340-585] bait was again noted 
in this assay as there was some growth in yeast co-transformed with the FHOD1 [340-
585] bait and the empty pACT2 plasmid.   The strength of the observed interactions was 
then tested by growing yeast on SD-agar –LWH + 2.5 mM 3AT (Figure 6.10 D).  Upon 
3AT treatment, the auto-activation previously observed with the FHOD1 [340-585] bait 
and the empty pACT2 plasmid disappeared.  Growth in yeast colonies co-transformed 
with the FHOD1 [340-585] bait and the SR5-7 construct was significantly reduced to 
almost undetectable levels.  Yeast co-transformed with the FHOD1 [340-585] bait and 
the SR5-6 construct were able to grow well on SD-agar + 2.5mM 3AT plates, therefore 
indicated a strong interaction between these two bait and prey protein fragments.  Co-
transformations of the SR5 constructs and the empty pLEXC vector yielded no reporter 
gene activity for LacZ (Figure 6.7 B) or HIS3 (Figure 6.7 C) and thus indicated that the 
interactions were specific for the FHOD1 [340-585] bait.  In line with the results seen in 
the GST pull-down assays, forced yeast two-hybrid analysis indicated that the FHOD1 
[340-585] interaction with the SR5-6 fragment of NRAP was stronger than the 
interaction with the SR5-7 fragment, although these data were somewhat inconclusive 
due to the presence of some autoactivation by the FHOD1 bait construct. Furthermore, 
these interactions should have been tested in the context of controls representative of 
























Overall, due to issues relating to the validity of the FHOD1 [340-585] bait construct and 
the purity of the GST-FHOD1 [1-513] protein preparation, we were unable to conclude 
with certainty that FHOD1 and NRAP represented bona fide interacting partners. While 
the potential of an interaction between FHOD1 and NRAP may pose interesting 
biological implications, further biochemical and molecular biology experiments will be 
required to validate this. Nevertheless, in the hopes of seeking further validation, we 
performed co-localisation studies by staining for FHOD1 and NRAP in mouse heart 
sections. 
 
Figure 6.10: Yeast Two-Hybrid Assay with the FHOD1 [340-585] Bait Construct.  
Photographs of co-transformed L40 yeast colonies in different reporter assays.  The FHOD1 
[340-585] bait was co-transformed with the prey SR5-6 and SR5-7 pACT2 fragments of 
NRAP.  Co-transformation between the prey proteins and the empty bait vector (pLEXC) 
were performed to ensure that the interactions were specific for FHOD1 [340-585]and not the 
LexA tag.  Co-transformation of the FHOD1 [340-585] bait and the empty pACT2 vector was 
performed to screen for autoactivation by the bait construct.  A) Yeast were grown on SD-
agar –LW to ensure the co-transformations had been performed successfully. B) Yeast were 
grown on nitrocellulose membranes placed on SD-agar –LW medium prior to incubation with 
X-gal for a -galactosidase assay to test for LacZ reporter gene activity.  Yeast were grown on 
SD-agar –LWH medium in the presence of C) no 3AT or D) 2.5mM 3AT to test for HIS3 
reporter gene activity.  Bait, FHOD1 [340-585] [1-340]; pLEX, empty pLEXC plasmid; 
pACT, empty pACT2 plasmid; L, Leucine; W, Tryptophan; H, Histidine; 3AT, 3-amino-
1,2,4-triazole. N=2. 
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6.3.4 Co-localisation Studies with FHOD1 and NRAP 
 
Interactions found in yeast two-hybrid assays require validation by multiple methods.  
One such method involves assessing the co-localisation of the proteins in question by 
confocal microscopy (Bruckner et al. 2009).  The interaction between FHOD1 with 
NRAP was further explored by performing in situ co-localisation studies.  Endogenous 
FHOD1 and NRAP were stained against in frozen sections of wild-type adult mouse 
hearts (Figure 6.11 A).  The anti-FHOD1 polyclonal goat C20 antibody (Santa Cruz) 
was used for visualisation of FHOD1 in hearts.  Images of longitudinal regions of heart 

















Figure 6.11: Co-Localisation of FHOD1 and NRAP in Murine Hearts.  Frozen heart 
sections of 1 year old male adult mice were stained with the anti-FHOD1 polyclonal goat C20 
antibody (Santa Cruz) and against NRAP prior to visualisation by confocal microscopy.  
Sections were stained for myomesin to visualise the M-bands of sarcomeres.  Images represent 
high magnification longitudinal sections.  Staining was performed in sections of A) wild-type 
(WT) C57/BL6 mouse hearts and B) MLP
-/-
 mouse hearts.  FHOD1 is seen in red, myomesin is 
seen in green, and NRAP seen in blue. Arrowheads indicate an intercalated disk, the subcellular 
structure where co-localisation between FHOD1 and NRAP was seen.  Scale bars represent 
10m. N=2. 
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During instances of cardiac disease, cytoskeletal proteins can undergo changes in their 
expression pattern and distribution. Altered stoichiometry of proteins found at the 
intercalated disk was suggested to be one of the defining characteristics of dilated 
cardiomyopathy (DCM) (Perriard et al. 2003) and other proteins have been shown to 
exhibit alterations in their expression (Estigoy et al. 2009). Formins may exhibit 
alterations in localisation during instances of DCM, as has been suggested by previous 
work in our laboratory with FHOD3 in a mouse model of DCM, the MLP
-/-
 mouse 
(Arber et al. 1997; Iskratsch et al. 2010).   MLP
-/-
 mice have been reported to display a 
number of alterations in cardiomyocyte structure.  Although overall structure of 
sarcomeres remains unchanged,  MLP
-/-
 mice display a number of abnormalities at the 
level of the intercalated disk.  The most notable feature is widening of the intercalated 
disk, which has been attributed to greater convolution of the structure (Ehler et al. 
2001).  MLP has a number of reported binding partners, including NRAP (Gehmlich et 
al. 2004).  An increase in NRAP expression has also been reported in  MLP
-/-
 mice, 
where it redistributes over the widened intercalated disks (Ehler et al. 2001).  With these 
factors in mind, we investigated the localisation of FHOD1 and NRAP in heart sections 
from MLP
-/-
 mice. As expected, our study revealed staining for NRAP as a broad signal 
over the intercalated disk (Figure 6.11 B).  Staining for FHOD1 revealed that it had also 
redistributed across the apparently widened intercalated disks, producing a bright signal 
at the structure.  Both the FHOD1 and NRAP signals co-localised at the intercalated 
disks of MLP
-/-
 mice. Co-localisation studies performed between FHOD1 and NRAP in 
adult mouse hearts would support the idea of an interaction between the two proteins.   
 
In the absence of single staining controls with the anti-FHOD1 and anti-NRAP 
antibodies alone, we were unable to determine with absolute certainty if the overlapping 
signals for FHOD1 and NRAP were due to cross-reactivity between the antibody 
conjugates. However, all secondary antibodies employed in this study were of “multi-
labelling” quality, i.e. had been tested for a lack of cross-reaction between the relevant 
species (mouse, rat, rabbit, and goat). These secondary antibodies were used in 
combination successfully in the past and no cross-reaction was ever seen. Nevertheless, 
in the absence of an antigen competition assay we could not conclude with certainty that 
the anti-FHOD1 antibody was not recognising other myocardial proteins.  
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We were however able to examine any potential non-specific reactivity of the 
secondary, fluorochrome-conjugated  antibodies on their own with the heart tissue 
sections (Figure 6.12). The Cy3-coupled donkey anti-goat antibody, which was used to 
detect the goat anti-FHOD1 antibodies, displayed homogeneous background 
fluorescence over the entire tissue in longitudinal sections, which was at much lower 
intensity using the same imaging conditions that the detected signal in the experiment 
(Figure 6.12).  The signal of the secondary antibody on its own was not associated with 
the intercalated disks nor did it produce the distinct cross striations seen with the anti-
FHOD1 antibodies. The Cy2-coupled donkey anti-mouse antibody, used to detect the 
mouse anti-myomesin antibody, produced similar homogeneous background staining 
along myofibrils and a somewhat more intense signal at cell boundaries, potentially due 
to reactivity with the extracellular matrix. This background staining was not observed 
when staining was performed with the appropriate primary antibody. The Cy5-coupled 
donkey anti-rabbit antibody, used to detect the rabbit anti-NRAP produced also diffuse 
background fluorescence over the entire cardiac tissue. Although the caveat remained 
regarding the specificity of the anti-FHOD1 antibodies in these experiments, we were 
therefore able to exclude that the detected signal in the experiment is due to non-specific 
background staining of the secondary antibodies when used in conjunction with the 
relevant primary antibodies. However, we only presently report on the background 
signal produced by the secondary antibodies in wild-type mice, therefore the extent of 



























Initial staining for endogenous FHOD1 in MLP
-/-
 mouse hearts revealed that the protein 
displayed a broad signal over the widened intercalated disks (Figure 6.11 B), which are 
a hallmark of this DCM model.  Alterations in levels and localisation of FHOD3 have 
also been reported in MLP
-/-
 mouse hearts (Iskratsch et al. 2010): FHOD3 was found to 
be downregulated in this mouse model of DCM. With initial staining for FHOD1 
suggesting a possible increase in its signal in MLP
-/-
 mice in comparison to wild-type 
mice, the possibility arose that FHOD1 may exhibit differential expression during 
instances of DCM. Therefore, the localisation and expression of FHOD1 was further 
examined in MLP
-/-
 hearts by staining with other anti-FHOD1 antibodies and by 
checking total FHOD1 protein levels via Western blotting. 




In order to visualise the subcellular localisation of FHOD1 in DCM mouse hearts, 
staining was performed with the commercially available FHOD1 antibodies.  Frozen 
Figure 6.12: Negative Control for Fluorophore-Coupled Secondary Antibodies.  In order 
to assess the extent of background staining produced by the secondary antibodies used for 
localisation studies in tissue sections, frozen heart sections of 1 year old male adult C57/BL6 
mice were stained with the following antibodies: the Cy3-coupled donkey anti-goat antibody, 
which was used to detect the goat anti-FHOD1 antibody; the Cy2-coupled donkey anti-
mouse antibody, which was used to detect the mouse anti-myomesin antibody; the Cy5-
coupled donkey anti-rabbit antibody, which was used to detect the anti-NRAP antibody. 
Samples were visualised by confocal microscopy.  Images represent portions of high 
magnification longitudinal sections. Cy3-coupled donkey anti-goat is seen in red, Cy2-
coupled donkey anti-mouse is seen in green, and the Cy5-coupled donkey anti-rabbit 
antibody is seen in blue. Scale bars represent 10m. N=1.   
 





 hearts were stained with the following antibodies: polyclonal goat 
anti-FHOD1 C14 (Santa Cruz); polyclonal goat anti-FHOD1 C20; polyclonal rabbit 
anti-FHOD1 phospho-Threonine1141 antibody (Figure 6.13).  The remaining anti-
FHOD1 antibodies were excluded from this study as they did not produce a signal in 
frozen heart sections.  Staining with all three antibodies revealed a strong signal for 
FHOD1 at the intercalated disks (Figure 6.13 A-C). Furthermore, the signal for FHOD1 
across the intercalated disks appeared broader than previously noted in wild-type mice. 
FHOD1 was also found to sometimes distribute in a striated manner. This was 
especially the case with the polyclonal goat anti-FHOD1 C14 (Figure 6.13 A, Zoom) 
and the polyclonal rabbit anti-FHOD1 phospho-Threonine1141 antibody (Figure 6.13 
C, Zoom)  An alternating pattern with myomesin indicated that the FHOD1 signal may 
have been present in some of the Z-disks of sarcomeres. While a similar striated pattern 
was present with the polyclonal goat anti-FHOD1 C20 antibody (Figure 6.13 B, Zoom), 
it was not as strong as that seen with the other two antibodies.  
 
Although we have demonstrated the capacity of the polyclonal goat antibodies to 
recognise FHOD1 and not FHOD3 using epitope-tagged recombinant human protein 
(See Figures 3.2-3.6), we could not rule out the possibility of cross-reactivity with other 
myocardial proteins. MLP
-/-
 mice undergo alterations in the expression profiles of a 
number of proteins, therefore an antigen competition assay would be required in heart 
sections of both wild-type and MLP
-/-
 mice to rule out the possibility of cross-reactivity 
in these separate samples.  
 
We previously attempted to characterise the specificity of the polyclonal rabbit anti-
FHOD1 phospho-Threonine1141 antibody and found that it specifically recognises 
phosphorylation in the FHOD1 DAD and due to conservation of the ROCK 
phosphorylation motif across human and rodents, that it could conceivably have 
recognised phosphorylated FHOD1 in mouse tissue (See Figures 4.5-4.8). We found no 
evidence of cross-reactivity with FHOD3, although we could not determine the actual 
extent of FHOD3 phosphorylation in vitro. While FHOD3 was previously shown to 
distribute in a similar manner as FHOD1 in wild-type mouse heart sections, FHOD3 
exhibited a dramatically different localisation pattern in MLP
-/-
 mice (Iskratsch et al. 
2010). In wild-type mice, FHOD3 concentrates along the intercalated disks and 
distributes in a striated manner along the Z-disks. In MLP
-/-
 mice, a decrease in total 
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FHOD3 was recorded at the protein level. Furthermore FHOD3 lost its characteristic 
staining pattern and instead distributed in a weak striated manner, where it tended to 
overlap with the signal for myomesin. Although staining for FHOD3 was not performed 
concurrently with that for phosphorylated FHOD1, the dramatically different staining 
pattern recorded for these two proteins can be taken as evidence that the polyclonal 
rabbit anti-FHOD1 phospho-Threonine1141 antibody was not recognising FHOD3, at 
least in MLP
-/-
 mice.  
 
Overall, the intensities at the intercalated disk and the striated appearance of FHOD1 
may have been greater in MLP
-/-
 mouse hearts than previously seen in wild-type mouse 
hearts (See Figures 3.12 and 3.13).  These changes could have reflected altered levels of 
FHOD1 expression, therefore FHOD1 protein levels were compared in wild-type and 
MLP
-/-


























In order to see if the levels of FHOD1 were altered in DCM mouse hearts, we compared 
levels of FHOD1 protein in wild-type and MLP
-/-
 mouse hearts.  Levels of FHOD1 were 
visualised using the polyclonal mouse anti-FHOD1 antibody (Abcam) (Figure 6.14 A) 
as it was the only commercially available antibody that produced a detectable signal on 
Western blots.  A single band for FHOD1 was seen running just above the 123 kDa 
marker in the lanes for both wild-type and MLP
-/-
 mouse hearts.  Levels of -actinin 
were also visualised to normalise protein levels for subsequent quantification (Figure 
6.14 B).  Relative expression levels of FHOD1 were determined by measuring the 
intensity of the FHOD1 bands and normalising to the intensity of the -actinin bands 
Figure 6.13: Localisation of FHOD1 in MLP
-/-
 Murine Hearts.  Frozen heart sections of 1 
year old male adult MLP
-/-
 mice were stained with the available anti-FHOD1 antibodies that 
produced a signal in heart sections.  Sections were stained against myomesin to visualise the 
M-bands of sarcomeres and counterstained with DAPI to visualise nuclei.  Sections were 
fixed in acetone prior to antibody staining and visualisation by confocal microscopy.  Images 
represent high magnification longitudinal sections.  The following antibodies were used: A) 
Polyclonal goat C14 anti-FHOD1 (Santa Cruz); B) Polyclonal goat C20 anti-FHOD1 (Santa 
Cruz); C) Polyclonal rabbit anti-phosphoThr1141 FHOD1 (ECM Biosciences).  FHOD1 is 
seen in red, myomesin is seen in green, and DAPI seen in blue. Arrowheads indicate an 
intercalated disk.  Scale bars represent 10m. White boxes show zoomed selections of merged 
images. N=2. 
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(Figure 6.14 C).  Levels of FHOD1 in MLP
-/-
 hearts were nearly two times greater than 
those seen in wild-type hearts (P = 0.0321), a result which reached statistical 
significance. We thus report a possible increase in cardiac FHOD1 expression in the 
hearts of MLP
-/-
 mice. However, the caveat remained that the polyclonal mouse anti-
FHOD1 antibody was not fully characterised since an antigen competition assay was 
not performed for Western blot studies. Therefore, we could not rule out the possibility 
that we were actually reporting relative expression levels of another protein in the 
present experiment.  
 
While the present finding would be in line with the notion that MLP
-/-
 hearts exhibited 
greater staining for FHOD1 at the intercalated disk and at the sarcomere, we were 
unable to demonstrate any changes in FHOD1 phosphorylation on Western blots. In 
order to detect such changes, one would need to quantify the signal for phosphorylated 
FHOD1 with respect to levels of total FHOD1. The apparently brighter signal for 
phosphorylated FHOD1 in MLP
-/-
 hearts might only have reflected the total increase in 
FHOD1, with the ratio of phosphorylated FHOD1 to total FHOD1 remaining as it was 
in wild-type hearts. We attempted to detect phosphorylation in wild-type and MLP
-/-
 
cardiac tissue but were unable to obtain a signal using the polyclonal rabbit anti-FHOD1 
phospho-Threonine1141 antibody (Results not shown). This could reflect that further 
optimisation of our lysis buffer is required in order to capture the signal for FHOD1 
phosphorylation in the DAD on blots. This might include use of milder sample 
preparation methods (e.g., lysis in RIPA buffer) and/or the inclusion of phosphatase 


























6.5.1 Interactions with the FHOD1 GBD-DID Region 
 
In the characterisation of FHOD1, two cDNA library screens were performed with 
different fragments of the FHOD1 N-terminus in the hope of finding novel binding 
partners.  The screens utilised a human cardiac muscle cDNA library to search for 
interacting partners of FHOD1 in striated muscle.  A yeast two-hybrid screen performed 
with the GBD-DID region of FHOD1 revealed three potential interacting partners.   
Figure 6.14: Expression of FHOD1 in MLP
-/-
 Murine Hearts.  Western blots of murine 
heart lysates.  Expression was examined in 1 year old male wild-type C57/BL6 mouse hearts 
and in MLP
-/-
 mouse hearts. A) Expression of FHOD1 was visualised with the polyclonal 
mouse anti-FHOD1 antibody (Abcam). B) Expression of sarcomeric -actinin. C) Bar chart 
displaying relative expression levels of FHOD1 in wild-type versus MLP
-/-
 mouse hearts.  
Relative levels were obtained by performing densitometric analysis on bands visualised by 
Western blotting.  The relative intensity of FHOD1 bands were normalised to that of the -
actinin bands. WT, wild-type. Statistical significance was determined by performing an 
unpaired, two-tailed student’s t-test *P<0.05 Error bars represent standard error mean. N=3 
repetitions of Western blots with samples from 2 wild-type and 2 MLP
-/-
 mouse hearts. 
  Novel Protein-Protein Interactions 
321 
 
A C-terminal fragment which contained the DAD of FHOD1 [1018-1091 on the long 
FHOD1 variant] was one of the protein regions identified in the screen. This interaction 
may have represented the autoinhibitory interaction between the FHOD1 DID and DAD 
which has already been extensively characterised (Schonichen et al. 2006).  This result 
thus independently confirmed the FHOD1 autoinhibitory interactions through an 
indiscriminate interaction screen. However, we were unable to recapitulate binding 
between the FHOD1 N-terminus and the C-terminus since our C-terminal FHOD1 
construct did not express to adequate levels for biochemical studies to be performed   
The same screen also identified DLG5 as another potential interacting partner of 
FHOD1 but this interaction remained questionable since it was almost undetectable in 
the LacZ reporter gene assay. Furthermore, we were unable to show binding between 
the FHOD1 GBD-DID region and the C-terminal fragment of DLG5 [1362-1568] that 
was identified in our cDNA library screen in GST pull-down assays. However, we 
unable to exclude the possibility that this was due to lack of optimisation of the buffer 
conditions used for the GST pull-down assays. It remains to be seen by way of further 
biochemical and molecular biology experiments if there is indeed an interaction 
between FHOD1 and DLG5.  
 
One of the proteins identified in the cDNA library screen with FHOD1 GBD-DID was a 
region of FHOD3 [969-1253] partly comprising the FH1 and FH2 domains.  The 
interaction was partially validated during yeast two-hybrid assays, which supported the 
notion of a strong interaction between the specified portions of FHOD1 and FHOD3.  
This interaction could have indicated that FHOD1 and FHOD3 may form heterodimers.  
This would not be the first report of heterodimerisation between two different DRFs.  
mDia1 has been reported to dimerise with mDia2 as the full-length variants of both 
proteins bound each other in co-immunoprecipitation assays (Copeland et al. 2007).  
However, this interaction was ascribed to inhibitory cross-regulation of these formins.  
Binding was dependent on the presence of the DAD regions and it was also found that 
the DID of mDia2 inhibited the activity of mDia1.  Furthermore, cross-regulation did 
not extend to the formin DAAM-1, implying that this mechanism was restricted to 
closely related members (Copeland et al. 2007).  The portion of FHOD3 that was 
identified in the interaction screen, which did not contain the DAD, would argue against 
a cross-regulatory mechanism like the one seen between mDia1 and mDia2.   
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In the absence of functional data we can only speculate as to the consequences that this 
interaction could entail. Perhaps FHOD1 could sterically block association between 
FHOD3 and actin by binding part of its actin polymerising module (FH1-FH2), thus 
providing a new means of negative regulation of FHOD3 besides autoinhibitory 
regulation.  This interaction could also be indicative of a new mechanism of activation 
for FHOD1.  Perhaps the exposed FH1-FH2 region of activated FHOD3 could bind the 
N-terminus of FHOD1 to sterically displace the FHOD1 autoinhibitory interaction. 
Alternatively, the present results could potentially have represented a binding artefact 
since the FHOD1 GBD-DID region seemed to indiscriminately bind both the FH1 
domain and the C-terminal fragment of FHOD3 in GST pull-down assays.   
One potentially confounding factor relating to the cDNA library screen with the 
FHOD1 GBD-DID region related to the quality of the LexA-tagged bait protein. An 
equally prominent and faster migrating band was noted on Western blots testing for 
expression of the bait construct. Such an occurrence could indicate the presence of a 
contaminating protein species, which could have adversely affected the interpretation of 
any of the interactions studied in yeast. However, the interactions were further 
investigated using the GST-tagged FHOD1 GBD-DID construct, which exhibited some 
degradation on Western blots but did not give the same cause for concern in terms of a 
potentially contaminated protein preparation. 
6.5.2 Interactions with FHOD1 [340-585] 
 
During the screens to search for novel interacting proteins of FHOD1, NRAP was 
identified as a potential binding partner with a central portion of FHOD1 comprising the 
alternatively spliced exons (exons 12-13) found in the long FHOD1 variant.  Although 
validation efforts were limited to a few NRAP fragments, we were able to show binding 
between the SR5-6 repeat and the N-terminus of FHOD1 [1-513] in GST pull-down 
experiments, although the binding appeared to be weak.  The notion of an interaction 
between these regions was partly supported by yeast two-hybrid experiments which 
suggested that FHOD1 preferentially interacted with the shorter variant of SR5 (SR5-6) 
rather than the long variant (SR5-7). Co-staining for endogenous FHOD1 and NRAP in 
frozen sections of adult mouse hearts also revealed that both proteins co-localised at the 
intercalated disks.  
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However, results from the yeast two-hybrid assays remained somewhat questionable 
since there was some autoactivation by the FHOD1 bait construct, although incubation 
with 3AT could abolish this. The fact that FHOD1 preferentially interacted with the 
SR5-6 fragment and not the SR5-7 and SR4 fragments also raises doubt as to the 
specificity of the interaction since the SR5-7 fragment represents a longer variant of the 
SR5-6 fragment and because the SR repeats exhibit a considerable degree of homology 
(Mohiddin et al. 2003). However, we could not completely rule out the absence of 
binding for all of the currently addressed regions of NRAP due to lack of a positive 
binding control for each fragment. The potential issues relating to the validity of the 
LexA-tagged FHOD1 [340-585] bait construct and the GST-tagged FHOD1 N-terminal 
construct [1-513] could have influenced the present results, therefore future efforts will 
need to recapitulate these findings in the context of trustworthy FHOD1 preparations.  
While the possibility of co-localisation of NRAP and FHOD1 at the intercalated disk 
suggested by immunofluorescence experiments would support the notion of an 
interaction between these two proteins, co-localisation does not necessarily equate to the 
association of two proteins in situ. Since we were unable to definitively show that 
FHOD1 and NRAP interact, their association at the intercalated disk can therefore only 
be concluded to be coincidental. Furthermore, we cannot conclude with certainty that 
the co-localisation of the two proteins at the intercalated disk was not mediated by 
cross-reaction of the antibody conjugates in the absence of single staining controls and 
controls in which the primary antibody is incubated with the secondary antibody of the 
other primary antibody used. Nevertheless, the use of multi-labelling quality antibodies 
likely reduced the chance of cross-reacting occurring.       
 
The potential interaction between FHOD1 and NRAP may pose a number of exciting 
implications regarding the regulation of certain striated muscle subcellular structures, 
namely thin filaments and the intercalated disk.  NRAP was originally identified as a 
striated muscle specific protein that was found to concentrate within the myotendinous 
junction in skeletal muscle and the intercalated disk in cardiac muscle (Luo et al. 
1997a).  Initial analysis of the C-terminus of NRAP revealed that it possessed 45% 
sequence similarity to the actin binding portion of the thin filament protein nebulin and 
that these nebulin SRs bound with high affinity to actin (Luo et al. 1997a; Luo et al. 
1999).  NRAP has also been shown to associate with the terminal ends of actin 
filaments (Herrera et al. 2000; Zhang et al. 2001).  Analysis of NRAP within 
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preparations of the intercalated disk revealed that it was associated with the adherens 
junctions, that this association was likely mediated through the cadherin system (Zhang 
et al. 2001), and that it may serve to link the terminal ends of myofibrils to the cell 
membrane.    
 
Aside from actin (Luo et al. 1997a), talin, vinculin (Luo et al. 1999), MLP (Ehler et al. 
2001),filamin, and krp1, NRAP has also been shown to bind -actinin (Zhang et al. 
2001; Lu et al. 2003).  The NRAP--actinin interaction initially implicated NRAP in 
participating in myofibrillogenesis, since both proteins co-localised in myofibril 
precursors near the membrane and in nascent myofibrils in cultured chick 
cardiomyocytes (Lu et al. 2003).  Further work looking at the localisation of NRAP in 
embryonic mouse cardiomyocytes confirmed the association between NRAP and 
developing premyofibrillar structures containing -actinin.  In more-mature myofibrils, 
NRAP was found at the level of the Z-disk and the M-band.  However, the myofibrillar 
association of NRAP is lost in the adult heart where it becomes preferentially associated 
with the intercalated disks (Lu et al. 2005).  Depletion of NRAP in embryonic mouse 
cardiomyocytes resulted in decreased myofibril assembly thus confirming that NRAP 
plays a role in the regulation of the myofibrillar apparatus. Given the importance of 
NRAP in the regulation of muscle cytoarchitecture, If FHOD1 and NRAP indeed 
represent interacting partners, they could cooperate in the regulation of actin in 
myofibrils and at the intercalated disk.   




Exploration of the potential FHOD1-NRAP interaction also revealed that there were 
possible alterations in FHOD1 expression and localisation in a mouse model of DCM, 
the MLP
-/-
 mouse (Arber et al. 1997; Ehler et al. 2001).  Co-localisation studies looking 
at endogenous FHOD1 and NRAP revealed that both of the proteins displayed a broader 
signal at the intercalated disks than previously noted in wild-type mice.  Furthermore, it 
appeared as if their signals had increased. Staining with the other anti-FHOD1 
antibodies also revealed what seemed to be a stronger signal at the intercalated disk for 
FHOD1.  
 
  Novel Protein-Protein Interactions 
325 
 
Early observations regarding the ultrastructural changes at the intercalated disk in MLP
-
/-
 mice suggested that their intercalated disks undergo widening, and this was purported 
to be due to greater convolution of the plicate regions of the intercalated disks (Arber et 
al. 1997; Ehler et al. 2001), similar to observations made in the aged heart (Forbes and 
Sperelakis 1985). However, earlier efforts did not perform quantitative measures of the 
amplitude or lateral width of the plicate region of the intercalated disks in these animals; 
therefore the apparent widening of this structure was based on consensus. Nevertheless, 
recent efforts have shed light on this issue. Wilson et al. 2014 scrupulously measured 
the amplitude and lateral width of intercalated disks in a number of DCM samples, 
which included heart sections of MLP
-/-
 mice, cΔex3 mice (overexpress a cardiac-
specific β-catenin mutant), and idiopathic DCM human samples. Here it was found that 
DCM samples were consistently associated with intercalated disks of higher amplitude 
(Wilson et al. 2014). The broader signal that FHOD1 exhibited along the intercalated 
disk of MLP
-/-
 mice could therefore have reflected redistribution of the formin along the 
widened intercalated disks (i.e., intercalated disks with greater amplitude). 
Alternatively, the brighter FHOD1 signal at the intercalated disks in DCM mice may 
have been due to enhanced access of the anti-FHOD1 antibodies to these sites. Gross 
ultrastructural alterations can potentially result in changes in accessibility of an antibody 
to a specific subcellular compartment.  However, analysis of intercalated disk proteins 
by immunostaining semithin cryosections prepared according to the Tokuyasu method 
(Tokuyasu 1989), which have a thickness of 0.2 micrometres, as done in the work by 
Ehler et al., 2001, should prevent potential antibody penetration or access problems. In 
this study it was shown that in DCM a duplication of the signal for NRAP could be 
observed, which is consistent with the interpretation that the plasma membranes get 
more convoluted and that NRAP actually is located at the tips of the intercalated disk 
membrane, analogous to spectrin and not at the base, where the adherens junctions 
would be found (Bennett et al. 2006). So far stainings for FHOD1 have only be carried 
out on conventional cryosections with a thickness of 10m, so it remains to be seen 
whether a duplication of the FHOD1 signal can also be resolved in DCM hearts using 
the Tokuyasu methodology and its improved resolution. 
 
When compared to wild-type mouse hearts, the striated appearance of endogenous 
FHOD1 in MLP
-/-
 mice was found to be more prominent.  This was more so the case 
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with the polyclonal goat C14 anti-FHOD1 antibody and the antibody that recognised 
phosphorylated FHOD1, which revealed strong signals for FHOD1 at the intercalated 
disks and at the lateral portions of sarcomeres, suggesting some Z-disk localisation. 
Furthermore, we demonstrated that FHOD1 protein levels were significantly higher in 
MLP
-/-
 mice than wild-type mice. We presently report a nearly two-fold increase in 
FHOD1 expression in this mouse model of DCM.   
 
These results were a complete reversal to that seen previously with FHOD3.  Analysis 
of FHOD3 expression in MLP
-/-
 mice revealed that there was a downregulation in 
FHOD3 expression and a switch to the non-muscle FHOD3 isoform. Furthermore, the 
Z-disk and intercalated disk localisations of FHOD3 were lost and instead the formin 
was found distributing as weak striations around the M-band or in p62 containing 
autophagosomes (Iskratsch et al. 2010). MLP
-/-
 mice may thus partly be characterised 
by an upregulation of FHOD1 expression with a concomitant decrease in FHOD3 
expression.    
 
Work in our laboratory has also suggested that the possible alterations in FHOD1 
localisation and expression in the present mouse model of DCM may also be 
characteristic of the changes seen in human DCM. In comparison to control samples, 
staining for phosphorylated FHOD1 appeared to be more intense in human DCM 
samples, where the formin also appeared to redistribute across the widened intercalated 
disks (Dwyer et al. 2014). Once again, this was in contrast to the expression and 
localisation of FHOD3 in human DCM. Under these circumstances, FHOD3 expression 
is reduced and it loses its intercalated disk and Z-disk localisations (Iskratsch et al. 
2010). 
 
However, due to a number of caveats and oversights, it was not possible to definitively 
confirm the notions presented with respect to FHOD1 in DCM mice in the present 
study. The anti-FHOD1 antibodies presently employed require validation in both wild-
type and MLP-deficient mice by way of antigen competition assays. Therefore we were 
not able to conclude with certainty that we were actually detecting FHOD1 in 
immunofluorescence samples and Western blots. Single staining controls and 
assessment of antibody cross-reactivity will also be required to confirm that the 
overlapping FHOD1-NRAP signal was genuine. Also, while we did not confirm loss of 
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MLP in the knockout mice on the protein level via Western blotting in the particular 
sample used for the analysis here, it is extremely unlikely that the hearts used were not 
from MLP knockout mice. The hearts were isolated from mice that were bred as a 
homozygous line for generations, so are most likely MLP knockouts. In addition, the 
mice have the characteristics that their light coat colour is linked to the MLP knockout 
phenotype making mix-ups with wild-type extremely unlikely (Elisabeth Ehler, 
personal communication). The MLP knockout mice are routinely checked for genotype 
and absence of MLP expression by Western blots and also their pronounced DCM 
phenotype, which was observed in the samples used for this study, indicates that we did 
indeed compare MLP knockout samples with wild-type.. 
6.5.4 Insights into DCM Phenotype 
 
Initial characterisation of MLP-deficient mice revealed a disorganised myofibrillar 
phenotype with no evident changes in total protein composition (Arber et al. 1997). A 
number of genes, including atrial natriuretic factor and muscle ankyrin repeat protein 
(MARP), were elevated, in line with induction of a hypertrophic response.  Further 
characterisation efforts of MLP-deficient mice subsequently revealed that, while overall 
sarcomeric ultrastructure remained intact, there were a number of alterations in 
cytoskeletal proteins, particularly those involved in cell-matrix and cell-cell adhesion 
(Ehler et al. 2001). Comparison of freshly isolated cardiomyocytes from wild-type and 
MLP-/- mice revealed an altered distribution of vinculin in MLP-/- mice. Vinculin was 
found to accumulate at the intercalated disks of cardiomyocytes and displayed aberrant 
distribution along the surface of cells, possibly indicating comprised costamere 
organisation in terms of the latter observation. Investigation of levels of a number of 
intercalated disk proteins also revealed trends in alterations of proteins within specific 
compartments of the intercalated disk. All of the adherens junction proteins that were 
investigated exhibit increased levels of expression. These proteins included the 
following: cadherin, β-catenin, plakoglobin, α-catenin, vinculin, and NRAP. The 
expression of the desmosomal proteins, desmoglobin and desmoplakin were seemingly 
unaffected. The gap junction protein, connexin-43 was downregulated. 
 
Do the alterations in cytoskeletal proteins, including the potential increase in FHOD1 
levels, account for some of the compensatory mechanisms that eventually result in 





 mice, or are they just artefacts resulting from perturbation of the 
signalling network which MLP forms a part of (Boateng et al. 2009)?  MLP could bind 
and modulate transcription factors like GATA-4 or serum response factor (SRF) 
(Buyandelger et al. 2011) and disruption of MLP perturbs gene expression in muscle 
(e.g. reduced BNP expression) (Knöll et al. 2010) thus accounting for some of the 
changes noted in the knock-out mice. However, a multitude of roles have been proposed 
for MLP, including mechanosensing and maintenance of cardiac cytoarchitecture, 
therefore the compromise in cardiac cell structure plays an undeniable role in the 
progression to DCM (Buyandelger et al. 2011). Indeed, insights from other models of 
DCM, such as the tropomodulin-overexpressing transgenic (TOT) mouse, suggested 
that many of the previously observed alterations are conserved across DCM phenotypes. 
TOT mice similarly develop DCM and are characterised by an upregulation of adherens 
junction proteins, downregulation of gap junction proteins, and little or no change in 
desmosomal proteins (Ehler et al. 2001). However, MLP is downregulated in adult TOT 
mouse hearts; therefore it is difficult to dissect away all the perpetuating factors leading 
to a phenotype in these mice with respect to MLP
-/-
 mice. Nevertheless, while the initial 
pathological insult and perpetuating factors may differ between experimental models 
and real-world cases of DCM, the end results can be similar.      
 
One might also ask, why do these compensatory changes occur? In the case of adult 
MLP-deficient mice, alterations in the hemodynamic work load placed on the heart may 
necessitate many of the changes noted at the intercalated disk. As the animals age, 
dilatation progresses (Costandi et al. 2006; Buyandelger et al. 2011) it becomes 
increasingly difficult for the heart to pump blood systemically. It can be speculated that 
the greater convolution of the intercalated disk in such an instance may facilitate 
insertion of more terminal myofibrils in order for more efficient contractions to occur. 
However, it must be noted that the progression to the phenotype in MLP
-/-
 mice is a 
gradual one. In fact, younger MLP
-/-
 mice exhibit a hypertrophic phase before 
progressing onto a DCM phenotype (Arber et al. 1997; Costandi et al. 2006). We 
therefore captured a snapshot of a particular time point in MLP
-/-
 mice in which they 
have already progressed to a DCM phenotype, although did not necessarily become 
globally decompensated. It remains to be seen how FHOD1 levels might change 
throughout the progression to DCM and finally heart failure. Nevertheless, the possible 
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increase in FHOD1 at the intercalated disk in DCM may have a number of interesting 
functional implications, given the actin regulatory role proposed for this formin.  
6.5.5 Conclusion 
 
Overall, we identified a novel set of potential interactions with the N-terminus of 
FHOD1. Some of the interacting proteins identified included FHOD3 and NRAP, which 
may have also bound the N-terminus of FHOD1, as suggested by GST pull-down 
assays. Although these interactions require extensive validation by way of biochemical 
means and functional assays, they may pose interesting biological implications. 
Furthermore, we report possible alterations in the localisation and expression pattern of 
FHOD1 in a mouse model of DCM.   
6.5.6 Future Directions 
 
The potential interaction between FHOD1 and FHOD3 represents an interesting finding 
in that it might suggest that these formins heterodimerise, a concept that is not 
completely foreign in the realm of formin biology (Copeland et al. 2007). However, 
GST pull-down assays suggested that FHOD1 bound multiple regions of FHOD3 and 
may have implied that binding between these two proteins was not specific. Further 
validation by co-immunoprecipitation assays will be essential in order to see if these 
formins can interact in a cellular environment. More importantly, interaction assays 
should also be performed in the context of a muscle cell background, although this 
might be difficult due to the lower transfection efficiency in primary muscle cells. This 
could be overcome with adenoviral mediated gene transfer however. Once there is 
reasonable grounds to claim an interaction (GST pull-down assays, co-
immunoprecipitation assays, and co-localisation studies), functional assays should be 
performed in muscle cells to assess the significance of this potential interaction.   
 
In the current experiments with FHOD1-NRAP it was difficult to definitively claim an 
interaction or binding between these two proteins. This stemmed from a number of 
factors. A questionable bait construct and a possibly contaminated GST-FHOD1 protein 
preparation made it difficult to conclude if the interactions were actually mediated by 
FHOD1. Future efforts should validate these constructs to confirm the identity of the 
unidentified protein species, which did not run at the expected molecular weight of the 
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FHOD1 constructs on gels. This could potentially be addressed by performing Western 
blots with the anti-FHOD1 antibodies. The FHOD1-NRAP interaction also remains 
doubtful since the GST-tagged N-terminal FHOD1 construct bound the shorter SR5 
fragment but not the longer SR-5 fragment. This might have reflected that the 
conditions used for the GST pull-downs were not optimised for binding to occur with 
both constructs. Future efforts should be directed towards confirming binding of 
FHOD1 to full-length NRAP before trying to map the interaction to a specific domain. 
Subsequent experiments should confirm the interaction by way of co-
immunoprecipitation assays and co-localisation studies. Further biophysical methods to 
characterise the possible interaction could also include isothermal titration calorimetry 
(ITC) and Biacore. The implementation of proximity ligation assays could subsequently 
help paint a picture of the FHOD-NRAP interaction in situ. The use of semithin 
cryosections will also help to better-delineate the relative localisations of NRAP and 
FHOD1 at the intercalated disk. Also, it will be of interest to see if the putative FHOD1-
NRAP interaction is dependent on the alternatively spliced exons in FHOD1.    
 
The present study and work in our laboratory suggested that the signal for 
phosphorylated FHOD1 was increased in DCM samples (Dwyer et al. 2014). However, 
the potential increase in total FHOD1 may have accounted for this change. Western blot 
studies may shed some light on this issue by quantifying relative levels of FHOD1 
phosphorylation to total FHOD1 levels. However, we were not able to demonstrate a 
signal for phosphorylated FHOD1 on blots. Milder sample preparation methods and 
inclusion of phosphatase inhibitor could represent potential avenues to address this 
issue. However, antigen competition assays will be required on both Western blots and 
immunofluorescence samples in order to conclude that the antibody designed to 
recognise phosphorylated FHOD1 recognises its designated epitope. 
 
The potential increase in FHOD1 levels found in the presently explored mouse model of 
DCM raises questions as to the role of FHOD1 in instances of cardiac disease and may 
imply diverging function with respect to FHOD3, which is downregulated in DCM. 
While pending antigen competition assays will be required to confirm the identity of 
FHOD1 in wild-type and DCM mice, it would be of interest to track FHOD1 protein 
levels and localisation throughout the progression to DCM in MLP
-/-
 mice. It will also 
be of interest to explore FHOD1 expression and localisation in other models of DCM, 
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In the present characterisation effort, the role of FHOD1 in striated muscle was explored 
on a number of levels.  The expression and localisation of FHOD1 was examined in 
cardiac and skeletal muscle.  A number of gain-of-function and loss-of-function studies 
were also performed in the hope of elucidating the cellular roles of FHOD1 in cultured 
striated muscle cells.  The characterisation effort was also extended to investigating 
possible regulatory mechanisms for FHOD1 through binding assays with various 
members of the Rho family small GTPases, their effectors, and Src.  Finally, yeast two-
hybrid assays were performed to screen for novel interacting partners of FHOD1.  
Overall, the present data implicated FHOD1 in the regulation of the myofibrillar 
apparatus and the cytoskeleton at the level of actin in striated muscle. 
7.1 Expression of FHOD1 
 
In the present study we attempted to elucidate the expression pattern of FHOD1 in 
striated muscle. Although pending validation by antigen competition assays, Western 
blot studies of whole muscle lysates indicated that FHOD1 was expressed in both 
cardiac and skeletal muscle. Closer analysis of FHOD1 expression in whole muscle 
lysates suggested that expression of FHOD1 was significantly higher in cardiac muscle 
than in skeletal muscle. This finding was in agreement with previous reports which also 
described higher expression of FHOD1 in cardiac versus skeletal muscle on both the 
mRNA transcript and protein level (Krainer et al. 2013). When expression of FHOD1 
was compared between samples of slow twitch (soleus) and fast twitch (tibialis anterior) 
muscle, expression seemed to be higher in fast twitch skeletal muscle. This was in 
contrast to many other cytoskeletal proteins, which seem to be regulated in their 
expression in a similar way in ventricular and slow twitch muscle (Schiaffino and 
Reggiani 1996). However, this may have also reflected differential rates of protein 
turnover in each type of skeletal muscle: muscle proteins are continuously being turned 
over but rates vary according to the type of muscle.  The average half-lives in rat adult 
slow twitch and fast twitch skeletal muscles are 12.1 and 18.3 days, respectively (Lewis 




have therefore been explained by the higher rate of protein turnover, resulting in less 
accumulation of FHOD1 in slow twitch skeletal muscle.  However, different levels of 
FHOD1 in each tissue may have also been indicative of specific requirements for the 
protein, such as varying degrees of actin regulation, which is the main function ascribed 
to FHOD1.  
 
The expression profiles of the different formin family members in striated muscle are 
also beginning to take shape. Analysis of the expression profiles of all 15 mammalian 
formins in striated muscle by quantitative real-time polymerase chain reaction (qRT-
PCR) revealed interesting differences in the levels of each formin (Krainer et al. 2013). 
All 15 formins exhibited some level of expression in adult human skeletal muscle; with 
Dia3 and FHOD3 being the most highly expressed and DAAM-2 exhibiting 
comparatively low expression levels. In adult human cardiac muscle, FMN-1, FHOD1, 
and FHOD3 exhibited the highest expression whereas many other formins exhibited 
comparatively low expression levels. Expression of Delphilin was absent in cardiac 
muscle. Interestingly, FHOD1 may have exhibited the highest expression levels when 
considered across all cell and tissue types (Krainer et al. 2013), indicating that 
expression is not solely limited to muscle, but whether it plays a ubiquitous role in all 
these cell types remains to be determined.  
 
Another study examined the expression profiles of all 15 mammalian formins at 
different stages of postnatal murine heart development, ranging from day 0 newborn 
mice to postnatal day 60 mice (Rosado et al. 2014). It was found that 13 of the 15 
formins were expressed in at least one time point during postnatal heart development, 
with many formins exhibiting differential expression levels according to the stage of 
heart development. FHOD1 was found to exhibit consistent levels of expression 
throughout the hyperplastic and hypertrophic growth phases as well as the phase in 
which cardiomyocytes transition from hypertrophic growth to their mature state. 
Interestingly, FHOD1 levels fell at postnatal day 60, which correlates to the 
maintenance phase in cardiac cells. While such data may point to distinct roles for each 
formin  and FHOD1 within separate stages of postnatal heart development, 
interpretation of qRT-PCR studies require caution since mRNA and protein expression 
profiles do not always fully correlate with each other, especially when considering that 




enhanced accumulation or degradation (Langley et al. 2012). The drop in FHOD1 
expression in postnatal day 60 mouse hearts (Rosado et al. 2014) is somewhat 
inconsistent with the expression pattern of FHOD1 that we observed in cardiac 
specimens. Although detection of FHOD1 varied according to the anti-FHOD1 antibody 
that was employed, the present study suggested that FHOD1expression could be 
detected in neonatal rat cardiomyocytes (NRCs), adult rat cardiomyocytes (ARCs), and 
adult mouse whole heart lysates. However, quantification of changes in FHOD1 protein 
expression will be required in order to determine if FHOD1 levels are maintained at 
later stages of postnatal heart development. 
7.2 Localisation of FHOD1 
 
In addition to the expression pattern of FHOD1 we attempted to elucidate the 
subcellular localisation of this formin in different muscle specimens. Staining for 
endogenous FHOD1 with the commercially available anti-FHOD1 antibodies in 
cultured NRCs, freshly isolated ARCs, and differentiating C2C12 cells revealed 
inconsistent results regarding the localisation of this formin. This stemmed from 
improper characterisation of the antibodies in the absence of blocking peptides that 
would have been required to perform antigen competition assays at the time of the 
study. However, the antibodies highlighted the possibility of FHOD1 localising to the 
sarcomere in cultured cardiomyocytes. Staining for FHOD1 in sections of adult mouse 
heart tissue sections revealed more consistent results in that the three antibodies that 
displayed reactivity in tissue sections suggested similar localisation patterns for 
FHOD1. In tissue sections, staining for FHOD1 revealed notable intensities at the 
intercalated disks between neighbouring cardiomyocytes. Staining for FHOD1 was also 
visible throughout cardiomyocytes and could be occasionally be resolved as striations 
around the area of the Z-disks. Interestingly this localization pattern may be 
evolutionally conserved; in Caenorhabditis elegans FHOD1 is also found as bright 
puncta at the muscle cell edges with faint striations at the dense bodies, the equivalent 
of the Z-disk (Mi-Mi et al. 2012). In the present study, some staining for FHOD1 was 
also noted in the interstitial spaces between neighbouring cardiomyocytes and may have 
suggested expression of this formin in resident cardiac fibroblasts. Indeed, the 
heterogeneity of cells found within the heart may have called into question the precise 




visible throughout cardiomyocytes in heart sections suggested that they could have been 
an abundant source of FHOD1 expression in the heart.   
 
Interestingly, FHOD1’s closest relative, FHOD3, may exhibit a similar localisation 
pattern in healthy adult mouse hearts. Although there have been some discrepancies as 
to the precise localisation of FHOD3 in adult cardiac specimens, with initial reports 
placing it near the A-bands of sarcomeres (Kan-o et al. 2012b), work in our laboratory 
and data from another study suggested that FHOD3 is found at the Z-disks (Iskratsch et 
al. 2010; Iskratsch et al. 2013a; Rosado et al. 2014) and the intercalated disks (Iskratsch 
et al. 2010; Iskratsch et al. 2013a). Similar localisation in adult heart specimens may 
imply some level of conservation in the roles of FHOD formins in cardiomyocytes. 
However, in NRCs, both endogenous and ectopically expressed FHOD3 were shown to 
exhibit a broader localisation pattern across myofibrils, which may have been consistent 
with a more dynamic role in myofibrillar maintenance when cardiomyocytes are 
actively remodelling their myofibrils in response to adapting to cell culture conditions 
(Iskratsch et al. 2010; Iskratsch and Ehler 2011; Iskratsch et al. 2013a). Furthermore, 
epitope-tagged full-length FHOD1 distributed in a predominantly diffuse cytoplasmic 
manner with strong intensities near the peripheries of cells and some myofibrillar 
targeting in NRCs, suggesting that if FHOD formins exert their functions in distinct 
subcellular compartments, that this may vary according to specific stages of heart 
development.  
 
The subcellular localisation of other formins has also been studied in cardiomyocytes. 
DAAM-1, which has been implicated in having an actin bundling role critical for 
filopodial organisation (Jaiswal et al. 2013), was found to localise to the cell peripheries 
in early myofibrillogenesis and to the Z-disks in mature myofibrils (Rosado et al. 2014). 
mDia2, which has been shown to possess actin polymerising (Pellegrin and Mellor 
2005), stress fibre organising (Tojkander et al. 2011; Tojkander et al. 2012), and 
bundling activities (Harris and Higgs 2006) was shown to localise to the cell peripheries 
during early myofibrillogenesis and to the Z-disks and M-band in mature myofibrils 
(Rosado et al. 2014). The lesser studied FMNL formins, which have been implicated in 
actin polymerising events downstream of Rac and Cdc42 (Yayoshi-Yamamoto et al. 
2000; Block et al. 2012), were also found to exhibit myofibrillar localisation in 




at the plasma membrane during myofibrillogenesis and was found near the region of the 
I-bands in mature myofibrils. FMNL2 exhibited localisation throughout the sarcomere, 
apart from the Z-disks. However, not all formins are necessarily found at a given 
sarcomeric compartment or even at myofibrils. For instance, FMNL3 and mDia1 are 
localised in puncta throughout cultured cardiomyocytes (Rosado et al. 2014). Thus, a 
number of formins with diverse sets of actin regulating activities have been found to be 
targeted within distinct compartments of cardiac cells at specific time points. However, 
localisations of the formins studied in Rosado et al. 2014 will require confirmation:  
This study employed only partially characterised antibodies from commercial studies so 
it remains to be confirmed by absorption studies that the signal seen for these formins 
during myofibrillogenesis and in mature myofibrils was indeed bona fide. 
 
Although a larger part of our data presently described related to the localisation of 
FHOD1 in terminally differentiated cardiomyocytes, we may have gained some insight 
into the localisation FHOD1 during the skeletal muscle differentiation process. C2C12 
cells can be used to study the cues and changes involved in myogenic differentiation, a 
process that is central to the development of skeletal muscle.  Myogenesis occurs during 
embryonic development and in post-natal skeletal muscle.  During embryogenesis, the 
first skeletal muscle fibres are derived from the embryonic mesoderm, and these are 
thought to serve as a template for further generation of muscle fibres.  Adult skeletal 
muscle still has a requirement for generation of skeletal muscle fibres, although this is 
mainly in response to damage, hence skeletal muscle regeneration occurs from a 
residing pool of satellite cells (Bentzinger et al. 2012).  C2C12 cells recapitulate the 
events involving the formation of skeletal muscle when they fuse and create newly 
formed myofibrils and sarcomeres.  Although these events occur within the context of 
two-dimensional culture conditions, the advantage of the C2C12 model is that it permits 
specific stages of muscle differentiation to be studied. Apart from day 0 undifferentiated 
myoblasts, where there may have been expression of an unreported FHOD1 variant, 
expression of FHOD1 was noted throughout the differentiation process from skeletal 
myoblasts to myotubes in C2C12 cells. However, future efforts should make it a priority 
to see if differential levels of FHOD1 expression and activation occur throughout 
skeletal muscle differentiation. Antibody staining in cells revealed a predominantly 
diffuse localisation for FHOD1 throughout the differentiation process. Some co-




and sarcomeric targeting were also noted in the later stages of differentiation, after the 
initiation of sarcomerogenesis (Burattini et al. 2004), although this varied between the 
anti-FHOD1 antibody that was used. Presently it is difficult to integrate the localisation 
of FHOD1 with the results from our knockdown studies, which suggested that FHOD1 
may be crucial in maintaining the F-actin cytoskeleton in day 3 C2C12 cells. Due to the 
potential technical issues relating to shRNA plasmid dilution in C2C12 cells, it remains 
to be determined if FHOD1 plays roles in myoblast fusion and sarcomere assembly by 
investigating the function of this formin at later time points.      
7.3 Potential Mechanisms Guiding FHOD1 Localisation 
 
In the present study we attempted to dissect the contribution of some of the individual 
FHOD1 domains. The subcellular targeting of GFP-tagged expression constructs that 
only encoded for individual domains of FHOD1 were explored in NRC. The FH2 
domain of FHOD1 on its own displays a strong signal at the Z-disks, as indicated by co-
localisation with -actinin, and with F-actin at the peripheries of cells. Constructs 
encoding the GBD-DID or GBD primarily displayed diffuse cytoplasmic localization 
with some evidence for myofibril targeting, which was similarly noted for full-length 
FHOD1 construct. The DID alone as well as the N-terminal deletion construct lacking 
the GBD domain (FHOD1 GBD) distributed as aggregates or small vesicular-like 
structures. This may have indicated that the GBD influenced the targeting of the full-
length wild-type FHOD1 construct in NRCs. However, the targeting of FHOD1 GBD 
may have been a result of instability of the construct in NRCs. Nevertheless, the notion 
of the FHOD1 GBD contributing to the targeting of this formin is partly supported by 
other work with this formin.    
 
The N-termini of formin proteins have been suggested to mediate their subcellular 
localisation (Seth et al. 2006; Ramalingam et al. 2010) and are coincidentally the 
regions of highest divergence amongst formins. Indeed, the importance of the FHOD1 
N-terminus has been highlighted by other studies (Schonichen et al. 2013; Schulze et al. 
2014). The N-terminal half of FHOD1 [1-568; short FHOD1 variant] was found to 
mediate targeting of this formin to transverse arcs and stress fibres (Schonichen et al. 
2013). Further mapping of the possible mechanism governing targeting of FHOD1 




transverse arcs and stress fibres (Schulze et al. 2014). However, in terms of FHOD1 
targeting to stress fibres, the GBD on its own was suggested to have a limited 
contribution, which would be in contrast to the present interpretation of our domain 
overexpression data in NRCs. Nevertheless, these differences in results could be 
accounted for by the use of different cell types used to explore the targeting of FHOD1 
(human U2OS osteosarcoma cells in Schulze et al. 2014, COS-7 cells in Schonichen et 
al. 2013, and NRCs in the present study) and could suggest that cell-type specific 
interacting proteins may influence targeting of FHOD1 via its N-terminus. 
 
It is tempting to speculate into the additional factors that may govern the localisation of 
FHOD1 in muscle cells. The notion of the GBD mediating the localisation of FHOD1 
raises the possibility that recruitment of this formin could be guided by a Rho family 
small GTPase.  However, no studies have demonstrated binding of a Rho family small 
GTPase to the FHOD1 N-terminus (Westendorf 2001; Schulte et al. 2008). There is also 
currently little known about the expression pattern of the Rho family GTPases in 
cardiac muscle.  Furthermore, while there is some evidence for the association between 
the Rho family GTPases and myofibrils (Ahuja et al. 2007), this remains to be fully 
elucidated; therefore there is little room for speculation. Nevertheless, while previous 
efforts have failed to show that a Rho family small GTPase binds the FHOD1 GBD 
(Schulte et al. 2008) and the present study failed to show binding of a handful of 
GTPases and their effectors to the FHOD1 N-terminus, comprising the alternatively 
spliced exons, cooperation with these proteins in regulating the localisation in muscle 
still remains a possibility. Rac has been shown to mediate targeting of FHOD1 in a 
number of instances (Gasteier et al. 2003; Alvarez and Agaisse 2013) and this could be 
a consequence of the physical association of both proteins, since Rac has been shown to 
bind the central portion of FHOD1 near the FH1 domain (Westendorf 2001; Gasteier et 
al. 2003; Wang et al. 2004). Nevertheless, binding may vary according to cell type and 
other interacting partners since co-immunoprecipitation studies in platelets suggested 
that FHOD1 and Rac did not interact (Thomas et al. 2011). We cannot however dismiss 
other mechanisms potentially guiding the targeting of FHOD1. In the case of FHOD3, 
targeting of this formin to sarcomeres relies on a phosphorylation dependent process in 
which CK2 phosphorylates the sequence encoded by the T(D/E)5XE exon found in the 






7.4 Effects of FHOD1 Activation in Cardiomyocytes 
 
In addition to addressing the expression and localisation of FHOD1, the present study 
also investigated the functional consequences of FHOD1 activation in cardiomyocytes. 
Overexpression of constitutively active FHOD1 has previously been associated with the 
appearance of stress fibres in cells (Gasteier et al. 2003; Koka et al. 2003; Gasteier et al. 
2005; Takeya et al. 2008). We overexpressed three different FHOD1 mutants that have 
previously been described as models for constitutive activation of this formin. 
Introduction of the V228E mutation in the FHOD1 GBD, which has been previously 
shown to disrupt the autoinhibitory interaction between the FHOD1 N and C-termini 
(Schulte et al. 2008), resulted in the formation of ventral stress fibres in NRCs. 
Truncation of the DAD, which also results in release of the autoinhibitory interaction 
that supposedly retains FHOD1 in an inactive state (Koka et al. 2003; Schonichen et al. 
2006), was associated with the formation of F-actin bundles. Introduction of three 
phosphomimetic Aspartate residues in the DAD, designed to mimic the effects of 
activation by ROCK-I phosphorylation (Takeya et al. 2008; Staus et al. 2011a), resulted 
in an elongated morphology in cells and may have resulted in increased staining for F-
actin. Although the phenotypes associated with these three FHOD1 mutants were 
slightly incongruous, they would generally suggest that upon activation FHOD1 might 
co-localise with F-actin and contribute to the reorganisation of the cardiac F-actin 
cytoskeleton via its actin bundling capabilities (Schonichen et al. 2013) or another of its 
proposed actin regulating roles (e.g., actin polymerisation) (Iskratsch et al. 2013b).   
 
The differences between the FHOD1 DAD and V228E mutants could be explained by 
the possibility that DAD is required for full biological activity of FHOD1 in cells. A 
previous study noted that the  FHOD1 V228E mutant was able to more potently induce 
the formation of stress fibres than the FHOD1 DAD construct (Schulze et al. 2014). 
The DAD of FHOD1 could therefore play other roles besides mediating autoinhibition 
of the protein. This has also been noted for mDia1, whose DAD has been suggested a 
role in filament nucleation (Gould et al. 2011). As for the ROCK-I phosphomimetic 
FHOD1 mutant, one possible explanation behind the difference with this construct is 




length wild-type FHOD1 construct, which did not result in overt effects on NRC 
morphology, was recognised by the anti-FHOD1 phospho-Threonine1141 antibody in 
NRCs, suggesting that phosphorylation of the construct was present. While this could 
be explained by incomplete phosphorylation of all three of the relevant residues in the 
DAD, it could be indicative that further cues are required for full activation of FHOD1 
to occur. 
 
However, the relevance of full FHOD1 activation in cardiomyocytes should be taken 
into consideration. The phenotype associated with the V228E construct could be 
considered to be that of an extreme nature in a physiological context, especially when 
considering the potential role of FHOD1 in myofibrillar maintenance. In terminally 
differentiated cardiomyocytes, myofibrillar maintenance seems to primarily take place 
through addition of new monomers at the ends of myofibrils (Ono 2010). Although de 
novo nucleation/polymerisation of filaments has been described (Skwarek-Maruszewska 
et al. 2009), neither of these processes seem to involve the formation of stress fibres. 
The stress fibre forming activity of FHOD1 may have been more relevant in the day 3 
C2C12 model since transfection with the FHOD1 shRNAs was associated with the 
disappearance of the characteristic stress fibres noted in cells at this time point. In 
striated muscle, the formation of stress fibres might have some relevance during 
myofibrillogenesis. One of the proposed models of myofibrillogenesis, namely the 
template model, describes the participation of stress fibres (Sanger et al. 2005). In this 
model, different components of myofibrils are recruited to surface of stress fibres or 
stress fibre-like structures at the plasma membrane. These include dense components of 
the Z-disk as well as the thin and thick filaments. Stress fibres disappear after assembly 
takes place and then reassemble for the new myofibril to be pieced together. Regardless 
of the potential of FHOD1’s stress fibre activity contributing to muscle development or 
maintenance, regulation by ROCK-I is currently the most accepted mechanism 
governing FHOD1 activation, therefore results gained using the V228E mutation in 
NRCs might not be entirely translatable to the context of terminally differentiated 
cardiomyocytes. 
 
Further insight into the functional activity of FHOD1 has previously been gained 
through the study of its FH2 domain. Not only is the FH2 domain required for the direct 




also suggested that its activity in cells was dependent on oligomerisation via the FH2 
domain (Takeya and Sumimoto 2003; Madrid et al. 2005). A coiled-coil motif found C-
terminal of the core FH2 domain, but still found within the presently accepted 
boundaries of the FH2 domain, was found to be essential for the self-association of 
FHOD1 as supported by yeast two-hybrid and co-immunoprecipitation studies. 
Furthermore, the presence of the coiled-coil motif was required for the targeting of 
FHOD1 to stress fibres in its constitutively active state, induced by truncation of the 
DAD (Madrid et al. 2005). These findings supported a previous study which suggested 
that FHOD1 self-associates via its FH2 domain (Takeya and Sumimoto 2003).  
 
In the present study, the FH2 domain of FHOD1 was targeted to the Z-disks and 
displayed co-localisation with F-actin at the peripheries of cardiomyocytes. As a 
component of the quintessential actin regulating module of formins, one might ask if the 
targeting of the FH2 domain in cardiomyocytes represents the functional localisation of 
FHOD1. Targeting of full-length inactive and constitutively active FHOD1 differed 
somewhat from the targeting of its isolated FH2 domain in NRCs. In cardiomyocytes, 
full-length FHOD1 displayed a diffuse cytoplasmic signal with strong intensities at the 
peripheries of cells with little co-localisation with myofibrils was noted in this instance. 
Upon activation, FHOD1 displayed targeting to F-actin, myofibrils, and the sarcomere. 
However, localisation of the constitutively active FHOD1 variants was not restricted to 
the Z-disks since their targeting within the sarcomere was often irregular with respect to 
the spacing of -actinin. Regardless of its localisation within the sarcomere, the FH2 
domain could still participate in targeting of active FHOD1 to F-actin. Unmasking of 
the functional FH domains following activation of FHOD1 could result in dimerisation 
of two FHOD1 molecules via their FH2 domains. Therefore, dimerisation via the FH2 
domain may have been an important factor governing the activity of constitutively 
active FHOD1 in NRCs. However, we cannot dismiss the notion that FHOD1 possesses 
biologically relevant activity in its monomeric inactive state, since the GFP-tagged full-
length wild-type FHOD1 constructs may have resulted in increases in the F-actin 
content in HeLa cells. However, the function of FHOD1 could vary considerably 
between cell types as previous studies investigating FHOD1’s multiple interacting 
partners have suggested (Gill et al. 2004; Kutscheidt et al. 2014). Nevertheless, the full 




can only be fully dissected by employing variants lacking the FH2 domain in both 
inhibited and uninhibited conformations.   
7.5 Role of FHOD1 and Formins in the Regulation of Muscle 
Cytoarchitecture 
 
One of the more important findings in the present study related to the possibility that 
FHOD1 may play a crucial role in the maintenance of the myofibrillar apparatus and the 
F-actin network in muscle cells. Although pending validation by confirming actual 
disruption of endogenous FHOD1 expression, transfection of NRCs and C2C12 cells 
with the shRNAs designed to knock down FHOD1 was associated with a number of 
cellular defects. In day 8 NRCs, these effects included disruption of myofibrils at the 
level of F-actin and sarcomeric proteins, distortion of cell shape, and disruption of cell-
cell contacts at the level of the intercalated disk. In day 3 C2C12 cells, effects included 
disruption of the F-actin cytoskeleton. Previous studies which looked at FHOD1 
disruption also reported disruption of F-actin in cells and would be in agreement with 
the present findings. Knockdown of FHOD1 blocked the formation of stress fibres in in 
Human Pulmonary Artery Endothelial Cells (HPAEC) (Takeya et al. 2008) and smooth 
muscle cells (Staus et al. 2011a).  Knockdown of FHOD1 was also associated with 
higher levels of G-actin compared to F-actin, possibly suggesting less actin 
polymerisation or destabilisation of F-actin filaments (Staus et al. 2011a).  Furthermore, 
silencing of FHOD1 in breast cancer cells also led to a loss of stress fibres, less cell 
elongation, and a diminished metastatic potential (Jurmeister et al. 2012). FHOD1 was 
also shown to contribute to development of the myofibrillar apparatus in 
Caenorhabditis elegans (Mi-Mi et al. 2012). Overexpression of two mutant variants of 
FHOD1, one  eliminating part of an intron and a DID-encoding exon and the other 
eliminating part of the FH2 domain, resulted in defects in development of body wall 
muscles (BWM) of larvae at the level of contractile lattice development, sarcomere 
organisation, and F-actin deposition. Interestingly, the FHOD1 mutant with the 
disrupted FH2 domain was associated with a more severe phenotype and may be 
explained by the ability of the FH2 domain to mediate self-association of FHOD1 and 
to directly regulate F-actin based structures. Furthermore, these defects were 
recapitulated with knockdown of endogenous FHOD1. The present data and the 




crucial role FHOD1 could play in the regulation of the F-actin network and the 
myofibrillar apparatus in muscle cells. 
 
In terms of the FHOD proteins, FHOD3 has been shown to play a role in regulation of 
cardiac cytoarchitecture. Knockdown of FHOD3 also resulted in myofibrillar disruption 
in NRCs (Taniguchi et al. 2009; Iskratsch et al. 2010).  Iskratsch et al. 2010 noted 
defects in myofibrils by day 5 of FHOD3 knockdown.  At this time point, FHOD3 
depleted NRCs presented with shortened myofibrils and fewer mature sarcomeres.  By 
day 8, FHOD3 depletion resulted in exacerbation of the myofibrillar phenotype 
(Iskratsch et al. 2010) similarly noted with the FHOD1 shRNA constructs.  The 
contribution of the FH2 domain of FHOD3 was found to be crucial in mediating its 
effects on myofibrillar maintenance: introduction of mutations into the FH2 domain in 
an siRNA resistant form of FHOD3 was unable to restore sarcomere organisation in 
NRCs depleted of endogenous FHOD3 (Taniguchi et al. 2009). The residues mutated in 
FHOD3 (I1127A and K1273D) corresponded to those found in yeast formin Bni1p, that 
when mutated disrupted the actin nucleating activity of Bni1p (Xu et al. 2004; Otomo et 
al. 2005b). The precise mechanism by which FHOD3 regulates myofibrillar and 
sarcomeric organisation via its FH2 domain remains to be determined however. While 
actin polymerisation remains a possibility, in vitro experiments suggested that FHOD3 
prevented actin polymerisation in both the presence and absence of profilin and that it 
specifically prevented elongation from the barbed end of filaments (Taniguchi et al. 
2009). Indeed, the multitude of actin regulatory functions that have been described for 
formins, ranging from actin bundling to severing (Breitsprecher and Goode 2013), could 
indicate roles for FHOD3 that go beyond actin polymerisation. However, the presence 
of actin assembly cofactors in cells could facilitate the potential actin polymerising 
activity of FHOD3. The effects of FHOD3 on the barbed ends of filaments and its 
localisation at the Z-disk in adult muscle has resulted in a ‘leaky’ capper role being 
proposed for FHOD3, in which FHOD3 could transiently associate with the barbed ends 
of actin filaments in myofibrils to contribute to their maintenance, possibly by addition 
of actin monomers at the barbed end (Iskratsch and Ehler 2011; Dwyer et al. 2012). 
Overall, these data can be taken as evidence for formin homology proteins as highly 





Insights into the role of formins in muscle have also been gained from studies using 
knock-out mice, specifically the FHOD3
-/-
 (Kan-o et al. 2012a) and DAAM-1
-/-
 (Li et al. 
2011) mice.  Homozygous null FHOD3 mice died during embryonic development due 
to a number of cardiac defects including improper cardiac looping and perturbed 
myocardial development.  The cardiomyocytes of homozygous null FHOD3 mice were 
able to assemble premyofibrils similarly to wild-type and heterozygous null FHOD3 
mouse littermates; however, mature myofibrils were never fully formed.  Defects were 
only rescued upon re-expression of the wild-type FHOD3 variant and not with the actin 
binding defective FHOD3 mutant (Kan-o et al. 2012a).  DAAM-1 was similarly 
required for proper heart development.  Homozygous null DAAM-1 mice also died 
during embryonic development due to a number of cardiac defects, including ventricular 
non-compaction and ventricular septal defects.  Cardiomyocytes from homozygous null 
DAAM-1 mice also displayed a perturbed myocardial cytoskeleton and presented with 
randomly oriented and aggregated striated F-actin. Cells also showed decreased staining 
for F-actin and fewer sarcomeric striations.  Compromised sarcomeric maturation was 
also made evident by the fact that there was diffuse staining for actin and sarcomeric -
actinin (Li et al. 2011).  These defects in myofibrillar and cytoskeletal organisation 
partly resonated the effects associated with the FHOD1 shRNA constructs in NRCs.  
The effects of DAAM-1 depletion were first speculated to be due to disruption of the 
plasma membrane cytoskeleton, where DAAM-1 was thought to primarily localise to 
(Iskratsch and Ehler 2011; Li et al. 2011). However, recent reports of DAAM-1 
additionally localising to the Z-disks in neonatal mouse cardiomyocytes also makes 
regulation of this cellular compartment a possibility (Rosado et al. 2014).  In the current 
study, the effects associated with FHOD1 depletion may have been due to impaired 
maintenance of multiple structures in cardiomyocytes, such as the myofibrils and the 
intercalated disks.  Overall, formins would seem to play an important role in the 
formation and maintenance of the myofibrillar apparatus and the cytoskeleton in the 
muscle cells. This notion would also be in agreement with our experiments employing 
the pan-formin inhibitor SMIFH2, which was associated with disruption of the F-actin 
network, myofibrils, sarcomere organisation, and the intercalated disk in cultured 
NRCs. However, not all formins might play an indispensable role in the muscle since no 




2007).  Thus, formins may not be redundant in their effects despite sharing a conserved 
actin regulating module (i.e., the FH1 and FH2 domains). 
 
Our current understanding of myofibrillar regulation describes a number of proteins that 
regulate the length and stability of myofibrils. For instance, CapZ is thought to cap and 
stabilise the barbed ends of filaments (Schafer et al. 1995; Papa et al. 1999), contribute 
to thin filament organisation (Hart and Cooper 1999), and prevent aberrant filament 
elongation from the barbed end (Ono 2010). Tropomodulin, which appears to be the 
main pointed end capping protein, has well-established roles in regulating thin filament 
lengths (Gregorio et al. 1995) and its importance has been resonated by gain-of-function 
and loss-of-function animals, which develop cardiac abnormalities (Sussman et al. 
1998; Fritz-Six et al. 2003). The actin side binding protein, tropomyosin contributes to 
thin filament stability and plays roles in the regulation of muscle contractility (Ono 
2010). However, many of the other mechanisms that govern regulation of myofibrils at 
the level of formation, maintenance, and turnover have yet to be fully elucidated. More-
recent efforts have suggested a number of actin regulatory proteins to participate in 
some of the processes. In terms of actin nucleation at the barbed ends of filaments in 
terminally differentiated muscle cells, the nebulin-NWASP complex was shown to 
stimulate formation of unbranched actin filaments downstream of IGF-1 and could 
represent a mode of sarcomeric actin filament formation during hypertrophic growth 
(Takano et al. 2010). The pointed end associated protein leiomodin has been suggested 
to have actin assembly activity by promoting addition of actin monomers at the pointed 
ends of filaments and may also serve as a means to regulate the lengths of sarcomeric 
actin filaments (Tsukada et al. 2010). Indeed, the reported roles of formins make them 
good candidates for myofibrillar regulation: the evidenced reviewed for DAAM-1 and 
FHOD3 in regulating cardiac cytoarchitecture (Iskratsch et al. 2010; Li et al. 2011; Kan-
o et al. 2012a; Kan-o et al. 2012b; Iskratsch et al. 2013a) as well as the present data 
presented for FHOD1 would support the addition of these proteins to the growing list of 
factors that regulate myofibrils (Ono 2010; Dwyer et al. 2012).  
 
While FHOD3, DAAM-1, and even FHOD1 may contribute to the maintenance of 
myofibrils in terminally differentiated muscle cells (i.e., postnatal NRCs in the case of 
FHOD1), their role in myofibrillogenesis remain to be clarified.  It would appear that 




but are still essential for maintenance of the myofibrillar apparatus (Li et al. 2011; Kan-
o et al. 2012a; Rosado et al. 2014). However, experiments in mouse cardiomyocytes 
implicated the importance of a number of formins in de novo myofibril formation 
(Rosado et al. 2014). Day 0-3 neonatal mouse cardiomyocytes were isolated and 
transfected with siRNA to disrupt expression of specific formins before plating. 
Cardiomyocytes temporarily disassemble their myofibrils before readapting to culture 
conditions, therefore disruption of expression of specific formins at this time could have 
potentially identified whether they play a role in myofibril formation. A particularly 
severe phenotype was associated with knockdown of FMNL2 in this setting, and may 
have been due to its ability to contribute to the formation/organisation of actin filaments 
in the early stages of myofibril formation (Rosado et al. 2014). The role of FHOD1 in 
de novo myofibril formation and myofibrillogenesis has yet to be demonstrated but its 
presently suggested role in myofibrillar maintenance and possible expression 
throughout the C2C12 differentiation process also makes it a candidate.  
 
Similarly to other formins and actin regulating proteins, the present study would 
indicate an important role for FHOD1 in striated muscle cells. However, the multitude 
of proposed actin regulating activities for FHOD1 highlights a number of possibilities 
by which it could regulate myofibrils and the F-actin network in muscle cells. FHOD1 
could be mediating its effects via its proposed function as an actin polymerising protein 
(Iskratsch et al. 2013b), actin capping protein, actin side binding, actin bundling protein 
(Schonichen et al. 2013; Schulze et al. 2014), signalling effector (Westendorf 2001; 
Gasteier et al. 2003; Staus et al. 2011a), or a mixture of these functions. The potential 
contributions of each of these putative FHOD1 functions are discussed below.  
7.5.1 FHOD1 as an Actin Polymerising Protein in Muscle 
 
There are a number of observations in the present study which may have suggested that 
FHOD1 exerted some of its effects in cells through the polymerisation of actin. 
Overexpression of constitutively active FHOD1 DAD and V228E mutants in NRCs 
seemingly resulted in an increased signal for F-actin along newly formed actin bundles 
and stress fibres, respectively. Overexpression of full-length FHOD1 was associated 
with an increased signal for F-actin in HeLa cells, possibly suggesting that the total F-




was observed when FHOD1 was overexpressed in its constitutively active forms, which 
also resulted in the formation of stress fibres. Furthermore, NRCs and C2C12 cells 
transfected with the FHOD1 shRNA constructs were associated with disruption of the 
F-actin network at days 8 and 3, respectively.      
 
Previous studies investigating the role of FHOD1 have also highlighted the possibility 
of an actin polymerising role for this formin. Iskratsch et al. 2013b suggested that 
FHOD1 partly contributed to the formation of early focal adhesions through the 
polymerisation of actin filaments. When knocked down in mouse embryonic fibroblasts 
(MEFs), polymerisation of actin filaments was reduced. Furthermore, an FHOD1 
mutant lacking the polyproline motifs in the FH1 domain was also associated with 
reduced actin assembly at early adhesion sites (Iskratsch et al. 2013b). While this may 
have been due to reduced recruitment of FHOD1 by Src at these sites, we cannot rule 
out the possibility that actin assembly was impaired due to a reduced interaction with 
profilin. Previous yeast-two-hybrid analysis suggested that FHOD1 and profilin IIa, the 
major profilin isoform in vertebrates, represented interacting partners (Tojo et al. 2003). 
Profilin is required for the actin filament elongation activities of formins (Romero et al. 
2004), thus an interaction between FHOD1 and profilin may point to a canonical actin 
polymerising role for FHOD1 in cells. 
 
As the classical mediator of formin-mediated actin assembly, the FH2 domain of 
FHOD1 represents a good candidate for mediating the potential actin polymerising role 
of FHOD1 in cardiomyocytes. When overexpressed in cardiomyocytes, the FH2 domain 
of FHOD1 displayed targeting to the Z-disks, the site of anchorage of the barbed ends 
of the cardiac thin filaments within the sarcomere. Furthermore, the FH2 domain co-
localised with F-actin in cardiomyocytes and may have induced its localised 
accumulation. The latter observation may have reflected that the FH2 domain of 
FHOD1 may have possessed the capacity to induce polymerisation of actin filaments in 
a similar manner to the isolated FH2 domain of mDia1, which was shown to be 
sufficient for inducing the accumulation of F-actin in cells (Copeland and Treisman 
2002). While the extent of polymerisation that occurs at the Z-disks of striated muscle 
remains to be elucidated, reports of N-WASP and nebulin forming a complex at the Z-
disk to stimulate actin assembly in response to IGF-1 stimulation in skeletal muscle 




Thus, a number of situations can be envisaged for FHOD1 as an actin polymerising 
protein in muscle. One line of thinking behind how myofibrils are maintained in 
terminally differentiated muscle cells describes the rapid incorporation of actin 
monomers into mature myofibrils that are stabilised by CapZ, tropomodulin, and 
tropomyosin (Ono 2010; Dwyer et al. 2012). This occurs without altering the overall 
stoichiometry of the thin filaments and is not driven by the treadmilling of actin 
filaments from the Z-disks (Littlefield and Fowler 2008).  The site of actin monomer 
addition has been a subject of dispute (Ono 2010) although many studies report that 
incorporation of monomers primarily occurs at the pointed ends of filaments (Littlefield 
et al. 2001; Ono 2010). However, the site of actin monomer addition may be subject to 
culture conditions and cell type, therefore filament growth could conceivably occur at 
the barbed end, pointed end, or both ends (Ono 2010). If FHOD1 is indeed partly found 
at the Z-disk, as suggested by antibody staining in mouse heart sections, it could 
transiently associate with the barbed ends of actin filaments. This model would imply 
that active FHOD1, dimerised via its FH2 domain, could facilitate the incorporation of 
actin monomers at the barbed ends of filaments.  However, this might not be the only 
mechanism by which FHOD1 contributes to myofibrillar maintenance by actin 
polymerisation. Other efforts have described more-dynamic populations of actin 
filaments in cardiomyocytes: FRAP experiments in NRCs have suggested that 
contractility-dependent actin nucleation and polymerisation occurs during sarcomere 
maturation. Furthermore, this population of actin filaments is inhibited by cytochalasin 
D, suggesting that new filament growth is driven by barbed end elongation (Skwarek-
Maruszewska et al. 2009). Barbed end elongators, potentially including FHOD1, could 
perhaps be responsible for creation of new, more-dynamic filament populations, 
whereas pointed end elongators, such as leiomodin could help regulate the lengths of 
mature myofibrils (Dwyer et al. 2012).   
7.5.2 FHOD1 as a Capping Protein in Muscle 
 
While regulation of myofibrils via actin assembly represents an interesting possibility 
for FHOD1, the actin polymerising function associated with many formins has been 
disputed in the case of FHOD1. FHOD1 was found to inhibit actin polymerisation in in 
vitro pyrene assays in its full-length, inactive form and the inhibition of polymerisation 




implementing the FHOD1 DAD mutant (Schonichen et al. 2013). Experiments 
employing lower concentrations of G-actin suggested that FHOD1 did not possess 
filament nucleating activity either. F-actin dilution assays revealed that both full-length 
FHOD1 and the FHOD1 DAD prevented actin depolymerisation. The full-length 
protein showed weaker inhibition of depolymerisation thereby suggesting that 
association with the filament barbed end is partly dependent on the autoinhibition status 
of FHOD1. However, such in vitro observations may not be completely applicable to 
situations in cyto. Indeed, it has been described how the actin polymerising activities of 
certain formins in cells require the participation of a cofactor. For example, in 
Drosophila melanogaster oocytes, the formin Cappuccino and the actin regulatory 
protein Spire form a complex to enhance actin nucleation (Quinlan et al. 2007). A 
similar situation for FHOD1 might not be completely out of the question, with one 
potential actin assembly cofactor that was highlighted in the present study even being 
FHOD3. Nevertheless, the potential capping activity of FHOD1 in muscle remains a 
strong possibility. 
 
A number of the present findings may have reflected the reported ability of FHOD1 to 
cap the barbed ends of actin filaments via its FH2 domain. The noted effects of the FH2 
domain in NRCs (i.e., co-localisation with F-actin and possible localised accumulation 
of F-actin) might not be explained only by actin assembly but rather by stabilisation and 
reduced degradation of F-actin. The capping behaviour of the FH2 domain of FHOD1 
may have also been reflected in the Latrunculin B experiments in NRCs. In this 
instance, the full-length FHOD1 constructs rescued the phenotype associated with 
Latrunculin B but the overexpressed FH2 domain on its own seemingly inhibited 
recovery of myofibrils and co-localised intensely with patches of F-actin throughout 
cells. In this instance it may have been the case that the capping activity of the FH2 
domain on its own was insufficient to stabilise myofibrils in the presence of Latrunculin 
B treatment but, upon wash-out, the FH2 domain was able to cap actin filaments to 
prevent their elongation.  
 
FHOD1’s putative capping role is somewhat more difficult to integrate into our current 
understanding of myofibrillar regulation. A role for stabilisation of myofibrils or 




mature myofibrils since CapZ is likely fulfilling this role (Dwyer et al. 2012). One 
possible mechanism by which FHOD1’s capping activity contributes to regulation of 
the myofibrillar apparatus could involve the stabilisation of a pool of actin filaments 
which are subsequently elongated by other actin assembly factors. This could 
theoretically be extended to instances of de novo actin filament assembly during 
myofibrillogenesis and assembly of more-dynamic filament populations during 
myofibrillar maintenance.  
7.5.3 FHOD1 as an Actin Side Binding Protein/Actin Bundler in 
Muscle 
 
Further explanations by which FHOD1 exerts its effects in muscle cells could involve 
the actin side binding and bundling activity of this formin. In the present study this 
notion was supported by a number of observations. Overexpression of the FHOD1 
DAD and V228E mutant constructs in NRCs resulted in the formation of actin bundles 
and stress fibres, respectively. In Latrunculin B-treated NRCs, overexpression of 
FHOD1 was able to rescue the phenotype associated with myofibrillar 
depolymerisation. This occurred irrespective of FHOD1’s activation status and could 
have suggested that even in FHOD1’s inactive confirmation, in which its functional FH 
domains are thought to be masked, this formin could have stabilised myofibrils in the 
presence of Latrunculin B to prevent their depolymerisation.    
 
Growing evidence from the scientific literature would suggest that FHOD1 possesses 
functionally relevant actin side binding and bundling activity. F-actin pelleting assays 
suggested that FHOD1 binds actin via two independent sites (Schonichen et al. 2013). 
The N-terminus of the protein may mediate binding to the side of actin filaments, 
whereas barbed end binding or dimerization via the FH2 domain could contribute to the 
efficiency of actin binding. Indeed, the pivotal study by Schonichen et al. 2013 
suggested that both regions work synergistically to increase F-actin binding efficiency. 
The F-actin bundling activity of FHOD1 was also tested through low speed 
centrifugation sedimentation assays: FHOD1 required both of its independent actin 
binding domains (the helical actin side binding region and the FH2 domain) in order to 
bundle F-actin. The N-terminus may thus possess actin side binding activity and the 




fibres, actin cables, etc.). TIRF microscopy experiments supported the results seen with 
the sedimentation assays: while both full-length and FHOD1 DAD promoted the 
formation of thick actin bundles when added to polymerizing actin filaments, the effect 
of the FHOD1 DAD construct was much stronger in promoting bundle formation. 
Electron microscopy also suggested greater bundling activity for FHOD1 DAD but 
also revealed that FHOD1 could also bundle filaments stabilized in the presence of 
tropomyosin, the actin side binding protein which stabilises actin filaments in 
myofibrils. 
 
One mechanism by which FHOD1’s actin side binding/bundling activity could directly 
contribute to myofibrillar maintenance in cardiac cells could involve a similar role 
proposed for FHOD1 in the regulation of transverse arcs and ventral stress fibres 
(Schulze et al. 2014). FHOD1 could mediate the end-to-end annealing of shorter actin 
filaments or myofibrillar fragments to contribute to assembly of myofibrils. While this 
mechanism could fit well in the context of de novo myofibril formation, end-to-end 
annealing of myofibrils in the context of maintenance is unlikely since mature 
myofibrils have been suggested to retain their lengths during myofibrillar turnover (Ono 
2010). However, binding alongside mature myofibrils could serve as a means to further 
stabilise them. In this context FHOD1 may act similarly to tropomyosin, which has been 
shown to antagonise the effects of actin depolymerising proteins such as ADF/cofilin to 
promote thin filament stability and sarcomeric organisation (Ono and Ono 2002; Ono 
2010).  
7.5.4 FHOD1 as a Signalling Effector in Muscle 
 
While a growing body of evidence suggests that FHOD1 contributes to the regulation of 
cytoarchitecture by directly acting on F-actin, the role of this formin in signalling to the 
nucleus is also a factor that merits consideration. Multiple studies have documented the 
involvement of FHOD1 in mediating signalling to the serum response element (SRE), a 
short gene regulatory sequence that controls transcription of immediate early genes like 
c-fos and β-actin upon growth factor stimulation.  It involves activation of the serum 
response factor (SRF) transcription factor which stimulates transcription after binding to 
specific promoter regions (Westendorf 2001; Gasteier et al. 2003; Koka et al. 2003; 




stimulates gene expression from the SRE remains to be elucidated, but a mechanism 
involving myocardin-related transcription factors (MRTFs) represents a viable 
explanation, especially in the context of muscle. MRTFs are coactivators of SRF and 
represent crucial mediators of muscle differentiation and cytoskeletal organisation 
(Parmacek 2007). They are bound and sequestered by G-actin outside of the nucleus. 
Upon reduction of the available pool of G-actin (e.g., by polymerisation into F-actin), 
MRTFs are liberated and can subsequently translocate to the nucleus where they 
directly interact with SRF and other MADS box transcription factors. FHOD1 was 
shown to regulate translocation of MRTF to the nucleus during vascular smooth muscle 
cell differentiation and this may have been due to FHOD1’s actin regulating activity, as 
suggested by experiments with Latrunculin B (Staus et al. 2011a). Furthermore, ability 
to mediate gene expression is not only restricted to FHOD1 and may be a result of the 
actin regulating activities of multiple formin proteins (Tominaga et al. 2000). 
 
The presently noted phenotypes associated with muscle cells transfected with the 
FHOD1 shRNAs may not have solely been a result from FHOD1’s direct effects on 
cytoarchitecture but may have also been a downstream product of disruption of the 
signalling events required to maintain muscle differentiation via promotion of 
expression of key myofibrillar proteins (e.g., actin) and assembly factors. In muscle, 
SRF regulates the expression of a number of contractile and cytoskeletal proteins 
including -skeletal muscle actin (SKA), -cardiac muscle actin (CAA), β-myosin 
heavy chain (β-MHC), myosin light chain-2 (MLC-2v), and dystrophin (Nelson et al. 
2005). Previous work employing SRF-null mice revealed that the cardiomyocytes of 
these animals were associated with a number of abnormalities that were comparable to 
those of the FHOD1 shRNAs, ranging from impaired organisation of the myofibrillar 
apparatus to suggestions that cell-cell contacts were disrupted (Balza and Misra 2006). 
Whether the effects associated with the FHOD1 shRNAs in NRCs and C2C12 cells 
resulted in reduced gene expression via the SRE remains to be seen, but the previously 
documented involvement of this pathway with FHOD1 could explain some of FHOD1’s 






7.5.6 Functional Significance of FHOD1 at the Intercalated Disk 
 
Another interesting notion that arose in this study was that FHOD1 may have played a 
role at the intercalated disk. The intercalated disks of cardiomyocytes represent a highly 
specialised junction that serves to electro-mechanically couple neighbouring cells. The 
intercalated disk is characterised by a step-like structure, with the membrane at the 
transverse regions of the steps taking on a folded appearance, resulting in it being 
referred to as plicate (Forbes and Sperelakis 1985; Wilson et al. 2014). Cells are electro-
chemically linked by gap junctions.  Mechanical coupling occurs through adherens 
junctions, the major structural component of the intercalated disks. Adherens junctions 
tether terminal myofibrils through the catenin system and link neighbouring cells via the 
cadherin system. Staining for endogenous FHOD1 suggested that the intercalated disk 
may be a major site of FHOD1 localisation in adult mouse cardiomyocytes; however, its 
precise localisation within the intercalated disk has yet to be fully elucidated. 
Transfection of NRCs with the shRNA constructs designed to target depletion of 
FHOD1 resulted in disruption the appearance of the intercalated disks and led to 
mislocalisation of -catenin. Treatment with the formin inhibitor also had an 
irreversible impact on the intercalated disks: SMIFH2 seemed to have a cumulative 
effect on cell-cell junctions which appeared increasingly widened and convoluted. 
Interestingly DAAM (Li et al. 2011) along with Formin1 (Zigmond 2004) were also 
found to be required for proper formation of adherens junctions and might suggest that 
multiple formins may play a role in regulating cell-cell contacts in both muscle and non-
muscle cells. 
 
There are a number of possible mechanisms by which FHOD1 could contribute to the 
regulation of the intercalated disks in cardiomyocytes. Previous studies and the present 
work suggested that FHOD1 may exert its effects by directly acting on F-actin; 
therefore regulation at the level of the thin filaments found at the intercalated disks 
remains a strong possibility. While the exact mechanisms responsible for the insertion 
of actin filaments into the intercalated disk remain to be elucidated, it would appear that 
they are elongated filaments that originate from the terminal sarcomeres most proximal 
to the intercalated disks. These undecorated actin filaments are thought to comprise the 
area, between the terminal sarcomeres and the intercalated disk membrane, referred to 




FHOD1 functions discussed above, FHOD1 could function as a nucleator and/or 
elongator of actin filaments in the transitional junction. Alternatively, as a capping 
protein, FHOD1 could stabilise a pool of available actin filaments for further elongation 
by other assembly factors. As an actin side binding protein, FHOD1 could serve to 
stabilise the actin network found at the intercalated disks. This would not be the first 
report of an actin side binding protein playing a role at the intercalated disks. Xin, a 
muscle-specific actin side binding/bundling protein, concentrates at the intercalated 
disks between cardiomyocytes and at the myotendinous junction in skeletal muscle 
(Pacholsky et al. 2004; Cherepanova et al. 2006; Choi et al. 2007; Ono 2010). 
Disruption of Xin in mice was associated with perturbation of intercalated disks at the 
ultrastructural level and at the level of the composition of the adherens and desmosomal 
proteins (Gustafson-Wagner et al. 2007; Otten et al. 2010; Wang et al. 2010). However, 
it is unknown if the effects of Xin depletion were due to its direct actin regulating 
capabilities or if they were due to compromised integrity of the cadherin-catenin 
system, since Xin also interacts with -catenin (Choi et al. 2007). Based on the results 
with Xin, it would be of interest to see if FHOD1 depletion in mice is also associated 
with similar intercalated disk defects given that both proteins possess actin side 
binding/bundling activity and localise to the intercalated disks.         
7.5.7 Unified View of Potential FHOD1 Functions in Muscle Cells 
 
Focusing on the contribution of individual FHOD1 domains may not give a complete 
picture of the function of this protein in cells. For instance, the sole contribution of the 
FHOD1 FH2 domain is likely modified by the other modules present on FHOD1. This 
was exemplified in experiments in which NRCs were subjected to treatment with 
Latrunculin B to promote disassembly of all cellular F-actin and their myofibrils. While 
the FH2 domain seemingly inhibited recovery of myofibrils, the full-length wild-type 
and constitutively active FHOD1 variants rescued the phenotype associated with 
Latrunculin B treatment, although it was not possible to discern if these effects were due 
to prevention of depolymerisation of F-actin and myofibrils, if re-assembly of these 
components were enhanced in the recovery phase when Latrunculin B was washed out, 
or both. Also, the localisation of the FH2 domain does not seem to be entirely 
representative of the localisation of constitutively active FHOD1 in NRCs. 




the other FHOD1 domains. N-terminal modules, such as the GBD, might participate in 
the targeting of FHOD1, and those in the C-terminus, such as the DAD, might not be 
solely restricted to regulating the inactive conformation of FHOD1 but might also 
directly contribute to FHOD1’s actin regulating activity. Ultimately, the role of FHOD1 
may be subject to tight spatio-temporal regulation which could involve its number of 
different actin regulating activities, therefore individual domains could contribute 
different functions in specific instances (i.e., in an activated state vs. inactive state of the 
full-length molecule), at different time points, and may be modulated by different sets 
of interacting partners. Further insight into these issues could be gained by establishing 
a profile of endogenous FHOD1 localisation during instances where there are different 
requirements for actin regulation (e.g., during myofibrillogenesis vs. myofibrillar 
maintenance) and assessing the extent of FHOD1 activation at these time points, 
possibly by gauging the extent of phosphorylation in the DAD, although the robustness 
of this model for activation needs to be further explored.     
 
Previous studies supported the notion of similarly important contributions of the 
individual FHOD1 domains that we observed in NRCs, especially through the 
description of multiple actin interacting domains. It seems that the GBD-DID region 
mediates targeting to stress fibres, but persistent association of FHOD1 with stress 
fibres was not required for induction of their formation (Schulze et al. 2014). On the 
other hand, deletion of the helical domain, the actin side binding domain of FHOD1 
(Schonichen et al. 2013), abrogated FHOD1 stimulated stress fibre formation in U2OS 
osteosarcoma cells (Schulze et al. 2014). However, the FH2 domain is still required for 
the actin bundling activity of FHOD1 (Schonichen et al. 2013). Therefore, the helical, 
FH modules, and C-terminal portion of FHOD1 were found to be required for both 
formation of transverse arcs and their maturation into ventral stress fibres (Schulze et al. 
2014). The central and C-terminal domain might be the actin organizing portions of 
FHOD1 whereas the N-terminal region could facilitate targeting and more subtly 
modify FHOD1’s function. In instances of stress fibre formation, FHOD1 might enrich 
a pool of short actin filaments by permanent or slow processive capping or even rapid 
polymerisation. It could then subsequently bundle those filaments. In muscle cells, 
FHOD1 could also mediate its effects through a combination of its activities. Further 




elucidate how each of FHOD1’s possible functions contribute to its effects in muscle 
cells.  
 
The mechanisms by which FHOD1 exerts its functions in muscle cells could therefore 
be very complex. But regulation of actin in muscle cells is not solely restricted to 
capping, bundling, and polymerisation. For instance, actin severing and depolymerising 
proteins also play a role in the maintenance of muscle cytoarchitecture, particularly at 
the level of degradation of actin-based structures (Ono 2010). In a human context, this 
has been exemplified by mutations in cofilin, which have been associated with nemaline 
myopathy, a disease in which nemaline rods (partly composed of actin) accumulate in 
muscle (Yamaguchi et al. 1982; Agrawal et al. 2007). Although processes such as actin 
severing and depolymerisation are of physiological relevance, the results of the present 
study and those of previous research efforts did not indicate that they would necessarily 
be associated with FHOD1. 
 
The contribution of FHOD1 at the subcellular sites discussed above, myofibrils and the 
intercalated disk, might only offer a narrow view of the functional relevance of this 
formin in muscle cells. While muscle actins represent the predominant actin isoforms of 
the myofibrils in cardiac and striated muscle cells (Tondeleir et al. 2009), the role of 
cytoplasmic actins cannot be dismissed (Kee et al. 2009). In muscle, cytoplasmic actins, 
namely -actin and -actin, could play roles involving membrane anchorage with the 
costameres (Dwyer et al. 2012). This may involve dystrophin and the dystrophin 
associated protein complex and different regions of the sarcoplasmic reticulum. The 
precise roles of cytoplasmic actins remain to be fully determined in muscle cells. 
Although knockout animals have indicated little importance of the cytoplasmic actins in 
myofibrillogenesis (Sonnemann et al. 2006; Prins et al. 2011), cytoplasmic actins seem 
to follow a function akin to their localisation and indeed seem to regulate membranous 
compartments, although this has only been shown in skeletal muscle so far (Gokhin and 
Fowler 2011; Dwyer et al. 2012). Whether FHOD1 plays a role in the regulation of the 
cytoplasmic actins at membranous compartments in muscle cells remains to be 
determined, although regulation of -actin is a possibility, since this has been suggested 




transitional junction to the intercalated disk (Bennett et al. 2006; Dwyer et al. 2012; 
Benz et al. 2013).    
 
Although not addressed in the present study, the potential ability of FHOD1 to regulate 
the microtubule network in muscle cells could represent a means by which this formin 
exerts some its effects. Indeed, previous reports of FHOD1 regulating microtubule 
dynamics (Gasteier et al. 2003; Floyd et al. 2013) as well as the growing evidence for 
formins as regulators of the microtubule cytoskeleton (Breitsprecher and Goode 2013) 
make this a possibility. The role of microtubules is slightly underrepresented in striated 
muscle research. While roles in muscle cell hyperplasia and differentiation have been 
suggested (Li et al. 1996; Mian et al. 2012), their role in postmitotic muscle cells 
requires further investigation (Ehler and Perriard 2000). Nevertheless, the role of 
FHOD1 and formins on the microtubule network in striated muscle could represent a 
future avenue worth exploring. 
7.6 FHOD1 in Cardiac Disease 
 
Another interesting finding in the present study related to the expression and 
localisation of FHOD1 in a mouse model of dilated cardiomyopathy (DCM), the MLP
-/-
 
mouse. We presently report a possible upregulation in FHOD1 expression in adult MLP
-
/-
 mouse hearts. This may have also reflected the increased signal we saw for FHOD1 
along myofibrils, but especially at the intercalated disks. MLP
-/-
 mice represent a model 
of cardiac disease in which there is a mixture of cardiac hypertrophy and dilatation 
which can eventually progress to heart failure (Arber et al. 1997; Buyandelger et al. 
2011). MLP
-/-
 mice, and DCM phenotypes in general, are characterised by 
ultrastructural abnormalities in cardiomyocyte architecture, myofibrillar disarray, and 
fibrosis (Machackova et al. 2006; Wilson et al. 2014). It is not always clear which of 
these factors perpetuate the disease or represent the end result of disease progression. 
Nevertheless, it is interesting to speculate as to the reasons behind FHOD1 upregulation 
in this model of DCM.   
 
Both cardiac hypertrophy and dilatation are characterised by alterations in a variety of 
subcellular compartments (e.g., mitochondria, nuclei, and sarcoplasmic reticulum) but 




associated with hypertrophic cardiomyopathy (HCM), some of the abnormalities that 
arise in cardiac hypertrophy associated with DCM are the expression of fetal genes, 
such as -SKA (Suurmeijer et al. 2003), which is thought to contribute to greater 
myofibrillar contractility (Machackova et al. 2006), although the increase in -SKA 
may depend on the extent of hypertrophy (Adachi et al. 1998). Other adaptive changes 
in response to hypertrophy include expression of atrial myosin light chain 1 (ALC1), 
which is also thought to contribute to increased cardiac contractility (Schaub et al. 
1998). Actin polymerisation has also been suggested to be required for mediating 
hypertrophic growth of cultured cardiomyocytes in response to phenylephrine treatment 
(Yanazume et al. 2002). Overall, alterations in composition of myofibrils, their 
remodelling, and their increased assembly may contribute to the compensatory 
remodelling mechanisms seen in cardiac hypertrophy and DCM. Given the potential 
roles of FHOD1 in myofibrillar regulation in the present study, the increase in FHOD1 
expression may alleviate the greater demand for myofibrillar assembly and maintenance 
via one or more of its different actin regulating activities.  
 
FHOD1’s proposed ability to stimulate SRF-mediated gene expression is also intriguing 
from a cardiac disease perspective. SRF has been suggested to be one the factors driving 
expression of the characteristic fetal gene expression signature noted in instances of 
cardiac hypertrophy and DCM. For instance, cardiac-specific overexpression of the 
human SRF gene in mice resulted in cardiomyopathy and a switch to fetal 
reprogramming (e.g., downregulation of -CAA and upregulation of -SKA) (Zhang et 
al. 2001). Furthermore, increased SRF expression has been noted in the hypertrophied 
hearts of ageing rats (Lu et al. 1998). Whether or not increased FHOD1 expression 
and/or activity could drive SRF activity during cardiac remodelling in instances of 
disease remains to be determined but FHOD1 upregulation could represent a 
perpetuating factor in compensatory and pathological remodelling responses not only on 
the level of direct cytoarchitectural regulation but also on the gene expression level.     
  
The potential role of FHOD1 in regulating cell-cell contacts in NRCs, its localisation at 
the intercalated disk in adult mouse hearts, and its upregulation in DCM are very 
interesting when considering the role of the intercalated disk in cardiomyocyte growth. 




of the defining characteristics of DCM (Perriard et al. 2003) and other proteins have 
been shown to exhibit alterations in their expression (Estigoy et al. 2009).  Generally 
speaking, adherens junction proteins tend to increase in expression whereas gap 
junction proteins are downregulated in their expression. The functional relevance of the 
upregulation of adherens junctions proteins may be of particular importance, since some 
these proteins (e.g., -catenin) are involved in anchoring the actin filaments at the 
intercalated disk (Ehler et al. 2001). Interestingly, there is also an upregulation of -
actin, the supposedly predominant actin isoform at the intercalated disk 
(Balasubramanian et al. 2010), during some instances of cardiac remodelling (e.g., 
hypertrophy) and may reflect an increased requirement for thin filament assembly and 
integration at the intercalated disk. The intercalated disks display with a broader 
appearance in DCM hearts (Wilson et al. 2014), similarly to that in aged hearts (Forbes 
and Sperelakis 1985), and this may be indicative of increased convolution of the 
structure during cardiomyocyte growth. Indeed, a recent study, which employed volume 
overloaded rabbits, suggested that cycles of broadening and narrowing of the 
intercalated disks, resulting in a transient interruption in the signal for intercalated disk 
proteins,  allowed for insertion of sarcomeres at the ends of cardiomyocytes and 
accordingly resulted in the proposition of the ‘weaving sarcomere hypothesis’ (Yoshida 
et al. 2010). During cardiac development, similar insertion of sarcomeres was noted in 
regions of increased membrane convolution (Wilson et al. 2014). Such observations 
would support the idea of the transitional junction as proposed by Bennett and 
colleagues (Bennett et al. 2006). During instances of cardiomyopathy, as ascertained 
using heart sections of MLP
-/-
 mice, cΔex3 mice (overexpress a cardiac-specific β-
catenin mutant (Hirschy et al. 2010)), and idiopathic DCM human samples, controlled 
insertion of terminal myofibrils at these sites was found to be disrupted (Wilson et al. 
2014). Regarding FHOD1, its different sets of potential actin regulating activities could 
contribute to the abnormalities in actin filament insertion seen in pathological 
remodelling and therefore may partly explain the phenotypes in DCM (Dwyer et al. 
2014).   
 
Another notion that arose in this study is that alterations in the relative levels of formins 
might be a characteristic of DCM, just as altered ratios in formin levels have been 






 mice have indicated differential expression of FHOD1 and FHOD3, 
possibly suggesting diverging roles for these two FHOD proteins in disease. The precise 
cause and functional consequences of these changes in expression have yet to be 
determined, although it may be conserved among human examples of DCM, which 
have suggested similar alterations in both FHOD1 (Dwyer et al. 2014) and FHOD3 
(Iskratsch et al. 2010). In MLP
-/-
 mice, there was also an isoform switch to the non-
muscle isoform of FHOD3, which is subject to degradation via p62 (Iskratsch et al. 
2010), and may have accounted for the reduction in FHOD3 levels. As to the reason 
behind the FHOD3 isoform switch, this may have been a consequence of the fetal 
reprogramming events that partly accompany the transition towards a heart failure 
phenotype (Machackova et al. 2006; Cappola 2008). The increase in total FHOD1 
levels may have reflected a switch to fetal reprogramming in hearts and/or may have 
resonated an increased requirement for its actin regulatory function. It also remains to 
be determined if there is an isoform switch relating to FHOD1 in instances of cardiac 
disease. While the two presently characterised FHOD1 isoforms exhibit similar 
behaviour in their supposedly inactive state in cardiomyocytes, comparison of their 
behaviours upon activation remains to be seen. The possibility of different sets of 
interacting partners, potentially mediated by the alternatively spliced exon 12-13, may 
also modulate function of the FHOD1 isoforms in healthy and diseased cells. 
7.7 Insights from Interacting Partners 
7.7.1 Potential Contribution of FHOD3 
 
In our search for novel interacting partners, we found a possible interaction between 
FHOD1 and FHOD3, which were suggested to directly interact.  This interaction could 
have indicated that FHOD1 and FHOD3 may form heterodimers.  This would not be the 
first report of heterodimerisation between two different DRFs.  mDia1 has been 
reported to dimerise with mDia2 as the full-length variants of both proteins bound each 
other in co-immunoprecipitation assays (Copeland et al. 2007).  However, this 
interaction was ascribed to contribute to an inhibitory cross-regulation of these formins.  
Binding was dependent on the presence of the DAD regions and it was also found that 
the DID of mDia2 inhibited the activity of mDia1.  Furthermore, cross-regulation did 
not extend to the formin DAAM-1 implying that this mechanism was restricted to 




revealed in the interaction screen would argue against a cross-regulatory mechanism 
like the one seen between mDia1 and mDia2.  Perhaps FHOD1 could sterically block 
association between FHOD3 and actin by binding part of its actin polymerising module 
(FH1-FH2), thus providing a new means of negative regulation of FHOD3 besides 
autoinhibitory regulation.  This interaction could also be indicative of a new mechanism 
of activation for FHOD1.  Perhaps the exposed FH1-FH2 region of activated FHOD3 
could bind the N-terminus of FHOD1 to sterically displace the FHOD1 autoinhibitory 
interaction. Alternatively, FHOD1 and FHOD3 could work synergistically to aid in the 
assembly or reorganisation of actin-based strictures. However, one can only speculate 
into the functional consequences of association between FHOD1 and FHOD3 until 
functional studies have been performed in cells. 
7.7.2 Potential Contribution of Src  
 
The present study may have uncovered evidence in support of a physical interaction 
between the FHOD1 N-terminus and Src kinase, which could have a number of 
functional consequences if it is indeed present in muscle cells. A large proportion of the 
research efforts into Src have largely focused on the role of this protein in the context of 
cancer cell biology. Although extensive data are lacking, there is some evidence that Src 
may play a role in both healthy and diseased striated muscle. For instance, Src has been 
suggested to have roles in skeletal muscle development. In C2C12 cells Src activation 
was shown to be required for differentiation into multinucleated myotubes (Lu et al. 
2002). However, the role of Src in muscle differentiation remains somewhat 
controversial since other reports have suggested that inhibition of Src activity actually 
stimulates skeletal muscle differentiation (Lim et al. 2007). In the heart, there have been 
some indications, although somewhat scarce, that SFKs accumulate at the intercalated 
disks between cardiomyocytes (Tsukita et al. 1991). However, a role for SKFs at the 
intercalated disks has been described and they may play a role in the regulation of gap 
junctions (Toyofuku et al. 1999). Src was suggested to be a potent inhibitor of gap 
junction communication by phosphorylating connexin43 and that this may have 
contributed to the deficits in gap junction communication noted in cardiomyopathic 
hamsters (Toyofuku et al. 1999; Palatinus et al. 2012). Src activity can also exhibit 




increased Src activity is involved in mediating the signal transduction events that 
contribute to cardiac hypertrophy (Takeishi et al. 2001). 
 
In terms of the known functions of Src with respect to muscle and FHOD1, a number of 
roles could be proposed for how Src could modulate the function of FHOD1 in muscle. 
One of the previously proposed roles for Src is that it mediates the localisation of 
FHOD1 in cells. Src seemed to regulate translocation of FHOD1 to the plasma 
membrane and to mediate its association with ROCK-I (Hannemann et al. 2008). In 
MEFs, Src mediated targeting of FHOD1 to early integrin clusters upstream of 
activation by ROCK-1 (Iskratsch et al. 2013b). In the present study we noted FHOD1 
localising to specific cardiomyocyte compartments. Given the previous role of Src in 
mediating the localisation of FHOD1 and the potential physical interaction between 
FHOD1 and Src, Src could conceivably be involved in targeting FHOD1 to some of 
these sites in cardiomyocytes. One such mode of translocation between the two proteins 
could involve a shuttling mechanism by which Src binds FHOD1 and delivers it to its 
subcellular destination. The functional relevance of the FHOD1-Src interactions 
remains to be fully elucidated but current lines of thinking suggest that Src mediates 
targeting of FHOD1 to the plasma membrane where FHOD1 is subsequently 
phosphorylated by ROCK-I (Hannemann et al. 2008; Iskratsch et al. 2013b). 
7.7.3 Potential Contribution of NRAP 
 
The potential FHOD1-NRAP interaction also poses interesting possibilities by which 
these proteins could contribute to regulation of actin filaments. Knock down of NRAP 
has so far been associated with impaired myofibrillogenesis but we have not been able 
to show the same so far with FHOD1.  Furthermore, it is unclear whether NRAP is 
required for myofibrillar maintenance since experiments have primarily employed 
embryonic mouse cardiomyocytes to study its function.  Overall, both proteins may play 
a role in regulation of the myofibrillar apparatus at the level of actin.  Perhaps their roles 
also extend to regulation of the intercalated disk, which may represent a major site of 
localisation of both proteins in adult cardiac muscle. The main function ascribed to 
NRAP in striated muscle is that of a scaffolding role.  Interestingly, FHOD1 may have 
interacted with an SR region of NRAP, which has been found to be essential in 




(Carroll et al. 2004).  Thus, a number of possibilities arise with respect to the functional 
consequences that an FHOD1-NRAP interaction may pose. If there is indeed a physical 
interaction between NRAP and FHOD1, NRAP could serve to tether FHOD1 within a 
given subcellular localisation and/or reinforce the interaction between FHOD1 and actin 
so that FHOD1 may fulfil one or more of its putative actin regulatory functions. The 
notion that these proteins are concomitantly increased in DCM could suggest greater 
cooperation between them to fulfil their actin regulating roles. Nevertheless, although 
an FHOD1-NRAP interaction could represent an exciting possibility, conformation of 
the interaction will be required and the functional consequences of the possible 




The present study attempted to characterise the formin protein FHOD1 in striated 
muscle.  Analysis of the expression pattern of FHOD1 suggested that it is expressed in 
striated muscle at the protein level.  It was also apparent that FHOD1 was more 
abundantly expressed in the heart than in skeletal muscle, where it was preferentially 
expressed in fast rather than slow skeletal muscle. Work exploring the localisation of 
FHOD1 in cultured muscle cells may have indicated sarcomeric targeting of 
endogenous FHOD1 but will require further exploration because of the technical issues 
relating to the commercial antibodies. Nevertheless, in sections of adult mouse heart 
tissue, FHOD1 may exhibit a prominent signal at the intercalated disks although it may 
have been present in some of the Z-disks. Overexpression of GFP-tagged human 
FHOD1 resulted in diffuse cytoplasmic distribution, accumulation at the cell 
peripheries, and some myofibrillar targeting. It would also seem that targeting of the 
full-length human FHOD1 construct was not mediated by the presence of the 
alternatively spliced exons 12-13. Although the precise mechanisms guiding the 
localisation of FHOD1 require further elucidation, a construct lacking its N-terminal 
GBD fail to target in a similar way to full-length FHOD1.  In trying to dissect the 
function of FHOD1 it was revealed that overexpression of constitutively active versions 
of this formin could induce cytoskeletal rearrangements. While there was a possibility 
that FHOD1 activation may have increased the F-actin content in cells, the precise 
mechanism by which this occurred by remains to be determined.  Although pending 




suggested that FHOD1 may have been involved in maintenance of muscle 
cytoarchitecture in both NRCs and C2C12 cells.  If the effects of the shRNA constructs 
were indeed due to FHOD1 depletion, the mechanisms by which the cellular defects 
arose remain to be explored given the various actin regulating roles that have been 
proposed for FHOD1. General inhibition of formin activity with the inhibitor SMIFH2 
also resulted in perturbation of the myofibrillar apparatus and the intercalated disks in 
cardiomyocytes, suggesting a broad role for formins in muscle cells.   
 
In trying to establish potential regulatory interactions for FHOD1, possibly mediated by 
the alternatively spliced exons 12-13, it was suggested that the N-terminal half of 
FHOD1 did not bind some of the classical Rho family small GTPases or the Rho 
effector molecule ROCK.  However, the FHOD1 N-terminus may have interacted 
physically with the cytoskeletal regulator Src.  A set of potential novel interactions were 
also described with the FHOD1 N-terminus, which included FHOD3 and NRAP.  
FHOD1 may have weakly bound one of the SR repeats of NRAP and both proteins may 
have co-localised at the intercalated disk in frozen sections of adult mouse hearts.  
FHOD1 levels were also suggested to increase dramatically in the MLP
-/- 
mouse model 
of DCM and this was associated with a greater signal for FHOD1 at the intercalated 
disk. Overall, functional studies and potential interactions with well-known cytoskeletal 
regulators, like Src and proteins involved in myofibril assembly, like NRAP may have 
implicated FHOD1 in regulation of the myofibrillar apparatus and cytoskeleton at the 
level of actin in striated muscle. 
 
In conclusion, the regulation and turnover of actin in striated muscle is continuously 
being revealed as a dynamic process and the involvement of the formin family of 
proteins is increasingly being shown.  The current study supported the notion that 
FHOD1 may represent a crucial regulator of myogenic cytoarchitecture at the level of 
F-actin and that this may occur in healthy and diseased muscle. 
 
7.9 Future Directions 
 
The current work involving FHOD1 has highlighted this formin protein as a possible 




be involved in myofibrillar maintenance, its role in myofibrillogenesis remains to be 
explored.  The expression and localisation of FHOD1 should thus be investigated in 
different models of myofibrillogenesis.  Embryonic mouse samples can be used to 
provide a clearer picture about the role of FHOD1 in developing skeletal muscle and 
heart.  Developing chicken muscle samples could also provide an excellent platform to 
look at FHOD1 expression and localisation at specific stages of development as gauged 
by number of somites.  Eventually, it will be necessary to have a complete spatio-
temporal expression and localisation profile for FHOD1 in developing, post-natal, and 
diseased muscle samples. 
 
The mechanisms governing regulation of FHOD1 in muscle have yet to be elucidated. 
While we may have identified novel sets of binding partners for FHOD1, it remains to 
be seen how they could modulate the function of FHOD1 in muscle cells. While, the 
direct physical interaction between FHOD1 and some of these interacting partners 
remains to be confirmed, functional studies by way of co-expression experiments and 
RNAi could help paint a picture of where these proteins interact in cells and if they can 
modulate each other’s behaviour.  In terms of known regulators of FHOD1, such as Rac 
and ROCK-I, it would also be of interest to examine the relevance of these protein 
interactions in muscle.   
 
Further functional studies will also eventually shed light on the actual role of FHOD1.  
One way of visualising FHOD1’s effect on actin could involve live imaging studies 
using Lifeact, which fluorescently labels F-actin in cells without altering its dynamics 
(Riedl et al. 2008).  Live imaging studies in cultured cells and ex vivo samples would 
also allow one to study the behaviour of FHOD1, when tagged with a fluorescent 
protein and could be done under different stimuli, such as IGF-1 treatment to induce 
actin assembly.  Ultimately, work involving FHOD1 should converge at the creation of 
knock-out and transgenic animals.  Global and muscle-specific depletion and 
overexpression of FHOD1 in vivo would paint a clearer picture of the function of this 
formin.  In summary, FHOD1 may be a crucial regulator of the myofibrillar apparatus 
and cytoskeleton in cardiac and skeletal muscle as suggested by work involving its 
expression, localisation, function, regulation, and interacting partners.  Future work 
involving the formin protein FHOD1 will hopefully further elucidate how actin is 
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